Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
32700.0 | 2020-04-16 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Edison Nation, Soligenix, Arcus Biosciences, Bed Bath & Beyond | ABT | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-edison-nation-soligenix-arcus-biosciences-bed-bath-beyond | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 and Dow Jones slipped on Thursday, giving up early gains as concerns about dismal first-quarter earnings and lasting economic damage from the coronavirus pandemic offset better-than-expected weekly jobless claims numbers..N
At 11:15 ET, the Dow Jones Industrial Average .DJI was down 0.13% at 23,474.8. The S&P 500 .SPX was up 0.45% at 2,795.87 and the Nasdaq Composite .IXIC was up 1.44% at 8,513.636. The top three S&P 500 .PG.INX percentage gainers: ** Nvidia Corp NVDA.OQ, up 5.6% ** Akamai Technologies AKAM.OQ, up 5.5% ** AutoZone Inc AZO.N, up 4.9% The top three S&P 500 .PL.INX percentage losers: ** United Airlines Holdings UAL.OQ, down 9.5% ** American Airlines Group AAL.OQ, down 7% ** Alaska Air Group ALK.N, down 6.5% The top three NYSE .PG.N percentage gainers: ** VanEck Vectors Energy Income ETF EINC.N, up 197.2% ** VanEck Vectors Rare Earth ETF REMX.N, up 185.7% ** Arcus Biosciences Inc RCUS.N, up 83.7% The top three NYSE .PL.N percentage losers: ** Rite Aid Corp RAD.N, down 24.5% ** Hertz Global Holdings HTZ.N, down 17.1% ** Apergy Corp APY.N, down 14.1% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings LTRPB.O, up 119% ** MoSys Inc MOSY.O, up 95.6% ** Edison Nation EDNT.O, up 91.6% The top three Nasdaq .PL.O percentage losers: ** Global Eagle Entertainment ENT.O, down 26.5% ** Athersys Inc ATHX.O, down 23.6% ** Calithera Biosciences Inc CALA.O, down 15.7%
** Cree CREE.O: down 4.7%
BUZZ-Cree drops on $500 mln convertible debt deal ** EBay EBAY.O: up 1.9%
BUZZ-EBay: Rises as Starboard withdraws board nominations ** PDS Biotechnology PDSB.O: up 63.9%
BUZZ-PDS Biotechnology: Jumps on plan to start COVID-19 vaccine development program ** Inovio INO.O: up 8.1%
BUZZ-Inovio rises as coronavirus vaccine study in S.Korea gets $6.9 mln funding ** Rite Aid RAD.N: down 24.5%
BUZZ-Rite Aid: Falls on wider Q4 loss, maintains 2021 outlook ** ConocoPhillips COP.N: down 2.7%
BUZZ-ConocoPhillips: Falls on output cut, share buyback suspension ** Jack in the Box JACK.O: up 17.9%
BUZZ-Jack in the Box: Surges after BTIG ups rating to "buy" ** Eagle Pharma EGRX.O: up 6.6%
BUZZ-Eagle Pharma: Rises as hyperthermia drug inhibits virus causing COVID-19 ** Atossa Therapeutics ATOS.O: up 37.9%
BUZZ-Atossa Therapeutics leaps on plans to develop potential COVID-19 therapy ** ThermoGenesis THMO.O: up 50.1%
BUZZ-ThermoGenesis: Gains after FDA allows COVID-19 diagnostic kit distribution ** Co-Diagnostics CODX.O: up 16.6% BUZZ-Co-Diagnostics: Jumps as COVID-19 test on saliva samples uses co's tech - Reuters News ** Calithera Biosciences CALA.O: down 15.7% Calithera Biosciences slides on equity raise ** Athersys ATHX.O: down 23.6% BUZZ-Athersys drops on $50 mln equity raise to fund COVID-19 trial ** Bed Bath & Beyond BBBY.O: up 18.2% BUZZ-Bed Bath & Beyond: Rises after escaping Q4 with a profit beat amid pandemic ** Arcus Biosciences RCUS.N: up 83.3% BUZZ-Arcus Biosciences: Surges on report of Gilead in talks for picking stake ** Soligenix Inc SNGX.O: up 14.3% BUZZ-Soligenix Inc: Rises on scoring license for potential COVID-19 vaccine ** Dynavax Tech DVAX.O: up 2.3% BUZZ-Dynavax Tech jumps on entering coronavirus vaccine tie-up ** Twitter TWTR.N: down 2.0% BUZZ-Twitter: Drops as JP Morgan downgrades to 'neutral' ** GoPro GPRO.O: down 1.9% BUZZ-GoPro: Falls after co scraps 2020 forecast on coronavirus fears ** Chegg Inc CHGG.N: down 3.6% BUZZ-Chegg Inc: New grading policy at universities to hurt online learning co ** Bloomin' Brands BLMN.O: up 4.3% BUZZ-Bloomin' Brands: Take-out, delivery sales nearly triple since March, shares rise ** Bank of New York Mellon BK.N: up 4.5% BUZZ-Bank of New York Mellon rises on Q1 results beat ** Edison Nation EDNT.O: up 91.6% BUZZ-Edison Nation: Surges after securing orders for personal protective equipment ** Abbott ABT.N: up 4.5% BUZZ-Abbott: Rises on quarterly results beat ** Diamond Offshore Drilling DO.N: down 40.5% BUZZ-Diamond Offshore Drilling: Slips after skipping interest payment ** Ra Medical Systems RMED.N: down 4.6% BUZZ-Ra Medical Systems: Falls after filing for stock offering ** Goodyear Tire GT.O: down 3.2% BUZZ-Goodyear Tire: Burns rubber after estimating quarterly loss ** UroGen Pharma URGN.O: down 3.0% BUZZ-UroGen Pharma: Jumps after cancer drug gets FDA nod ** Netflix NFLX.O: up 4.6% BUZZ-Netflix: Evercore ISI raises PT on favorable trends amid virus outbreak ** Taiwan Semiconductor Manufacturing Co TSM.N: up 6.8% BUZZ-Taiwan Semiconductor Manufacturing rises as profit nearly doubles ** Pulmatrix PULM.O: up 10.6% BUZZ-Pulmatrix: Jumps after granting license for respiratory disease products ** Marathon Petroleum MPC.N: down 6.2% BUZZ-Marathon Petroleum: Costs, midstream structure keeps Cowen on sidelines ** Square Inc SQ.N: down 5.4% BUZZ-Square Inc: Drops after Raymond James downgrades on COVID-19 risks
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
up 0.32%
Consumer Discretionary
.SPLRCD
up 1.99%
Consumer Staples
.SPLRCS
up 0.31%
Energy
.SPNY
down 2.30%
Financial
.SPSY
down 1.27%
Health
.SPXHC
up 1.47%
Industrial
.SPLRCI
down 0.99%
Information Technology
.SPLRCT
up 0.99%
Materials
.SPLRCM
down 0.77%
Real Estate
.SPLRCR
down 0.24%
Utilities
.SPLRCU
up 0.20%
(Compiled by Amal S in Bengaluru)
((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Nvidia Corp NVDA.OQ, up 5.6% ** Akamai Technologies AKAM.OQ, up 5.5% ** AutoZone Inc AZO.N, up 4.9% The top three S&P 500 .PL.INX percentage losers: ** United Airlines Holdings UAL.OQ, down 9.5% ** American Airlines Group AAL.OQ, down 7% ** Alaska Air Group ALK.N, down 6.5% The top three NYSE .PG.N percentage gainers: ** VanEck Vectors Energy Income ETF EINC.N, up 197.2% ** VanEck Vectors Rare Earth ETF REMX.N, up 185.7% ** Arcus Biosciences Inc RCUS.N, up 83.7% The top three NYSE .PL.N percentage losers: ** Rite Aid Corp RAD.N, down 24.5% ** Hertz Global Holdings HTZ.N, down 17.1% ** Apergy Corp APY.N, down 14.1% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings LTRPB.O, up 119% ** MoSys Inc MOSY.O, up 95.6% ** Edison Nation EDNT.O, up 91.6% The top three Nasdaq .PL.O percentage losers: ** Global Eagle Entertainment ENT.O, down 26.5% ** Athersys Inc ATHX.O, down 23.6% ** Calithera Biosciences Inc CALA.O, down 15.7% ** Cree CREE.O: down 4.7% BUZZ-Cree drops on $500 mln convertible debt deal ** EBay EBAY.O: up 1.9% BUZZ-EBay: Rises as Starboard withdraws board nominations ** PDS Biotechnology PDSB.O: up 63.9% BUZZ-PDS Biotechnology: Jumps on plan to start COVID-19 vaccine development program ** Inovio INO.O: up 8.1% BUZZ-Inovio rises as coronavirus vaccine study in S.Korea gets $6.9 mln funding ** Rite Aid RAD.N: down 24.5% BUZZ-Rite Aid: Falls on wider Q4 loss, maintains 2021 outlook ** ConocoPhillips COP.N: down 2.7% BUZZ-ConocoPhillips: Falls on output cut, share buyback suspension ** Jack in the Box JACK.O: up 17.9% BUZZ-Jack in the Box: Surges after BTIG ups rating to "buy" ** Eagle Pharma EGRX.O: up 6.6% BUZZ-Eagle Pharma: Rises as hyperthermia drug inhibits virus causing COVID-19 ** Atossa Therapeutics ATOS.O: up 37.9% BUZZ-Atossa Therapeutics leaps on plans to develop potential COVID-19 therapy ** ThermoGenesis THMO.O: up 50.1% BUZZ-ThermoGenesis: Gains after FDA allows COVID-19 diagnostic kit distribution ** Co-Diagnostics CODX.O: up 16.6% BUZZ-Co-Diagnostics: Jumps as COVID-19 test on saliva samples uses co's tech - Reuters News ** Calithera Biosciences CALA.O: down 15.7% Calithera Biosciences slides on equity raise ** Athersys ATHX.O: down 23.6% BUZZ-Athersys drops on $50 mln equity raise to fund COVID-19 trial ** Bed Bath & Beyond BBBY.O: up 18.2% BUZZ-Bed Bath & Beyond: Rises after escaping Q4 with a profit beat amid pandemic ** Arcus Biosciences RCUS.N: up 83.3% BUZZ-Arcus Biosciences: Surges on report of Gilead in talks for picking stake ** Soligenix Inc SNGX.O: up 14.3% BUZZ-Soligenix Inc: Rises on scoring license for potential COVID-19 vaccine ** Dynavax Tech DVAX.O: up 2.3% BUZZ-Dynavax Tech jumps on entering coronavirus vaccine tie-up ** Twitter TWTR.N: down 2.0% BUZZ-Twitter: Drops as JP Morgan downgrades to 'neutral' ** GoPro GPRO.O: down 1.9% BUZZ-GoPro: Falls after co scraps 2020 forecast on coronavirus fears ** Chegg Inc CHGG.N: down 3.6% BUZZ-Chegg Inc: New grading policy at universities to hurt online learning co ** Bloomin' Brands BLMN.O: up 4.3% BUZZ-Bloomin' Brands: Take-out, delivery sales nearly triple since March, shares rise ** Bank of New York Mellon BK.N: up 4.5% BUZZ-Bank of New York Mellon rises on Q1 results beat ** Edison Nation EDNT.O: up 91.6% BUZZ-Edison Nation: Surges after securing orders for personal protective equipment ** Abbott ABT.N: up 4.5% BUZZ-Abbott: Rises on quarterly results beat ** Diamond Offshore Drilling DO.N: down 40.5% BUZZ-Diamond Offshore Drilling: Slips after skipping interest payment ** Ra Medical Systems RMED.N: down 4.6% BUZZ-Ra Medical Systems: Falls after filing for stock offering ** Goodyear Tire GT.O: down 3.2% BUZZ-Goodyear Tire: Burns rubber after estimating quarterly loss ** UroGen Pharma URGN.O: down 3.0% BUZZ-UroGen Pharma: Jumps after cancer drug gets FDA nod ** Netflix NFLX.O: up 4.6% BUZZ-Netflix: Evercore ISI raises PT on favorable trends amid virus outbreak ** Taiwan Semiconductor Manufacturing Co TSM.N: up 6.8% BUZZ-Taiwan Semiconductor Manufacturing rises as profit nearly doubles ** Pulmatrix PULM.O: up 10.6% BUZZ-Pulmatrix: Jumps after granting license for respiratory disease products ** Marathon Petroleum MPC.N: down 6.2% BUZZ-Marathon Petroleum: Costs, midstream structure keeps Cowen on sidelines ** Square Inc SQ.N: down 5.4% BUZZ-Square Inc: Drops after Raymond James downgrades on COVID-19 risks The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and Dow Jones slipped on Thursday, giving up early gains as concerns about dismal first-quarter earnings and lasting economic damage from the coronavirus pandemic offset better-than-expected weekly jobless claims numbers..N At 11:15 ET, the Dow Jones Industrial Average .DJI was down 0.13% at 23,474.8. up 0.20% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Nvidia Corp NVDA.OQ, up 5.6% ** Akamai Technologies AKAM.OQ, up 5.5% ** AutoZone Inc AZO.N, up 4.9% The top three S&P 500 .PL.INX percentage losers: ** United Airlines Holdings UAL.OQ, down 9.5% ** American Airlines Group AAL.OQ, down 7% ** Alaska Air Group ALK.N, down 6.5% The top three NYSE .PG.N percentage gainers: ** VanEck Vectors Energy Income ETF EINC.N, up 197.2% ** VanEck Vectors Rare Earth ETF REMX.N, up 185.7% ** Arcus Biosciences Inc RCUS.N, up 83.7% The top three NYSE .PL.N percentage losers: ** Rite Aid Corp RAD.N, down 24.5% ** Hertz Global Holdings HTZ.N, down 17.1% ** Apergy Corp APY.N, down 14.1% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings LTRPB.O, up 119% ** MoSys Inc MOSY.O, up 95.6% ** Edison Nation EDNT.O, up 91.6% The top three Nasdaq .PL.O percentage losers: ** Global Eagle Entertainment ENT.O, down 26.5% ** Athersys Inc ATHX.O, down 23.6% ** Calithera Biosciences Inc CALA.O, down 15.7% ** Cree CREE.O: down 4.7% BUZZ-Cree drops on $500 mln convertible debt deal ** EBay EBAY.O: up 1.9% BUZZ-EBay: Rises as Starboard withdraws board nominations ** PDS Biotechnology PDSB.O: up 63.9% BUZZ-PDS Biotechnology: Jumps on plan to start COVID-19 vaccine development program ** Inovio INO.O: up 8.1% BUZZ-Inovio rises as coronavirus vaccine study in S.Korea gets $6.9 mln funding ** Rite Aid RAD.N: down 24.5% BUZZ-Rite Aid: Falls on wider Q4 loss, maintains 2021 outlook ** ConocoPhillips COP.N: down 2.7% BUZZ-ConocoPhillips: Falls on output cut, share buyback suspension ** Jack in the Box JACK.O: up 17.9% BUZZ-Jack in the Box: Surges after BTIG ups rating to "buy" ** Eagle Pharma EGRX.O: up 6.6% BUZZ-Eagle Pharma: Rises as hyperthermia drug inhibits virus causing COVID-19 ** Atossa Therapeutics ATOS.O: up 37.9% BUZZ-Atossa Therapeutics leaps on plans to develop potential COVID-19 therapy ** ThermoGenesis THMO.O: up 50.1% BUZZ-ThermoGenesis: Gains after FDA allows COVID-19 diagnostic kit distribution ** Co-Diagnostics CODX.O: up 16.6% BUZZ-Co-Diagnostics: Jumps as COVID-19 test on saliva samples uses co's tech - Reuters News ** Calithera Biosciences CALA.O: down 15.7% Calithera Biosciences slides on equity raise ** Athersys ATHX.O: down 23.6% BUZZ-Athersys drops on $50 mln equity raise to fund COVID-19 trial ** Bed Bath & Beyond BBBY.O: up 18.2% BUZZ-Bed Bath & Beyond: Rises after escaping Q4 with a profit beat amid pandemic ** Arcus Biosciences RCUS.N: up 83.3% BUZZ-Arcus Biosciences: Surges on report of Gilead in talks for picking stake ** Soligenix Inc SNGX.O: up 14.3% BUZZ-Soligenix Inc: Rises on scoring license for potential COVID-19 vaccine ** Dynavax Tech DVAX.O: up 2.3% BUZZ-Dynavax Tech jumps on entering coronavirus vaccine tie-up ** Twitter TWTR.N: down 2.0% BUZZ-Twitter: Drops as JP Morgan downgrades to 'neutral' ** GoPro GPRO.O: down 1.9% BUZZ-GoPro: Falls after co scraps 2020 forecast on coronavirus fears ** Chegg Inc CHGG.N: down 3.6% BUZZ-Chegg Inc: New grading policy at universities to hurt online learning co ** Bloomin' Brands BLMN.O: up 4.3% BUZZ-Bloomin' Brands: Take-out, delivery sales nearly triple since March, shares rise ** Bank of New York Mellon BK.N: up 4.5% BUZZ-Bank of New York Mellon rises on Q1 results beat ** Edison Nation EDNT.O: up 91.6% BUZZ-Edison Nation: Surges after securing orders for personal protective equipment ** Abbott ABT.N: up 4.5% BUZZ-Abbott: Rises on quarterly results beat ** Diamond Offshore Drilling DO.N: down 40.5% BUZZ-Diamond Offshore Drilling: Slips after skipping interest payment ** Ra Medical Systems RMED.N: down 4.6% BUZZ-Ra Medical Systems: Falls after filing for stock offering ** Goodyear Tire GT.O: down 3.2% BUZZ-Goodyear Tire: Burns rubber after estimating quarterly loss ** UroGen Pharma URGN.O: down 3.0% BUZZ-UroGen Pharma: Jumps after cancer drug gets FDA nod ** Netflix NFLX.O: up 4.6% BUZZ-Netflix: Evercore ISI raises PT on favorable trends amid virus outbreak ** Taiwan Semiconductor Manufacturing Co TSM.N: up 6.8% BUZZ-Taiwan Semiconductor Manufacturing rises as profit nearly doubles ** Pulmatrix PULM.O: up 10.6% BUZZ-Pulmatrix: Jumps after granting license for respiratory disease products ** Marathon Petroleum MPC.N: down 6.2% BUZZ-Marathon Petroleum: Costs, midstream structure keeps Cowen on sidelines ** Square Inc SQ.N: down 5.4% BUZZ-Square Inc: Drops after Raymond James downgrades on COVID-19 risks The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and Dow Jones slipped on Thursday, giving up early gains as concerns about dismal first-quarter earnings and lasting economic damage from the coronavirus pandemic offset better-than-expected weekly jobless claims numbers..N At 11:15 ET, the Dow Jones Industrial Average .DJI was down 0.13% at 23,474.8. up 0.20% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Nvidia Corp NVDA.OQ, up 5.6% ** Akamai Technologies AKAM.OQ, up 5.5% ** AutoZone Inc AZO.N, up 4.9% The top three S&P 500 .PL.INX percentage losers: ** United Airlines Holdings UAL.OQ, down 9.5% ** American Airlines Group AAL.OQ, down 7% ** Alaska Air Group ALK.N, down 6.5% The top three NYSE .PG.N percentage gainers: ** VanEck Vectors Energy Income ETF EINC.N, up 197.2% ** VanEck Vectors Rare Earth ETF REMX.N, up 185.7% ** Arcus Biosciences Inc RCUS.N, up 83.7% The top three NYSE .PL.N percentage losers: ** Rite Aid Corp RAD.N, down 24.5% ** Hertz Global Holdings HTZ.N, down 17.1% ** Apergy Corp APY.N, down 14.1% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings LTRPB.O, up 119% ** MoSys Inc MOSY.O, up 95.6% ** Edison Nation EDNT.O, up 91.6% The top three Nasdaq .PL.O percentage losers: ** Global Eagle Entertainment ENT.O, down 26.5% ** Athersys Inc ATHX.O, down 23.6% ** Calithera Biosciences Inc CALA.O, down 15.7% ** Cree CREE.O: down 4.7% BUZZ-Cree drops on $500 mln convertible debt deal ** EBay EBAY.O: up 1.9% BUZZ-EBay: Rises as Starboard withdraws board nominations ** PDS Biotechnology PDSB.O: up 63.9% BUZZ-PDS Biotechnology: Jumps on plan to start COVID-19 vaccine development program ** Inovio INO.O: up 8.1% BUZZ-Inovio rises as coronavirus vaccine study in S.Korea gets $6.9 mln funding ** Rite Aid RAD.N: down 24.5% BUZZ-Rite Aid: Falls on wider Q4 loss, maintains 2021 outlook ** ConocoPhillips COP.N: down 2.7% BUZZ-ConocoPhillips: Falls on output cut, share buyback suspension ** Jack in the Box JACK.O: up 17.9% BUZZ-Jack in the Box: Surges after BTIG ups rating to "buy" ** Eagle Pharma EGRX.O: up 6.6% BUZZ-Eagle Pharma: Rises as hyperthermia drug inhibits virus causing COVID-19 ** Atossa Therapeutics ATOS.O: up 37.9% BUZZ-Atossa Therapeutics leaps on plans to develop potential COVID-19 therapy ** ThermoGenesis THMO.O: up 50.1% BUZZ-ThermoGenesis: Gains after FDA allows COVID-19 diagnostic kit distribution ** Co-Diagnostics CODX.O: up 16.6% BUZZ-Co-Diagnostics: Jumps as COVID-19 test on saliva samples uses co's tech - Reuters News ** Calithera Biosciences CALA.O: down 15.7% Calithera Biosciences slides on equity raise ** Athersys ATHX.O: down 23.6% BUZZ-Athersys drops on $50 mln equity raise to fund COVID-19 trial ** Bed Bath & Beyond BBBY.O: up 18.2% BUZZ-Bed Bath & Beyond: Rises after escaping Q4 with a profit beat amid pandemic ** Arcus Biosciences RCUS.N: up 83.3% BUZZ-Arcus Biosciences: Surges on report of Gilead in talks for picking stake ** Soligenix Inc SNGX.O: up 14.3% BUZZ-Soligenix Inc: Rises on scoring license for potential COVID-19 vaccine ** Dynavax Tech DVAX.O: up 2.3% BUZZ-Dynavax Tech jumps on entering coronavirus vaccine tie-up ** Twitter TWTR.N: down 2.0% BUZZ-Twitter: Drops as JP Morgan downgrades to 'neutral' ** GoPro GPRO.O: down 1.9% BUZZ-GoPro: Falls after co scraps 2020 forecast on coronavirus fears ** Chegg Inc CHGG.N: down 3.6% BUZZ-Chegg Inc: New grading policy at universities to hurt online learning co ** Bloomin' Brands BLMN.O: up 4.3% BUZZ-Bloomin' Brands: Take-out, delivery sales nearly triple since March, shares rise ** Bank of New York Mellon BK.N: up 4.5% BUZZ-Bank of New York Mellon rises on Q1 results beat ** Edison Nation EDNT.O: up 91.6% BUZZ-Edison Nation: Surges after securing orders for personal protective equipment ** Abbott ABT.N: up 4.5% BUZZ-Abbott: Rises on quarterly results beat ** Diamond Offshore Drilling DO.N: down 40.5% BUZZ-Diamond Offshore Drilling: Slips after skipping interest payment ** Ra Medical Systems RMED.N: down 4.6% BUZZ-Ra Medical Systems: Falls after filing for stock offering ** Goodyear Tire GT.O: down 3.2% BUZZ-Goodyear Tire: Burns rubber after estimating quarterly loss ** UroGen Pharma URGN.O: down 3.0% BUZZ-UroGen Pharma: Jumps after cancer drug gets FDA nod ** Netflix NFLX.O: up 4.6% BUZZ-Netflix: Evercore ISI raises PT on favorable trends amid virus outbreak ** Taiwan Semiconductor Manufacturing Co TSM.N: up 6.8% BUZZ-Taiwan Semiconductor Manufacturing rises as profit nearly doubles ** Pulmatrix PULM.O: up 10.6% BUZZ-Pulmatrix: Jumps after granting license for respiratory disease products ** Marathon Petroleum MPC.N: down 6.2% BUZZ-Marathon Petroleum: Costs, midstream structure keeps Cowen on sidelines ** Square Inc SQ.N: down 5.4% BUZZ-Square Inc: Drops after Raymond James downgrades on COVID-19 risks The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and Dow Jones slipped on Thursday, giving up early gains as concerns about dismal first-quarter earnings and lasting economic damage from the coronavirus pandemic offset better-than-expected weekly jobless claims numbers..N At 11:15 ET, the Dow Jones Industrial Average .DJI was down 0.13% at 23,474.8. up 0.32% Consumer Discretionary | The top three S&P 500 .PG.INX percentage gainers: ** Nvidia Corp NVDA.OQ, up 5.6% ** Akamai Technologies AKAM.OQ, up 5.5% ** AutoZone Inc AZO.N, up 4.9% The top three S&P 500 .PL.INX percentage losers: ** United Airlines Holdings UAL.OQ, down 9.5% ** American Airlines Group AAL.OQ, down 7% ** Alaska Air Group ALK.N, down 6.5% The top three NYSE .PG.N percentage gainers: ** VanEck Vectors Energy Income ETF EINC.N, up 197.2% ** VanEck Vectors Rare Earth ETF REMX.N, up 185.7% ** Arcus Biosciences Inc RCUS.N, up 83.7% The top three NYSE .PL.N percentage losers: ** Rite Aid Corp RAD.N, down 24.5% ** Hertz Global Holdings HTZ.N, down 17.1% ** Apergy Corp APY.N, down 14.1% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings LTRPB.O, up 119% ** MoSys Inc MOSY.O, up 95.6% ** Edison Nation EDNT.O, up 91.6% The top three Nasdaq .PL.O percentage losers: ** Global Eagle Entertainment ENT.O, down 26.5% ** Athersys Inc ATHX.O, down 23.6% ** Calithera Biosciences Inc CALA.O, down 15.7% ** Cree CREE.O: down 4.7% BUZZ-Cree drops on $500 mln convertible debt deal ** EBay EBAY.O: up 1.9% BUZZ-EBay: Rises as Starboard withdraws board nominations ** PDS Biotechnology PDSB.O: up 63.9% BUZZ-PDS Biotechnology: Jumps on plan to start COVID-19 vaccine development program ** Inovio INO.O: up 8.1% BUZZ-Inovio rises as coronavirus vaccine study in S.Korea gets $6.9 mln funding ** Rite Aid RAD.N: down 24.5% BUZZ-Rite Aid: Falls on wider Q4 loss, maintains 2021 outlook ** ConocoPhillips COP.N: down 2.7% BUZZ-ConocoPhillips: Falls on output cut, share buyback suspension ** Jack in the Box JACK.O: up 17.9% BUZZ-Jack in the Box: Surges after BTIG ups rating to "buy" ** Eagle Pharma EGRX.O: up 6.6% BUZZ-Eagle Pharma: Rises as hyperthermia drug inhibits virus causing COVID-19 ** Atossa Therapeutics ATOS.O: up 37.9% BUZZ-Atossa Therapeutics leaps on plans to develop potential COVID-19 therapy ** ThermoGenesis THMO.O: up 50.1% BUZZ-ThermoGenesis: Gains after FDA allows COVID-19 diagnostic kit distribution ** Co-Diagnostics CODX.O: up 16.6% BUZZ-Co-Diagnostics: Jumps as COVID-19 test on saliva samples uses co's tech - Reuters News ** Calithera Biosciences CALA.O: down 15.7% Calithera Biosciences slides on equity raise ** Athersys ATHX.O: down 23.6% BUZZ-Athersys drops on $50 mln equity raise to fund COVID-19 trial ** Bed Bath & Beyond BBBY.O: up 18.2% BUZZ-Bed Bath & Beyond: Rises after escaping Q4 with a profit beat amid pandemic ** Arcus Biosciences RCUS.N: up 83.3% BUZZ-Arcus Biosciences: Surges on report of Gilead in talks for picking stake ** Soligenix Inc SNGX.O: up 14.3% BUZZ-Soligenix Inc: Rises on scoring license for potential COVID-19 vaccine ** Dynavax Tech DVAX.O: up 2.3% BUZZ-Dynavax Tech jumps on entering coronavirus vaccine tie-up ** Twitter TWTR.N: down 2.0% BUZZ-Twitter: Drops as JP Morgan downgrades to 'neutral' ** GoPro GPRO.O: down 1.9% BUZZ-GoPro: Falls after co scraps 2020 forecast on coronavirus fears ** Chegg Inc CHGG.N: down 3.6% BUZZ-Chegg Inc: New grading policy at universities to hurt online learning co ** Bloomin' Brands BLMN.O: up 4.3% BUZZ-Bloomin' Brands: Take-out, delivery sales nearly triple since March, shares rise ** Bank of New York Mellon BK.N: up 4.5% BUZZ-Bank of New York Mellon rises on Q1 results beat ** Edison Nation EDNT.O: up 91.6% BUZZ-Edison Nation: Surges after securing orders for personal protective equipment ** Abbott ABT.N: up 4.5% BUZZ-Abbott: Rises on quarterly results beat ** Diamond Offshore Drilling DO.N: down 40.5% BUZZ-Diamond Offshore Drilling: Slips after skipping interest payment ** Ra Medical Systems RMED.N: down 4.6% BUZZ-Ra Medical Systems: Falls after filing for stock offering ** Goodyear Tire GT.O: down 3.2% BUZZ-Goodyear Tire: Burns rubber after estimating quarterly loss ** UroGen Pharma URGN.O: down 3.0% BUZZ-UroGen Pharma: Jumps after cancer drug gets FDA nod ** Netflix NFLX.O: up 4.6% BUZZ-Netflix: Evercore ISI raises PT on favorable trends amid virus outbreak ** Taiwan Semiconductor Manufacturing Co TSM.N: up 6.8% BUZZ-Taiwan Semiconductor Manufacturing rises as profit nearly doubles ** Pulmatrix PULM.O: up 10.6% BUZZ-Pulmatrix: Jumps after granting license for respiratory disease products ** Marathon Petroleum MPC.N: down 6.2% BUZZ-Marathon Petroleum: Costs, midstream structure keeps Cowen on sidelines ** Square Inc SQ.N: down 5.4% BUZZ-Square Inc: Drops after Raymond James downgrades on COVID-19 risks The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and Dow Jones slipped on Thursday, giving up early gains as concerns about dismal first-quarter earnings and lasting economic damage from the coronavirus pandemic offset better-than-expected weekly jobless claims numbers..N At 11:15 ET, the Dow Jones Industrial Average .DJI was down 0.13% at 23,474.8. The S&P 500 .SPX was up 0.45% at 2,795.87 and the Nasdaq Composite .IXIC was up 1.44% at 8,513.636. |
32701.0 | 2020-04-16 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABT | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2020-04-16 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
STOCK RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
UGI Corp. (Symbol: UGI) $44.23 $53.67 21.33%
New Jersey Resources Corp (Symbol: NJR) $44.04 $52.00 18.07%
Smith (A O) Corp (Symbol: AOS) $46.61 $52.43 12.48%
International Business Machines Corp (Symbol: IBM) $136.62 $153.54 12.38%
Abbott Laboratories (Symbol: ABT) $87.38 $95.50 9.29%
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
STOCK DIVIDEND YIELD % UPSIDE TO ANALYST TARGET IMPLIED TOTAL RETURN POTENTIAL
UGI Corp. (Symbol: UGI) 4.76% 21.33% 26.09%
New Jersey Resources Corp (Symbol: NJR) 3.84% 18.07% 21.91%
Smith (A O) Corp (Symbol: AOS) 2.40% 12.48% 14.88%
International Business Machines Corp (Symbol: IBM) 5.46% 12.38% 17.84%
Abbott Laboratories (Symbol: ABT) 1.58% 9.29% 10.87%
Another consideration with dividend growth stocks is just how much the dividend is growing. We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
STOCK PRIOR TTM DIVIDEND TTM DIVIDEND % GROWTH
UGI Corp. (Symbol: UGI) $1.04 $1.275 22.60%
New Jersey Resources Corp (Symbol: NJR) $1.152 $1.232 6.94%
Smith (A O) Corp (Symbol: AOS) $0.8 $0.92 15.00%
International Business Machines Corp (Symbol: IBM) $6.28 $6.48 3.18%
Abbott Laboratories (Symbol: ABT) $1.2 $1.36 13.33%
These five stocks are part of our full Dividend Aristocrats List. The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on IBM — FREE
Get the latest Zacks research report on ABT — FREE
Dividend Growth Stocks: 25 Aristocrats »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Get the latest Zacks research report on IBM — FREE Get the latest Zacks research report on ABT — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. UGI Corp. (Symbol: UGI) $44.23 $53.67 21.33% New Jersey Resources Corp (Symbol: NJR) $44.04 $52.00 18.07% Smith (A O) Corp (Symbol: AOS) $46.61 $52.43 12.48% International Business Machines Corp (Symbol: IBM) $136.62 $153.54 12.38% Abbott Laboratories (Symbol: ABT) $87.38 $95.50 9.29% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. UGI Corp. (Symbol: UGI) 4.76% 21.33% 26.09% New Jersey Resources Corp (Symbol: NJR) 3.84% 18.07% 21.91% Smith (A O) Corp (Symbol: AOS) 2.40% 12.48% 14.88% International Business Machines Corp (Symbol: IBM) 5.46% 12.38% 17.84% Abbott Laboratories (Symbol: ABT) 1.58% 9.29% 10.87% Another consideration with dividend growth stocks is just how much the dividend is growing. | UGI Corp. (Symbol: UGI) $44.23 $53.67 21.33% New Jersey Resources Corp (Symbol: NJR) $44.04 $52.00 18.07% Smith (A O) Corp (Symbol: AOS) $46.61 $52.43 12.48% International Business Machines Corp (Symbol: IBM) $136.62 $153.54 12.38% Abbott Laboratories (Symbol: ABT) $87.38 $95.50 9.29% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. UGI Corp. (Symbol: UGI) 4.76% 21.33% 26.09% New Jersey Resources Corp (Symbol: NJR) 3.84% 18.07% 21.91% Smith (A O) Corp (Symbol: AOS) 2.40% 12.48% 14.88% International Business Machines Corp (Symbol: IBM) 5.46% 12.38% 17.84% Abbott Laboratories (Symbol: ABT) 1.58% 9.29% 10.87% Another consideration with dividend growth stocks is just how much the dividend is growing. UGI Corp. (Symbol: UGI) $1.04 $1.275 22.60% New Jersey Resources Corp (Symbol: NJR) $1.152 $1.232 6.94% Smith (A O) Corp (Symbol: AOS) $0.8 $0.92 15.00% International Business Machines Corp (Symbol: IBM) $6.28 $6.48 3.18% Abbott Laboratories (Symbol: ABT) $1.2 $1.36 13.33% These five stocks are part of our full Dividend Aristocrats List. | UGI Corp. (Symbol: UGI) $44.23 $53.67 21.33% New Jersey Resources Corp (Symbol: NJR) $44.04 $52.00 18.07% Smith (A O) Corp (Symbol: AOS) $46.61 $52.43 12.48% International Business Machines Corp (Symbol: IBM) $136.62 $153.54 12.38% Abbott Laboratories (Symbol: ABT) $87.38 $95.50 9.29% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. UGI Corp. (Symbol: UGI) 4.76% 21.33% 26.09% New Jersey Resources Corp (Symbol: NJR) 3.84% 18.07% 21.91% Smith (A O) Corp (Symbol: AOS) 2.40% 12.48% 14.88% International Business Machines Corp (Symbol: IBM) 5.46% 12.38% 17.84% Abbott Laboratories (Symbol: ABT) 1.58% 9.29% 10.87% Another consideration with dividend growth stocks is just how much the dividend is growing. UGI Corp. (Symbol: UGI) $1.04 $1.275 22.60% New Jersey Resources Corp (Symbol: NJR) $1.152 $1.232 6.94% Smith (A O) Corp (Symbol: AOS) $0.8 $0.92 15.00% International Business Machines Corp (Symbol: IBM) $6.28 $6.48 3.18% Abbott Laboratories (Symbol: ABT) $1.2 $1.36 13.33% These five stocks are part of our full Dividend Aristocrats List. | UGI Corp. (Symbol: UGI) $44.23 $53.67 21.33% New Jersey Resources Corp (Symbol: NJR) $44.04 $52.00 18.07% Smith (A O) Corp (Symbol: AOS) $46.61 $52.43 12.48% International Business Machines Corp (Symbol: IBM) $136.62 $153.54 12.38% Abbott Laboratories (Symbol: ABT) $87.38 $95.50 9.29% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. UGI Corp. (Symbol: UGI) 4.76% 21.33% 26.09% New Jersey Resources Corp (Symbol: NJR) 3.84% 18.07% 21.91% Smith (A O) Corp (Symbol: AOS) 2.40% 12.48% 14.88% International Business Machines Corp (Symbol: IBM) 5.46% 12.38% 17.84% Abbott Laboratories (Symbol: ABT) 1.58% 9.29% 10.87% Another consideration with dividend growth stocks is just how much the dividend is growing. UGI Corp. (Symbol: UGI) $1.04 $1.275 22.60% New Jersey Resources Corp (Symbol: NJR) $1.152 $1.232 6.94% Smith (A O) Corp (Symbol: AOS) $0.8 $0.92 15.00% International Business Machines Corp (Symbol: IBM) $6.28 $6.48 3.18% Abbott Laboratories (Symbol: ABT) $1.2 $1.36 13.33% These five stocks are part of our full Dividend Aristocrats List. |
32702.0 | 2020-04-16 00:00:00 UTC | US STOCKS-Lockdown easing hopes lift futures ahead of jobless claims | ABT | https://www.nasdaq.com/articles/us-stocks-lockdown-easing-hopes-lift-futures-ahead-of-jobless-claims-2020-04-16 | nan | nan | By Medha Singh
April 16 (Reuters) - U.S. stock index futures edged higher on Thursday, as hopes President Donald Trump would ease strict stay-at-home restrictions lifted the mood even as investors braced for another staggering jobless claims figure.
Trump is expected to announce "new guidelines" for re-opening the economy at a news conference on Thursday as he said data suggested the United States had passed the peak on new coronavirus infections.
After a 27% rally from its March lows, the S&P 500 index inched down this week and stands 18% below its record high, as first-quarter earnings began with U.S. banks preparing for a wave of future loan defaults following a halt in business activity.
Economic data on Wednesday showed U.S. retail sales plunged a record 8.7% in March, while manufacturing output dropped by the most in over 74 years, signaling worse numbers to come as the lockdowns continue.
Economists polled by Reuters expect weekly jobless claims likely topped 5 million last week, which would take total unemployment claims to an astounding 20 million in the past month.
"Expectations for economic data and the current earnings season are already extremely low (but) these figures could act as a reminder that the global economy is facing a deep recession and that recovery might take longer than initially expected," said Milan Cutkovic, market analyst at AxiCorp.
"Despite the numerous economic stimulus packages and signs of stabilization from the Covid-19 crisis, it is still too early for investors to relax."
Analysts forecast earnings for S&P 500 companies slumped 12.8% in the first quarter, with U.S. economic growth expected to have contracted at its fastest pace since World War Two.
On Thursday, BlackRock Inc BLK.N, the world's largest asset manager saw the capital it manages fall by almost $1 trillion in the quarter as investors pulled money out of its marquee funds.
Medical equipment maker Abbott Laboratories Inc ABT.N posted a 16% drop in quarterly profit and suspended its full-year forecast due to uncertainty caused by the virus outbreak.
Morgan Stanley MS.N reported a 32% fall in quarterly profit as its advisory and wealth management businesses took a hit from the economic fallout of the pandemic. Its shares slipped 0.9%.
At 7:47 a.m. ET, Dow e-minis 1YMcv1 were up 4 points, or 0.02%, S&P 500 e-minis EScv1 were up 3.25 points, or 0.12% and Nasdaq 100 e-minis NQcv1 were up 41.75 points, or 0.49%.
Chipmakers Qualcomm Inc QCOM.O, Intel Corp INTC.O, Nvidia Corp NVDA.O and Advanced Micro Devices Inc AMD.O were up between 1.2% and 1.6% after the world's largest contract chipmaker Taiwan Semiconductor Manufacturing Co Ltd (TSMC) 2330.TW reported a near doubling in first-quarter net profit.
Netflix Inc NFLX.O rose 1.9% after multiple brokerages hiked their price targets on the stock expecting higher subscriber growth during the lockdown.
However, United Airlines Holdings Inc UAL.O slipped 2.7% as the carrier said it cut its flight schedule by 90% for May and warned travel demand, now "essentially at zero shows no sign of improving in the near term", making job cuts likely.
(Reporting by Medha Singh and Akanksha Rana in Bengaluru; Editing by Sagarika Jaisinghani and Shounak Dasgupta)
((Medha.Singh@thomsonreuters.com; within U.S. +1646 223 8780, outside U.S. +91 80 6749 1130; Twitter: https://twitter.com/medhasinghs))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medical equipment maker Abbott Laboratories Inc ABT.N posted a 16% drop in quarterly profit and suspended its full-year forecast due to uncertainty caused by the virus outbreak. By Medha Singh April 16 (Reuters) - U.S. stock index futures edged higher on Thursday, as hopes President Donald Trump would ease strict stay-at-home restrictions lifted the mood even as investors braced for another staggering jobless claims figure. After a 27% rally from its March lows, the S&P 500 index inched down this week and stands 18% below its record high, as first-quarter earnings began with U.S. banks preparing for a wave of future loan defaults following a halt in business activity. | Medical equipment maker Abbott Laboratories Inc ABT.N posted a 16% drop in quarterly profit and suspended its full-year forecast due to uncertainty caused by the virus outbreak. By Medha Singh April 16 (Reuters) - U.S. stock index futures edged higher on Thursday, as hopes President Donald Trump would ease strict stay-at-home restrictions lifted the mood even as investors braced for another staggering jobless claims figure. Economists polled by Reuters expect weekly jobless claims likely topped 5 million last week, which would take total unemployment claims to an astounding 20 million in the past month. | Medical equipment maker Abbott Laboratories Inc ABT.N posted a 16% drop in quarterly profit and suspended its full-year forecast due to uncertainty caused by the virus outbreak. By Medha Singh April 16 (Reuters) - U.S. stock index futures edged higher on Thursday, as hopes President Donald Trump would ease strict stay-at-home restrictions lifted the mood even as investors braced for another staggering jobless claims figure. "Expectations for economic data and the current earnings season are already extremely low (but) these figures could act as a reminder that the global economy is facing a deep recession and that recovery might take longer than initially expected," said Milan Cutkovic, market analyst at AxiCorp. | Medical equipment maker Abbott Laboratories Inc ABT.N posted a 16% drop in quarterly profit and suspended its full-year forecast due to uncertainty caused by the virus outbreak. By Medha Singh April 16 (Reuters) - U.S. stock index futures edged higher on Thursday, as hopes President Donald Trump would ease strict stay-at-home restrictions lifted the mood even as investors braced for another staggering jobless claims figure. Trump is expected to announce "new guidelines" for re-opening the economy at a news conference on Thursday as he said data suggested the United States had passed the peak on new coronavirus infections. |
32703.0 | 2020-04-16 00:00:00 UTC | 3 Great Stocks That Are Still Ridiculously Cheap Right Now | ABT | https://www.nasdaq.com/articles/3-great-stocks-that-are-still-ridiculously-cheap-right-now-2020-04-16 | nan | nan | After one of the fastest meltdowns ever, the stock market has rebounded quite a bit. There's even an argument to be made about whether we really still have a bear market.
But despite the bounce for many stocks, most of them still haven't regained their previous highs. Plenty of bargains can be found. Here are three great stocks that are still ridiculously cheap right now.
Image source: Getty Images.
1. AbbVie
AbbVie (NYSE: ABBV) shares trade at a little over eight times expected earnings. That makes AbbVie one of the cheapest big pharma stocks on the market. There's one word that explains why the stock is so inexpensive: Humira.
Since AbbVie was spun off from Abbott Labs in 2013 (and even before then), its management team has been bracing for the day when Humira would lose patent exclusivity. That day has already come in Europe and is on the way in the U.S. in 2023. The problem for AbbVie is that it's highly dependent on its top-selling drug.
If AbbVie didn't have a plan to deal with the sales declines for Humira, the stock would be a value trap instead of a value play. But AbbVie does have a plan. Its lineup includes several drugs that will fuel revenue growth for years to come, with cancer drugs Imbruvica and Venclexta and new immunology drugs Rinvoq and Skyrizi at the top of the list. The company also awaits the closing of its acquisition of Allergan, a deal that will significantly reduce its dependence on Humira.
AbbVie probably won't deliver tremendous growth over the next several years in the aftermath of Humira's loss of exclusivity. However, it doesn't have to do so to be able to generate solid total returns for long-term investors. AbbVie's dividend yield stands at close to 5.9%. The company ranks as a Dividend Aristocrat with 47 consecutive years of dividend increases and places a high priority on its dividend program.
2. Berkshire Hathaway
Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) hasn't been this cheap in years. The stock trades at only a little over its book value, less than six times trailing-12-month earnings, and around 18 times expected earnings. Berkshire CEO Warren Buffett might not be a big fan of any of these valuation metrics, but he undoubtedly likes the stock's current valuation considering that the company was buying back shares last year when the stock was priced well above current levels.
Like many companies, Berkshire Hathaway's near-term prospects will be impacted by the COVID-19 outbreak. Several of its retail businesses, in particular, could experience revenue and earnings declines. However, Berkshire also owns businesses that aren't likely to be affected much by the coronavirus pandemic, notably including its insurance operations.
But the negative impact on Berkshire from COVID-19 will only be temporary. The company's subsidiaries and its massive investment portfolio will almost certainly recover quickly once the crisis is over.
Remember, too, that Buffett is a master at making smart investments during market downturns. And he has a lot of cash at his disposal to use in investing. Berkshire's cash stockpile, including cash and equivalents, totaled $125 billion at the end of 2019.
3. Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) is another big pharma stock that, like AbbVie, appears to be attractively priced right now. Its shares trade at around 9.4 times expected earnings. However, unlike AbbVie, BMS should deliver strong growth over the next several years.
Wall Street analysts predict that the big drugmaker will be able to increase its earnings by more than 18% annually on average over the next five years. This estimate seems achievable considering BMS' solid product lineup and promising pipeline candidates.
Two of the top five best-selling drugs in the world over the next few years belong to BMS -- blood thinner Eliquis and cancer immunotherapy Opdivo. The company also has other blockbuster drugs with fast-growing sales, including Abraxane, Orencia, Pomalyst, and Revlimid. New products such as blood disease drug Reblozyl and multiple sclerosis drug Zeposia are also likely to be huge winners.
Bristol Myers Squibb also offers an appealing dividend with a current yield of a little over 3%. For investors looking for value, growth, and income, it's hard to beat BMS.
10 stocks we like better than Bristol Myers Squibb
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Bristol Myers Squibb wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), and Bristol Myers Squibb. The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares) and Bristol Myers Squibb and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and short June 2020 $205 calls on Berkshire Hathaway (B shares). The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Since AbbVie was spun off from Abbott Labs in 2013 (and even before then), its management team has been bracing for the day when Humira would lose patent exclusivity. However, Berkshire also owns businesses that aren't likely to be affected much by the coronavirus pandemic, notably including its insurance operations. Two of the top five best-selling drugs in the world over the next few years belong to BMS -- blood thinner Eliquis and cancer immunotherapy Opdivo. | Bristol Myers Squibb Bristol Myers Squibb (NYSE: BMY) is another big pharma stock that, like AbbVie, appears to be attractively priced right now. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), and Bristol Myers Squibb. The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares) and Bristol Myers Squibb and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and short June 2020 $205 calls on Berkshire Hathaway (B shares). | Berkshire CEO Warren Buffett might not be a big fan of any of these valuation metrics, but he undoubtedly likes the stock's current valuation considering that the company was buying back shares last year when the stock was priced well above current levels. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), and Bristol Myers Squibb. The Motley Fool owns shares of and recommends Berkshire Hathaway (B shares) and Bristol Myers Squibb and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and short June 2020 $205 calls on Berkshire Hathaway (B shares). | If AbbVie didn't have a plan to deal with the sales declines for Humira, the stock would be a value trap instead of a value play. Berkshire Hathaway Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) hasn't been this cheap in years. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Berkshire Hathaway (B shares), and Bristol Myers Squibb. |
32704.0 | 2020-04-16 00:00:00 UTC | Abbott posts 16% fall in profit, suspends 2020 forecast on coronavirus concerns | ABT | https://www.nasdaq.com/articles/abbott-posts-16-fall-in-profit-suspends-2020-forecast-on-coronavirus-concerns-2020-04-16 | nan | nan | April 16 (Reuters) - Abbott Laboratories Inc ABT.N posted a 16% drop in quarterly profit on Thursday partly due to a tax expense and suspended its full-year forecast citing the uncertainty caused by the coronavirus outbreak.
The company's net earnings fell to $564 million, or 31 cents per share, in the first quarter ended March 31, from $672 million, or 38 cents per share, a year earlier.
Net sales rose to $7.73 billion from $7.54 billion.
Abbott has so far launched three coronavirus tests in the U.S., including an on-site diagnostic kit that can deliver results within minutes and heralded as a game changer by President Donald Trump.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Sriraj Kalluvila)
((saumya.joseph@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 2676; Twitter: @SaumyaSibi;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | April 16 (Reuters) - Abbott Laboratories Inc ABT.N posted a 16% drop in quarterly profit on Thursday partly due to a tax expense and suspended its full-year forecast citing the uncertainty caused by the coronavirus outbreak. Abbott has so far launched three coronavirus tests in the U.S., including an on-site diagnostic kit that can deliver results within minutes and heralded as a game changer by President Donald Trump. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Sriraj Kalluvila) ((saumya.joseph@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 2676; Twitter: @SaumyaSibi;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | April 16 (Reuters) - Abbott Laboratories Inc ABT.N posted a 16% drop in quarterly profit on Thursday partly due to a tax expense and suspended its full-year forecast citing the uncertainty caused by the coronavirus outbreak. The company's net earnings fell to $564 million, or 31 cents per share, in the first quarter ended March 31, from $672 million, or 38 cents per share, a year earlier. Net sales rose to $7.73 billion from $7.54 billion. | April 16 (Reuters) - Abbott Laboratories Inc ABT.N posted a 16% drop in quarterly profit on Thursday partly due to a tax expense and suspended its full-year forecast citing the uncertainty caused by the coronavirus outbreak. The company's net earnings fell to $564 million, or 31 cents per share, in the first quarter ended March 31, from $672 million, or 38 cents per share, a year earlier. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Sriraj Kalluvila) ((saumya.joseph@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 2676; Twitter: @SaumyaSibi;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | April 16 (Reuters) - Abbott Laboratories Inc ABT.N posted a 16% drop in quarterly profit on Thursday partly due to a tax expense and suspended its full-year forecast citing the uncertainty caused by the coronavirus outbreak. The company's net earnings fell to $564 million, or 31 cents per share, in the first quarter ended March 31, from $672 million, or 38 cents per share, a year earlier. Net sales rose to $7.73 billion from $7.54 billion. |
32705.0 | 2020-04-16 00:00:00 UTC | Abbott Laboratories Q1 adjusted earnings Beat Estimates | ABT | https://www.nasdaq.com/articles/abbott-laboratories-q1-adjusted-earnings-beat-estimates-2020-04-16 | nan | nan | (RTTNews) - Abbott Laboratories (ABT) announced a profit for first quarter that dropped from last year.
The company's earnings came in at $564 million, or $0.31 per share. This compares with $672 million, or $0.38 per share, in last year's first quarter.
Excluding items, Abbott Laboratories reported adjusted earnings of $1.16 billion or $0.65 per share for the period.
Analysts had expected the company to earn $0.58 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 2.5% to $7.73 billion from $7.54 billion last year.
Abbott Laboratories earnings at a glance:
-Earnings (Q1): $1.16 Bln. vs. $1.13 Bln. last year. -EPS (Q1): $0.65 vs. $0.63 last year. -Analysts Estimate: $0.58 -Revenue (Q1): $7.73 Bln vs. $7.54 Bln last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) announced a profit for first quarter that dropped from last year. Excluding items, Abbott Laboratories reported adjusted earnings of $1.16 billion or $0.65 per share for the period. Analysts had expected the company to earn $0.58 per share, according to figures compiled by Thomson Reuters. | (RTTNews) - Abbott Laboratories (ABT) announced a profit for first quarter that dropped from last year. Excluding items, Abbott Laboratories reported adjusted earnings of $1.16 billion or $0.65 per share for the period. Analysts' estimates typically exclude special items. | (RTTNews) - Abbott Laboratories (ABT) announced a profit for first quarter that dropped from last year. Excluding items, Abbott Laboratories reported adjusted earnings of $1.16 billion or $0.65 per share for the period. The company's revenue for the quarter rose 2.5% to $7.73 billion from $7.54 billion last year. | (RTTNews) - Abbott Laboratories (ABT) announced a profit for first quarter that dropped from last year. The company's earnings came in at $564 million, or $0.31 per share. Abbott Laboratories earnings at a glance: -Earnings (Q1): $1.16 Bln. |
32706.0 | 2020-04-16 00:00:00 UTC | How Safe Are AbbVie Stock and Its Dividend? | ABT | https://www.nasdaq.com/articles/how-safe-are-abbvie-stock-and-its-dividend-2020-04-16 | nan | nan | Recent market volatility has unfairly whipsawed many stocks that are usually considered steady eddies, and the effects have been even stronger for specific sectors and speculative stocks. That said, some stocks were wildly overvalued when the market was hitting new highs not so long ago, and were ready for a correction.
Pharmaceutical maker AbbVie (NYSE: ABBV) has been caught in the downdraft, down 7% since the beginning of the year. The company pays a juicy 5.9% dividend. Which category does AbbVie fall into, and is the dividend safe?
When Humira and Botox got married
Spun off from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has grown annual revenue from $18.8 billion that year to $33.3 billion in 2019. The multipurpose drug Humira has been the main engine behind this growth; in fact, it's now the top-selling drug in the world.
Humira is a pretty big blockbuster, and the reason is its ability to block the body's inflammatory process. Like mutinous pirates, autoimmune disease causes your body's immune system to attack your own healthy cells by mistake. Any part of your body can be mistakenly attacked, resulting in conditions like lupus, Crohn's disease, rheumatoid arthritis, chronic plaque psoriasis, and other illnesses. Humira's versatility comes from its ability to block that inflammatory process, a central mechanism in autoimmune disease.
Image source: Getty Images.
But AbbVie has more going for it. In 2019, a deal was struck for AbbVie to acquire Allergan (NYSE: AGN), expanding the reach and scope of the company. The new AbbVie is expected to generate 40% of revenue from Humira and 60% from growth opportunities made possible by the integration of the two companies. The deal is expected to close in May.
Regarding the acquisition, AbbVie CEO Richard Gonzalez said:
You look at [the drugs] Skyrizi, Rinvoq, Venclexta, Imbruvica. Those all have significant growth opportunities ahead of them on the AbbVie side. And then you look at the Allergan side, you have Vraylar. This is a product that is about an $850 million product. I think the last numbers I saw showed it was growing about 70%.
Allergan also has a big presence in the growing aesthetics sector thanks to its ownership of Botox and CoolSculpting. Such elective procedures are being canceled or postponed during the coronavirus crisis, but the aesthetics sector should bounce back after the pandemic has passed.
AbbVie reported strong 2019 year-end results on Feb. 7. Net revenue of $33.3 billion increased 9.9% operationally year over year. Strong growth came from Imbruvica, which grossed sales of $4.7 billion, up 30% from the previous year.
AbbVie also reported adjusted earnings per share of $8.94, reflecting 13% year-over-year growth and beating the company's initial guidance midpoint by $0.24.
Guidance for 2020 reflects growth of 8.1% at the midpoint, with an EPS forecast between $9.61 and $9.71. Management expects to see revenue growth for 2020 approaching 8% on an operational basis. AbbVie will issue 2020 pro forma guidance following the close of the planned Allergan acquisition.
What this means for investors
The Allergan deal will help AbbVie diversify away from Humira, its major moneymaker. It already faces biosimilar competition in Europe, and will lose U.S. patent protection in 2023. In the U.S., Humira is still growing, but in Europe, sales are dropping as cheaper options become available.
AbbVie's management expects several financial benefits from the merger, including an immediate 10% increase to earnings per share over the first full year of the combination, cost reductions of at least $2 billion by year three, and operating cash flow estimated at $19 billion.
Regarding dividend safety, AbbVie said in a company announcement regarding the Allergan acquisition: "The combined company will produce robust cash flow which will support continued growth of our dividend, further investment in our pipeline, and reduction of debt. We intend to reduce debt levels by [$15 billion to] $18 billion by the end of 2021, with further deleveraging through 2023."
AbbVie has done well to position itself for the future, and the stock price should remain relatively strong through the coronavirus crisis, especially considering its price-to-earnings ratio of 15.1 versus the industry average P/E of 29.7. AbbVie looks like a safe stock to own.
A lot is riding on the finalization of the Allergan deal, but the likelihood of its going through is high at this point because all requirements have been met.
I think the dividend is safe for the short term even without the Allergan deal, but its conclusion will secure the payout for the long run. In fact, I think AbbVie is a buy at these levels, with an upside expected shortly after the Allergan deal closes. This is a very synergistic combination. I think Abbvie will deliver very nice returns for investors.
10 stocks we like better than Allergan
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Allergan wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Anne Burdakin owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | When Humira and Botox got married Spun off from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has grown annual revenue from $18.8 billion that year to $33.3 billion in 2019. Any part of your body can be mistakenly attacked, resulting in conditions like lupus, Crohn's disease, rheumatoid arthritis, chronic plaque psoriasis, and other illnesses. AbbVie also reported adjusted earnings per share of $8.94, reflecting 13% year-over-year growth and beating the company's initial guidance midpoint by $0.24. | When Humira and Botox got married Spun off from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has grown annual revenue from $18.8 billion that year to $33.3 billion in 2019. Net revenue of $33.3 billion increased 9.9% operationally year over year. AbbVie also reported adjusted earnings per share of $8.94, reflecting 13% year-over-year growth and beating the company's initial guidance midpoint by $0.24. | When Humira and Botox got married Spun off from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has grown annual revenue from $18.8 billion that year to $33.3 billion in 2019. AbbVie's management expects several financial benefits from the merger, including an immediate 10% increase to earnings per share over the first full year of the combination, cost reductions of at least $2 billion by year three, and operating cash flow estimated at $19 billion. Regarding dividend safety, AbbVie said in a company announcement regarding the Allergan acquisition: "The combined company will produce robust cash flow which will support continued growth of our dividend, further investment in our pipeline, and reduction of debt. | When Humira and Botox got married Spun off from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has grown annual revenue from $18.8 billion that year to $33.3 billion in 2019. But AbbVie has more going for it. The deal is expected to close in May. |
32707.0 | 2020-04-16 00:00:00 UTC | U.S. stock index futures gain ahead of earnings reports, jobless claims | ABT | https://www.nasdaq.com/articles/u.s.-stock-index-futures-gain-ahead-of-earnings-reports-jobless-claims-2020-04-16 | nan | nan | By Medha Singh
April 16 (Reuters) - U.S. stock index futures edged higher on Thursday, with investors weighing the prospects of the economy re-opening against worsening macroeconomic data and dour first-quarter earnings reports.
The S&P 500 .SPX recoiled from a four-week high on Wednesday as the big U.S. banks braced for a wave of potential loan defaults as the coronavirus crushed business activity.
On Thursday, BlackRock Inc BLK.N, the world's largest asset manager, reported a drop in quarterly profit as investors pulled money out of its marquee funds and preferred cash management services.
Medical equipment maker Abbott Laboratories Inc ABT.N and Morgan Stanley MS.N are scheduled to report quarterly results later in the day.
Focus will also be on weekly jobless claims, which are likely to have surged past 5 million last week, taking total unemployment claims to an astounding 20 million in the past month.
Meanwhile, President Donald Trump is expected to announce "new guidelines" for re-opening the economy as he said data suggested the United States had passed the peak on new coronavirus infections.
At 6:05 a.m. ET, Dow e-minis 1YMcv1 were up 53 points, or 0.23%. S&P 500 e-minis EScv1 were up 9.25 points, or 0.33% and Nasdaq 100 e-minis NQcv1 were up 55 points, or 0.64%.
SPDR S&P 500 ETFs .SPY rose 0.4%.
(Reporting by Medha Singh in Bengaluru; Editing by Arun Koyyur)
((Medha.Singh@thomsonreuters.com; within U.S. +1646 223 8780, outside U.S. +91 80 6749 1130; Twitter: https://twitter.com/medhasinghs))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medical equipment maker Abbott Laboratories Inc ABT.N and Morgan Stanley MS.N are scheduled to report quarterly results later in the day. By Medha Singh April 16 (Reuters) - U.S. stock index futures edged higher on Thursday, with investors weighing the prospects of the economy re-opening against worsening macroeconomic data and dour first-quarter earnings reports. The S&P 500 .SPX recoiled from a four-week high on Wednesday as the big U.S. banks braced for a wave of potential loan defaults as the coronavirus crushed business activity. | Medical equipment maker Abbott Laboratories Inc ABT.N and Morgan Stanley MS.N are scheduled to report quarterly results later in the day. Focus will also be on weekly jobless claims, which are likely to have surged past 5 million last week, taking total unemployment claims to an astounding 20 million in the past month. S&P 500 e-minis EScv1 were up 9.25 points, or 0.33% and Nasdaq 100 e-minis NQcv1 were up 55 points, or 0.64%. | Medical equipment maker Abbott Laboratories Inc ABT.N and Morgan Stanley MS.N are scheduled to report quarterly results later in the day. By Medha Singh April 16 (Reuters) - U.S. stock index futures edged higher on Thursday, with investors weighing the prospects of the economy re-opening against worsening macroeconomic data and dour first-quarter earnings reports. S&P 500 e-minis EScv1 were up 9.25 points, or 0.33% and Nasdaq 100 e-minis NQcv1 were up 55 points, or 0.64%. | Medical equipment maker Abbott Laboratories Inc ABT.N and Morgan Stanley MS.N are scheduled to report quarterly results later in the day. By Medha Singh April 16 (Reuters) - U.S. stock index futures edged higher on Thursday, with investors weighing the prospects of the economy re-opening against worsening macroeconomic data and dour first-quarter earnings reports. The S&P 500 .SPX recoiled from a four-week high on Wednesday as the big U.S. banks braced for a wave of potential loan defaults as the coronavirus crushed business activity. |
32708.0 | 2020-04-16 00:00:00 UTC | Abbott Laboratories Q1 20 Earnings Conference Call At 9:00 AM ET | ABT | https://www.nasdaq.com/articles/abbott-laboratories-q1-20-earnings-conference-call-at-9%3A00-am-et-2020-04-16 | nan | nan | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 16, 2020, to discuss Q1 20 earnings results.
To access the live webcast, log on to www.abbottinvestor.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 16, 2020, to discuss Q1 20 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 16, 2020, to discuss Q1 20 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 16, 2020, to discuss Q1 20 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 16, 2020, to discuss Q1 20 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
32709.0 | 2020-04-16 00:00:00 UTC | Wall St set for higher open on lockdown easing hopes, jobless claims | ABT | https://www.nasdaq.com/articles/wall-st-set-for-higher-open-on-lockdown-easing-hopes-jobless-claims-2020-04-16 | nan | nan | By Medha Singh and Akanksha Rana
April 16 (Reuters) - Wall Street was set to open higher on Thursday as weekly jobless claims fell slightly from the previous week and on hopes President Donald Trump would push to ease strict stay-at-home restrictions.
Latest data showed jobless claims fell slightly to 5.2 million last week from an upwardly revised 6.62 million the week before, but the total figure for the past month still topped 20 million as the outbreak crushed business activity.
"This is an awful number, but it is lower than the prior two weeks and I do believe we have peaked," said David Bahnsen, chief investment officer at Bahnsen Group in Newport Beach, California.
"What the market cannot price in perfectly is when the economy re-opens, what the nuances in that reopening will look like and what its impact will be to corporate profits one quarter, two quarters and a year away."
Trump is expected to announce "new guidelines" for re-opening the economy at a news conference on Thursday as he said data suggested the United States had passed the peak on new coronavirus infections.
After a 27% rally from its March lows, the S&P 500 index inched down this week and stands 18% below its record high, as first-quarter earnings began with U.S. banks preparing for a wave of future loan defaults following a halt in business activity.
Analysts estimate earnings for S&P 500 companies slumped 12.8% in the first quarter, with U.S. economic growth expected to have contracted at its fastest pace since World War Two.
"There is some potential for a rebound (in the economy) later this year and into next year, but the risks are still predominantly to the downside," said Scott Brown, chief economist at Raymond James in St. Petersburg, Florida.
On Thursday, BlackRock Inc BLK.N, the world's largest asset manager saw the capital it manages fall by almost $1 trillion in the quarter as investors pulled money out of its marquee funds.
Medical equipment maker Abbott Laboratories Inc ABT.N beat quarterly profit estimates, but suspended its full-year forecast due to uncertainty caused by the virus outbreak.
Morgan Stanley MS.N reported a 32% fall in quarterly profit as its advisory and wealth management businesses took a hit from the economic fallout of the pandemic. Its shares slipped 2.8%.
At 8:58 a.m. ET, Dow e-minis 1YMcv1 were up 93 points, or 0.4%, S&P 500 e-minis EScv1 were up 15 points, or 0.54% and Nasdaq 100 e-minis NQcv1 were up 87.25 points, or 1.02%.
Chipmakers Qualcomm Inc QCOM.O, Intel Corp INTC.O, Nvidia Corp NVDA.O and Advanced Micro Devices Inc AMD.O were up between 1.5% and 2.1% after the world's largest contract chipmaker Taiwan Semiconductor Manufacturing Co Ltd (TSMC) 2330.TW reported a near doubling in first-quarter net profit.
Netflix Inc NFLX.O rose 1.8% after multiple brokerages hiked their price targets on the stock expecting higher subscriber growth during the lockdown.
However, United Airlines Holdings Inc UAL.O slipped 2.9% as the carrier said it cut its flight schedule by 90% for May and warned travel demand now "essentially at zero shows no sign of improving in the near term", making job cuts likely.
(Reporting by Medha Singh and Akanksha Rana in Bengaluru; Editing by Sagarika Jaisinghani and Shounak Dasgupta)
((Medha.Singh@thomsonreuters.com; within U.S. +1646 223 8780, outside U.S. +91 80 6749 1130; Twitter: https://twitter.com/medhasinghs))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medical equipment maker Abbott Laboratories Inc ABT.N beat quarterly profit estimates, but suspended its full-year forecast due to uncertainty caused by the virus outbreak. Trump is expected to announce "new guidelines" for re-opening the economy at a news conference on Thursday as he said data suggested the United States had passed the peak on new coronavirus infections. After a 27% rally from its March lows, the S&P 500 index inched down this week and stands 18% below its record high, as first-quarter earnings began with U.S. banks preparing for a wave of future loan defaults following a halt in business activity. | Medical equipment maker Abbott Laboratories Inc ABT.N beat quarterly profit estimates, but suspended its full-year forecast due to uncertainty caused by the virus outbreak. By Medha Singh and Akanksha Rana April 16 (Reuters) - Wall Street was set to open higher on Thursday as weekly jobless claims fell slightly from the previous week and on hopes President Donald Trump would push to ease strict stay-at-home restrictions. Latest data showed jobless claims fell slightly to 5.2 million last week from an upwardly revised 6.62 million the week before, but the total figure for the past month still topped 20 million as the outbreak crushed business activity. | Medical equipment maker Abbott Laboratories Inc ABT.N beat quarterly profit estimates, but suspended its full-year forecast due to uncertainty caused by the virus outbreak. By Medha Singh and Akanksha Rana April 16 (Reuters) - Wall Street was set to open higher on Thursday as weekly jobless claims fell slightly from the previous week and on hopes President Donald Trump would push to ease strict stay-at-home restrictions. Latest data showed jobless claims fell slightly to 5.2 million last week from an upwardly revised 6.62 million the week before, but the total figure for the past month still topped 20 million as the outbreak crushed business activity. | Medical equipment maker Abbott Laboratories Inc ABT.N beat quarterly profit estimates, but suspended its full-year forecast due to uncertainty caused by the virus outbreak. By Medha Singh and Akanksha Rana April 16 (Reuters) - Wall Street was set to open higher on Thursday as weekly jobless claims fell slightly from the previous week and on hopes President Donald Trump would push to ease strict stay-at-home restrictions. "This is an awful number, but it is lower than the prior two weeks and I do believe we have peaked," said David Bahnsen, chief investment officer at Bahnsen Group in Newport Beach, California. |
32710.0 | 2020-04-15 00:00:00 UTC | Notable Wednesday Option Activity: T, ABT, BBBY | ABT | https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-t-abt-bbby-2020-04-15 | nan | nan | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AT&T Inc (Symbol: T), where a total volume of 349,678 contracts has been traded thus far today, a contract volume which is representative of approximately 35.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 59.1% of T's average daily trading volume over the past month, of 59.2 million shares. Especially high volume was seen for the $31 strike call option expiring April 17, 2020, with 109,180 contracts trading so far today, representing approximately 10.9 million underlying shares of T. Below is a chart showing T's trailing twelve month trading history, with the $31 strike highlighted in orange:
Abbott Laboratories (Symbol: ABT) saw options trading volume of 80,505 contracts, representing approximately 8.1 million underlying shares or approximately 58.5% of ABT's average daily trading volume over the past month, of 13.7 million shares. Especially high volume was seen for the $95 strike call option expiring April 17, 2020, with 6,318 contracts trading so far today, representing approximately 631,800 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $95 strike highlighted in orange:
And Bed, Bath & Beyond, Inc. (Symbol: BBBY) options are showing a volume of 68,127 contracts thus far today. That number of contracts represents approximately 6.8 million underlying shares, working out to a sizeable 55.3% of BBBY's average daily trading volume over the past month, of 12.3 million shares. Especially high volume was seen for the $5 strike call option expiring April 17, 2020, with 12,381 contracts trading so far today, representing approximately 1.2 million underlying shares of BBBY. Below is a chart showing BBBY's trailing twelve month trading history, with the $5 strike highlighted in orange:
For the various different available expirations for T options, ABT options, or BBBY options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $95 strike call option expiring April 17, 2020, with 6,318 contracts trading so far today, representing approximately 631,800 underlying shares of ABT. Especially high volume was seen for the $31 strike call option expiring April 17, 2020, with 109,180 contracts trading so far today, representing approximately 10.9 million underlying shares of T. Below is a chart showing T's trailing twelve month trading history, with the $31 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 80,505 contracts, representing approximately 8.1 million underlying shares or approximately 58.5% of ABT's average daily trading volume over the past month, of 13.7 million shares. Below is a chart showing ABT's trailing twelve month trading history, with the $95 strike highlighted in orange: And Bed, Bath & Beyond, Inc. (Symbol: BBBY) options are showing a volume of 68,127 contracts thus far today. | Especially high volume was seen for the $31 strike call option expiring April 17, 2020, with 109,180 contracts trading so far today, representing approximately 10.9 million underlying shares of T. Below is a chart showing T's trailing twelve month trading history, with the $31 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 80,505 contracts, representing approximately 8.1 million underlying shares or approximately 58.5% of ABT's average daily trading volume over the past month, of 13.7 million shares. Especially high volume was seen for the $95 strike call option expiring April 17, 2020, with 6,318 contracts trading so far today, representing approximately 631,800 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $95 strike highlighted in orange: And Bed, Bath & Beyond, Inc. (Symbol: BBBY) options are showing a volume of 68,127 contracts thus far today. | Especially high volume was seen for the $31 strike call option expiring April 17, 2020, with 109,180 contracts trading so far today, representing approximately 10.9 million underlying shares of T. Below is a chart showing T's trailing twelve month trading history, with the $31 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 80,505 contracts, representing approximately 8.1 million underlying shares or approximately 58.5% of ABT's average daily trading volume over the past month, of 13.7 million shares. Especially high volume was seen for the $95 strike call option expiring April 17, 2020, with 6,318 contracts trading so far today, representing approximately 631,800 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $95 strike highlighted in orange: And Bed, Bath & Beyond, Inc. (Symbol: BBBY) options are showing a volume of 68,127 contracts thus far today. | Especially high volume was seen for the $31 strike call option expiring April 17, 2020, with 109,180 contracts trading so far today, representing approximately 10.9 million underlying shares of T. Below is a chart showing T's trailing twelve month trading history, with the $31 strike highlighted in orange: Abbott Laboratories (Symbol: ABT) saw options trading volume of 80,505 contracts, representing approximately 8.1 million underlying shares or approximately 58.5% of ABT's average daily trading volume over the past month, of 13.7 million shares. Especially high volume was seen for the $95 strike call option expiring April 17, 2020, with 6,318 contracts trading so far today, representing approximately 631,800 underlying shares of ABT. Below is a chart showing ABT's trailing twelve month trading history, with the $95 strike highlighted in orange: And Bed, Bath & Beyond, Inc. (Symbol: BBBY) options are showing a volume of 68,127 contracts thus far today. |
32711.0 | 2020-04-15 00:00:00 UTC | Abbott Rolling Out a Coronavirus Antibody Test | ABT | https://www.nasdaq.com/articles/abbott-rolling-out-a-coronavirus-antibody-test-2020-04-15 | nan | nan | Abbott (NYSE: ABT) announced Wednesday it is launching a third test for SARS-CoV-2 -- and its first antibody test for the coronavirus.
Antibodies are blood proteins produced by the body in the latter stages of fighting an infection, and which bind to antigens -- molecules on the surface of alien substances, such as bacteria and viruses. Those antibodies can persist in the bloodstream for months or years following a person's recovery from an illness. Abbott's new product tests for the presence of a particular antibody, IgG, that is produced during a SARS-CoV-2 infection.
Image source: Getty Images.
Abbott's previous two tests were molecular; a positive result indicates that a person currently has the coronavirus. Antibody tests are different, as they can determine whether the patient was previously infected or otherwise exposed.
In addition to determining whether a person has been exposed to or infected by the coronavirus, the new test's results will aid researchers in determining how long it remains in the body, and whether those who have fought it off once develop an immunity from further infection.
The medical device and pharmaceutical company aims not only to roll out the new test quickly -- the first shipments should go out on Thursday -- but also with significant volume. It said its goal is to ship almost 1 million of them this week, and 4 million by the end of the month. Ultimately, it would like to ramp production up to 20 million in June and in future months.
This news helped lift Abbott shares by 1.5% in mid-afternoon trading Wednesday, in contrast to the wider stock market as reflected by the S&P 500, which was down by more than 2%.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (NYSE: ABT) announced Wednesday it is launching a third test for SARS-CoV-2 -- and its first antibody test for the coronavirus. Antibodies are blood proteins produced by the body in the latter stages of fighting an infection, and which bind to antigens -- molecules on the surface of alien substances, such as bacteria and viruses. The medical device and pharmaceutical company aims not only to roll out the new test quickly -- the first shipments should go out on Thursday -- but also with significant volume. | Abbott (NYSE: ABT) announced Wednesday it is launching a third test for SARS-CoV-2 -- and its first antibody test for the coronavirus. Abbott's previous two tests were molecular; a positive result indicates that a person currently has the coronavirus. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | Abbott (NYSE: ABT) announced Wednesday it is launching a third test for SARS-CoV-2 -- and its first antibody test for the coronavirus. In addition to determining whether a person has been exposed to or infected by the coronavirus, the new test's results will aid researchers in determining how long it remains in the body, and whether those who have fought it off once develop an immunity from further infection. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Abbott (NYSE: ABT) announced Wednesday it is launching a third test for SARS-CoV-2 -- and its first antibody test for the coronavirus. Abbott's new product tests for the presence of a particular antibody, IgG, that is produced during a SARS-CoV-2 infection. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. |
32712.0 | 2020-04-15 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-U.S. oil stocks, retailers, restaurants, BofA, J.C. Penny, IBM, Gilead, LyondellBasell | ABT | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-u.s.-oil-stocks-retailers-restaurants-bofa-j.c.-penny-ibm | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
The S&P 500 recoiled on Wednesday from a four-week high, as dire forecasts for the worst economic downturn since the Great Depression were strengthened by a crash in business activity and dismal first-quarter earnings reports. .N
At 12:45 ET, the Dow Jones Industrial Average .DJI was down 2.11% at 23,443.39. The S&P 500 .SPX was down 2.49% at 2,775.17 and the Nasdaq Composite .IXIC was down 1.74% at 8,367.315. The top three S&P 500 .PG.INX percentage gainers: ** Netflix Inc , up 4.4% ** UnitedHealth Group , up 4% ** Activision Blizzard Inc , up 3% The top three S&P 500 .PL.INX percentage losers: ** Noble Energy Inc , down 13.6% ** Helmerich & Payne Inc , down 13% ** PVH Corp , down 11.9% The top NYSE .PG.N percentage gainers: ** Manning & Napier Inc , up 21.8% The top NYSE .PL.N percentage losers: ** Chesapeake Energy , down 35.6% ** Pfenex Inc , down 30.1% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings Inc , up 1,435.1% ** Comstock Holding Companies Inc , up 111.9% ** ShiftPixy Inc , up 59.2% The top three Nasdaq .PL.O percentage losers: ** Medallion Bank , down 21.3% ** Lizhi Inc , down 18.2% ** 9F Inc , down 17.8% ** Wells Fargo & Co WFC.N : down 5.3%
BUZZ-Street View: Wells Fargo's losses manageable at this stage ** UnitedHealth Group UNH.N: up 4.0%
BUZZ-Rises on Q1 profit beat ** Goldman Sachs GS.N: down 0.5%
BUZZ-Goldman slips as profit halves on hit from loan loss provisions ** Aphria APHA.N: up 4.1%
BUZZ-Gains as co swings to quarterly profit ** Tesla TSLA.O: up 1.8%
BUZZ-Rises as China car registrations surge in March ** Bank of America Corp BAC.N: down 6.3%
BUZZ-BofA slips as profit nearly halves, loan loss provisions soar ** ToughBuilt Industries TBLT.O: down 5.0%
BUZZ-Plunges on reverse stock split ** J.C. Penny JCP.N: down 25.8%
BUZZ-Falls on report of co considering bankruptcy ** JB Hunt Transport JBHT.O: up 2.8%
BUZZ-Rises after revenue beats amid coronavirus-led disruption ** Chesapeake Energy CHK.N: down 35.6%
BUZZ-Credit Suisse cuts PT on reverse stock split, lowers outlook ** Applied DNA APDN.O: up 34.1%
BUZZ-Surges after co says mice will be tested with COVID-19 vaccines ** Noble Energy NBL.O: down 13.6%
BUZZ-Drops as liquidity needs prompt dividend cut ** Oragenics OGEN.A: down 46.1%
BUZZ-Plunges after drug for cancer therapy side-effect fails study ** Carnival Corp CCL.N: down 3.2%
BUZZ-Falls as virus-stricken cruise line drops anchor till July ** Lifeway Foods LWAY.O: up 21.3%
BUZZ-Gains on expectations for increased sales ** Citigroup C.N: down 3.9%
BUZZ-Falls as quarterly profit nearly halves ** Frontier Communications FTR.O: down 31.4%
BUZZ-Slumps after filing for bankruptcy protection ** Netflix InNFLX.O: up 4.4%
BUZZ-Hits record high as analysts see strong Q1 amid coronavirus outbreak ** Dick's Sporting Goods Inc DKS.N: down 1.7%
BUZZ-Drops after $500 mln liquidity boost ** Top Ships Inc TOPS.O: down 24.4%
BUZZ-Sinks on $6 mln direct offering ** Apple Inc AAPL.O: down 1.1%
BUZZ-Launches new budget iPhone ** Exxon Mobil Corp XOM.N: down 5.7% ** Chevron Corp CVX.N: down 4.9% ** Apache Corp APA.N: down 8.8% ** Whiting Petroleum CorpWLL.N: down 6.4% ** Marathon Oil Corp MRO.N: down 4.5% ** Hess Corp HES.N: down 10.6% ** Occidental Petroleum Corp OXY.N: down 11.3% ** Devon Energy DVN.N: down 9.4% ** Helmerich & Payne HP.N: down 13.0% ** Halliburton HAL.N: down 7.5% ** Schlumberger NV SLB.N: down 6.6% ** Cheaspeake Energy CHK.N: down 35.6%
BUZZ-Energy stocks lose ground as oil slides towards $28 a barrel ** International Business Corp IBM.N: down 4.8%
BUZZ-Brokerages cut PT on virus impact ** LyondellBasell Industries NV LYB.N: down 9.9%
BUZZ-LyondellBasell: Falls as Q1 expectations disappoint ** Howmet Aerospace Inc HWM.N: down 11.1%
BUZZ-Drops on scrapping outlook, dividend ** Chembio Diagnostics Inc CEMI.O: up 3.5%
BUZZ-Up after FDA approves emergency use of COVID-19 test ** Gilead Sciences Inc GILD.O: down 3.8%
BUZZ-Down on suspension of China remdesivir trial in COVID-19 patients ** Abbott Laboratories ABT.N: up 1.8%
BUZZ-Wells Fargo says 3rd COVID-19 test gives additional boost to diagnostics unit ** Nike Inc NKE.N: down 2.6% ** Under Armour Inc UAA.N: down 3.9% ** Gap Inc GPS.N: down 10.4% ** Guess Inc GES.N: down 6.9% ** Abercrombie & Fitch ANF.N: down 9.3% ** American Eagle AEO.N: down 10.9% ** Tapestry TPR.N: down 7.2% ** Capri Holdings CPRI.N: down 7.1% ** Ralph Lauren RL.N: down 8.8% ** Macy's M.N: down 7.3% ** Kohl's KSS.N: down 7.4% ** Nordstrom JWN.N: down 11.3% ** J.C. Penney JCP.N: down 25.8% ** Chipotle CMG.N: down 2.0% ** Starbucks SBUX.O: down 2.4% ** McDonald's MCD.N: down 3.1% ** Shake Shack SHAK.N: down 5.6%
BUZZ-Shares of U.S. retailers, restaurants dive on gloomy March sales data
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
down 1.13%
Consumer Discretionary
.SPLRCD
down 1.65%
Consumer Staples
.SPLRCS
down 1.65%
Energy
.SPNY
down 6.22%
Financial
.SPSY
down 4.10%
Health
.SPXHC
down 0.87%
Industrial
.SPLRCI
down 3.41%
Information Technology
.SPLRCT
down 2.02%
Materials
.SPLRCM
down 4.57%
Real Estate
.SPLRCR
down 3.67%
Utilities
.SPLRCU
down 2.95%
(Compiled by Shanti S Nair and Arundhati Sarkar in Bengaluru)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Netflix Inc , up 4.4% ** UnitedHealth Group , up 4% ** Activision Blizzard Inc , up 3% The top three S&P 500 .PL.INX percentage losers: ** Noble Energy Inc , down 13.6% ** Helmerich & Payne Inc , down 13% ** PVH Corp , down 11.9% The top NYSE .PG.N percentage gainers: ** Manning & Napier Inc , up 21.8% The top NYSE .PL.N percentage losers: ** Chesapeake Energy , down 35.6% ** Pfenex Inc , down 30.1% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings Inc , up 1,435.1% ** Comstock Holding Companies Inc , up 111.9% ** ShiftPixy Inc , up 59.2% The top three Nasdaq .PL.O percentage losers: ** Medallion Bank , down 21.3% ** Lizhi Inc , down 18.2% ** 9F Inc , down 17.8% ** Wells Fargo & Co WFC.N : down 5.3% BUZZ-Street View: Wells Fargo's losses manageable at this stage ** UnitedHealth Group UNH.N: up 4.0% BUZZ-Rises on Q1 profit beat ** Goldman Sachs GS.N: down 0.5% BUZZ-Goldman slips as profit halves on hit from loan loss provisions ** Aphria APHA.N: up 4.1% BUZZ-Gains as co swings to quarterly profit ** Tesla TSLA.O: up 1.8% BUZZ-Rises as China car registrations surge in March ** Bank of America Corp BAC.N: down 6.3% BUZZ-BofA slips as profit nearly halves, loan loss provisions soar ** ToughBuilt Industries TBLT.O: down 5.0% BUZZ-Plunges on reverse stock split ** J.C. Penny JCP.N: down 25.8% BUZZ-Falls on report of co considering bankruptcy ** JB Hunt Transport JBHT.O: up 2.8% BUZZ-Rises after revenue beats amid coronavirus-led disruption ** Chesapeake Energy CHK.N: down 35.6% BUZZ-Credit Suisse cuts PT on reverse stock split, lowers outlook ** Applied DNA APDN.O: up 34.1% BUZZ-Surges after co says mice will be tested with COVID-19 vaccines ** Noble Energy NBL.O: down 13.6% BUZZ-Drops as liquidity needs prompt dividend cut ** Oragenics OGEN.A: down 46.1% BUZZ-Plunges after drug for cancer therapy side-effect fails study ** Carnival Corp CCL.N: down 3.2% BUZZ-Falls as virus-stricken cruise line drops anchor till July ** Lifeway Foods LWAY.O: up 21.3% BUZZ-Gains on expectations for increased sales ** Citigroup C.N: down 3.9% BUZZ-Falls as quarterly profit nearly halves ** Frontier Communications FTR.O: down 31.4% BUZZ-Slumps after filing for bankruptcy protection ** Netflix InNFLX.O: up 4.4% BUZZ-Hits record high as analysts see strong Q1 amid coronavirus outbreak ** Dick's Sporting Goods Inc DKS.N: down 1.7% BUZZ-Drops after $500 mln liquidity boost ** Top Ships Inc TOPS.O: down 24.4% BUZZ-Sinks on $6 mln direct offering ** Apple Inc AAPL.O: down 1.1% BUZZ-Launches new budget iPhone ** Exxon Mobil Corp XOM.N: down 5.7% ** Chevron Corp CVX.N: down 4.9% ** Apache Corp APA.N: down 8.8% ** Whiting Petroleum CorpWLL.N: down 6.4% ** Marathon Oil Corp MRO.N: down 4.5% ** Hess Corp HES.N: down 10.6% ** Occidental Petroleum Corp OXY.N: down 11.3% ** Devon Energy DVN.N: down 9.4% ** Helmerich & Payne HP.N: down 13.0% ** Halliburton HAL.N: down 7.5% ** Schlumberger NV SLB.N: down 6.6% ** Cheaspeake Energy CHK.N: down 35.6% BUZZ-Energy stocks lose ground as oil slides towards $28 a barrel ** International Business Corp IBM.N: down 4.8% BUZZ-Brokerages cut PT on virus impact ** LyondellBasell Industries NV LYB.N: down 9.9% BUZZ-LyondellBasell: Falls as Q1 expectations disappoint ** Howmet Aerospace Inc HWM.N: down 11.1% BUZZ-Drops on scrapping outlook, dividend ** Chembio Diagnostics Inc CEMI.O: up 3.5% BUZZ-Up after FDA approves emergency use of COVID-19 test ** Gilead Sciences Inc GILD.O: down 3.8% BUZZ-Down on suspension of China remdesivir trial in COVID-19 patients ** Abbott Laboratories ABT.N: up 1.8% BUZZ-Wells Fargo says 3rd COVID-19 test gives additional boost to diagnostics unit ** Nike Inc NKE.N: down 2.6% ** Under Armour Inc UAA.N: down 3.9% ** Gap Inc GPS.N: down 10.4% ** Guess Inc GES.N: down 6.9% ** Abercrombie & Fitch ANF.N: down 9.3% ** American Eagle AEO.N: down 10.9% ** Tapestry TPR.N: down 7.2% ** Capri Holdings CPRI.N: down 7.1% ** Ralph Lauren RL.N: down 8.8% ** Macy's M.N: down 7.3% ** Kohl's KSS.N: down 7.4% ** Nordstrom JWN.N: down 11.3% ** J.C. Penney JCP.N: down 25.8% ** Chipotle CMG.N: down 2.0% ** Starbucks SBUX.O: down 2.4% ** McDonald's MCD.N: down 3.1% ** Shake Shack SHAK.N: down 5.6% BUZZ-Shares of U.S. retailers, restaurants dive on gloomy March sales data The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 recoiled on Wednesday from a four-week high, as dire forecasts for the worst economic downturn since the Great Depression were strengthened by a crash in business activity and dismal first-quarter earnings reports. down 2.95% (Compiled by Shanti S Nair and Arundhati Sarkar in Bengaluru) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Netflix Inc , up 4.4% ** UnitedHealth Group , up 4% ** Activision Blizzard Inc , up 3% The top three S&P 500 .PL.INX percentage losers: ** Noble Energy Inc , down 13.6% ** Helmerich & Payne Inc , down 13% ** PVH Corp , down 11.9% The top NYSE .PG.N percentage gainers: ** Manning & Napier Inc , up 21.8% The top NYSE .PL.N percentage losers: ** Chesapeake Energy , down 35.6% ** Pfenex Inc , down 30.1% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings Inc , up 1,435.1% ** Comstock Holding Companies Inc , up 111.9% ** ShiftPixy Inc , up 59.2% The top three Nasdaq .PL.O percentage losers: ** Medallion Bank , down 21.3% ** Lizhi Inc , down 18.2% ** 9F Inc , down 17.8% ** Wells Fargo & Co WFC.N : down 5.3% BUZZ-Street View: Wells Fargo's losses manageable at this stage ** UnitedHealth Group UNH.N: up 4.0% BUZZ-Rises on Q1 profit beat ** Goldman Sachs GS.N: down 0.5% BUZZ-Goldman slips as profit halves on hit from loan loss provisions ** Aphria APHA.N: up 4.1% BUZZ-Gains as co swings to quarterly profit ** Tesla TSLA.O: up 1.8% BUZZ-Rises as China car registrations surge in March ** Bank of America Corp BAC.N: down 6.3% BUZZ-BofA slips as profit nearly halves, loan loss provisions soar ** ToughBuilt Industries TBLT.O: down 5.0% BUZZ-Plunges on reverse stock split ** J.C. Penny JCP.N: down 25.8% BUZZ-Falls on report of co considering bankruptcy ** JB Hunt Transport JBHT.O: up 2.8% BUZZ-Rises after revenue beats amid coronavirus-led disruption ** Chesapeake Energy CHK.N: down 35.6% BUZZ-Credit Suisse cuts PT on reverse stock split, lowers outlook ** Applied DNA APDN.O: up 34.1% BUZZ-Surges after co says mice will be tested with COVID-19 vaccines ** Noble Energy NBL.O: down 13.6% BUZZ-Drops as liquidity needs prompt dividend cut ** Oragenics OGEN.A: down 46.1% BUZZ-Plunges after drug for cancer therapy side-effect fails study ** Carnival Corp CCL.N: down 3.2% BUZZ-Falls as virus-stricken cruise line drops anchor till July ** Lifeway Foods LWAY.O: up 21.3% BUZZ-Gains on expectations for increased sales ** Citigroup C.N: down 3.9% BUZZ-Falls as quarterly profit nearly halves ** Frontier Communications FTR.O: down 31.4% BUZZ-Slumps after filing for bankruptcy protection ** Netflix InNFLX.O: up 4.4% BUZZ-Hits record high as analysts see strong Q1 amid coronavirus outbreak ** Dick's Sporting Goods Inc DKS.N: down 1.7% BUZZ-Drops after $500 mln liquidity boost ** Top Ships Inc TOPS.O: down 24.4% BUZZ-Sinks on $6 mln direct offering ** Apple Inc AAPL.O: down 1.1% BUZZ-Launches new budget iPhone ** Exxon Mobil Corp XOM.N: down 5.7% ** Chevron Corp CVX.N: down 4.9% ** Apache Corp APA.N: down 8.8% ** Whiting Petroleum CorpWLL.N: down 6.4% ** Marathon Oil Corp MRO.N: down 4.5% ** Hess Corp HES.N: down 10.6% ** Occidental Petroleum Corp OXY.N: down 11.3% ** Devon Energy DVN.N: down 9.4% ** Helmerich & Payne HP.N: down 13.0% ** Halliburton HAL.N: down 7.5% ** Schlumberger NV SLB.N: down 6.6% ** Cheaspeake Energy CHK.N: down 35.6% BUZZ-Energy stocks lose ground as oil slides towards $28 a barrel ** International Business Corp IBM.N: down 4.8% BUZZ-Brokerages cut PT on virus impact ** LyondellBasell Industries NV LYB.N: down 9.9% BUZZ-LyondellBasell: Falls as Q1 expectations disappoint ** Howmet Aerospace Inc HWM.N: down 11.1% BUZZ-Drops on scrapping outlook, dividend ** Chembio Diagnostics Inc CEMI.O: up 3.5% BUZZ-Up after FDA approves emergency use of COVID-19 test ** Gilead Sciences Inc GILD.O: down 3.8% BUZZ-Down on suspension of China remdesivir trial in COVID-19 patients ** Abbott Laboratories ABT.N: up 1.8% BUZZ-Wells Fargo says 3rd COVID-19 test gives additional boost to diagnostics unit ** Nike Inc NKE.N: down 2.6% ** Under Armour Inc UAA.N: down 3.9% ** Gap Inc GPS.N: down 10.4% ** Guess Inc GES.N: down 6.9% ** Abercrombie & Fitch ANF.N: down 9.3% ** American Eagle AEO.N: down 10.9% ** Tapestry TPR.N: down 7.2% ** Capri Holdings CPRI.N: down 7.1% ** Ralph Lauren RL.N: down 8.8% ** Macy's M.N: down 7.3% ** Kohl's KSS.N: down 7.4% ** Nordstrom JWN.N: down 11.3% ** J.C. Penney JCP.N: down 25.8% ** Chipotle CMG.N: down 2.0% ** Starbucks SBUX.O: down 2.4% ** McDonald's MCD.N: down 3.1% ** Shake Shack SHAK.N: down 5.6% BUZZ-Shares of U.S. retailers, restaurants dive on gloomy March sales data The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 recoiled on Wednesday from a four-week high, as dire forecasts for the worst economic downturn since the Great Depression were strengthened by a crash in business activity and dismal first-quarter earnings reports. down 2.95% (Compiled by Shanti S Nair and Arundhati Sarkar in Bengaluru) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Netflix Inc , up 4.4% ** UnitedHealth Group , up 4% ** Activision Blizzard Inc , up 3% The top three S&P 500 .PL.INX percentage losers: ** Noble Energy Inc , down 13.6% ** Helmerich & Payne Inc , down 13% ** PVH Corp , down 11.9% The top NYSE .PG.N percentage gainers: ** Manning & Napier Inc , up 21.8% The top NYSE .PL.N percentage losers: ** Chesapeake Energy , down 35.6% ** Pfenex Inc , down 30.1% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings Inc , up 1,435.1% ** Comstock Holding Companies Inc , up 111.9% ** ShiftPixy Inc , up 59.2% The top three Nasdaq .PL.O percentage losers: ** Medallion Bank , down 21.3% ** Lizhi Inc , down 18.2% ** 9F Inc , down 17.8% ** Wells Fargo & Co WFC.N : down 5.3% BUZZ-Street View: Wells Fargo's losses manageable at this stage ** UnitedHealth Group UNH.N: up 4.0% BUZZ-Rises on Q1 profit beat ** Goldman Sachs GS.N: down 0.5% BUZZ-Goldman slips as profit halves on hit from loan loss provisions ** Aphria APHA.N: up 4.1% BUZZ-Gains as co swings to quarterly profit ** Tesla TSLA.O: up 1.8% BUZZ-Rises as China car registrations surge in March ** Bank of America Corp BAC.N: down 6.3% BUZZ-BofA slips as profit nearly halves, loan loss provisions soar ** ToughBuilt Industries TBLT.O: down 5.0% BUZZ-Plunges on reverse stock split ** J.C. Penny JCP.N: down 25.8% BUZZ-Falls on report of co considering bankruptcy ** JB Hunt Transport JBHT.O: up 2.8% BUZZ-Rises after revenue beats amid coronavirus-led disruption ** Chesapeake Energy CHK.N: down 35.6% BUZZ-Credit Suisse cuts PT on reverse stock split, lowers outlook ** Applied DNA APDN.O: up 34.1% BUZZ-Surges after co says mice will be tested with COVID-19 vaccines ** Noble Energy NBL.O: down 13.6% BUZZ-Drops as liquidity needs prompt dividend cut ** Oragenics OGEN.A: down 46.1% BUZZ-Plunges after drug for cancer therapy side-effect fails study ** Carnival Corp CCL.N: down 3.2% BUZZ-Falls as virus-stricken cruise line drops anchor till July ** Lifeway Foods LWAY.O: up 21.3% BUZZ-Gains on expectations for increased sales ** Citigroup C.N: down 3.9% BUZZ-Falls as quarterly profit nearly halves ** Frontier Communications FTR.O: down 31.4% BUZZ-Slumps after filing for bankruptcy protection ** Netflix InNFLX.O: up 4.4% BUZZ-Hits record high as analysts see strong Q1 amid coronavirus outbreak ** Dick's Sporting Goods Inc DKS.N: down 1.7% BUZZ-Drops after $500 mln liquidity boost ** Top Ships Inc TOPS.O: down 24.4% BUZZ-Sinks on $6 mln direct offering ** Apple Inc AAPL.O: down 1.1% BUZZ-Launches new budget iPhone ** Exxon Mobil Corp XOM.N: down 5.7% ** Chevron Corp CVX.N: down 4.9% ** Apache Corp APA.N: down 8.8% ** Whiting Petroleum CorpWLL.N: down 6.4% ** Marathon Oil Corp MRO.N: down 4.5% ** Hess Corp HES.N: down 10.6% ** Occidental Petroleum Corp OXY.N: down 11.3% ** Devon Energy DVN.N: down 9.4% ** Helmerich & Payne HP.N: down 13.0% ** Halliburton HAL.N: down 7.5% ** Schlumberger NV SLB.N: down 6.6% ** Cheaspeake Energy CHK.N: down 35.6% BUZZ-Energy stocks lose ground as oil slides towards $28 a barrel ** International Business Corp IBM.N: down 4.8% BUZZ-Brokerages cut PT on virus impact ** LyondellBasell Industries NV LYB.N: down 9.9% BUZZ-LyondellBasell: Falls as Q1 expectations disappoint ** Howmet Aerospace Inc HWM.N: down 11.1% BUZZ-Drops on scrapping outlook, dividend ** Chembio Diagnostics Inc CEMI.O: up 3.5% BUZZ-Up after FDA approves emergency use of COVID-19 test ** Gilead Sciences Inc GILD.O: down 3.8% BUZZ-Down on suspension of China remdesivir trial in COVID-19 patients ** Abbott Laboratories ABT.N: up 1.8% BUZZ-Wells Fargo says 3rd COVID-19 test gives additional boost to diagnostics unit ** Nike Inc NKE.N: down 2.6% ** Under Armour Inc UAA.N: down 3.9% ** Gap Inc GPS.N: down 10.4% ** Guess Inc GES.N: down 6.9% ** Abercrombie & Fitch ANF.N: down 9.3% ** American Eagle AEO.N: down 10.9% ** Tapestry TPR.N: down 7.2% ** Capri Holdings CPRI.N: down 7.1% ** Ralph Lauren RL.N: down 8.8% ** Macy's M.N: down 7.3% ** Kohl's KSS.N: down 7.4% ** Nordstrom JWN.N: down 11.3% ** J.C. Penney JCP.N: down 25.8% ** Chipotle CMG.N: down 2.0% ** Starbucks SBUX.O: down 2.4% ** McDonald's MCD.N: down 3.1% ** Shake Shack SHAK.N: down 5.6% BUZZ-Shares of U.S. retailers, restaurants dive on gloomy March sales data The 11 major S&P 500 sectors: Communication Services down 1.13% Consumer Discretionary down 1.65% Consumer Staples | The top three S&P 500 .PG.INX percentage gainers: ** Netflix Inc , up 4.4% ** UnitedHealth Group , up 4% ** Activision Blizzard Inc , up 3% The top three S&P 500 .PL.INX percentage losers: ** Noble Energy Inc , down 13.6% ** Helmerich & Payne Inc , down 13% ** PVH Corp , down 11.9% The top NYSE .PG.N percentage gainers: ** Manning & Napier Inc , up 21.8% The top NYSE .PL.N percentage losers: ** Chesapeake Energy , down 35.6% ** Pfenex Inc , down 30.1% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings Inc , up 1,435.1% ** Comstock Holding Companies Inc , up 111.9% ** ShiftPixy Inc , up 59.2% The top three Nasdaq .PL.O percentage losers: ** Medallion Bank , down 21.3% ** Lizhi Inc , down 18.2% ** 9F Inc , down 17.8% ** Wells Fargo & Co WFC.N : down 5.3% BUZZ-Street View: Wells Fargo's losses manageable at this stage ** UnitedHealth Group UNH.N: up 4.0% BUZZ-Rises on Q1 profit beat ** Goldman Sachs GS.N: down 0.5% BUZZ-Goldman slips as profit halves on hit from loan loss provisions ** Aphria APHA.N: up 4.1% BUZZ-Gains as co swings to quarterly profit ** Tesla TSLA.O: up 1.8% BUZZ-Rises as China car registrations surge in March ** Bank of America Corp BAC.N: down 6.3% BUZZ-BofA slips as profit nearly halves, loan loss provisions soar ** ToughBuilt Industries TBLT.O: down 5.0% BUZZ-Plunges on reverse stock split ** J.C. Penny JCP.N: down 25.8% BUZZ-Falls on report of co considering bankruptcy ** JB Hunt Transport JBHT.O: up 2.8% BUZZ-Rises after revenue beats amid coronavirus-led disruption ** Chesapeake Energy CHK.N: down 35.6% BUZZ-Credit Suisse cuts PT on reverse stock split, lowers outlook ** Applied DNA APDN.O: up 34.1% BUZZ-Surges after co says mice will be tested with COVID-19 vaccines ** Noble Energy NBL.O: down 13.6% BUZZ-Drops as liquidity needs prompt dividend cut ** Oragenics OGEN.A: down 46.1% BUZZ-Plunges after drug for cancer therapy side-effect fails study ** Carnival Corp CCL.N: down 3.2% BUZZ-Falls as virus-stricken cruise line drops anchor till July ** Lifeway Foods LWAY.O: up 21.3% BUZZ-Gains on expectations for increased sales ** Citigroup C.N: down 3.9% BUZZ-Falls as quarterly profit nearly halves ** Frontier Communications FTR.O: down 31.4% BUZZ-Slumps after filing for bankruptcy protection ** Netflix InNFLX.O: up 4.4% BUZZ-Hits record high as analysts see strong Q1 amid coronavirus outbreak ** Dick's Sporting Goods Inc DKS.N: down 1.7% BUZZ-Drops after $500 mln liquidity boost ** Top Ships Inc TOPS.O: down 24.4% BUZZ-Sinks on $6 mln direct offering ** Apple Inc AAPL.O: down 1.1% BUZZ-Launches new budget iPhone ** Exxon Mobil Corp XOM.N: down 5.7% ** Chevron Corp CVX.N: down 4.9% ** Apache Corp APA.N: down 8.8% ** Whiting Petroleum CorpWLL.N: down 6.4% ** Marathon Oil Corp MRO.N: down 4.5% ** Hess Corp HES.N: down 10.6% ** Occidental Petroleum Corp OXY.N: down 11.3% ** Devon Energy DVN.N: down 9.4% ** Helmerich & Payne HP.N: down 13.0% ** Halliburton HAL.N: down 7.5% ** Schlumberger NV SLB.N: down 6.6% ** Cheaspeake Energy CHK.N: down 35.6% BUZZ-Energy stocks lose ground as oil slides towards $28 a barrel ** International Business Corp IBM.N: down 4.8% BUZZ-Brokerages cut PT on virus impact ** LyondellBasell Industries NV LYB.N: down 9.9% BUZZ-LyondellBasell: Falls as Q1 expectations disappoint ** Howmet Aerospace Inc HWM.N: down 11.1% BUZZ-Drops on scrapping outlook, dividend ** Chembio Diagnostics Inc CEMI.O: up 3.5% BUZZ-Up after FDA approves emergency use of COVID-19 test ** Gilead Sciences Inc GILD.O: down 3.8% BUZZ-Down on suspension of China remdesivir trial in COVID-19 patients ** Abbott Laboratories ABT.N: up 1.8% BUZZ-Wells Fargo says 3rd COVID-19 test gives additional boost to diagnostics unit ** Nike Inc NKE.N: down 2.6% ** Under Armour Inc UAA.N: down 3.9% ** Gap Inc GPS.N: down 10.4% ** Guess Inc GES.N: down 6.9% ** Abercrombie & Fitch ANF.N: down 9.3% ** American Eagle AEO.N: down 10.9% ** Tapestry TPR.N: down 7.2% ** Capri Holdings CPRI.N: down 7.1% ** Ralph Lauren RL.N: down 8.8% ** Macy's M.N: down 7.3% ** Kohl's KSS.N: down 7.4% ** Nordstrom JWN.N: down 11.3% ** J.C. Penney JCP.N: down 25.8% ** Chipotle CMG.N: down 2.0% ** Starbucks SBUX.O: down 2.4% ** McDonald's MCD.N: down 3.1% ** Shake Shack SHAK.N: down 5.6% BUZZ-Shares of U.S. retailers, restaurants dive on gloomy March sales data The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 recoiled on Wednesday from a four-week high, as dire forecasts for the worst economic downturn since the Great Depression were strengthened by a crash in business activity and dismal first-quarter earnings reports. .N At 12:45 ET, the Dow Jones Industrial Average .DJI was down 2.11% at 23,443.39. |
32713.0 | 2020-04-15 00:00:00 UTC | BUZZ-U.S. STOCKS ON THE MOVE-Netflix, Wells Fargo, Tesla, BofA, J.C. Penny, Noble Energy | ABT | https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-netflix-wells-fargo-tesla-bofa-j.c.-penny-noble-energy-2020 | nan | nan | Eikon search string for individual stock moves: STXBZ
The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi
The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh
Wall Street's main indexes slid 2% on Wednesday, as a record drop in retail sales and dour first-quarter earnings reports lent weight to forecasts for the biggest economic slump since the Great Depression. .N
At 11:12 a.m. ET, the Dow Jones Industrial Average .DJI was down 2.66% at 23,312.97. The S&P 500 .SPX was down 2.43% at 2,776.81 and the Nasdaq Composite .IXIC was down 1.54% at 8,384.365. The top three S&P 500 .PG.INX percentage gainers: ** Netflix Inc , up 3.6% ** Abbott Labs , up 2.6% ** Nortonlifelock Inc , up 2% The top three S&P 500 .PL.INX percentage losers: ** Noble Energy Inc , down 16% ** PVH Corp , down 14.1% ** Helmerich Payne , down 13.5% The top three NYSE .PL.N percentage losers: ** Chesapeake Energy , down 39.7% ** Independence Contract Drilling , down 29.1% ** Pfenex Inc , down 24% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings Inc , up 205.3% ** Comstock Holding Companies Inc , up 168.1% ** Shiftpixy Inc , up 67.9% The top three Nasdaq .PL.O percentage losers: ** Summit Wireless Technologies Inc , down 21.3% ** Penn Virgin Corp , down 19.4% ** 9F Inc , down 18.5% ** Wells Fargo & Co WFC.N : down 6.1%
BUZZ-Street View: Wells Fargo's losses manageable at this stage ** UnitedHealth Group UNH.N: up 1.6%
BUZZ-Rises on Q1 profit beat ** Goldman Sachs GS.N: down 0.8%
BUZZ-Goldman slips as profit halves on hit from loan loss provisions ** Aphria APHA.N: up 5.2%
BUZZ-Gains as co swings to quarterly profit ** Tesla TSLA.O: up 3.7%
BUZZ-Rises as China car registrations surge in March ** Bank of America Corp BAC.N: down 6.4%
BUZZ-BofA slips as profit nearly halves, loan loss provisions soar ** ToughBuilt Industries TBLT.O: down 9.1%
BUZZ-Plunges on reverse stock split ** J.C. Penny JCP.N: down 27.8%
BUZZ-Falls on report of co considering bankruptcy ** JB Hunt Transport JBHT.O: up 1.8%
BUZZ-Rises after revenue beats amid coronavirus-led disruption ** Chesapeake Energy CHK.N: down 39.7%
BUZZ-Credit Suisse cuts PT on reverse stock split, lowers outlook ** Applied DNA APDN.O: up 40.5%
BUZZ-Surges after co says mice will be tested with COVID-19 vaccines ** Noble Energy NBL.O: down 15.9%
BUZZ-Drops as liquidity needs prompt dividend cut ** Oragenics OGEN.A: down 45.0%
BUZZ-Plunges after drug for cancer therapy side-effect fails study ** Carnival Corp CCL.N : down 6.6%
BUZZ-Falls as virus-stricken cruise line drops anchor till July ** Lifeway Foods LWAY.O: up 22.4%
BUZZ-Gains on expectations for increased sales ** Citigroup C.N: down 3.5%
BUZZ-Citigroup: Falls as quarterly profit nearly halves ** Frontier Communications FTR.O: down 31.4%
BUZZ-Frontier Communications: Slumps after filing for bankruptcy protection ** Netflix InNFLX.O: up 3.6%
BUZZ-Hits record high as analysts see strong Q1 amid coronavirus outbreak
The 11 major S&P 500 sectors:
Communication Services
.SPLRCL
down 1.56%
Consumer Discretionary
.SPLRCD
down 2.22%
Consumer Staples
.SPLRCS
down 1.85%
Energy
.SPNY
down 7.28%
Financial
.SPSY
down 4.32%
Health
.SPXHC
down 1.37%
Industrial
.SPLRCI
down 4.04%
Information Technology
.SPLRCT
down 1.92%
Materials
.SPLRCM
down 4.50%
Real Estate
.SPLRCR
down 3.97%
Utilities
.SPLRCU
down 3.46%
(Compiled by Shanti S Nair and Arundhati Sarkar in Bengaluru)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes slid 2% on Wednesday, as a record drop in retail sales and dour first-quarter earnings reports lent weight to forecasts for the biggest economic slump since the Great Depression. The top three S&P 500 .PG.INX percentage gainers: ** Netflix Inc , up 3.6% ** Abbott Labs , up 2.6% ** Nortonlifelock Inc , up 2% The top three S&P 500 .PL.INX percentage losers: ** Noble Energy Inc , down 16% ** PVH Corp , down 14.1% ** Helmerich Payne , down 13.5% The top three NYSE .PL.N percentage losers: ** Chesapeake Energy , down 39.7% ** Independence Contract Drilling , down 29.1% ** Pfenex Inc , down 24% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings Inc , up 205.3% ** Comstock Holding Companies Inc , up 168.1% ** Shiftpixy Inc , up 67.9% The top three Nasdaq .PL.O percentage losers: ** Summit Wireless Technologies Inc , down 21.3% ** Penn Virgin Corp , down 19.4% ** 9F Inc , down 18.5% ** Wells Fargo & Co WFC.N : down 6.1% BUZZ-Street View: Wells Fargo's losses manageable at this stage ** UnitedHealth Group UNH.N: up 1.6% BUZZ-Rises on Q1 profit beat ** Goldman Sachs GS.N: down 0.8% BUZZ-Goldman slips as profit halves on hit from loan loss provisions ** Aphria APHA.N: up 5.2% BUZZ-Gains as co swings to quarterly profit ** Tesla TSLA.O: up 3.7% BUZZ-Rises as China car registrations surge in March ** Bank of America Corp BAC.N: down 6.4% BUZZ-BofA slips as profit nearly halves, loan loss provisions soar ** ToughBuilt Industries TBLT.O: down 9.1% BUZZ-Plunges on reverse stock split ** J.C. Penny JCP.N: down 27.8% BUZZ-Falls on report of co considering bankruptcy ** JB Hunt Transport JBHT.O: up 1.8% BUZZ-Rises after revenue beats amid coronavirus-led disruption ** Chesapeake Energy CHK.N: down 39.7% BUZZ-Credit Suisse cuts PT on reverse stock split, lowers outlook ** Applied DNA APDN.O: up 40.5% BUZZ-Surges after co says mice will be tested with COVID-19 vaccines ** Noble Energy NBL.O: down 15.9% BUZZ-Drops as liquidity needs prompt dividend cut ** Oragenics OGEN.A: down 45.0% BUZZ-Plunges after drug for cancer therapy side-effect fails study ** Carnival Corp CCL.N : down 6.6% BUZZ-Falls as virus-stricken cruise line drops anchor till July ** Lifeway Foods LWAY.O: up 22.4% BUZZ-Gains on expectations for increased sales ** Citigroup C.N: down 3.5% BUZZ-Citigroup: Falls as quarterly profit nearly halves ** Frontier Communications FTR.O: down 31.4% BUZZ-Frontier Communications: Slumps after filing for bankruptcy protection ** Netflix InNFLX.O: up 3.6% BUZZ-Hits record high as analysts see strong Q1 amid coronavirus outbreak The 11 major S&P 500 sectors: Communication Services down 3.46% (Compiled by Shanti S Nair and Arundhati Sarkar in Bengaluru) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes slid 2% on Wednesday, as a record drop in retail sales and dour first-quarter earnings reports lent weight to forecasts for the biggest economic slump since the Great Depression. The top three S&P 500 .PG.INX percentage gainers: ** Netflix Inc , up 3.6% ** Abbott Labs , up 2.6% ** Nortonlifelock Inc , up 2% The top three S&P 500 .PL.INX percentage losers: ** Noble Energy Inc , down 16% ** PVH Corp , down 14.1% ** Helmerich Payne , down 13.5% The top three NYSE .PL.N percentage losers: ** Chesapeake Energy , down 39.7% ** Independence Contract Drilling , down 29.1% ** Pfenex Inc , down 24% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings Inc , up 205.3% ** Comstock Holding Companies Inc , up 168.1% ** Shiftpixy Inc , up 67.9% The top three Nasdaq .PL.O percentage losers: ** Summit Wireless Technologies Inc , down 21.3% ** Penn Virgin Corp , down 19.4% ** 9F Inc , down 18.5% ** Wells Fargo & Co WFC.N : down 6.1% BUZZ-Street View: Wells Fargo's losses manageable at this stage ** UnitedHealth Group UNH.N: up 1.6% BUZZ-Rises on Q1 profit beat ** Goldman Sachs GS.N: down 0.8% BUZZ-Goldman slips as profit halves on hit from loan loss provisions ** Aphria APHA.N: up 5.2% BUZZ-Gains as co swings to quarterly profit ** Tesla TSLA.O: up 3.7% BUZZ-Rises as China car registrations surge in March ** Bank of America Corp BAC.N: down 6.4% BUZZ-BofA slips as profit nearly halves, loan loss provisions soar ** ToughBuilt Industries TBLT.O: down 9.1% BUZZ-Plunges on reverse stock split ** J.C. Penny JCP.N: down 27.8% BUZZ-Falls on report of co considering bankruptcy ** JB Hunt Transport JBHT.O: up 1.8% BUZZ-Rises after revenue beats amid coronavirus-led disruption ** Chesapeake Energy CHK.N: down 39.7% BUZZ-Credit Suisse cuts PT on reverse stock split, lowers outlook ** Applied DNA APDN.O: up 40.5% BUZZ-Surges after co says mice will be tested with COVID-19 vaccines ** Noble Energy NBL.O: down 15.9% BUZZ-Drops as liquidity needs prompt dividend cut ** Oragenics OGEN.A: down 45.0% BUZZ-Plunges after drug for cancer therapy side-effect fails study ** Carnival Corp CCL.N : down 6.6% BUZZ-Falls as virus-stricken cruise line drops anchor till July ** Lifeway Foods LWAY.O: up 22.4% BUZZ-Gains on expectations for increased sales ** Citigroup C.N: down 3.5% BUZZ-Citigroup: Falls as quarterly profit nearly halves ** Frontier Communications FTR.O: down 31.4% BUZZ-Frontier Communications: Slumps after filing for bankruptcy protection ** Netflix InNFLX.O: up 3.6% BUZZ-Hits record high as analysts see strong Q1 amid coronavirus outbreak The 11 major S&P 500 sectors: Communication Services down 3.46% (Compiled by Shanti S Nair and Arundhati Sarkar in Bengaluru) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 .PG.INX percentage gainers: ** Netflix Inc , up 3.6% ** Abbott Labs , up 2.6% ** Nortonlifelock Inc , up 2% The top three S&P 500 .PL.INX percentage losers: ** Noble Energy Inc , down 16% ** PVH Corp , down 14.1% ** Helmerich Payne , down 13.5% The top three NYSE .PL.N percentage losers: ** Chesapeake Energy , down 39.7% ** Independence Contract Drilling , down 29.1% ** Pfenex Inc , down 24% The top three Nasdaq .PG.O percentage gainers: ** Liberty TripAdvisor Holdings Inc , up 205.3% ** Comstock Holding Companies Inc , up 168.1% ** Shiftpixy Inc , up 67.9% The top three Nasdaq .PL.O percentage losers: ** Summit Wireless Technologies Inc , down 21.3% ** Penn Virgin Corp , down 19.4% ** 9F Inc , down 18.5% ** Wells Fargo & Co WFC.N : down 6.1% BUZZ-Street View: Wells Fargo's losses manageable at this stage ** UnitedHealth Group UNH.N: up 1.6% BUZZ-Rises on Q1 profit beat ** Goldman Sachs GS.N: down 0.8% BUZZ-Goldman slips as profit halves on hit from loan loss provisions ** Aphria APHA.N: up 5.2% BUZZ-Gains as co swings to quarterly profit ** Tesla TSLA.O: up 3.7% BUZZ-Rises as China car registrations surge in March ** Bank of America Corp BAC.N: down 6.4% BUZZ-BofA slips as profit nearly halves, loan loss provisions soar ** ToughBuilt Industries TBLT.O: down 9.1% BUZZ-Plunges on reverse stock split ** J.C. Penny JCP.N: down 27.8% BUZZ-Falls on report of co considering bankruptcy ** JB Hunt Transport JBHT.O: up 1.8% BUZZ-Rises after revenue beats amid coronavirus-led disruption ** Chesapeake Energy CHK.N: down 39.7% BUZZ-Credit Suisse cuts PT on reverse stock split, lowers outlook ** Applied DNA APDN.O: up 40.5% BUZZ-Surges after co says mice will be tested with COVID-19 vaccines ** Noble Energy NBL.O: down 15.9% BUZZ-Drops as liquidity needs prompt dividend cut ** Oragenics OGEN.A: down 45.0% BUZZ-Plunges after drug for cancer therapy side-effect fails study ** Carnival Corp CCL.N : down 6.6% BUZZ-Falls as virus-stricken cruise line drops anchor till July ** Lifeway Foods LWAY.O: up 22.4% BUZZ-Gains on expectations for increased sales ** Citigroup C.N: down 3.5% BUZZ-Citigroup: Falls as quarterly profit nearly halves ** Frontier Communications FTR.O: down 31.4% BUZZ-Frontier Communications: Slumps after filing for bankruptcy protection ** Netflix InNFLX.O: up 3.6% BUZZ-Hits record high as analysts see strong Q1 amid coronavirus outbreak The 11 major S&P 500 sectors: Communication Services down 1.56% Consumer Discretionary down 2.22% Consumer Staples | Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes slid 2% on Wednesday, as a record drop in retail sales and dour first-quarter earnings reports lent weight to forecasts for the biggest economic slump since the Great Depression. ET, the Dow Jones Industrial Average .DJI was down 2.66% at 23,312.97. The S&P 500 .SPX was down 2.43% at 2,776.81 and the Nasdaq Composite .IXIC was down 1.54% at 8,384.365. |
32714.0 | 2020-04-15 00:00:00 UTC | Abbott launches COVID-19 antibody test, plans 20 mln tests per month by June | ABT | https://www.nasdaq.com/articles/abbott-launches-covid-19-antibody-test-plans-20-mln-tests-per-month-by-june-2020-04-15 | nan | nan | Adds details on launch, background
April 15 (Reuters) - Abbott Laboratories Inc ABT.N said on Wednesday it launched a coronavirus blood test that could show whether a person has been infected and plans to ramp up manufacturing to produce 20 million tests per month by June.
The test helps identify disease-fighting antibodies in people who have been infected but may have had mild symptoms or none at all, making it different from the current diagnostic tests that require nasal swabs to confirm active infection.
Antibody tests are considered a potential game changer in the battle to contain infections and offers the chance to get the economy back on track by identifying people who may have immunity to the virus and could return to their jobs.
The company said it plans to file for FDA approval for its test through the emergency use pathway.
Last month, the U.S. Food and Drug Administration relaxed the rules on use of diagnostic tests by allowing body-fluid tests to proceed to market without full agency review and approval. (https://reut.rs/2RFgway)
Abbott's test identifies the IgG antibody, a protein that the body produces in the late stages of infection and may remain for up to months and possibly years after a person has recovered.
The company expects to immediately ship close to 1 million tests this week to U.S. customers, and will ship a total of 4 million tests for April.
Abbott has previously won U.S. authorization for two coronavirus testing kits: an automated test that can be used in labs and a test that can deliver results within minutes and be used in physicians' offices, clinics and hospitals.
The company also said it would work on expanding its testing to detect the antibody, IgM, made by the body a few days after infection.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shailesh Kuber)
((saumya.joseph@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 2676; Twitter: @SaumyaSibi;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds details on launch, background April 15 (Reuters) - Abbott Laboratories Inc ABT.N said on Wednesday it launched a coronavirus blood test that could show whether a person has been infected and plans to ramp up manufacturing to produce 20 million tests per month by June. Antibody tests are considered a potential game changer in the battle to contain infections and offers the chance to get the economy back on track by identifying people who may have immunity to the virus and could return to their jobs. (https://reut.rs/2RFgway) Abbott's test identifies the IgG antibody, a protein that the body produces in the late stages of infection and may remain for up to months and possibly years after a person has recovered. | Adds details on launch, background April 15 (Reuters) - Abbott Laboratories Inc ABT.N said on Wednesday it launched a coronavirus blood test that could show whether a person has been infected and plans to ramp up manufacturing to produce 20 million tests per month by June. The test helps identify disease-fighting antibodies in people who have been infected but may have had mild symptoms or none at all, making it different from the current diagnostic tests that require nasal swabs to confirm active infection. (https://reut.rs/2RFgway) Abbott's test identifies the IgG antibody, a protein that the body produces in the late stages of infection and may remain for up to months and possibly years after a person has recovered. | Adds details on launch, background April 15 (Reuters) - Abbott Laboratories Inc ABT.N said on Wednesday it launched a coronavirus blood test that could show whether a person has been infected and plans to ramp up manufacturing to produce 20 million tests per month by June. The test helps identify disease-fighting antibodies in people who have been infected but may have had mild symptoms or none at all, making it different from the current diagnostic tests that require nasal swabs to confirm active infection. Abbott has previously won U.S. authorization for two coronavirus testing kits: an automated test that can be used in labs and a test that can deliver results within minutes and be used in physicians' offices, clinics and hospitals. | Adds details on launch, background April 15 (Reuters) - Abbott Laboratories Inc ABT.N said on Wednesday it launched a coronavirus blood test that could show whether a person has been infected and plans to ramp up manufacturing to produce 20 million tests per month by June. The test helps identify disease-fighting antibodies in people who have been infected but may have had mild symptoms or none at all, making it different from the current diagnostic tests that require nasal swabs to confirm active infection. Antibody tests are considered a potential game changer in the battle to contain infections and offers the chance to get the economy back on track by identifying people who may have immunity to the virus and could return to their jobs. |
32715.0 | 2020-04-15 00:00:00 UTC | Abbott Launches Antibody Blood Test For COVID-19 - Quick Facts | ABT | https://www.nasdaq.com/articles/abbott-launches-antibody-blood-test-for-covid-19-quick-facts-2020-04-15 | nan | nan | (RTTNews) - Abbott (ABT) launched its third COVID-19 test, a lab-based serology blood test for the detection of the antibody, IgG. The SARS-CoV-2 IgG test identifies the IgG antibody, which is a protein that the body produces in the late stages of infection and may remain for up to months and possibly years after a person has recovered. The antibody test adds to the company's existing COVID-19 tests, m2000 molecular laboratory system and ID NOW molecular point-of-care device.
Abbott said the company is significantly scaling up its manufacturing for antibody testing and is expecting to immediately ship close to 1 million tests in the current week to U.S. customers. The company will ship a total of 4 million tests in total for April. Abbott is ramping up to 20 million tests in the U.S. in June and beyond.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) launched its third COVID-19 test, a lab-based serology blood test for the detection of the antibody, IgG. The SARS-CoV-2 IgG test identifies the IgG antibody, which is a protein that the body produces in the late stages of infection and may remain for up to months and possibly years after a person has recovered. The antibody test adds to the company's existing COVID-19 tests, m2000 molecular laboratory system and ID NOW molecular point-of-care device. | (RTTNews) - Abbott (ABT) launched its third COVID-19 test, a lab-based serology blood test for the detection of the antibody, IgG. The SARS-CoV-2 IgG test identifies the IgG antibody, which is a protein that the body produces in the late stages of infection and may remain for up to months and possibly years after a person has recovered. The antibody test adds to the company's existing COVID-19 tests, m2000 molecular laboratory system and ID NOW molecular point-of-care device. | (RTTNews) - Abbott (ABT) launched its third COVID-19 test, a lab-based serology blood test for the detection of the antibody, IgG. The antibody test adds to the company's existing COVID-19 tests, m2000 molecular laboratory system and ID NOW molecular point-of-care device. Abbott said the company is significantly scaling up its manufacturing for antibody testing and is expecting to immediately ship close to 1 million tests in the current week to U.S. customers. | (RTTNews) - Abbott (ABT) launched its third COVID-19 test, a lab-based serology blood test for the detection of the antibody, IgG. The SARS-CoV-2 IgG test identifies the IgG antibody, which is a protein that the body produces in the late stages of infection and may remain for up to months and possibly years after a person has recovered. The antibody test adds to the company's existing COVID-19 tests, m2000 molecular laboratory system and ID NOW molecular point-of-care device. |
32716.0 | 2020-04-15 00:00:00 UTC | Abbott launches antibody test for coronavirus, plans to deliver 20 mln tests by June | ABT | https://www.nasdaq.com/articles/abbott-launches-antibody-test-for-coronavirus-plans-to-deliver-20-mln-tests-by-june-2020 | nan | nan | April 15 (Reuters) - Abbott Laboratories Inc ABT.N on Wednesday launched a coronavirus blood test that could show whether a person has been infected and plans to ramp up manufacturing to produce 20 million tests in June.
The test helps identify disease-fighting antibodies in people who have been infected but may have had mild symptoms or none at all, making it different from the current diagnostic tests that require nasal swabs to confirm active infection.
Abbott has previously won U.S. authorization for two coronavirus testing kits: an automated test that can be used in labs and a test that can deliver results within minutes and be used in physicians' offices, clinics and hospitals.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shailesh Kuber)
((saumya.joseph@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 2676; Twitter: @SaumyaSibi;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | April 15 (Reuters) - Abbott Laboratories Inc ABT.N on Wednesday launched a coronavirus blood test that could show whether a person has been infected and plans to ramp up manufacturing to produce 20 million tests in June. The test helps identify disease-fighting antibodies in people who have been infected but may have had mild symptoms or none at all, making it different from the current diagnostic tests that require nasal swabs to confirm active infection. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shailesh Kuber) ((saumya.joseph@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 2676; Twitter: @SaumyaSibi;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | April 15 (Reuters) - Abbott Laboratories Inc ABT.N on Wednesday launched a coronavirus blood test that could show whether a person has been infected and plans to ramp up manufacturing to produce 20 million tests in June. Abbott has previously won U.S. authorization for two coronavirus testing kits: an automated test that can be used in labs and a test that can deliver results within minutes and be used in physicians' offices, clinics and hospitals. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shailesh Kuber) ((saumya.joseph@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 2676; Twitter: @SaumyaSibi;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | April 15 (Reuters) - Abbott Laboratories Inc ABT.N on Wednesday launched a coronavirus blood test that could show whether a person has been infected and plans to ramp up manufacturing to produce 20 million tests in June. The test helps identify disease-fighting antibodies in people who have been infected but may have had mild symptoms or none at all, making it different from the current diagnostic tests that require nasal swabs to confirm active infection. Abbott has previously won U.S. authorization for two coronavirus testing kits: an automated test that can be used in labs and a test that can deliver results within minutes and be used in physicians' offices, clinics and hospitals. | April 15 (Reuters) - Abbott Laboratories Inc ABT.N on Wednesday launched a coronavirus blood test that could show whether a person has been infected and plans to ramp up manufacturing to produce 20 million tests in June. The test helps identify disease-fighting antibodies in people who have been infected but may have had mild symptoms or none at all, making it different from the current diagnostic tests that require nasal swabs to confirm active infection. Abbott has previously won U.S. authorization for two coronavirus testing kits: an automated test that can be used in labs and a test that can deliver results within minutes and be used in physicians' offices, clinics and hospitals. |
32717.0 | 2020-04-13 00:00:00 UTC | Ex-Dividend Reminder: AbbVie, Allergan and Abbott Laboratories | ABT | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-abbvie-allergan-and-abbott-laboratories-2020-04-13 | nan | nan | Looking at the universe of stocks we cover at Dividend Channel, on 4/14/20, AbbVie Inc (Symbol: ABBV), Allergan PLC (Symbol: AGN), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.18 on 5/15/20, Allergan PLC will pay its quarterly dividend of $0.74 on 6/15/20, and Abbott Laboratories will pay its quarterly dividend of $0.36 on 5/15/20. As a percentage of ABBV's recent stock price of $81.08, this dividend works out to approximately 1.46%, so look for shares of AbbVie Inc to trade 1.46% lower — all else being equal — when ABBV shares open for trading on 4/14/20. Similarly, investors should look for AGN to open 0.40% lower in price and for ABT to open 0.42% lower, all else being equal.
Below are dividend history charts for ABBV, AGN, and ABT, showing historical dividends prior to the most recent ones declared.
AbbVie Inc (Symbol: ABBV):
Allergan PLC (Symbol: AGN):
Abbott Laboratories (Symbol: ABT):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 5.82% for AbbVie Inc, 1.61% for Allergan PLC, and 1.67% for Abbott Laboratories.
In Monday trading, AbbVie Inc shares are currently up about 1.7%, Allergan PLC shares are up about 0.8%, and Abbott Laboratories shares are up about 0.3% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel, on 4/14/20, AbbVie Inc (Symbol: ABBV), Allergan PLC (Symbol: AGN), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for AGN to open 0.40% lower in price and for ABT to open 0.42% lower, all else being equal. Below are dividend history charts for ABBV, AGN, and ABT, showing historical dividends prior to the most recent ones declared. | Looking at the universe of stocks we cover at Dividend Channel, on 4/14/20, AbbVie Inc (Symbol: ABBV), Allergan PLC (Symbol: AGN), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc (Symbol: ABBV): Allergan PLC (Symbol: AGN): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for AGN to open 0.40% lower in price and for ABT to open 0.42% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel, on 4/14/20, AbbVie Inc (Symbol: ABBV), Allergan PLC (Symbol: AGN), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc (Symbol: ABBV): Allergan PLC (Symbol: AGN): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for AGN to open 0.40% lower in price and for ABT to open 0.42% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel, on 4/14/20, AbbVie Inc (Symbol: ABBV), Allergan PLC (Symbol: AGN), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for AGN to open 0.40% lower in price and for ABT to open 0.42% lower, all else being equal. Below are dividend history charts for ABBV, AGN, and ABT, showing historical dividends prior to the most recent ones declared. |
32718.0 | 2020-04-11 00:00:00 UTC | Is Ecolab Stock a Buy? | ABT | https://www.nasdaq.com/articles/is-ecolab-stock-a-buy-2020-04-11 | nan | nan | Food safety, clean water, and hygiene company Ecolab (NYSE: ECL) is what Wall Street analysts might describe as a battleground stock. In other words, it's the kind of stock that's going to generate sharp disagreement between bulls and bears in the current environment. Is Ecolab a net beneficiary of a post-COVID-19 world or is it set to struggle? Let's take a look at the case for and against buying Ecolab stock.
Ecolab
Ecolab's management describes the company as being the global leader with a 10% share of a highly fragmented market. In a nutshell, Ecolab provides companies and institutions with cleaning, sanitation, washing, and filtration and treatment solutions aimed at ensuring a secure, hygienic environment. Its key end markets are food service, healthcare, food and beverage, and a host of industrial end markets. As such, key customers include companies like McDonald's, Coca-Cola, Walmart, Unilever, and Abbott Labs.
Image source: Getty images.
The bullish case
The best investment case for the stock has five key arguments attached to it:
In a post-COVID-19 world there will be an extra emphasis on issues such as public health and sanitation, so Ecolab has a long runway of growth ahead of it.
The upcoming deal to separate Ecolab's upstream energy business and merge it with Apergy will remove Ecolab's exposure to dramatic movements in the price of oil.
Ecolab is a company with 90% of its revenue from recurring sources -- something that should provide it with relative stability in any economic slowdown.
It's a dividend aristocrat -- a company that has raised its dividend for more than 25 consecutive years -- and has raised its earnings at 11% a year over the last 20 years.
Environmental concerns and regulatory compliance on hygiene are only going to rise in an increasingly connected and urbanized world.
Putting these points together, there's clearly a powerful case to be made for buying the stock. Moreover, the recent price falls have left its valuation looking attractive compared to what it's been in recent years. A current price-to-earnings ratio of 29 times earnings may seem high, but if the bullish case above is correct, then Ecolab's double-digit growth prospects and relatively stable income stream would seem to justify it.
Throw in some extra growth in a post-COVID-19 world -- due to extra emphasis on hygiene maters -- and you have a powerful case to argue that its valuation deserves a positive rerating.
Data by YCharts
The bearish response
Just like Goldilocks, the bulls have three different bears to contend with. The strong bear argument has it that the global economy is heading for a recessionary environment. In such a scenario, Ecolab will turn out to be a highly rated stock whose earnings are about to come under pressure.
A more moderate bear argument is that the economy will recover, but the measures taken to contain the COVID-19 pandemic will lead to multiple bankruptcies in hotels, restaurants, and hospitality companies. These are all industries containing key customers of Ecolab. In other words, Ecolab's growth aspirations are going to receive a negative shock, and so will Ecolab's earnings in the near term.
The third bear argument is that in the post-COVID-19 world, there will be an extended period of unwillingness among consumers to travel, visit restaurants, or attend public events. This will lead to a sales slowdown at Ecolab.
Image source: Getty Images.
What it means to investors
There's obviously some merit in both the bullish and bearish arguments. For example, Ecolab's CEO Douglas Baker talked of how government action to limit social interaction has "significantly affected our restaurant and hospitality customers and are negatively impacting demand for our products in these segments" on a press release on March 18. As such, there's little doubt that Ecolab's earnings are going to come under severe pressure in the near term. Moreover, no one really knows when the crisis will end or how consumers will behave afterwards.
On the other hand, Ecolab's stock is down around 20% on a year-to-date basis at the time of writing. If the bulls are right, then the company's long-term earnings prospects are still intact, and they might even be enhanced by extra awareness around public health. If this argument holds, then it doesn't make sense to discount a stock's value by 20% just because of a few quarters of weak earnings.
Ultimately, the decision to buy or sell the stock comes down to your view on how the crisis will play out. A relatively quick resolution followed by a gradual normalization would probably mean Ecolab is worth buying on weakness, but a protracted slowdown would put it in the "one to avoid" box.
10 stocks we like better than Ecolab
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Ecolab wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Ecolab. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In a nutshell, Ecolab provides companies and institutions with cleaning, sanitation, washing, and filtration and treatment solutions aimed at ensuring a secure, hygienic environment. A current price-to-earnings ratio of 29 times earnings may seem high, but if the bullish case above is correct, then Ecolab's double-digit growth prospects and relatively stable income stream would seem to justify it. For example, Ecolab's CEO Douglas Baker talked of how government action to limit social interaction has "significantly affected our restaurant and hospitality customers and are negatively impacting demand for our products in these segments" on a press release on March 18. | Image source: Getty images. The bullish case The best investment case for the stock has five key arguments attached to it: In a post-COVID-19 world there will be an extra emphasis on issues such as public health and sanitation, so Ecolab has a long runway of growth ahead of it. Image source: Getty Images. | Let's take a look at the case for and against buying Ecolab stock. Ecolab Ecolab's management describes the company as being the global leader with a 10% share of a highly fragmented market. The bullish case The best investment case for the stock has five key arguments attached to it: In a post-COVID-19 world there will be an extra emphasis on issues such as public health and sanitation, so Ecolab has a long runway of growth ahead of it. | Let's take a look at the case for and against buying Ecolab stock. The bullish case The best investment case for the stock has five key arguments attached to it: In a post-COVID-19 world there will be an extra emphasis on issues such as public health and sanitation, so Ecolab has a long runway of growth ahead of it. A current price-to-earnings ratio of 29 times earnings may seem high, but if the bullish case above is correct, then Ecolab's double-digit growth prospects and relatively stable income stream would seem to justify it. |
32719.0 | 2020-04-11 00:00:00 UTC | 3 Top Pharma Stocks to Buy in April | ABT | https://www.nasdaq.com/articles/3-top-pharma-stocks-to-buy-in-april-2020-04-11-0 | nan | nan | In most years, April isn't a special month to buy stocks. It's not a bad time to invest, but there's nothing that makes April better than other months. But this April is different.
Because of the coronavirus pandemic and the subsequent stock market plunge, this month is a very good time to invest in stocks. I'd argue that it's an especially great time to invest in shares of big drugmakers. Many pharma stocks have been hammered much harder than is warranted. My view is that three pharma stocks stand out as the top picks to buy in April.
Image source: Getty Images.
1. AbbVie
There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). The drugmaker's dividend yields 6%. Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future.
Including the time that it was part of Abbott Labs, AbbVie has paid out a dividend in every year since 1924. It's increased the dividend payout for a remarkable 47 consecutive years. And since being spun off from Abbott in 2013, AbbVie's dividend has nearly tripled.
Can AbbVie keep the dividends flowing and growing? I think so. Sales continue to soar for the company's cancer drugs Imbruvica and Venclexta. AbbVie's new immunology drugs Rinvoq and Skyrizi are expected to become megablockbusters over the next few years. The drugmaker's pending acquisition of Allergan will bring successful products including Botox and antipsychotic drug Vraylar into its lineup.
The primary headwind for AbbVie is the loss of exclusivity for its top-selling drug Humira in Europe, with the prospects of biosimilar competition in the U.S. only three years away. However, AbbVie should be able to offset the sales declines for Humira with its current products, promising pipeline candidates, and the addition of Allergan. The company might not deliver awe-inspiring earnings growth, but with its tremendous dividend, it doesn't need to in order for investors to still enjoy solid total returns.
2. Bristol Myers Squibb
If you're looking for great growth prospects in addition to a nice dividend, check out Bristol Myers Squibb (NYSE: BMY). The big drugmaker's dividend yield stands at more than 3%, which isn't too shabby at all. But I think that BMS is poised to generate impressive growth over the next few years.
It certainly helps that BMS claims two of the drugs that market researcher EvaluatePharma projects will rank in the top five best-selling blockbusters in the world by 2024 -- blood thinner Eliquis and cancer immunotherapy Opdivo. BMS also has a couple of rising stars with arthritis drug Orencia and multiple myeloma drug Empliciti.
But the acquisition of Celgene in November 2019 was a game changer for Bristol Myers Squibb. The company's lineup now includes blockbuster blood cancer drugs Revlimid and Pomalyst, along with solid tumor drug Abraxane. And thanks to the Celgene deal, BMS also now has recently approved drugs Reblozyl and Zeposia that have blockbuster-sales potential.
More winners should be on the way. Celgene's pipeline was loaded with great candidates that BMS now has. The most promising of these include cell therapies ide-cel and liso-cel. Wall Street analysts project that BMS will grow its earnings by an average of more than 18% annually over the next five years. With this kind of growth plus its attractive valuation and strong dividend, Bristol Myers Squibb appears to be a no-brainer big pharma stock to buy in April.
3. Pfizer
Pfizer (NYSE: PFE) is a good pick to buy right now for investors who want to get ahead of what's on the way. I'm referring to Pfizer's plan to spin off its Upjohn unit and merge it with Mylan (NASDAQ: MYL) to form a new company that will be named Viatris. Although the COVID-19 pandemic has caused Pfizer to delay the transaction, it's still set to wrap up later this year.
My view is that Pfizer will be set to deliver growth that's better than most big pharma companies once the Upjohn-Mylan deal finalizes. The "new" Pfizer" will have a strong lineup including breast cancer drug Ibrance, Eliquis (which it co-markets with Bristol Myers Squibb), prostate cancer drug Xtandi, and rare-disease drug Vyndaquel.
The company's pipeline also includes eight programs awaiting regulatory approvals and over 20 programs in late-stage clinical studies. I'm especially optimistic about the prospects for pneumococcal vaccine PF-06482077.
Pfizer's dividend currently yields close to 4.4%. Although the dividend will be reduced after the Upjohn-Mylan transaction is completed, the combination of the dividend that Viatris is expected to pay out and the "new" Pfizer's dividend should be close to the level of Pfizer's current dividend.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company might not deliver awe-inspiring earnings growth, but with its tremendous dividend, it doesn't need to in order for investors to still enjoy solid total returns. It certainly helps that BMS claims two of the drugs that market researcher EvaluatePharma projects will rank in the top five best-selling blockbusters in the world by 2024 -- blood thinner Eliquis and cancer immunotherapy Opdivo. With this kind of growth plus its attractive valuation and strong dividend, Bristol Myers Squibb appears to be a no-brainer big pharma stock to buy in April. | The company's lineup now includes blockbuster blood cancer drugs Revlimid and Pomalyst, along with solid tumor drug Abraxane. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. The Motley Fool owns shares of and recommends Bristol Myers Squibb. | The "new" Pfizer" will have a strong lineup including breast cancer drug Ibrance, Eliquis (which it co-markets with Bristol Myers Squibb), prostate cancer drug Xtandi, and rare-disease drug Vyndaquel. Although the dividend will be reduced after the Upjohn-Mylan transaction is completed, the combination of the dividend that Viatris is expected to pay out and the "new" Pfizer's dividend should be close to the level of Pfizer's current dividend. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. | My view is that three pharma stocks stand out as the top picks to buy in April. The "new" Pfizer" will have a strong lineup including breast cancer drug Ibrance, Eliquis (which it co-markets with Bristol Myers Squibb), prostate cancer drug Xtandi, and rare-disease drug Vyndaquel. Although the dividend will be reduced after the Upjohn-Mylan transaction is completed, the combination of the dividend that Viatris is expected to pay out and the "new" Pfizer's dividend should be close to the level of Pfizer's current dividend. |
32720.0 | 2020-04-11 00:00:00 UTC | 3 Top Pharma Stocks to Buy in April | ABT | https://www.nasdaq.com/articles/3-top-pharma-stocks-to-buy-in-april-2020-04-11 | nan | nan | In most years, April isn't a special month to buy stocks. It's not a bad time to invest, but there's nothing that makes April better than other months. But this April is different.
Because of the coronavirus pandemic and the subsequent stock market plunge, this month is a very good time to invest in stocks. I'd argue that it's an especially great time to invest in shares of big drugmakers. Many pharma stocks have been hammered much harder than is warranted. My view is that three pharma stocks stand out as the top picks to buy in April.
Image source: Getty Images.
1. AbbVie
There's one overwhelmingly compelling argument for buying shares of AbbVie (NYSE: ABBV). The drugmaker's dividend yields 6%. Investors who buy AbbVie now will lock in a juicy yield that should only get better in the future.
Including the time that it was part of Abbott Labs, AbbVie has paid out a dividend in every year since 1924. It's increased the dividend payout for a remarkable 47 consecutive years. And since being spun off from Abbott in 2013, AbbVie's dividend has nearly tripled.
Can AbbVie keep the dividends flowing and growing? I think so. Sales continue to soar for the company's cancer drugs Imbruvica and Venclexta. AbbVie's new immunology drugs Rinvoq and Skyrizi are expected to become megablockbusters over the next few years. The drugmaker's pending acquisition of Allergan will bring successful products including Botox and antipsychotic drug Vraylar into its lineup.
The primary headwind for AbbVie is the loss of exclusivity for its top-selling drug Humira in Europe, with the prospects of biosimilar competition in the U.S. only three years away. However, AbbVie should be able to offset the sales declines for Humira with its current products, promising pipeline candidates, and the addition of Allergan. The company might not deliver awe-inspiring earnings growth, but with its tremendous dividend, it doesn't need to in order for investors to still enjoy solid total returns.
2. Bristol Myers Squibb
If you're looking for great growth prospects in addition to a nice dividend, check out Bristol Myers Squibb (NYSE: BMY). The big drugmaker's dividend yield stands at more than 3%, which isn't too shabby at all. But I think that BMS is poised to generate impressive growth over the next few years.
It certainly helps that BMS claims two of the drugs that market researcher EvaluatePharma projects will rank in the top five best-selling blockbusters in the world by 2024 -- blood thinner Eliquis and cancer immunotherapy Opdivo. BMS also has a couple of rising stars with arthritis drug Orencia and multiple myeloma drug Empliciti.
But the acquisition of Celgene in November 2019 was a game changer for Bristol Myers Squibb. The company's lineup now includes blockbuster blood cancer drugs Revlimid and Pomalyst, along with solid tumor drug Abraxane. And thanks to the Celgene deal, BMS also now has recently approved drugs Reblozyl and Zeposia that have blockbuster-sales potential.
More winners should be on the way. Celgene's pipeline was loaded with great candidates that BMS now has. The most promising of these include cell therapies ide-cel and liso-cel. Wall Street analysts project that BMS will grow its earnings by an average of more than 18% annually over the next five years. With this kind of growth plus its attractive valuation and strong dividend, Bristol Myers Squibb appears to be a no-brainer big pharma stock to buy in April.
3. Pfizer
Pfizer (NYSE: PFE) is a good pick to buy right now for investors who want to get ahead of what's on the way. I'm referring to Pfizer's plan to spin off its Upjohn unit and merge it with Mylan (NASDAQ: MYL) to form a new company that will be named Viatris. Although the COVID-19 pandemic has caused Pfizer to delay the transaction, it's still set to wrap up later this year.
My view is that Pfizer will be set to deliver growth that's better than most big pharma companies once the Upjohn-Mylan deal finalizes. The "new" Pfizer" will have a strong lineup including breast cancer drug Ibrance, Eliquis (which it co-markets with Bristol Myers Squibb), prostate cancer drug Xtandi, and rare-disease drug Vyndaquel.
The company's pipeline also includes eight programs awaiting regulatory approvals and over 20 programs in late-stage clinical studies. I'm especially optimistic about the prospects for pneumococcal vaccine PF-06482077.
Pfizer's dividend currently yields close to 4.4%. Although the dividend will be reduced after the Upjohn-Mylan transaction is completed, the combination of the dividend that Viatris is expected to pay out and the "new" Pfizer's dividend should be close to the level of Pfizer's current dividend.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company might not deliver awe-inspiring earnings growth, but with its tremendous dividend, it doesn't need to in order for investors to still enjoy solid total returns. It certainly helps that BMS claims two of the drugs that market researcher EvaluatePharma projects will rank in the top five best-selling blockbusters in the world by 2024 -- blood thinner Eliquis and cancer immunotherapy Opdivo. With this kind of growth plus its attractive valuation and strong dividend, Bristol Myers Squibb appears to be a no-brainer big pharma stock to buy in April. | The company's lineup now includes blockbuster blood cancer drugs Revlimid and Pomalyst, along with solid tumor drug Abraxane. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. The Motley Fool owns shares of and recommends Bristol Myers Squibb. | The "new" Pfizer" will have a strong lineup including breast cancer drug Ibrance, Eliquis (which it co-markets with Bristol Myers Squibb), prostate cancer drug Xtandi, and rare-disease drug Vyndaquel. Although the dividend will be reduced after the Upjohn-Mylan transaction is completed, the combination of the dividend that Viatris is expected to pay out and the "new" Pfizer's dividend should be close to the level of Pfizer's current dividend. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. | My view is that three pharma stocks stand out as the top picks to buy in April. The "new" Pfizer" will have a strong lineup including breast cancer drug Ibrance, Eliquis (which it co-markets with Bristol Myers Squibb), prostate cancer drug Xtandi, and rare-disease drug Vyndaquel. Although the dividend will be reduced after the Upjohn-Mylan transaction is completed, the combination of the dividend that Viatris is expected to pay out and the "new" Pfizer's dividend should be close to the level of Pfizer's current dividend. |
32721.0 | 2020-04-09 00:00:00 UTC | iShares S&P 100 ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/ishares-sp-100-etf-experiences-big-inflow-2020-04-09 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $144.6 million dollar inflow -- that's a 2.8% increase week over week in outstanding units (from 40,500,000 to 41,650,000). Among the largest underlying components of OEF, in trading today Adobe Inc (Symbol: ADBE) is down about 1%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and Costco Wholesale Corp (Symbol: COST) is lower by about 2.2%. For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average:
Looking at the chart above, OEF's low point in its 52 week range is $101.8696 per share, with $152.576 as the 52 week high point — that compares with a last trade of $127.12. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of OEF, in trading today Adobe Inc (Symbol: ADBE) is down about 1%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and Costco Wholesale Corp (Symbol: COST) is lower by about 2.2%. For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $101.8696 per share, with $152.576 as the 52 week high point — that compares with a last trade of $127.12. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of OEF, in trading today Adobe Inc (Symbol: ADBE) is down about 1%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and Costco Wholesale Corp (Symbol: COST) is lower by about 2.2%. For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $101.8696 per share, with $152.576 as the 52 week high point — that compares with a last trade of $127.12. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of OEF, in trading today Adobe Inc (Symbol: ADBE) is down about 1%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and Costco Wholesale Corp (Symbol: COST) is lower by about 2.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $144.6 million dollar inflow -- that's a 2.8% increase week over week in outstanding units (from 40,500,000 to 41,650,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $101.8696 per share, with $152.576 as the 52 week high point — that compares with a last trade of $127.12. | Among the largest underlying components of OEF, in trading today Adobe Inc (Symbol: ADBE) is down about 1%, Abbott Laboratories (Symbol: ABT) is down about 0.5%, and Costco Wholesale Corp (Symbol: COST) is lower by about 2.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $144.6 million dollar inflow -- that's a 2.8% increase week over week in outstanding units (from 40,500,000 to 41,650,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $101.8696 per share, with $152.576 as the 52 week high point — that compares with a last trade of $127.12. |
32722.0 | 2020-04-09 00:00:00 UTC | Abbott's TriClip Transcatheter Tricuspid Valve Repair System Gets CE Mark | ABT | https://www.nasdaq.com/articles/abbotts-triclip-transcatheter-tricuspid-valve-repair-system-gets-ce-mark-2020-04-09 | nan | nan | (RTTNews) - Abbott (ABT) said that its TriClip Transcatheter Tricuspid Valve Repair System has received CE Mark and is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical treatment for people with a leaky tricuspid valve, a condition known as tricuspid regurgitation.
Abbott said that its TriClip device is the first minimally invasive, clip-based tricuspid valve repair device to be commercially available in the world.
The tricuspid valve, often referred to as the "forgotten heart valve," has three leaflets that control the flow of blood between the two chambers on the right side of the heart. When those leaflets do not close properly, blood can flow in the reverse direction - known as regurgitation - forcing the heart to work harder.
When left untreated, TR can lead to conditions such as atrial fibrillation, heart failure, and ultimately, death. The condition is difficult to treat, however, and options for patients have historically been extremely limited. People with TR are typically older and suffer from multiple co-morbidities, making open-heart surgery a high-risk procedure.
The company noted that the TriClip procedure repairs the tricuspid valve without the need for open-heart surgery. The device is delivered to the heart through the femoral vein in the leg and works by clipping together a portion of the leaflets of the tricuspid valve to reduce the backflow of blood. This approach allows the heart to pump blood more efficiently, relieving symptoms of TR and improving a person's quality of life.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) said that its TriClip Transcatheter Tricuspid Valve Repair System has received CE Mark and is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical treatment for people with a leaky tricuspid valve, a condition known as tricuspid regurgitation. People with TR are typically older and suffer from multiple co-morbidities, making open-heart surgery a high-risk procedure. The device is delivered to the heart through the femoral vein in the leg and works by clipping together a portion of the leaflets of the tricuspid valve to reduce the backflow of blood. | (RTTNews) - Abbott (ABT) said that its TriClip Transcatheter Tricuspid Valve Repair System has received CE Mark and is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical treatment for people with a leaky tricuspid valve, a condition known as tricuspid regurgitation. Abbott said that its TriClip device is the first minimally invasive, clip-based tricuspid valve repair device to be commercially available in the world. The company noted that the TriClip procedure repairs the tricuspid valve without the need for open-heart surgery. | (RTTNews) - Abbott (ABT) said that its TriClip Transcatheter Tricuspid Valve Repair System has received CE Mark and is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical treatment for people with a leaky tricuspid valve, a condition known as tricuspid regurgitation. The tricuspid valve, often referred to as the "forgotten heart valve," has three leaflets that control the flow of blood between the two chambers on the right side of the heart. The device is delivered to the heart through the femoral vein in the leg and works by clipping together a portion of the leaflets of the tricuspid valve to reduce the backflow of blood. | (RTTNews) - Abbott (ABT) said that its TriClip Transcatheter Tricuspid Valve Repair System has received CE Mark and is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical treatment for people with a leaky tricuspid valve, a condition known as tricuspid regurgitation. Abbott said that its TriClip device is the first minimally invasive, clip-based tricuspid valve repair device to be commercially available in the world. The company noted that the TriClip procedure repairs the tricuspid valve without the need for open-heart surgery. |
32723.0 | 2020-04-08 00:00:00 UTC | Abbott's CGM Available For Hospitalized Patients With Diabetes During COVID-19 | ABT | https://www.nasdaq.com/articles/abbotts-cgm-available-for-hospitalized-patients-with-diabetes-during-covid-19-2020-04-08 | nan | nan | (RTTNews) - Abbott (ABT) said that its continuous glucose monitoring technology, FreeStyle Libre 14 day system, is now available in U.S. for hospitalized patients with diabetes during the COVID-19 pandemic.
The system can be used by frontline healthcare workers in hospitals to remotely monitor patients with diabetes who can scan to minimize exposure to COVID-19 and preserve use of personal protective equipment.
According to a recent report by the Centers for Disease Control and Prevention (CDC), more than 50% of people with diabetes who have been diagnosed with COVID-19 are hospitalized.
Abbott said it will donate 25,000 FreeStyle Libre 14 day sensors to U.S. hospitals and medical centers in outbreak hotspots to help accelerate access to technology.
With a one-second scan using a reader or smartphone over the FreeStyle Libre 14 day sensor worn on the back of the upper arm, users get real-time glucose readings every minute, historical trends and patterns. Its arrows shows where glucose levels are going without having to fingerstick.
At the same time, physicians will receive real-time glucose data and actionable information to help make important treatment decisions through LibreView, a secure, cloud-based diabetes management system.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) said that its continuous glucose monitoring technology, FreeStyle Libre 14 day system, is now available in U.S. for hospitalized patients with diabetes during the COVID-19 pandemic. The system can be used by frontline healthcare workers in hospitals to remotely monitor patients with diabetes who can scan to minimize exposure to COVID-19 and preserve use of personal protective equipment. With a one-second scan using a reader or smartphone over the FreeStyle Libre 14 day sensor worn on the back of the upper arm, users get real-time glucose readings every minute, historical trends and patterns. | (RTTNews) - Abbott (ABT) said that its continuous glucose monitoring technology, FreeStyle Libre 14 day system, is now available in U.S. for hospitalized patients with diabetes during the COVID-19 pandemic. Abbott said it will donate 25,000 FreeStyle Libre 14 day sensors to U.S. hospitals and medical centers in outbreak hotspots to help accelerate access to technology. With a one-second scan using a reader or smartphone over the FreeStyle Libre 14 day sensor worn on the back of the upper arm, users get real-time glucose readings every minute, historical trends and patterns. | (RTTNews) - Abbott (ABT) said that its continuous glucose monitoring technology, FreeStyle Libre 14 day system, is now available in U.S. for hospitalized patients with diabetes during the COVID-19 pandemic. Abbott said it will donate 25,000 FreeStyle Libre 14 day sensors to U.S. hospitals and medical centers in outbreak hotspots to help accelerate access to technology. With a one-second scan using a reader or smartphone over the FreeStyle Libre 14 day sensor worn on the back of the upper arm, users get real-time glucose readings every minute, historical trends and patterns. | (RTTNews) - Abbott (ABT) said that its continuous glucose monitoring technology, FreeStyle Libre 14 day system, is now available in U.S. for hospitalized patients with diabetes during the COVID-19 pandemic. According to a recent report by the Centers for Disease Control and Prevention (CDC), more than 50% of people with diabetes who have been diagnosed with COVID-19 are hospitalized. Abbott said it will donate 25,000 FreeStyle Libre 14 day sensors to U.S. hospitals and medical centers in outbreak hotspots to help accelerate access to technology. |
32724.0 | 2020-04-07 00:00:00 UTC | Walgreens to Expand Drive-Thru COVID-19 Testing | ABT | https://www.nasdaq.com/articles/walgreens-to-expand-drive-thru-covid-19-testing-2020-04-07 | nan | nan | On Tuesday, Walgreens Boots Alliance (NASDAQ: WBA) announced plans to expand a drive-thru coronavirus testing service that can provide rapid results while customers wait. The company's pharmacists will run patient samples through Abbott's (NYSE: ABT) ID NOW machines, which can provide results in less than 15 minutes.
Walgreens opened its first drive-through testing location in March and is still finalizing plans for the next 15 locations. The company is working with the Department of Health and Human Services to select hot spots in Arizona, Florida, Illinois, Kentucky, Louisiana, Tennessee, and Texas.
Image source: Getty Images.
Abbott's toaster-sized testing machines are already popular because they can amplify genetic material from patient samples without the long incubation process that slows down most molecular testing services. The ID NOW COVID-19 test can tell if a sample is positive in as little as 5 minutes, and give a negative result within 13 minutes.
Not to be outdone
This move will make Walgreens the second retail pharmacy chain in the U.S. to offer drive-thru COVID-19 testing at multiple locations. On Monday, CVS Health (NYSE: CVS) began providing Abbott's ID NOW COVID-19 test in two parking lots outside of retail medical clinics it operates in Rhode Island and Georgia.
Between them, CVS Health and Walgreens could do a lot to ramp up the country's testing capacity. Walgreens plans to test up to 3,000 people per day across those 15 locations. CVS Health expects each of its drive-thru testing sites will be able to process thousands of samples daily.
10 stocks we like better than Walgreens Boots Alliance
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Walgreens Boots Alliance wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company's pharmacists will run patient samples through Abbott's (NYSE: ABT) ID NOW machines, which can provide results in less than 15 minutes. On Tuesday, Walgreens Boots Alliance (NASDAQ: WBA) announced plans to expand a drive-thru coronavirus testing service that can provide rapid results while customers wait. The company is working with the Department of Health and Human Services to select hot spots in Arizona, Florida, Illinois, Kentucky, Louisiana, Tennessee, and Texas. | The company's pharmacists will run patient samples through Abbott's (NYSE: ABT) ID NOW machines, which can provide results in less than 15 minutes. On Tuesday, Walgreens Boots Alliance (NASDAQ: WBA) announced plans to expand a drive-thru coronavirus testing service that can provide rapid results while customers wait. On Monday, CVS Health (NYSE: CVS) began providing Abbott's ID NOW COVID-19 test in two parking lots outside of retail medical clinics it operates in Rhode Island and Georgia. | The company's pharmacists will run patient samples through Abbott's (NYSE: ABT) ID NOW machines, which can provide results in less than 15 minutes. On Tuesday, Walgreens Boots Alliance (NASDAQ: WBA) announced plans to expand a drive-thru coronavirus testing service that can provide rapid results while customers wait. On Monday, CVS Health (NYSE: CVS) began providing Abbott's ID NOW COVID-19 test in two parking lots outside of retail medical clinics it operates in Rhode Island and Georgia. | The company's pharmacists will run patient samples through Abbott's (NYSE: ABT) ID NOW machines, which can provide results in less than 15 minutes. Walgreens plans to test up to 3,000 people per day across those 15 locations. The Motley Fool recommends CVS Health. |
32725.0 | 2020-04-07 00:00:00 UTC | Walgreens to expand drive-through coronavirus testing sites | ABT | https://www.nasdaq.com/articles/walgreens-to-expand-drive-through-coronavirus-testing-sites-2020-04-07 | nan | nan | Adds details, background
April 7 (Reuters) - Walgreens Boots Alliance WBA.O is launching 15 "drive-thru" testing sites for coronavirus infections, the company said on Tuesday, as it follows up on a pledge it made to work with the Trump Administration on expanding diagnostic centers.
Like CVS Health Corp CVS.N, which said on Monday it was launching two offsite testing locations, Walgreens will also use Abbott Laboratories's ABT.N faster test kits, allowing the drugstore chain to do 3,000 tests per day across the sites.
CVS had said it would be able to handle 1,000 tests per day.
Abbott's tests deliver results in as little as five minutes and negative results within 13 minutes, Walgreens said, adding that it would set up centers in Arizona, Florida, Illinois, Kentucky, Louisiana, Tennessee and Texas.
It is working with the U.S. Department of Health and Human Services (HHS) to finalize the 15 locations in these states.
Testing for COVID-19, the serious respiratory illness caused by the new coronavirus, has been slow in the United States due to a lack of test kits and other equipment.
While more than 300,000 people in America have tested positive for the new coronavirus, officials believe there are the undercounted cases because of a shortage of kits.
Testing, including at drive-through sites like these, is also seen as key in fighting the coronavirus pandemic, which has led to sweeping shutdowns of many businesses and mass layoffs.
Other major retailers including Walmart Inc WMT.N, Target Corp TGT.N and CVS Health Corp CVS.N pledged at a White House news conference in March to provide space for drive-through sites in their parking lots.
Walmart has one testing site in Chicago and is opening another pilot site in Bentonville, Arkansas.
(Reporting by Trisha Roy in Bengaluru; Editing by Amy Caren Daniel and Saumyadeb Chakrabarty)
((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Like CVS Health Corp CVS.N, which said on Monday it was launching two offsite testing locations, Walgreens will also use Abbott Laboratories's ABT.N faster test kits, allowing the drugstore chain to do 3,000 tests per day across the sites. Adds details, background April 7 (Reuters) - Walgreens Boots Alliance WBA.O is launching 15 "drive-thru" testing sites for coronavirus infections, the company said on Tuesday, as it follows up on a pledge it made to work with the Trump Administration on expanding diagnostic centers. While more than 300,000 people in America have tested positive for the new coronavirus, officials believe there are the undercounted cases because of a shortage of kits. | Like CVS Health Corp CVS.N, which said on Monday it was launching two offsite testing locations, Walgreens will also use Abbott Laboratories's ABT.N faster test kits, allowing the drugstore chain to do 3,000 tests per day across the sites. Testing, including at drive-through sites like these, is also seen as key in fighting the coronavirus pandemic, which has led to sweeping shutdowns of many businesses and mass layoffs. Other major retailers including Walmart Inc WMT.N, Target Corp TGT.N and CVS Health Corp CVS.N pledged at a White House news conference in March to provide space for drive-through sites in their parking lots. | Like CVS Health Corp CVS.N, which said on Monday it was launching two offsite testing locations, Walgreens will also use Abbott Laboratories's ABT.N faster test kits, allowing the drugstore chain to do 3,000 tests per day across the sites. Adds details, background April 7 (Reuters) - Walgreens Boots Alliance WBA.O is launching 15 "drive-thru" testing sites for coronavirus infections, the company said on Tuesday, as it follows up on a pledge it made to work with the Trump Administration on expanding diagnostic centers. Testing for COVID-19, the serious respiratory illness caused by the new coronavirus, has been slow in the United States due to a lack of test kits and other equipment. | Like CVS Health Corp CVS.N, which said on Monday it was launching two offsite testing locations, Walgreens will also use Abbott Laboratories's ABT.N faster test kits, allowing the drugstore chain to do 3,000 tests per day across the sites. Adds details, background April 7 (Reuters) - Walgreens Boots Alliance WBA.O is launching 15 "drive-thru" testing sites for coronavirus infections, the company said on Tuesday, as it follows up on a pledge it made to work with the Trump Administration on expanding diagnostic centers. Abbott's tests deliver results in as little as five minutes and negative results within 13 minutes, Walgreens said, adding that it would set up centers in Arizona, Florida, Illinois, Kentucky, Louisiana, Tennessee and Texas. |
32726.0 | 2020-04-07 00:00:00 UTC | Walgreens to expand drive-through COVID-19 testing sites | ABT | https://www.nasdaq.com/articles/walgreens-to-expand-drive-through-covid-19-testing-sites-2020-04-07 | nan | nan | April 7 (Reuters) - Walgreens Boots Alliance WBA.O is working to expand its drive-through testing for COVID-19 to 15 new sites in seven states, the drugstore chain said on Tuesday. (https://reut.rs/2RiC1NT)
The new sites will use Abbot Laboratories's ABT.N COVID-19 diagnostic tests, which deliver positive results in as little as five minutes and negative results within 13 minutes.
(Reporting by Trisha Roy in Bengaluru; Editing by Amy Caren Daniel)
((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (https://reut.rs/2RiC1NT) The new sites will use Abbot Laboratories's ABT.N COVID-19 diagnostic tests, which deliver positive results in as little as five minutes and negative results within 13 minutes. April 7 (Reuters) - Walgreens Boots Alliance WBA.O is working to expand its drive-through testing for COVID-19 to 15 new sites in seven states, the drugstore chain said on Tuesday. (Reporting by Trisha Roy in Bengaluru; Editing by Amy Caren Daniel) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (https://reut.rs/2RiC1NT) The new sites will use Abbot Laboratories's ABT.N COVID-19 diagnostic tests, which deliver positive results in as little as five minutes and negative results within 13 minutes. April 7 (Reuters) - Walgreens Boots Alliance WBA.O is working to expand its drive-through testing for COVID-19 to 15 new sites in seven states, the drugstore chain said on Tuesday. (Reporting by Trisha Roy in Bengaluru; Editing by Amy Caren Daniel) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (https://reut.rs/2RiC1NT) The new sites will use Abbot Laboratories's ABT.N COVID-19 diagnostic tests, which deliver positive results in as little as five minutes and negative results within 13 minutes. April 7 (Reuters) - Walgreens Boots Alliance WBA.O is working to expand its drive-through testing for COVID-19 to 15 new sites in seven states, the drugstore chain said on Tuesday. (Reporting by Trisha Roy in Bengaluru; Editing by Amy Caren Daniel) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (https://reut.rs/2RiC1NT) The new sites will use Abbot Laboratories's ABT.N COVID-19 diagnostic tests, which deliver positive results in as little as five minutes and negative results within 13 minutes. April 7 (Reuters) - Walgreens Boots Alliance WBA.O is working to expand its drive-through testing for COVID-19 to 15 new sites in seven states, the drugstore chain said on Tuesday. (Reporting by Trisha Roy in Bengaluru; Editing by Amy Caren Daniel) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
32727.0 | 2020-04-07 00:00:00 UTC | Here Are All the Companies Working on COVID-19 Vaccines, Treatments, and Testing | ABT | https://www.nasdaq.com/articles/here-are-all-the-companies-working-on-covid-19-vaccines-treatments-and-testing-2020-04-07 | nan | nan | Help is on the way.
In the midst of a societal upheaval resulting from the novel coronavirus and the disease that it causes, COVID-19, there are many efforts in progress to find solutions to slow the spread of the disease and treat those who already have it. These efforts include those from governments, nonprofit organizations, and companies both privately held and publicly traded.
To help investors who desire to keep tabs on the publicly traded companies with COVID-19 programs, here are lists of all the companies with market caps of at least $200 million that are developing or have developed COVID-19 vaccines, treatments, and tests.
Image source: Getty Images.
Vaccines
Several companies already had vaccine platforms targeting other coronaviruses such as MERS and SARS. This enabled them to rapidly prototype experimental vaccines for immunizing against the novel coronavirus that causes COVID-19. Following are all of the companies that are actively developing COVID-19 vaccines either on their own or in partnership with another drugmaker.
COMPANY
MARKET CAP
Arcturus Therapeutics (NASDAQ:ARCT) $249.1 million
BioNTech (NASDAQ: BNTX) $12.2 billion
CSL Behring (OTC: CSLLY) $89.8 billion
Dynavax (NASDAQ: DVAX) $293.9 million
GlaxoSmithKline (NYSE: GSK) $93.7 billion
Inovio Pharmaceuticals (NASDAQ: INO) $1.2 billion
Johnson & Johnson (NYSE: JNJ) $357.9 billion
Moderna (NASDAQ: MRNA) $11.4 billion
Novavax (NASDAQ: NVAX) $821.8 million
Pfizer (NYSE: PFE) $190.2 billion
Sanofi (NASDAQ: SNY) $112.9 billion
TranslateBio (NASDAQ: TBIO) $614.1 million
Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! Finance.
Two of these companies appear to be in the lead right now. In March, Moderna initiated the first clinical testing in humans of an experimental COVID-19 vaccine. The biotech's messenger RNA (mRNA) vaccine was developed in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). Inovio announced on April 6 that it had begun a phase 1 clinical study of experimental COVID-19 DNA vaccine INO-4800.
Treatments
Several companies already have approved products on the market that could hold potential in treating patients with COVID-19. Others have experimental drugs that have been included in testing for other viruses that could be effective in targeting novel coronavirus infection. Some are scrambling to develop new therapies for COVID-19. Following are the companies that are developing or testing potential COVID-19 therapies.
COMPANY
MARKET CAP
AbbVie (NYSE: ABBV) $113.7 billion
Adaptive Biotechnologies (NASDAQ: ADPT) $3.4 billion
Alnylam Pharmaceuticals (NASDAQ: ALNY) $12.6 billion
Amgen (NASDAQ: AMGN) $122.9 billion
Bayer (OTC: BAYRY) $60.2 billion
Biogen (NASDAQ: BIIB) $54.1 billion
CSL Behring $89.8 billion
CytoDyn (NASDAQOTH:CYDY) $1.3 billion
Gilead Sciences (NASDAQ: GILD) $96.6 billion
Grifols (NASDAQ: GRFS) $19.5 billion
Incyte (NASDAQ: INCY) $18 billion
Eli Lilly (NYSE: LLY) $135.8 billion
Novartis (NYSE: NVS) $193.1 billion
Regeneron Pharmaceuticals (NASDAQ: REGN) $55.5 billion
Roche Holding (OTC: RHHBY) $286.7 billion
Sanofi $112.9 billion
Takeda Pharmaceutical (NYSE: TAK) $47.6 billion
Vanda Pharmaceuticals (NASDAQ: VNDA) $568.7 million
Vir Biotechnology (NASDAQ: VIR) $3.9 billion
Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! Finance.
Three drugs with the potential to treat COVID-19 have received the most public attention. Gilead's remdesivir, which was originally developed to treat the Ebola virus, is in late-stage clinical studies and could be the most promising treatment, according to World Health Organization Assistant Director-General Bruce Aylward. President Trump has spoken frequently about his view that anti-malaria drugs chloroquine and hydroxychloroquine, which are marketed by companies including Sanofi, could be effective in treating COVID-19, although health officials have stressed that the efficacy of the drugs in treating COVID-19 remains unproven at this point.
Testing
The most pressing immediate need in the battle against COVID-19 is for diagnostic tests to determine if individuals are infected by the novel coronavirus. Companies both large and small quickly developed such tests, with several receiving emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to be marketed commercially. Other companies have helped by providing COVID-19 testing services. Here are the companies engaged in activities related to testing for COVID-19.
COMPANY
MARKET CAP
Abbott Labs (NYSE: ABT) $142 billion
Bayer $60.2 billion
Becton Dickinson (NYSE: BDX) $63.2 billion
bioMerieux (OTC: BMXMF) $13.2 billion
Co-Diagnostics (NASDAQ: CODX) $273 million
Danaher (NYSE: DHR) $98.5 billion
Eli Lilly $135.8 billion
Grifols $19.5 billion
LabCorp (NYSE: LH) $11.9 billion
OPKO Health (NASDAQ: OPK) $817.2 million
Quest Diagnostics (NYSE: DGX) $10.4 billion
Roche Holdings $286.7 billion
Thermo Fisher Scientific (NYSE: TMO) $117.7 billion
Data sources: Biotechnology Innovation Organization, EvaluateMedTech, company press releases, Yahoo! Finance.
Roche and Thermo Fisher Scientific have committed to producing millions of COVID-19 tests. Abbott Labs recently launched the fastest COVID-19 test so far. Its test, which runs on the company's widely used ID NOW molecular diagnostics platform, can deliver positive results within five minutes and negative results within 13 minutes.
Investing considerations
Investors looking to buy shares of companies with COVID-19 programs should first determine how much risk they're willing to take. Several of the companies are relatively small. The odds of failure, especially with experimental COVID-19 vaccines and treatments, are relatively high.
It's also important to evaluate each stock's prospects beyond the companies' COVID-19 efforts. If you would be interested in buying a given stock even if it wasn't developing a COVID-19 vaccine, treatment, or test, that should put the stock much higher on your list.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals, Biogen, and Gilead Sciences. The Motley Fool recommends Amgen, Becton Dickinson, Incyte, and Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs (NYSE: ABT) $142 billion Bayer $60.2 billion Becton Dickinson (NYSE: BDX) $63.2 billion bioMerieux (OTC: BMXMF) $13.2 billion Co-Diagnostics (NASDAQ: CODX) $273 million Danaher (NYSE: DHR) $98.5 billion Eli Lilly $135.8 billion Grifols $19.5 billion LabCorp (NYSE: LH) $11.9 billion OPKO Health (NASDAQ: OPK) $817.2 million Quest Diagnostics (NYSE: DGX) $10.4 billion Roche Holdings $286.7 billion Thermo Fisher Scientific (NYSE: TMO) $117.7 billion Data sources: Biotechnology Innovation Organization, EvaluateMedTech, company press releases, Yahoo! The biotech's messenger RNA (mRNA) vaccine was developed in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). Gilead's remdesivir, which was originally developed to treat the Ebola virus, is in late-stage clinical studies and could be the most promising treatment, according to World Health Organization Assistant Director-General Bruce Aylward. | Abbott Labs (NYSE: ABT) $142 billion Bayer $60.2 billion Becton Dickinson (NYSE: BDX) $63.2 billion bioMerieux (OTC: BMXMF) $13.2 billion Co-Diagnostics (NASDAQ: CODX) $273 million Danaher (NYSE: DHR) $98.5 billion Eli Lilly $135.8 billion Grifols $19.5 billion LabCorp (NYSE: LH) $11.9 billion OPKO Health (NASDAQ: OPK) $817.2 million Quest Diagnostics (NYSE: DGX) $10.4 billion Roche Holdings $286.7 billion Thermo Fisher Scientific (NYSE: TMO) $117.7 billion Data sources: Biotechnology Innovation Organization, EvaluateMedTech, company press releases, Yahoo! Arcturus Therapeutics (NASDAQ:ARCT) $249.1 million BioNTech (NASDAQ: BNTX) $12.2 billion CSL Behring (OTC: CSLLY) $89.8 billion Dynavax (NASDAQ: DVAX) $293.9 million GlaxoSmithKline (NYSE: GSK) $93.7 billion Inovio Pharmaceuticals (NASDAQ: INO) $1.2 billion Johnson & Johnson (NYSE: JNJ) $357.9 billion Moderna (NASDAQ: MRNA) $11.4 billion Novavax (NASDAQ: NVAX) $821.8 million Pfizer (NYSE: PFE) $190.2 billion Sanofi (NASDAQ: SNY) $112.9 billion TranslateBio (NASDAQ: TBIO) $614.1 million Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! AbbVie (NYSE: ABBV) $113.7 billion Adaptive Biotechnologies (NASDAQ: ADPT) $3.4 billion Alnylam Pharmaceuticals (NASDAQ: ALNY) $12.6 billion Amgen (NASDAQ: AMGN) $122.9 billion Bayer (OTC: BAYRY) $60.2 billion Biogen (NASDAQ: BIIB) $54.1 billion CSL Behring $89.8 billion CytoDyn (NASDAQOTH:CYDY) $1.3 billion Gilead Sciences (NASDAQ: GILD) $96.6 billion Grifols (NASDAQ: GRFS) $19.5 billion Incyte (NASDAQ: INCY) $18 billion Eli Lilly (NYSE: LLY) $135.8 billion Novartis (NYSE: NVS) $193.1 billion Regeneron Pharmaceuticals (NASDAQ: REGN) $55.5 billion Roche Holding (OTC: RHHBY) $286.7 billion Sanofi $112.9 billion Takeda Pharmaceutical (NYSE: TAK) $47.6 billion Vanda Pharmaceuticals (NASDAQ: VNDA) $568.7 million Vir Biotechnology (NASDAQ: VIR) $3.9 billion Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! | Abbott Labs (NYSE: ABT) $142 billion Bayer $60.2 billion Becton Dickinson (NYSE: BDX) $63.2 billion bioMerieux (OTC: BMXMF) $13.2 billion Co-Diagnostics (NASDAQ: CODX) $273 million Danaher (NYSE: DHR) $98.5 billion Eli Lilly $135.8 billion Grifols $19.5 billion LabCorp (NYSE: LH) $11.9 billion OPKO Health (NASDAQ: OPK) $817.2 million Quest Diagnostics (NYSE: DGX) $10.4 billion Roche Holdings $286.7 billion Thermo Fisher Scientific (NYSE: TMO) $117.7 billion Data sources: Biotechnology Innovation Organization, EvaluateMedTech, company press releases, Yahoo! Arcturus Therapeutics (NASDAQ:ARCT) $249.1 million BioNTech (NASDAQ: BNTX) $12.2 billion CSL Behring (OTC: CSLLY) $89.8 billion Dynavax (NASDAQ: DVAX) $293.9 million GlaxoSmithKline (NYSE: GSK) $93.7 billion Inovio Pharmaceuticals (NASDAQ: INO) $1.2 billion Johnson & Johnson (NYSE: JNJ) $357.9 billion Moderna (NASDAQ: MRNA) $11.4 billion Novavax (NASDAQ: NVAX) $821.8 million Pfizer (NYSE: PFE) $190.2 billion Sanofi (NASDAQ: SNY) $112.9 billion TranslateBio (NASDAQ: TBIO) $614.1 million Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! AbbVie (NYSE: ABBV) $113.7 billion Adaptive Biotechnologies (NASDAQ: ADPT) $3.4 billion Alnylam Pharmaceuticals (NASDAQ: ALNY) $12.6 billion Amgen (NASDAQ: AMGN) $122.9 billion Bayer (OTC: BAYRY) $60.2 billion Biogen (NASDAQ: BIIB) $54.1 billion CSL Behring $89.8 billion CytoDyn (NASDAQOTH:CYDY) $1.3 billion Gilead Sciences (NASDAQ: GILD) $96.6 billion Grifols (NASDAQ: GRFS) $19.5 billion Incyte (NASDAQ: INCY) $18 billion Eli Lilly (NYSE: LLY) $135.8 billion Novartis (NYSE: NVS) $193.1 billion Regeneron Pharmaceuticals (NASDAQ: REGN) $55.5 billion Roche Holding (OTC: RHHBY) $286.7 billion Sanofi $112.9 billion Takeda Pharmaceutical (NYSE: TAK) $47.6 billion Vanda Pharmaceuticals (NASDAQ: VNDA) $568.7 million Vir Biotechnology (NASDAQ: VIR) $3.9 billion Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! | Abbott Labs (NYSE: ABT) $142 billion Bayer $60.2 billion Becton Dickinson (NYSE: BDX) $63.2 billion bioMerieux (OTC: BMXMF) $13.2 billion Co-Diagnostics (NASDAQ: CODX) $273 million Danaher (NYSE: DHR) $98.5 billion Eli Lilly $135.8 billion Grifols $19.5 billion LabCorp (NYSE: LH) $11.9 billion OPKO Health (NASDAQ: OPK) $817.2 million Quest Diagnostics (NYSE: DGX) $10.4 billion Roche Holdings $286.7 billion Thermo Fisher Scientific (NYSE: TMO) $117.7 billion Data sources: Biotechnology Innovation Organization, EvaluateMedTech, company press releases, Yahoo! To help investors who desire to keep tabs on the publicly traded companies with COVID-19 programs, here are lists of all the companies with market caps of at least $200 million that are developing or have developed COVID-19 vaccines, treatments, and tests. Others have experimental drugs that have been included in testing for other viruses that could be effective in targeting novel coronavirus infection. |
32728.0 | 2020-04-06 00:00:00 UTC | CVS Health to Open Rapid Drive-Through COVID-19 Testing Sites | ABT | https://www.nasdaq.com/articles/cvs-health-to-open-rapid-drive-through-covid-19-testing-sites-2020-04-06 | nan | nan | Some CVS Health (NYSE: CVS) customers are getting a fast new option for COVID-19 testing. Healthcare providers that normally work at the company's retail medical clinics in Georgia and Rhode Island will begin providing drive-up testing in two parking lot pop-ups with results provided while customers wait.
The technology making this new rapid drive-up service possible is Abbott's (NYSE: ABT) ID NOW system. Abbott's machines can amplify and read genetic material quickly enough to provide results for COVID-19 (or a handful of other infections) in minutes.
Image source: Getty Images.
For the safety of its customers and staff, CVS Health will run the rapid-testing services outside its stores. The testers will set up shop in parking lots large enough to accommodate multiple vehicle lanes. Eligible patients will need to register online before showing up at one of CVS Health's pop-up test locations.
Rhode Island Gov. Gina Raimondo said the rapid-testing site CVS Health has planned will double her state's capacity to provide on-the-spot results to thousands daily. Patients will need to meet state residency and age guidelines.
Lessons learned
On March 19, CVS Health opened a parking lot test site in Shrewsbury, Massachusetts, that initially focused on serving first responders and healthcare workers. CVS Health intends to apply lessons learned from that first pop-up molecular diagnostics service center to the new sites in Rhode Island and Georgia.
Rapid testing isn't the first step CVS Health has taken to address the coronavirus pandemic. In recent weeks, the company has also waived charges for home delivery of prescription drugs and dropped the copays for telemedicine visits for those covered by its health insurance service, Aetna.
10 stocks we like better than CVS Health
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and CVS Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The technology making this new rapid drive-up service possible is Abbott's (NYSE: ABT) ID NOW system. Lessons learned On March 19, CVS Health opened a parking lot test site in Shrewsbury, Massachusetts, that initially focused on serving first responders and healthcare workers. CVS Health intends to apply lessons learned from that first pop-up molecular diagnostics service center to the new sites in Rhode Island and Georgia. | The technology making this new rapid drive-up service possible is Abbott's (NYSE: ABT) ID NOW system. Some CVS Health (NYSE: CVS) customers are getting a fast new option for COVID-19 testing. Healthcare providers that normally work at the company's retail medical clinics in Georgia and Rhode Island will begin providing drive-up testing in two parking lot pop-ups with results provided while customers wait. | The technology making this new rapid drive-up service possible is Abbott's (NYSE: ABT) ID NOW system. Some CVS Health (NYSE: CVS) customers are getting a fast new option for COVID-19 testing. Healthcare providers that normally work at the company's retail medical clinics in Georgia and Rhode Island will begin providing drive-up testing in two parking lot pop-ups with results provided while customers wait. | The technology making this new rapid drive-up service possible is Abbott's (NYSE: ABT) ID NOW system. Some CVS Health (NYSE: CVS) customers are getting a fast new option for COVID-19 testing. Healthcare providers that normally work at the company's retail medical clinics in Georgia and Rhode Island will begin providing drive-up testing in two parking lot pop-ups with results provided while customers wait. |
32729.0 | 2020-04-06 00:00:00 UTC | CVS ramps up drive-through coronavirus testing sites with faster kits | ABT | https://www.nasdaq.com/articles/cvs-ramps-up-drive-through-coronavirus-testing-sites-with-faster-kits-2020-04-06 | nan | nan | By Michael Erman
April 6 (Reuters) - CVS Health Corp CVS.N, called on by the Trump administration last month to help test Americans for infections from the new coronavirus, said it was launching two offsite testing locations with Abbott Laboratories' ABT.N faster diagnostic kit and would be able to handle 1,000 tests per day.
Testing for COVID-19, the serious respiratory illness cased by the new coronavirus, has been held back by a lack of test kits and other equipment. While more than 300,000 people in America have tested positive for the new coronavirus, officials believe a shortage of kits has undercounted cases.
Testing, including at drive-through sites like these, is also seen as a key component for U.S. workers and restarting the economy as most states have ordered many non-essential businesses to close.
Executives from Walmart IncWMT.N, Walgreens Boots Alliance Inc WBA.N and Target Corp TGT.N also said in March as part of the government announcement that they would start this testing.
In recent weeks, CVS and Walgreens had said that they each had a pilot site running.
CVS' two new drive-through COVID-19 testing sites in Georgia and Rhode Island will use the new Abbott tests, which can work in 15 minutes, and that up to four more locations to follow.
"We want to get some experience under our belt with these sites and understand exactly sort of what the volume looks like," CVS Chief Medical Officer Troy Brennan said in an interview.
Brennan said the company expects to announce a third testing site in a different state on Tuesday and could launch up to three more sites afterward.
Brennan said it was changing the pilot model it had tested - a single-lane drive-through in the parking lot of one of its stores. The new testing sites will be located at Georgia Tech university and the other will be in the parking lot of a casino in Rhode Island.
CVS will supply personnel from its MinuteClinic unit to oversee the testing. The states will provide security and protective equipment.
The testing is currently available at no cost to patients and is being paid for by the federal government, CVS said.
Walgreens said last week on a conference call with analysts that it had a pilot running in Chicago that was doing about 150 tests a day under the direction of the government. Target said in March that because CVS handled the pharmacy operations in its stores, it would partner with them to bring any sites online.
(Reporting by Michael Erman and Caroline Humer Editing by Nick Zieminski and Alistair Bell)
((michael.erman@thomsonreuters.com; +1 646-223-6021; Reuters Messaging: michael.erman.thomsonreuters.com@thomsonreuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Michael Erman April 6 (Reuters) - CVS Health Corp CVS.N, called on by the Trump administration last month to help test Americans for infections from the new coronavirus, said it was launching two offsite testing locations with Abbott Laboratories' ABT.N faster diagnostic kit and would be able to handle 1,000 tests per day. Testing, including at drive-through sites like these, is also seen as a key component for U.S. workers and restarting the economy as most states have ordered many non-essential businesses to close. Executives from Walmart IncWMT.N, Walgreens Boots Alliance Inc WBA.N and Target Corp TGT.N also said in March as part of the government announcement that they would start this testing. | By Michael Erman April 6 (Reuters) - CVS Health Corp CVS.N, called on by the Trump administration last month to help test Americans for infections from the new coronavirus, said it was launching two offsite testing locations with Abbott Laboratories' ABT.N faster diagnostic kit and would be able to handle 1,000 tests per day. In recent weeks, CVS and Walgreens had said that they each had a pilot site running. CVS' two new drive-through COVID-19 testing sites in Georgia and Rhode Island will use the new Abbott tests, which can work in 15 minutes, and that up to four more locations to follow. | By Michael Erman April 6 (Reuters) - CVS Health Corp CVS.N, called on by the Trump administration last month to help test Americans for infections from the new coronavirus, said it was launching two offsite testing locations with Abbott Laboratories' ABT.N faster diagnostic kit and would be able to handle 1,000 tests per day. CVS' two new drive-through COVID-19 testing sites in Georgia and Rhode Island will use the new Abbott tests, which can work in 15 minutes, and that up to four more locations to follow. Brennan said the company expects to announce a third testing site in a different state on Tuesday and could launch up to three more sites afterward. | By Michael Erman April 6 (Reuters) - CVS Health Corp CVS.N, called on by the Trump administration last month to help test Americans for infections from the new coronavirus, said it was launching two offsite testing locations with Abbott Laboratories' ABT.N faster diagnostic kit and would be able to handle 1,000 tests per day. Testing for COVID-19, the serious respiratory illness cased by the new coronavirus, has been held back by a lack of test kits and other equipment. The new testing sites will be located at Georgia Tech university and the other will be in the parking lot of a casino in Rhode Island. |
32730.0 | 2020-04-06 00:00:00 UTC | CVS to launch two new drive-through COVID-19 testing sites | ABT | https://www.nasdaq.com/articles/cvs-to-launch-two-new-drive-through-covid-19-testing-sites-2020-04-06 | nan | nan | By Michael Erman
April 6 (Reuters) - CVS Health Corp CVS.N said that it will launch two new drive-through COVID-19 testing sites in Georgia and Rhode Island on Monday using new, faster tests than had previously been available, with up to four more locations to follow.
The company said both drive-through testing sites will use testing equipment made by Abbott Laboratories ABT.N that can deliver results within minutes. It expects to be able to perform around 1,000 tests per day at each site.
"We want to get some experience under our belt with these sites and understand exactly sort of what the volume looks like. And we'll also be improving the logistics associated with each of the sites over time," CVS Chief Medical Officer Troy Brennan said in an interview.
Brennan said the company expects to announce a third testing site in a different state on Tuesday and could launch up to three more sites afterward.
CVS was part of a group of U.S. retailers that pledged at a White House news conference on March 13 to open the testing sites in their parking lots. CVS has only opened one drive-through testing site, in the parking lot of a CVS Pharmacy in Shrewsbury, Massachusetts.
Brennan said CVS was basically "shutting down that other model" of a single lane drive-through in the parking lot of one of its stores. A CVS spokeswoman said the Shrewsbury site is still operational, but the company is evaluating how and when to transition to this new model in Massachusetts.
The new testing sites will not be located in CVS parking lots. Instead, one will be located at Georgia Tech university and the other will be in the parking lot of a casino in Rhode Island.
CVS will supply personnel from its MinuteClinic unit to oversee the testing. The states will provide security and protective equipment.
The testing is currently available at no cost to patients, CVS said.
"Right now, the federal government's paying for these tests and will do so for a specific duration of time," Brennan said. "Then we'll develop the capability to bill insurance."
Patients will need to pre-register in advance online at CVS.com in order to schedule a same-day time slot for testing, the company said. Testing at the sites is for eligible individuals who meet criteria established by the Centers for Disease Control and Prevention (CDC), in addition to state residency and age guidelines.
(Reporting by Michael Erman Editing by Nick Zieminski)
((michael.erman@thomsonreuters.com; +1 646-223-6021; Reuters Messaging: michael.erman.thomsonreuters.com@thomsonreuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company said both drive-through testing sites will use testing equipment made by Abbott Laboratories ABT.N that can deliver results within minutes. CVS was part of a group of U.S. retailers that pledged at a White House news conference on March 13 to open the testing sites in their parking lots. Brennan said CVS was basically "shutting down that other model" of a single lane drive-through in the parking lot of one of its stores. | The company said both drive-through testing sites will use testing equipment made by Abbott Laboratories ABT.N that can deliver results within minutes. By Michael Erman April 6 (Reuters) - CVS Health Corp CVS.N said that it will launch two new drive-through COVID-19 testing sites in Georgia and Rhode Island on Monday using new, faster tests than had previously been available, with up to four more locations to follow. CVS has only opened one drive-through testing site, in the parking lot of a CVS Pharmacy in Shrewsbury, Massachusetts. | The company said both drive-through testing sites will use testing equipment made by Abbott Laboratories ABT.N that can deliver results within minutes. By Michael Erman April 6 (Reuters) - CVS Health Corp CVS.N said that it will launch two new drive-through COVID-19 testing sites in Georgia and Rhode Island on Monday using new, faster tests than had previously been available, with up to four more locations to follow. Brennan said the company expects to announce a third testing site in a different state on Tuesday and could launch up to three more sites afterward. | The company said both drive-through testing sites will use testing equipment made by Abbott Laboratories ABT.N that can deliver results within minutes. By Michael Erman April 6 (Reuters) - CVS Health Corp CVS.N said that it will launch two new drive-through COVID-19 testing sites in Georgia and Rhode Island on Monday using new, faster tests than had previously been available, with up to four more locations to follow. CVS has only opened one drive-through testing site, in the parking lot of a CVS Pharmacy in Shrewsbury, Massachusetts. |
32731.0 | 2020-04-05 00:00:00 UTC | 30 Top Stocks and Funds to Beat the COVID-19 Bear Market | ABT | https://www.nasdaq.com/articles/30-top-stocks-and-funds-to-beat-the-covid-19-bear-market-2020-04-05 | nan | nan | With the Dow Jones Industrial Average, the Nasdaq Composite Index, and the S&P 500 all down by more than 20% from their recent highs, there's no doubt that the COVID-19 pandemic has pushed U.S. stock markets into bear territory. What's more, the social distancing measures being used to control the spread of the SARS-CoV-2 virus have badly damaged the global economy and global supply chains and have put a number of industries, such as airlines, brick-and-mortar retailers, and sit-down restaurants, in a serious financial bind.
The good news is that this pandemic will eventually end. Several pharmaceutical companies are trialing a variety of novel therapeutics that could shorten the clinical course of the disease and perhaps lessen its severity in acute cases, leading to fewer fatalities. Moreover, numerous vaccine candidates are under development, some of which could be available for widespread use as soon as mid-2021.
Image source: Getty Images.
So from an investing perspective, this coronavirus-induced correction should ultimately play out like nearly all other bear markets throughout history. Specifically, bear markets have rarely persisted for periods longer than two years, and most fade away in about 14 months. What this means is that investors willing to buy high-quality equities and hold them for at least five years should come out of this chaotic period in outstanding shape, financially speaking.
Which investing vehicles are the best buys right now? Here's a breakdown of 30 of the most attractively priced exchange-traded funds (ETFs) and individual stocks in the market today.
3 high-quality ETFs
One of the easiest and best ways to invest is by buying ETFs that sport low expense ratios. By doing so, you can gain broad exposure to specific economic sectors, without the hassle of buying dozens of individual stocks. While there are literally hundreds of ETFs to choose from, the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB), the Vanguard Consumer Staples Index Fund ETF Shares (NYSEMKT: VDC), and the Vanguard Information Technology Index Fund ETF Shares (NYSEMKT: VGT) are three of the most highly regarded among passive fund enthusiasts -- and for good reason.
Image source: Getty Images.
The iShares Nasdaq Biotechnology ETF sports an expense ratio of 0.47%, which is reasonable for a top-performing fund. This fund enables investors to take advantage of the red-hot growth in the biotech industry, without the stomach-churning volatility that comes with owning individual biotech stocks. Before this downturn, the iShares Nasdaq Biotechnology ETF was up by more than 300% over the past 10 years. That's well above the returns on capital generated by the major U.S. stock indices during the same period.
The Vanguard Consumer Staples Index Fund comes with both an ultra-low expense ratio of 0.10% and a noteworthy dividend yield of 2.76%. This fund is composed of numerous defensively oriented blue-chip equities that track the MSCI US Investable Market Index. While the Vanguard Consumer Staples Index Fund underperformed the broader markets during the prior decade, it has also lost significantly less of its value during the current sell-off. Thus, this fund is a great way to collect a healthy dividend and conserve capital in an uncertain market environment.
The Vanguard Information Technology Index Fund is a true gem in the ETF universe. This technology-oriented ETF sports an expense ratio of just 0.10% and an annualized yield of 1.4%, and it generated market-crushing returns for investors over the past 10-year period. What's more, the Vanguard Information Technology Index Fund has so far held up better than every major stock index in 2020.
12 blue-chip value stocks that pay top-notch dividends
Blue chips are companies with sound balance sheets, proven economic moats, and healthy free cash flows. They frequently make the esteemed list of Dividend Aristocrats, a select group of companies that have increased their dividends for a minimum of 25 consecutive years. As a result, these top-shelf equities and highly coveted passive income generators tend to weather economic downturns fairly well. Here are 12 blue chips worth buying right now.
Image source: Getty Images.
Abbott Laboratories (NYSE: ABT) is a medical device and molecular diagnostic company. The company has raised its dividend for 48 straight years, easily making it a Dividend Aristocrat. Although Abbott's shares are fairly expensive from the perspective of a forward-looking price-to-earnings ratio, the company could benefit enormously from its recently approved COVID-19 molecular diagnostic tests. At a minimum, Abbott should remain an outstanding passive income vehicle, and it should continue to be generally immune to this marketwide downturn because of its top-notch portfolio of essential healthcare products.
Apple (NASDAQ: AAPL) is one of the largest and most visible tech companies in the world today. Even so, the company's shares have been hit hard this year by the COVID-19 pandemic. That's not surprising in the least, given that Apple has already stated that it will miss Wall Street's financial targets in 2020. This sizable downturn, though, should prove to be a once-in-a-lifetime opportunity to pick up some shares of the tech giant on the cheap. Apple currently offers a modest yield of 1.26%, and Wall Street has the company's average 12-month price target at $310.90 per share. That amounts to a healthy 28.7% upside potential.
Bristol Myers Squibb (NYSE: BMY) has turned into a juggernaut following its acquisition of Celgene. The company is currently trading at under 3 times forward-looking sales, it offers an above-average dividend yield of 3.26%, and it sports multiple megablockbuster drugs such as Opdivo, Revlimid, and Eliquis. Although nothing is guaranteed in the stock market, Bristol stands a great chance of generating market-beating returns for investors over the next five to 10 years.
Chevron (NYSE: CVX) is an oil and gas megagiant. Nonetheless, the company's shares have gotten pounded into the dirt this year in response to the ongoing oil war between Russia and OPEC, which has caused crude oil prices to plummet into the low $20s. On the bright side, Chevron has been slashing costs to protect its highly coveted dividend. Now, Chevron may have to rethink its dividend policy if crude oil prices don't rebound fairly soon. The company's yield, after all, currently stands at a jaw-dropping 6.78%. The bigger picture, though, is that Chevron should eventually rebound and should continue to pay a respectable dividend over the long haul.
JPMorgan Chase (NYSE: JPM) is a titan of the financial-services sector. The bank's shares, however, have lost almost 40% of their value since the start of 2020 over concerns about falling interest rates, along with the potential for a prolonged recession sparked by the ongoing COVID-19 pandemic. While JPMorgan's stock may continue to slump in the coming weeks as the public health crisis deepens, investors should gladly catch this falling knife. JPMorgan has almost $900 billion in cash, it offers a dividend yield of 4.11%, and it's an American institution in many ways. There is no plausible scenario where this top bank stock doesn't recover within the next five years.
Johnson & Johnson (NYSE: JNJ) is a diversified healthcare behemoth. And the company's Dividend Aristocrat status is well earned thanks to its track record of raising its dividend for nearly 58 straight years. Moreover, J&J is one of only two publicly traded companies with a Standard & Poor's AAA credit rating. J&J's dividend yield isn't exactly anything to write home about, at 2.85%. But the company has a long history of beating the broader markets in terms of total returns on capital , when including its dividend. J&J, in turn, arguably deserves a spot in any type of portfolio.
McDonald's (NYSE: MCD) is the quintessential American fast-food restaurant. While the company's top-line has been struggling of late because of the influx of numerous competitors and a shift in American eating habits in general, McDonald's was still forecast to see a nice bump in revenue next year before this pandemic took hold. The company's heavy investment in delivery services and new technologies such as self-serve kiosks was expected to be a big boon to its business in 2021 and beyond. Still, McDonald's is a Dividend Aristocrat, it offers a respectable yield of 3.1% at current levels, and it has a decent cash reserve. McDonald's stock is therefore one of the safest passive income plays in this turbulent market right now.
Pfizer (NYSE: PFE) started off the year on a sour note but has since found its footing as investors flocked to its top-notch dividend yield of 4.62%, strong balance sheet, and above-average near-term outlook. The big draw with this pharma titan is its portfolio of high-growth prescription drugs that includes products such as Vyndaqel, Ibrance, and Xeljanz, combined with the upcoming spinoff of its legacy products business slated for later this year. The bottom line is that Pfizer's days as being one of the worst components of the Dow Jones appear to be drawing to a close.
Coca-Cola (NYSE: KO) had a historically bad first quarter because of the impact of the coronavirus on restaurant traffic, major sporting events, and large public entertainment events in general. Even now, though, Coca-Cola's stock is anything but cheap, for a variety of reasons. In short, Coca-Cola has been a tremendous cash cow for several generations, and its dividend is a big draw for income investors. At present, Coca-Cola's shares yield a juicy 3.73%, which is well above average for a consumer-staples play. So even though the company's first- and second-quarter earnings are probably going to be downright terrible, this is one blue-chip stock that every investor should want to scoop up on this pullback.
Clorox (NYSE: CLX) has been a rare bright spot in this dour market. Investors have piled in to Clorox this year, presumably in anticipation of a spike in demand for disinfectants such as Clorox bleach. In 2020, the company's shares have gained a healthy 15.6% because of its tie-in to the coronavirus. The bad news is that Clorox's shares are now trading at close to 28 times earnings, making it one of the most expensive blue-chip stocks on this list. That said, its dividend yield still stands at an attractive 2.36%, and it should remain a red-hot equity as long as the coronavirus maintains a virtual monopoly on the news cycle.
Walt Disney (NYSE: DIS) is a downright steal at these levels. After a dreadful first quarter, the company's shares are now bumping up against their five-year low and sport a modest dividend yield of 1.81%. Now, the harsh truth is that Disney's theme parks are going to be costly to maintain during the lockdown, and there will be a sharp decline in box office revenue for a good chunk of 2020. That can't be helped in a global pandemic. But Disney is a proven long-term winner because of its outstanding studio entertainment properties such as the Frozen and Star Wars franchises, among many, many others. Bottom line: Disney's stock is almost certainly going to continue to head lower in the weeks ahead, but long-term investors should take definitely advantage of this weakness. This blue-chip stock, after all, will probably post a stunning reversal once this pandemic peters out.
Verizon Communications (NYSE: VZ) is a telecom giant. The company's shares have fallen by around 11% this year, but that's not too bad considering how poorly the broader markets have performed so far in 2020. Investors seem to be sticking with Verizon in the wake of this downturn because of the company's outstanding dividend yield of 4.45%, leadership in the area of 5G technology, and partnership with Disney revolving around the Disney+ streaming service. Verizon does have one of the weaker balance sheets on this list, and it is facing an increasing amount of competition. But the big picture is that Verizon's shares are simply too cheap at 11.7 times earnings, especially for a company that offers a reliable, above-average dividend.
2 megacap growth stocks
Megacap companies, or companies with market caps of at least $200 billion, are rarely coveted for their growth prospects. Instead, these towering figures of industry are usually viewed as top-notch passive income vehicles, or capital preservation plays. These two e-commerce titans absolutely demolish this stereotype.
Image source: Getty Images.
Alibaba Group (NYSE: BABA) has been a big winner since its IPO in 2014. The Chinese e-commerce, cloud computing, digital media, and mobile payment megagiant, however, will probably only continue to surge higher in the months and years ahead. The core reason is that Alibaba has invested heavily in new technologies to remain at the cutting edge of its most lucrative markets. Equally as important, China's cloud computing market is expected to see explosive growth over the next decade. Alibaba is thus well positioned to deliver market-beating returns for the foreseeable future, despite its monstrous market cap of $510 billion.
Amazon.com (NASDAQ: AMZN) has transformed scores of its early shareholders into multimillionaires. Amazon Prime, with its free shipping and online entertainment component, has now attracted over 150 million members, and the company has built out a first-class data management business known as Amazon Web Services. Amazon, in effect, has weaved its way into the heart of American life. So even though the company's market cap stands at a jaw-dropping $949 billion, its stock should still produce healthy gains over the next decade, thanks to its loyal customer base and highly profitable Web services segment.
3 large-cap growth stocks
Like their megacap counterparts, large-cap equities, defined as companies with market caps of $10 billion or more, tend to attract conservative-minded investors or those seeking a safe dividend. However, these three large-cap stocks are unique in that they are best viewed as top-notch growth stocks.
Image source: Getty Images.
BioMarin Pharmaceutical (NASDAQ: BMRN) is a rare-disease drugmaker with multiple products on the market. So far this year, BioMarin's shares have essentially traded sideways, down 0.4%. The company has been able to swim against the current during this pandemic because many of its patients simply cannot forgo treatment without dire consequences. In addition, BioMarin is closing in on two major regulatory decisions for its next set of product candidates. The main attraction here is that BioMarin's top line could realistically double within five years, and it operates within one of the few segments of the economy that should be basically immune to the COVID-19 pandemic.
DexCom (NASDAQ: DXCM) is a medical-device company that specializes in diabetes. The company's shares have gained a stately 19% in 2020, thanks to the breakout success of its G6 continuous glucose monitoring (CGM) system. Although DexCom's shares are some of the most expensive within the healthcare sector right now, the company's rich valuation shouldn't scare you away. There are close to half a million adults living with diabetes worldwide, and this number is expected to rise markedly over the next decade. DexCom's CGM franchise is poised to play a critical role in the fight against this raging pandemic, which should translate into some truly eye-catching revenue figures.
MercadoLibre (NASDAQ: MELI) is the undisputed king of Latin American e-commerce. Even so, the company's shares were battered and bruised last month by the COVID-19 panic. COVID-19 has only recently started to have a major impact in Latin America, and the good news is that it shouldn't have any long-term consequences on MercadoLibre's e-commerce business. Now, the company's near-term sales might take a sizable hit as Latin America enforces shelter-in-place mandates. But this barrier to economic activity won't last forever. Thus, bargain hunters may want to pounce on this beaten-down e-commerce play soon.
3 mid-cap growth stocks
Investors often overlook mid-cap stocks, or companies with market caps ranging from $2 billion to $10 billion. But they shouldn't. Mid-cap stocks often offer a compelling mix of healthy growth and safety. In fact, mid-cap equities have consistently been some of the best growth vehicles in the entire market for the better part of the past decade. With this theme in mind, here are three mid-cap healthcare stocks that should be outstanding bargains at current levels.
Image source: Getty Images.
Intercept Pharmaceuticals (NASDAQ: ICPT) is a mid-cap biopharma focused on the development of drugs for non-viral liver diseases. The company's shares have lost over half their value this year because of a regulatory delay for its non-alcoholic steatohepatitis (NASH) drug candidate, Ocaliva. Specifically, Ocaliva's advisory committee meeting was moved from April 22 to June 9 of this year as a result of COVID-19. Intercept's shares, in turn, might be one of the best bargains in the entire market right now. While Ocaliva isn't a surefire slam dunk to become the first drug ever approved for NASH, the fact is that it would easily rack up sales in the $2 billion to $3 billion range if it does cross this key regulatory hurdle. The big deal is that Intercept's market cap is currently hovering right around a mere $2 billion at the time of writing. As such, there's a real shot that Intercept's shares could double, or even triple, in value by this time next year.
Sarepta Therapeutics (NASDAQ: SRPT) is a rare-disease and gene therapy company with a virtual monopoly on treatments for the muscle-wasting disorder known as Duchenne muscular dystrophy (DMD). The company's stock has traded in lockstep with the broader markets this year presumably because of its formerly rich valuation. What's important to understand is that Sarepta's shares are quite possibly trading at less than 0.5 times 2026 sales. There are a lot of moving parts that could drastically change this outlook, but the bottom line is that Sarepta's stock is dirt cheap at these levels. Despite multiple would-be competitors in DMD, after all, Sarepta is still the only game in town for the most part.
Tandem Diabetes Care (NASDAQ: TNDM) is another high-growth diabetes play, thanks to its outsize portion of the insulin pump market. The company's shares have been on fire over the past three years because of the rapid growth of its market share in the insulin pump space. And in 2020, Tandem's share have even been able to eke out a modest gain of about 3%, which arguably reflects the strong demand for its insulin pumps for individuals with type 1 and type 2 diabetes. Wall Street's current consensus price target implies that Tandem's shares could rise by another 44.9% over the next 12 months. With the diabetes market growing by leaps and bounds, this rosy outlook doesn't seem to be unreasonable in the least.
3 small-cap growth stocks
Small-cap growth stocks are typically the first group of equities to lose favor in a crisis. These stocks are generally riskier than mid- and large-cap equities. As the market derisks, though, some small-cap stocks become outstanding bargains by default. The following three names fit that description to a T.
Image source: Getty Images.
Catalyst Pharmaceuticals (NASDAQ: CPRX) is an orphan-drug maker that sells Firdpase, an FDA-approved drug for treating Lambert-Eaton myasthenic syndrome (LEMS). Firdapse is competing with another recently approved LEMS medication, but this drug has yet to take a meaningful share of the market. In fact, there are several good reasons to think that this rival LEMS drug never will morph into a serious competitive threat. Nonetheless, the market has treated Catalyst's shares as if Firdapse's sales are set to collapse. Underscoring this point, Catalyst's stock is trading at an absurd 1.87 times 2021 projected sales. While this small-cap biopharma does have an elevated risk profile, the market is arguably taking it way too far with this rock-bottom valuation. Catalyst, in fact, should eventually shake off this key overhang to go on to become a top growth stock within the next 12 to 18 months.
Novavax (NASDAQ: NVAX) is a pre-revenue vaccine company. The biotech's shares have gained almost 300% this year because of a successful top-line readout for its experimental flu vaccine, dubbed NanoFlu, combined with its entrance into the race to develop a vaccine for COVID-19. Novavax is gearing up to submit NanoFlu's regulatory application to the FDA for review, meaning it might be available for next year's flu season. Estimates vary wildly, but the current consensus has NanoFlu generating around $740 million in peak sales. That's quite a potential haul for a company with a market cap of $801 million. So if NanoFlu does indeed gain the FDA's blessing, Novavax's stock should bolt higher. The main risk factor associated with this biotech stock is that the FDA may request additional clinical data before approval, which certainly isn't out of the realm of possibility.
Wyndham Destinations (NYSE: WYND) is a vacation ownership and exchange company. The company's shares have lost over 63% of their value this year, thanks to the impact of COVID-19 on the leisure travel industry. Wyndham, for its part, recently pulled its financial guidance and suspended share buybacks because of the uncertain outlook for the industry as a result of this deadly respiratory ailment. The bad news is that Wyndham's stock probably hasn't hit rock bottom quite yet. In fact, it's unlikely that demand for leisurely travel lodging will rebound in 2020. But if you're willing to hold this stock for a full five years, it should pay off handsomely after these enormous declines. Wyndham's underlying business model is still a big hit, after all. We just need to get back to the point where tourism -- especially international tourism -- is a thing again.
3 home-run stocks
Home-run stocks are equities that are seemingly grossly mispriced relative to their long-term value proposition. These types of high-risk, high-reward stocks should never make up an outsize portion of a portfolio, but they are sometimes worth owning in small doses. The following home-run stocks offer investors an attractive risk-to-reward profile, especially after their rough start to 2020.
Image source: Getty Images.
Canopy Growth (NYSE: CGC) is a medical and recreational cannabis company that operates out of Smiths Falls, Ontario. Canopy is worth checking out because it's reasonably well capitalized and a leader in terms of cannabis production, product diversity, and annual sales, and it underwent a recent managerial turnover that should lead to a more cost-conscious approach to value creation. Now, this legal marijuana company definitely won't be a big winner for shareholders anytime soon because of the various headwinds facing the industry as a whole. But Canopy's stock might produce stellar gains for investors willing to hold for at least 10 years. Eventually the legal cannabis market will come into its own as a highly lucrative commercial space, a fact that bodes well for leaders in the industry like Canopy.
Delta Air Lines (NYSE: DAL) is among the world's best known airlines. Unfortunately, the company's shares have gotten blasted this year by the dramatic drop in air travel stemming from the COVID-19 crisis. In fact, Delta's shares are down by an eye-popping 64% from their 52-week highs right now. The bad news is that Delta's stock is surely in for more pain in the weeks ahead. That's an unavoidable outcome, with demand for commercial air travel hitting all-time lows. Like some of the other names on this list, however, Delta's shares should sharply rebound post-pandemic.
Virgin Galactic (NYSE: SPCE) is a leader in the race to make space tourism a viable industry. Virgin Galactic's shares have slid by almost 15% this year in response to the possibility of a recession and, hence, lower demand for space tourism. But this sell-off might be a perfect opportunity to buy shares. By the end of the decade, Virgin Galactic could prove to be a cutting-edge innovator that makes space tourism a possibility for wide swath of society -- not just millionaires and billionaires with cash to burn. Virgin Galactic may never fully realize this lofty goal, but this novel company definitely qualifies as a possible home-run play.
10 stocks we like better than Walmart
When investing geniuses David and Tom Gardner have an investing tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Walmart wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
Stock Advisor returns as of 2/1/20
John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alibaba Group Holding Ltd., Amazon, Apple, Bristol Myers Squibb, Delta Air Lines, MercadoLibre, and Walt Disney. The Motley Fool owns shares of Virgin Galactic Holdings Inc. The Motley Fool recommends BioMarin Pharmaceutical, DexCom, Intercept Pharmaceuticals, Johnson & Johnson, and Verizon Communications and recommends the following options: long January 2021 $60 calls on Walt Disney, short April 2020 $135 calls on Walt Disney, short January 2022 $1940 calls on Amazon, and long January 2022 $1920 calls on Amazon. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT) is a medical device and molecular diagnostic company. While the company's top-line has been struggling of late because of the influx of numerous competitors and a shift in American eating habits in general, McDonald's was still forecast to see a nice bump in revenue next year before this pandemic took hold. Pfizer (NYSE: PFE) started off the year on a sour note but has since found its footing as investors flocked to its top-notch dividend yield of 4.62%, strong balance sheet, and above-average near-term outlook. | Abbott Laboratories (NYSE: ABT) is a medical device and molecular diagnostic company. While there are literally hundreds of ETFs to choose from, the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB), the Vanguard Consumer Staples Index Fund ETF Shares (NYSEMKT: VDC), and the Vanguard Information Technology Index Fund ETF Shares (NYSEMKT: VGT) are three of the most highly regarded among passive fund enthusiasts -- and for good reason. The Motley Fool owns shares of and recommends Alibaba Group Holding Ltd., Amazon, Apple, Bristol Myers Squibb, Delta Air Lines, MercadoLibre, and Walt Disney. | Abbott Laboratories (NYSE: ABT) is a medical device and molecular diagnostic company. While there are literally hundreds of ETFs to choose from, the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB), the Vanguard Consumer Staples Index Fund ETF Shares (NYSEMKT: VDC), and the Vanguard Information Technology Index Fund ETF Shares (NYSEMKT: VGT) are three of the most highly regarded among passive fund enthusiasts -- and for good reason. 2 megacap growth stocks Megacap companies, or companies with market caps of at least $200 billion, are rarely coveted for their growth prospects. | Abbott Laboratories (NYSE: ABT) is a medical device and molecular diagnostic company. Even so, the company's shares have been hit hard this year by the COVID-19 pandemic. The bad news is that Clorox's shares are now trading at close to 28 times earnings, making it one of the most expensive blue-chip stocks on this list. |
32732.0 | 2020-04-05 00:00:00 UTC | 3 Coronavirus Stocks That Could Lead the Market to Recovery | ABT | https://www.nasdaq.com/articles/3-coronavirus-stocks-that-could-lead-the-market-to-recovery-2020-04-05 | nan | nan | Almost three months have passed since COVID-19 began its spread beyond China’s borders, and the market remains in free fall. Capping off another volatile week, stocks fell on Friday April 3 in response to disappointing U.S. economic data, offsetting gains posted in the previous session.
Based on a new report from the Labor Department, the U.S. economy saw 701,000 jobs erased in March, much more than economists originally expected as the figure doesn’t even include the 10 million unemployment filings that occurred after March 14.
In addition, New York Governor Andrew Cuomo announced on Friday that the state had experienced the biggest jump in COVID-19-related deaths the day before, sending the market plummeting even further.
For those investors feeling hopeless right now, there’s a bright spot on the horizon. Several companies have stepped up to the plate, developing innovative solutions to fight off the deadly virus. According to some Wall Street pros, these new technologies represent a possible inflection point in the war against COVID-19, and could even help drive the stock market’s recovery.
Taking all of this into consideration, we used TipRanks’ database to get more information on three stocks at the frontline of the COVID-19 battle. The investing platform revealed that all of these Buy-rated tickers have been flagged by some analysts for their technology’s huge potential. Let’s get started.
Abbott Laboratories (ABT)
In the fight against COVID-19, Abbott’s tests to identify the virus have helped healthcare providers make significant headway.
Along with its molecular test that is already being used in labs throughout the U.S., the company revealed on April 3 that the FDA granted emergency use authorization (EUA) for a rapid coronavirus testing system. As the product can detect positive results in five minutes and negative results in 13 minutes, much faster than any other available COVID-19 tests, Wall Street focus has locked in on ABT.
Weighing in for Barclays, analyst Kristen Stewart believes the test will be performed on the ID NOW platform, an isothermal nucleic acid amplification technology, and thus offers advantages that go beyond its speed.
“The system is easy to use with minimal training. The tests are CLIA waived, which is an advantage and allows for the placement in physician offices and urgent care offices. We estimate there are at least 15,000 systems in the United States, placed throughout physician offices, urgent care offices, and other healthcare facilities,” Stewart explained.
As for the total opportunity, Stewart doesn’t dispute that Abbott’s manufacturing capacity, which she thinks would be the rate limiting factor as there is significant demand for the test, remains unclear. “The pricing would likely be under the non-CDC pricing ~$51 level, perhaps in the $35-$45 range. We hope Abbott would supply these details when it announces approval,” the analyst noted.
That being said, 4 million of its molecular tests can be conducted each month on its m2000 systems, with ABT charging about $30 per test. As a result, Stewart kept an Overweight call and $98 price target on the stock. Should this target be met, a twelve-month gain of 23% could be in the cards. (To watch Stewart’s track record, click here)
Turning now to other Wall Street analysts, the bulls have it. With 8 Buy ratings and 3 Holds assigned in the last three months, the consensus rating comes in as a Moderate Buy. The $97.89 average price target implies only slightly less upside potential than Stewart’s forecast. (See Abbott stock analysis on TipRanks)
Johnson & Johnson (JNJ)
Next up is a consumer goods and healthcare heavyweight, Johnson & Johnson, which is developing a vaccine against COVID-19. After the company identified a lead candidate, one analyst thinks JNJ is one of the names capable of fueling the stock market’s turnaround.
With a lead experimental vaccine candidate selected, Kristen Stewart, who also covers ABT, points out that at the latest, JNJ can kick off Phase 1 human clinical studies by September 2020. According to management, the first doses of the vaccine could be available under Emergency Use Authorization (EUA) in early 2021.
Adding to the good news, JNJ has significantly expanded its partnership with the Biomedical Advanced Research and Development Authority (BARDA), with both entities pledging more than $1 billion to co-fund the vaccine’s development and clinical testing. If that wasn’t enough, Stewart notes “BARDA and JNJ have provided additional funding to allow expansion of ongoing work to identify anti-viral treatments against COVID-19.”
However, while JNJ has ramped up the scaling of manufacturing capacity and has a target of supplying more than 1 billion vaccine doses, there is a risk that the candidate won’t eventually receive approval.
Having said that, Stewart argues the real goal is to develop an affordable vaccine “on a not-for-profit basis for emergency pandemic use.” She added, “Thus we would anticipate the cost it would charge for the vaccine would recoup the cost of development, cost of scaling up the manufacturing, and cost of production. Thus, we would not look at the vaccine as being a windfall or major positive from a financial perspective. We believe J&J is doing the right thing and adhering to the company’s long-running Credo.”
Despite the fact that its medical device business could take a hit as elective procedures are delayed, its COVID-19 vaccine candidate, balanced portfolio, strong balance sheet and dividend, yielding 2.8% and paying out $3.80 per share annually, reaffirm Stewart’s confidence. Bearing this in mind, she maintained a Buy rating and $173 price target. This implies shares could surge 29% in the next year.
What does the rest of the Street have to say? Out of 9 recent reviews, 8 were bullish, making the consensus rating a Strong Buy. In addition, the $157.22 average price target brings the upside potential to 17%. (See Johnson & Johnson stock analysis on TipRanks)
Gilead Sciences (GILD)
Biotech Gilead Sciences has grabbed headlines left and right thanks to its experimental COVID-19 treatment, remdesivir. With the company now stating it will donate 1.5 million doses of the drug, which could treat 140,000 patients, it’s no wonder some analysts are standing firmly behind GILD.
Shares are up 20% year-to-date, but Jeffries’ Michael Yee believes its growth story is still heating up. Looking at the big picture, he argues, “GILD remains a defensive positioning stock particularly in this macro environment. We appreciate short-term trading has been mostly dictated around market volatility risk-on/off and expectations on remdesivir for COVID-19 data starting in April.”
That being said, there’s more to this biotech’s “improving story”. The company has placed a significant focus on expansion, with its recent M&A activity including a $5 billion deal with immuno-oncology company Forty Seven. Additionally, its second quarter Phase 3 filgotinib UC data readout could send shares on an upward trajectory as well as improve sentiment surrounding the drug’s differentiation from AbbVie.
Yee already thinks that the pbo-adjusted remission rates imply that filgotinib is “competitive with other UC drugs.” Expounding on this, he stated, “While we expect investors to make cross-trial comparisons, we caution comparing directly to other UC datasets is imprecise due to differing baseline characteristics such as proportion of biologic naive/experienced and slightly different endpoints of the Mayo score. However -- recent commentary from GILD suggests positive confidence around results and good activity in both biologic naive and experienced.”
With an August PDUFA date for filgotinib in RA, Yee does, however, acknowledge that a class label Black Box could be given as a result of uncertainty related to degree of bleeding difference between various JAK drugs. It’s also still unclear if filgotinib will be approved at the 200mg dose.
Commenting on the second issue, Yee said, “In any case, it's reasonable to approve 200mg particularly if the MANTA interim look is OK but FDA is a conservative bunch. Also, even if not, we point out ABBV was only approved at the low dose in RA as well so it would not be a totally critical issue.” To this end, Yee reiterated a Buy recommendation and $89 price target, indicating 14% upside potential. (To watch Yee’s track record, click here)
Looking at the consensus breakdown, 10 Buys, 9 Holds and 2 Sells add up to a Moderate Buy consensus rating. At $76.88, the average price target puts the downside potential at 2%. (See Gilead stock analysis on TipRanks)
To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With a lead experimental vaccine candidate selected, Kristen Stewart, who also covers ABT, points out that at the latest, JNJ can kick off Phase 1 human clinical studies by September 2020. Abbott Laboratories (ABT) In the fight against COVID-19, Abbott’s tests to identify the virus have helped healthcare providers make significant headway. As the product can detect positive results in five minutes and negative results in 13 minutes, much faster than any other available COVID-19 tests, Wall Street focus has locked in on ABT. | Abbott Laboratories (ABT) In the fight against COVID-19, Abbott’s tests to identify the virus have helped healthcare providers make significant headway. As the product can detect positive results in five minutes and negative results in 13 minutes, much faster than any other available COVID-19 tests, Wall Street focus has locked in on ABT. That being said, 4 million of its molecular tests can be conducted each month on its m2000 systems, with ABT charging about $30 per test. | Abbott Laboratories (ABT) In the fight against COVID-19, Abbott’s tests to identify the virus have helped healthcare providers make significant headway. As the product can detect positive results in five minutes and negative results in 13 minutes, much faster than any other available COVID-19 tests, Wall Street focus has locked in on ABT. That being said, 4 million of its molecular tests can be conducted each month on its m2000 systems, with ABT charging about $30 per test. | Abbott Laboratories (ABT) In the fight against COVID-19, Abbott’s tests to identify the virus have helped healthcare providers make significant headway. As the product can detect positive results in five minutes and negative results in 13 minutes, much faster than any other available COVID-19 tests, Wall Street focus has locked in on ABT. That being said, 4 million of its molecular tests can be conducted each month on its m2000 systems, with ABT charging about $30 per test. |
32733.0 | 2020-04-04 00:00:00 UTC | EXCLUSIVE-Amazon in contact with coronavirus test makers for potential screenings on employees | ABT | https://www.nasdaq.com/articles/exclusive-amazon-in-contact-with-coronavirus-test-makers-for-potential-screenings-on | nan | nan | By Jeffrey Dastin and Krystal Hu
April 4 (Reuters) - Amazon.com Inc AMZN.O has been in contact with the CEOs of two coronavirus test makers as it considers how to screen its staff and reduce the risk of infection at its warehouses, according to internal meeting notes seen by Reuters.
The chief executives of Abbott Laboratories ABT.N and Thermo Fisher Scientific Inc TMO.N have told Amazon they would like to work with the e-commerce company, though the U.S. government is taking up all of their testing capacity at present, the notes said.
The company also discussed whether it could start such tests in at least one warehouse near its Seattle headquarters, the status of which was unclear. The nature of Amazon's conversations with the test makers and the exact assistance they might offer were unclear.
The document separately indicated Amazon is looking into the ability to screen more than one person at a time for the virus, and it also wants to partner with a medical organization in its testing efforts. It did not give further details on multi-person testing or name a partner.
In a statement on Saturday, Abbott Laboratories confirmed it has been contacted by Amazon and other companies to provide testing for their workforces.
"We know it's important for several industries for their workforces to be safe, but as we've said, right now we've prioritized the healthcare frontline workforce in outbreak hotspots and have been working with the White House Task Force, FDA, FEMA and CDC and state authorities to ensure they get to those areas," said an Abbott spokesperson.
Thermo Fisher did not return a request for comment late Friday. Amazon declined to comment.
Amazon, the world's largest online retailer, is rolling out face masks and temperature checks for workers at all its U.S. and European warehouses by next week.
Longer term, however, it wants to test workers for the virus and hopes other companies will follow suit, according to the notes, in which Amazon's general counsel also criticized an employee who was fired on Monday.
The notes reveal how the company is focused on coronavirus testing as important to its operation and to bolstering the U.S. economy. They also show how Amazon remains in the early stages of determining how to start checks for the virus and tackle a shortage of tests.
The attempts to increase screening measures come at a time when high-profile protests have hit several Amazon warehouses, as employees increasingly fear they will contract the virus by showing up to work. The COVID-19 disease already has been reported among staff from at least 19 of its U.S. warehouses.
More than a million people globally have been infected and more than 58,000 have died in the pandemic.
Abbott has U.S. marketing approval for a diagnostic test that can give patients results in minutes, for use in physicians' offices and other community healthcare settings. The U.S. Food and Drug Administration has approved a Thermo Fisher test as well.
The type of evaluation Amazon was considering was also unclear, whether diagnostic to detect current infections or an antibody test to tell if someone may be immune.
Amazon has had a growing interest in healthcare. The company announced a partnership with Berkshire Hathaway Inc BRKa.N and JPMorgan Chase & Co JPM.N two years ago to lower health costs for their employees, a venture now known as Haven.
Other retailers, meanwhile, including rival Walmart Inc WMT.N, have worked with the White House on drive-through testing for first responders.
(Reporting By Jeffrey Dastin in San Francisco, and Krystal Hu and Carl O'Donnell in New York; Editing by Peter Henderson, Pravin Char and Daniel Wallis)
((Jeffrey.Dastin@thomsonreuters.com; +1 415 344 4914;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The chief executives of Abbott Laboratories ABT.N and Thermo Fisher Scientific Inc TMO.N have told Amazon they would like to work with the e-commerce company, though the U.S. government is taking up all of their testing capacity at present, the notes said. Longer term, however, it wants to test workers for the virus and hopes other companies will follow suit, according to the notes, in which Amazon's general counsel also criticized an employee who was fired on Monday. The company announced a partnership with Berkshire Hathaway Inc BRKa.N and JPMorgan Chase & Co JPM.N two years ago to lower health costs for their employees, a venture now known as Haven. | The chief executives of Abbott Laboratories ABT.N and Thermo Fisher Scientific Inc TMO.N have told Amazon they would like to work with the e-commerce company, though the U.S. government is taking up all of their testing capacity at present, the notes said. By Jeffrey Dastin and Krystal Hu April 4 (Reuters) - Amazon.com Inc AMZN.O has been in contact with the CEOs of two coronavirus test makers as it considers how to screen its staff and reduce the risk of infection at its warehouses, according to internal meeting notes seen by Reuters. The attempts to increase screening measures come at a time when high-profile protests have hit several Amazon warehouses, as employees increasingly fear they will contract the virus by showing up to work. | The chief executives of Abbott Laboratories ABT.N and Thermo Fisher Scientific Inc TMO.N have told Amazon they would like to work with the e-commerce company, though the U.S. government is taking up all of their testing capacity at present, the notes said. By Jeffrey Dastin and Krystal Hu April 4 (Reuters) - Amazon.com Inc AMZN.O has been in contact with the CEOs of two coronavirus test makers as it considers how to screen its staff and reduce the risk of infection at its warehouses, according to internal meeting notes seen by Reuters. Longer term, however, it wants to test workers for the virus and hopes other companies will follow suit, according to the notes, in which Amazon's general counsel also criticized an employee who was fired on Monday. | The chief executives of Abbott Laboratories ABT.N and Thermo Fisher Scientific Inc TMO.N have told Amazon they would like to work with the e-commerce company, though the U.S. government is taking up all of their testing capacity at present, the notes said. By Jeffrey Dastin and Krystal Hu April 4 (Reuters) - Amazon.com Inc AMZN.O has been in contact with the CEOs of two coronavirus test makers as it considers how to screen its staff and reduce the risk of infection at its warehouses, according to internal meeting notes seen by Reuters. "We know it's important for several industries for their workforces to be safe, but as we've said, right now we've prioritized the healthcare frontline workforce in outbreak hotspots and have been working with the White House Task Force, FDA, FEMA and CDC and state authorities to ensure they get to those areas," said an Abbott spokesperson. |
32734.0 | 2020-04-03 00:00:00 UTC | Why Abbott Labs Shares Rose 2.44% in March | ABT | https://www.nasdaq.com/articles/why-abbott-labs-shares-rose-2.44-in-march-2020-04-03 | nan | nan | What happened
Though many stocks entered a bear market in March, shares of Abbott Laboratories (NYSE: ABT) gained 2.44% in the month, according to data provided by S&P Global Market Intelligence. The stock climbed as Abbott announced the clearance of its coronavirus test.
The coronavirus outbreak has now reached 900,300 cases worldwide, and countries are facing shortages of tests and related equipment. In March, the U.S. Food and Drug Administration granted Abbott emergency-use authorization for its molecular point-of-care test. As the fastest test currently available, it can deliver positive results in as few as 5 minutes and negative results in 13 minutes. The test operates on Abbott's ID NOW platform, a device about the size of a toaster that can be used in a variety of locations from hospitals to doctors' offices.
Image source: Getty Images.
So what
The ID NOW platform is already widely used throughout the U.S., making it likely that facilities with the platform will order the coronavirus tests. Abbott said it was boosting production to deliver 50,000 COVID-19 tests per day to sites in the U.S. In March, the company also announced the emergency-use authorization for its COVID-19 molecular test to be used in laboratories. Since a key part of controlling the pandemic is through testing, Abbott is set to play an important role in the coming weeks.
Now what
That said, the coronavirus test is a very small part of this massive company, with expertise in areas including glucose monitoring, adult and pediatric nutrition, and remote heart failure monitoring. For example, in the fourth quarter, diagnostics totaled $2 billion in sales, while medical devices generated $3.2 billion. While diagnostics sales rose 6.4% year over year, medical device sales gained even more, growing 11.3%. Sales of the COVID-19 tests surely will add to Abbott's sales, but over time, the company's portfolio as a whole is what will drive gains.
Though the shares resisted last month's market decline, April's performance might depend on what Abbott says -- especially about any impact from the coronavirus outbreak on business -- during its first-quarter earnings report on April 16.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Though many stocks entered a bear market in March, shares of Abbott Laboratories (NYSE: ABT) gained 2.44% in the month, according to data provided by S&P Global Market Intelligence. The coronavirus outbreak has now reached 900,300 cases worldwide, and countries are facing shortages of tests and related equipment. The test operates on Abbott's ID NOW platform, a device about the size of a toaster that can be used in a variety of locations from hospitals to doctors' offices. | What happened Though many stocks entered a bear market in March, shares of Abbott Laboratories (NYSE: ABT) gained 2.44% in the month, according to data provided by S&P Global Market Intelligence. In March, the company also announced the emergency-use authorization for its COVID-19 molecular test to be used in laboratories. While diagnostics sales rose 6.4% year over year, medical device sales gained even more, growing 11.3%. | What happened Though many stocks entered a bear market in March, shares of Abbott Laboratories (NYSE: ABT) gained 2.44% in the month, according to data provided by S&P Global Market Intelligence. The stock climbed as Abbott announced the clearance of its coronavirus test. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Adria Cimino has no position in any of the stocks mentioned. | What happened Though many stocks entered a bear market in March, shares of Abbott Laboratories (NYSE: ABT) gained 2.44% in the month, according to data provided by S&P Global Market Intelligence. In March, the company also announced the emergency-use authorization for its COVID-19 molecular test to be used in laboratories. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. |
32735.0 | 2020-04-02 00:00:00 UTC | ABT May 22nd Options Begin Trading | ABT | https://www.nasdaq.com/articles/abt-may-22nd-options-begin-trading-2020-04-02 | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the May 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 22nd contracts and identified one put and one call contract of particular interest.
The put contract at the $74.50 strike price has a current bid of $2.70. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $74.50, but will also collect the premium, putting the cost basis of the shares at $71.80 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $77.60/share today.
Because the $74.50 strike represents an approximate 4% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 62%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 3.62% return on the cash commitment, or 26.46% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $74.50 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $78.50 strike price has a current bid of $2.50. If an investor was to purchase shares of ABT stock at the current price level of $77.60/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $78.50. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 4.38% if the stock gets called away at the May 22nd expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $78.50 strike highlighted in red:
Considering the fact that the $78.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 54%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 3.22% boost of extra return to the investor, or 23.52% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 78%, while the implied volatility in the call contract example is 71%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $77.60) to be 34%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks Analysts Like »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $78.50 strike highlighted in red: Considering the fact that the $78.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the May 22nd expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $78.50 strike highlighted in red: Considering the fact that the $78.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the May 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 22nd contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $78.50 strike highlighted in red: Considering the fact that the $78.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the May 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 22nd contracts and identified one put and one call contract of particular interest. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 22nd contracts and identified one put and one call contract of particular interest. Below is a chart showing ABT's trailing twelve month trading history, with the $78.50 strike highlighted in red: Considering the fact that the $78.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the May 22nd expiration. |
32736.0 | 2020-04-02 00:00:00 UTC | Better Coronavirus Stock: Abbott Labs vs. Gilead Sciences | ABT | https://www.nasdaq.com/articles/better-coronavirus-stock%3A-abbott-labs-vs.-gilead-sciences-2020-04-02 | nan | nan | I'll admit that labeling Abbott Laboratories (NYSE: ABT) and Gilead Sciences (NASDAQ: GILD) as "coronavirus stocks" is kind of like calling Michael Jordan a once-aspiring minor league baseball player. The descriptions are technically accurate, but they leave out a lot.
However, it's fair to say that the coronavirus programs of Abbott Labs and Gilead Sciences have put both stocks on the forefront of investors' minds in recent weeks. Which of these two "coronavirus stocks" is the better choice for long-term investors? Here's how Abbott and Gilead stack up against each other.
Image source: Getty Images.
The case for Abbott Labs
Abbott is poised to make a major difference in the fight against the novel coronavirus disease (COVID-19). The big healthcare company announced last week that it received emergency use authorization from the Food and Drug Administration for a new COVID-19 test that can provide results in as little as five minutes.
The company's new COVID-19 test runs on its ID NOW platform, the most widely used point-of-care molecular testing platform in the U.S. Expect demand for Abbott's COVID-19 test -- and its ID NOW technology -- to soar over the next few weeks and months.
Sales are already soaring for one of Abbott's most important growth drivers. The company's Freestyle Libre continuous glucose monitoring (CGM) system generated revenue of close to $2 billion, up 70% year over year. Growth should accelerate even more once Abbott wins FDA clearance for the next generation of the CGM system, which will support interoperability with other devices including insulin pumps.
Abbott Labs also continues to enjoy strong momentum for several other products in its lineup. The company's Alinity line of lab diagnostics systems has had a successful launch in Europe and will almost certainly be a big hit in the U.S. as additional assays are approved. Abbott's MitraClip device for mitral regurgitation (leaky heart valve) and its HeartMate 3 left ventricular assist device (LVAD) are also key to the company's growth.
Even with its shares down year to date due to the coronavirus-fueled market sell-off, Abbott's shares still trade at 21 times expected earnings. That's pricey in a market with plenty of stocks with lower valuations. However, Abbott's strong growth prospects make the stock attractive.
It also helps that Abbott boasts an exceptionally solid dividend program. The company has increased its dividend for a remarkable 48 consecutive years. Its dividend yield currently stands at close to 1.8%.
The case for Gilead Sciences
Gilead Sciences appears to be in the lead position in developing an effective treatment for COVID-19. Its antiviral drug remdesivir is in late-stage clinical studies. Demand has been so high for the experimental drug in treating patients with severe cases of COVID-19 under emergency-use provisions that the company had to stop accepting new requests for remdesivir with a few exceptions.
This overwhelming demand isn't surprising. World Health Organization (WHO) assistant director-general Bruce Aylward singled out remdesivir in late February as the most promising drug for treating COVID-19. Since then, Gilead and its experimental coronavirus drug have been featured by many news organizations, garnering a lot of favorable publicity.
But Gilead Sciences is best known for two other antiviral programs. The company has been a longtime leader in fighting HIV. Its newest drug in the franchise, Biktarvy, appears to be on track to become the biggest commercial success ever in treating HIV. Gilead also has made billions of dollars by curing hepatitis C in most patients taking its hep-C drugs. It's been so successful, in fact, that the company's revenue from those drugs has declined significantly in part because there are fewer patients to treat.
Gilead has also made its mark outside of the antiviral arena. The company is a leader in cancer cell therapy thanks to its acquisition of Kite Pharma in 2017. It could soon be a major player in the rheumatoid arthritis market, with potential blockbuster drug filgotinib awaiting regulatory approvals in the U.S. and in Europe.
While most stocks have plunged so far in 2020, Gilead's shares are up by a double-digit percentage. However, the stock still appears to be inexpensive with shares trading at less than 12 times expected earnings.
Most biotech stocks don't pay dividends. Gilead is a notable exception. The company boasts a juicy dividend yield of more than 3.7%. Since initiating its dividend program in 2015, Gilead has increased its dividend payout by 58%.
Better pick
I liked both of these stocks before the coronavirus pandemic and like them even more now. Which is the better pick? I think it depends on your investing style.
Investors who are more risk-averse will probably prefer Abbott Labs. It's a Dividend Aristocrat with solid growth prospects. However, more aggressive investors could find Gilead more to their liking. The biotech's pipeline could turbocharge growth over the next few years. This growth, combined with Gilead's dividend, should enable the stock to deliver market-beating total returns.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | I'll admit that labeling Abbott Laboratories (NYSE: ABT) and Gilead Sciences (NASDAQ: GILD) as "coronavirus stocks" is kind of like calling Michael Jordan a once-aspiring minor league baseball player. Growth should accelerate even more once Abbott wins FDA clearance for the next generation of the CGM system, which will support interoperability with other devices including insulin pumps. Demand has been so high for the experimental drug in treating patients with severe cases of COVID-19 under emergency-use provisions that the company had to stop accepting new requests for remdesivir with a few exceptions. | I'll admit that labeling Abbott Laboratories (NYSE: ABT) and Gilead Sciences (NASDAQ: GILD) as "coronavirus stocks" is kind of like calling Michael Jordan a once-aspiring minor league baseball player. The company's Freestyle Libre continuous glucose monitoring (CGM) system generated revenue of close to $2 billion, up 70% year over year. However, Abbott's strong growth prospects make the stock attractive. | I'll admit that labeling Abbott Laboratories (NYSE: ABT) and Gilead Sciences (NASDAQ: GILD) as "coronavirus stocks" is kind of like calling Michael Jordan a once-aspiring minor league baseball player. However, it's fair to say that the coronavirus programs of Abbott Labs and Gilead Sciences have put both stocks on the forefront of investors' minds in recent weeks. 10 stocks we like better than Gilead Sciences When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | I'll admit that labeling Abbott Laboratories (NYSE: ABT) and Gilead Sciences (NASDAQ: GILD) as "coronavirus stocks" is kind of like calling Michael Jordan a once-aspiring minor league baseball player. Demand has been so high for the experimental drug in treating patients with severe cases of COVID-19 under emergency-use provisions that the company had to stop accepting new requests for remdesivir with a few exceptions. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! |
32737.0 | 2020-04-01 00:00:00 UTC | There's a New 15-Minute Coronavirus Test | ABT | https://www.nasdaq.com/articles/theres-a-new-15-minute-coronavirus-test-2020-04-01 | nan | nan | A new coronavirus test from Becton Dickinson (NYSE: BDX) can deliver results about 15 minutes after a healthcare provider drops a person's blood sample in the test kit. The new test was developed by BioMedomics, a privately held company based in North Carolina that will also manufacture the point-of-care diagnostic.
Unlike a recently approved point-of-care test from Abbott (NYSE: ABT) that looks for genetic material specific to SARS-CoV-2, Becton Dickinson's new test looks for some of the proteins produced from that genetic material. On Sunday, the FDA authorized the use of a rapid test that runs on Abbott's toaster-sized nucleic acid amplification machines, which are already in use by healthcare providers across the U.S.
Image source: Getty Images.
Becton Dickinson's new antibody test hasn't been reviewed by the FDA, but the company will be allowed to distribute it immediately to U.S. healthcare providers thanks to emergency guidance issued by the regulator in March. However, that guidance also makes it clear that results from antibody tests -- whether performed at an urgent care center or a giant laboratory -- should not be used as the sole basis to diagnose a patient or inform them of their infection status.
Becton Dickinson's more widely known for marketing infusion systems than diagnostic tests. Sales of the company's popular Alaris systems, which are used by a majority of healthcare providers in the U.S., are under pressure at the moment. And investors hoping that this new COVID-19 test will offset the decreasing revenue from the infusion system line could be disappointed.
Healthcare providers can order the new coronavirus antibody test from Becton Dickinson, although a company with more experience in the point-of-care diagnostics field, Henry Schein will distribute the test exclusively.
10 stocks we like better than Becton, Dickinson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Becton, Dickinson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Becton, Dickinson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Unlike a recently approved point-of-care test from Abbott (NYSE: ABT) that looks for genetic material specific to SARS-CoV-2, Becton Dickinson's new test looks for some of the proteins produced from that genetic material. On Sunday, the FDA authorized the use of a rapid test that runs on Abbott's toaster-sized nucleic acid amplification machines, which are already in use by healthcare providers across the U.S. Becton Dickinson's new antibody test hasn't been reviewed by the FDA, but the company will be allowed to distribute it immediately to U.S. healthcare providers thanks to emergency guidance issued by the regulator in March. | Unlike a recently approved point-of-care test from Abbott (NYSE: ABT) that looks for genetic material specific to SARS-CoV-2, Becton Dickinson's new test looks for some of the proteins produced from that genetic material. A new coronavirus test from Becton Dickinson (NYSE: BDX) can deliver results about 15 minutes after a healthcare provider drops a person's blood sample in the test kit. Becton Dickinson's more widely known for marketing infusion systems than diagnostic tests. | Unlike a recently approved point-of-care test from Abbott (NYSE: ABT) that looks for genetic material specific to SARS-CoV-2, Becton Dickinson's new test looks for some of the proteins produced from that genetic material. A new coronavirus test from Becton Dickinson (NYSE: BDX) can deliver results about 15 minutes after a healthcare provider drops a person's blood sample in the test kit. Becton Dickinson's new antibody test hasn't been reviewed by the FDA, but the company will be allowed to distribute it immediately to U.S. healthcare providers thanks to emergency guidance issued by the regulator in March. | Unlike a recently approved point-of-care test from Abbott (NYSE: ABT) that looks for genetic material specific to SARS-CoV-2, Becton Dickinson's new test looks for some of the proteins produced from that genetic material. Becton Dickinson's new antibody test hasn't been reviewed by the FDA, but the company will be allowed to distribute it immediately to U.S. healthcare providers thanks to emergency guidance issued by the regulator in March. Healthcare providers can order the new coronavirus antibody test from Becton Dickinson, although a company with more experience in the point-of-care diagnostics field, Henry Schein will distribute the test exclusively. |
32738.0 | 2020-04-01 00:00:00 UTC | OEF, COST, ABT, BMY: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/oef-cost-abt-bmy%3A-etf-inflow-alert-2020-04-01 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $154.2 million dollar inflow -- that's a 3.3% increase week over week in outstanding units (from 39,200,000 to 40,500,000). Among the largest underlying components of OEF, in trading today Costco Wholesale Corp (Symbol: COST) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is down about 3.5%, and Bristol-Myers Squibb Co. (Symbol: BMY) is lower by about 2.6%. For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average:
Looking at the chart above, OEF's low point in its 52 week range is $101.8696 per share, with $152.576 as the 52 week high point — that compares with a last trade of $115.16. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of OEF, in trading today Costco Wholesale Corp (Symbol: COST) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is down about 3.5%, and Bristol-Myers Squibb Co. (Symbol: BMY) is lower by about 2.6%. For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $101.8696 per share, with $152.576 as the 52 week high point — that compares with a last trade of $115.16. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of OEF, in trading today Costco Wholesale Corp (Symbol: COST) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is down about 3.5%, and Bristol-Myers Squibb Co. (Symbol: BMY) is lower by about 2.6%. For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $101.8696 per share, with $152.576 as the 52 week high point — that compares with a last trade of $115.16. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of OEF, in trading today Costco Wholesale Corp (Symbol: COST) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is down about 3.5%, and Bristol-Myers Squibb Co. (Symbol: BMY) is lower by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $154.2 million dollar inflow -- that's a 3.3% increase week over week in outstanding units (from 39,200,000 to 40,500,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $101.8696 per share, with $152.576 as the 52 week high point — that compares with a last trade of $115.16. | Among the largest underlying components of OEF, in trading today Costco Wholesale Corp (Symbol: COST) is down about 0.3%, Abbott Laboratories (Symbol: ABT) is down about 3.5%, and Bristol-Myers Squibb Co. (Symbol: BMY) is lower by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $154.2 million dollar inflow -- that's a 3.3% increase week over week in outstanding units (from 39,200,000 to 40,500,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $101.8696 per share, with $152.576 as the 52 week high point — that compares with a last trade of $115.16. |
32739.0 | 2020-04-01 00:00:00 UTC | Got $5,000 to Invest? 3 Great Medical Device Stocks to Buy Right Now | ABT | https://www.nasdaq.com/articles/got-%245000-to-invest-3-great-medical-device-stocks-to-buy-right-now-2020-04-01 | nan | nan | Sure, many stocks have bounced back somewhat from their lows during the massive market meltdown caused by the coronavirus pandemic. However, there are still lots of attractive opportunities for long-term investors.
One of the best places to invest over the last five years has been in medical device stocks. The iShares U.S. Medical Devices ETF has more than tripled the performance of the S&P 500 index during the period. I think medical device stocks will continue to beat the overall market throughout this decade.
But which stocks are the best picks? If you have $5,000 to invest (or even less), here are three great medical device stocks to buy right now.
Image source: Getty Images.
1. Abbott Labs
Abbott Labs (NYSE: ABT) stock has rebounded stronger than most stocks have in recent days. It definitely helped that the company received emergency use authorization last week from the FDA to launch the fastest molecular point-of-care test for diagnosing novel coronavirus disease COVID-19. I fully expect this new test, which will run on the already-popular ID NOW testing platform, will be an enormous winner for Abbott.
But as difficult as the challenges are right now, the COVID-19 crisis will only be temporary. Abbott's primary growth drivers lie in addressing health issues that won't go away.
Wall Street analysts project that Abbott will increase its earnings by more than 10% on average annually over the next five years. One key to achieving that growth is the company's successful continuous glucose monitoring (CGM) system Freestyle Libre. Abbott hopes to soon win FDA clearance for a new version of the device that should pave the way for an even greater market opportunity.
In addition to its strong growth prospects, Abbott reigns as one of the more attractive dividend stocks around. The company has increased its dividend for 48 consecutive years and has paid a dividend for a remarkable 384 consecutive quarters. That's 96 years of steady dividends. Abbott's dividend currently yields around 1.8%.
2. DexCom
DexCom's (NASDAQ: DXCM) shares have also made a solid comeback. Although the company doesn't have any products that can be used in the fight against COVID-19, it does have one important thing in common with Abbott Labs.
Like Abbott, DexCom markets a super-successful CGM device. DexCom's G6 has become one of the most popular tools for individuals with diabetes to monitor and manage their condition. The G6 is the first FDA-approved integrated CGM that's interoperable with other medical devices such as insulin pumps.
DexCom has an even more promising product on the way. CEO Kevin Sayer stated in the company's Q4 conference call in February that the G7 CGM, which will be less expensive and smaller than the G6, should be "the biggest product launch in DexCom's history." The company expects to launch the new device in 2021.
Analysts think that DexCom will grow its earnings by an average of nearly 55% annually over the next five years. That kind of growth doesn't seem farfetched considering the likely market opportunity for the company's G7 device.
3. ShockWave Medical
ShockWave Medical (NASDAQ: SWAV) stock took a bigger beating during the coronavirus market sell-off than either Abbott or DexCom. That's not surprising considering that ShockWave is smaller and not yet profitable. But like the larger medical device makers, ShockWave's share price has bounced back in a major way even though it's still down year to date.
The company took an old idea and applied it in an innovative new way. Lithotripsy has been used for decades as a way to break up calcium in kidney stones using sound waves. ShockWave uses intravascular lithotripsy (IVL) to crack calcium in arteries.
This IVL approach reduces some of the major risks associated with current therapies for treating atherosclerosis. For example, balloons and surgery can cause perforations to blood vessels and tissue damage. IVL's sound waves expand blood vessels under low pressure, lowering the risk of perforation and minimizing the chances of harming soft tissue.
ShockWave estimates that its market opportunity tops $6 billion annually. The company should generate around $75 million in revenue this year. It's not surprising that Wall Street analysts project tremendous growth for ShockWave over the next few years.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends ShockWave Medical. The Motley Fool recommends DexCom. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs Abbott Labs (NYSE: ABT) stock has rebounded stronger than most stocks have in recent days. It definitely helped that the company received emergency use authorization last week from the FDA to launch the fastest molecular point-of-care test for diagnosing novel coronavirus disease COVID-19. CEO Kevin Sayer stated in the company's Q4 conference call in February that the G7 CGM, which will be less expensive and smaller than the G6, should be "the biggest product launch in DexCom's history." | Abbott Labs Abbott Labs (NYSE: ABT) stock has rebounded stronger than most stocks have in recent days. Wall Street analysts project that Abbott will increase its earnings by more than 10% on average annually over the next five years. ShockWave Medical ShockWave Medical (NASDAQ: SWAV) stock took a bigger beating during the coronavirus market sell-off than either Abbott or DexCom. | Abbott Labs Abbott Labs (NYSE: ABT) stock has rebounded stronger than most stocks have in recent days. I think medical device stocks will continue to beat the overall market throughout this decade. ShockWave Medical ShockWave Medical (NASDAQ: SWAV) stock took a bigger beating during the coronavirus market sell-off than either Abbott or DexCom. | Abbott Labs Abbott Labs (NYSE: ABT) stock has rebounded stronger than most stocks have in recent days. I think medical device stocks will continue to beat the overall market throughout this decade. The company expects to launch the new device in 2021. |
32740.0 | 2020-03-31 00:00:00 UTC | How The Parts Add Up: PWB Targets $53 | ABT | https://www.nasdaq.com/articles/how-the-parts-add-up%3A-pwb-targets-%2453-2020-03-31 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Dynamic Large Cap Growth ETF (Symbol: PWB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $53.42 per unit.
With PWB trading at a recent price near $44.49 per unit, that means that analysts see 20.08% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of PWB's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), Visa Inc (Symbol: V), and Mastercard Inc (Symbol: MA). Although ABT has traded at a recent price of $79.34/share, the average analyst target is 23.86% higher at $98.27/share. Similarly, V has 23.40% upside from the recent share price of $165.57 if the average analyst target price of $204.32/share is reached, and analysts on average are expecting MA to reach a target price of $311.71/share, which is 23.08% above the recent price of $253.25. Below is a twelve month price history chart comparing the stock performance of ABT, V, and MA:
Combined, ABT, V, and MA represent 10.44% of the Invesco Dynamic Large Cap Growth ETF. Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
Invesco Dynamic Large Cap Growth ETF PWB $44.49 $53.42 20.08%
Abbott Laboratories ABT $79.34 $98.27 23.86%
Visa Inc V $165.57 $204.32 23.40%
Mastercard Inc MA $253.25 $311.71 23.08%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of ABT, V, and MA: Combined, ABT, V, and MA represent 10.44% of the Invesco Dynamic Large Cap Growth ETF. Invesco Dynamic Large Cap Growth ETF PWB $44.49 $53.42 20.08% Abbott Laboratories ABT $79.34 $98.27 23.86% Visa Inc V $165.57 $204.32 23.40% Mastercard Inc MA $253.25 $311.71 23.08% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of PWB's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), Visa Inc (Symbol: V), and Mastercard Inc (Symbol: MA). | Three of PWB's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), Visa Inc (Symbol: V), and Mastercard Inc (Symbol: MA). Invesco Dynamic Large Cap Growth ETF PWB $44.49 $53.42 20.08% Abbott Laboratories ABT $79.34 $98.27 23.86% Visa Inc V $165.57 $204.32 23.40% Mastercard Inc MA $253.25 $311.71 23.08% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Although ABT has traded at a recent price of $79.34/share, the average analyst target is 23.86% higher at $98.27/share. | Three of PWB's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), Visa Inc (Symbol: V), and Mastercard Inc (Symbol: MA). Although ABT has traded at a recent price of $79.34/share, the average analyst target is 23.86% higher at $98.27/share. Below is a twelve month price history chart comparing the stock performance of ABT, V, and MA: Combined, ABT, V, and MA represent 10.44% of the Invesco Dynamic Large Cap Growth ETF. | Although ABT has traded at a recent price of $79.34/share, the average analyst target is 23.86% higher at $98.27/share. Three of PWB's underlying holdings with notable upside to their analyst target prices are Abbott Laboratories (Symbol: ABT), Visa Inc (Symbol: V), and Mastercard Inc (Symbol: MA). Below is a twelve month price history chart comparing the stock performance of ABT, V, and MA: Combined, ABT, V, and MA represent 10.44% of the Invesco Dynamic Large Cap Growth ETF. |
32741.0 | 2020-03-31 00:00:00 UTC | 3 Big Stock Charts for Tuesday: Abbott Laboratories, Johnson & Johnson, and Regeneron Pharmaceuticals | ABT | https://www.nasdaq.com/articles/3-big-stock-charts-for-tuesday%3A-abbott-laboratories-johnson-johnson-and-regeneron | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Big daily moves are still the trend in big stock charts, it seems. The coronavirus from China remained in focus on Monday but with a strong sense of optimism. Major market indexes pushed higher.
Source: Shutterstock
Perhaps the trading community felt hopeful that the U.S. government would be successful in extending its efforts to contain the contagion. Even so, the S&P 500 remains well below its all-time high.
7 Stocks to Buy That Trump’s Tax Cut Truly Rewarded
Tuesday’s big stock charts focus on three companies that investors are hoping will make progress in fighting the spread of the coronavirus. You can root for them while considering a position if you like the charts and, just as importantly, the company’s business model.
Abbott Laboratories (ABT)
Source: Source: Provided by Finviz
The first of Tuesday’s big stock charts, Abbott Laboratories (NYSE:ABT) stock, soared on Monday as investors cheered the news that the company had received regulatory approval for its five-minute COVID-19 test. Let’s see how the stock stands after this encouraging development.
Don’t get greedy with this one. It’s okay to be a bull, but pigs get roasted! Therefore, take profits at the $90 resistance price point.
Feast your eyes on Monday’s enormous volume bar. There’s conviction behind that move, so you wouldn’t want to go short with this one.
The falling wedge is broken to the upside. However, it’s too early to call the wedge invalidated. Still, it’s painting a bullish picture.
Johnson & Johnson (JNJ)
Source: Source: Provided by Finviz
Traders cheered Johnson & Johnson (NYSE:JNJ) and bid up its stock price heartily on Monday. That’s because the company announced that it plans to test out an anti-coronavirus vaccine by September. But do the charts suggest further upside?
The stock is now peeking above that sharply declining resistance line. It’s too soon to determine whether that line will provide support going forward.
Two weeks of heavy volume and large candlesticks suggests that this one’s a big mover. Kind of funny since JNJ is usually viewed as a safety stock.
Monday’s candle is perfectly perched on that horizontal support/resistance line at $127.50. Watch it closely to see whether it provides a floor or a ceiling in the coming days.
Regeneron Pharmaceuticals (REGN)
Source: Source: Provided by Finviz
Auspicious news came from Regeneron Pharmaceuticals (NASDAQ:REGN) as the company revealed its involvement in a clinical trial of a drug treatment for patients with severe COVID-19. So far the results appear to indicate progress. With that in mind, let’s evaluate the third of Tuesday’s big stock charts.
As you can see, this stock didn’t decline as much as the major market indexes. In fact, it has bounced quite nicely off of the $425 support line. If it returns to that price point, that’s a good time to consider a long position.
The channel that started back in October is just getting wider. This suggests bigger price movements in both directions, so be prepared for that.
Resistance is at $500 until proven otherwise. It’s perfectly okay to take profits there and wait for other opportunities. Remember, it’s always better to be safe than sorry!
As of this writing, David Moadel did not hold a position in any of the aforementioned securities.
The post 3 Big Stock Charts for Tuesday: Abbott Laboratories, Johnson & Johnson, and Regeneron Pharmaceuticals appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) Source: Source: Provided by Finviz The first of Tuesday’s big stock charts, Abbott Laboratories (NYSE:ABT) stock, soared on Monday as investors cheered the news that the company had received regulatory approval for its five-minute COVID-19 test. Source: Shutterstock Perhaps the trading community felt hopeful that the U.S. government would be successful in extending its efforts to contain the contagion. Regeneron Pharmaceuticals (REGN) Source: Source: Provided by Finviz Auspicious news came from Regeneron Pharmaceuticals (NASDAQ:REGN) as the company revealed its involvement in a clinical trial of a drug treatment for patients with severe COVID-19. | Abbott Laboratories (ABT) Source: Source: Provided by Finviz The first of Tuesday’s big stock charts, Abbott Laboratories (NYSE:ABT) stock, soared on Monday as investors cheered the news that the company had received regulatory approval for its five-minute COVID-19 test. Johnson & Johnson (JNJ) Source: Source: Provided by Finviz Traders cheered Johnson & Johnson (NYSE:JNJ) and bid up its stock price heartily on Monday. Regeneron Pharmaceuticals (REGN) Source: Source: Provided by Finviz Auspicious news came from Regeneron Pharmaceuticals (NASDAQ:REGN) as the company revealed its involvement in a clinical trial of a drug treatment for patients with severe COVID-19. | Abbott Laboratories (ABT) Source: Source: Provided by Finviz The first of Tuesday’s big stock charts, Abbott Laboratories (NYSE:ABT) stock, soared on Monday as investors cheered the news that the company had received regulatory approval for its five-minute COVID-19 test. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Big daily moves are still the trend in big stock charts, it seems. Johnson & Johnson (JNJ) Source: Source: Provided by Finviz Traders cheered Johnson & Johnson (NYSE:JNJ) and bid up its stock price heartily on Monday. | Abbott Laboratories (ABT) Source: Source: Provided by Finviz The first of Tuesday’s big stock charts, Abbott Laboratories (NYSE:ABT) stock, soared on Monday as investors cheered the news that the company had received regulatory approval for its five-minute COVID-19 test. 7 Stocks to Buy That Trump’s Tax Cut Truly Rewarded Tuesday’s big stock charts focus on three companies that investors are hoping will make progress in fighting the spread of the coronavirus. Therefore, take profits at the $90 resistance price point. |
32742.0 | 2020-03-31 00:00:00 UTC | Is Abbott Labs Stock a Screaming Buy Because of Its Game-Changing COVID-19 Test? | ABT | https://www.nasdaq.com/articles/is-abbott-labs-stock-a-screaming-buy-because-of-its-game-changing-covid-19-test-2020-03-31 | nan | nan | One of the biggest problems for healthcare professionals in the coronavirus pandemic has been the lack of tests to determine if patients have been infected by the virus. And even when tests were available to use, the results usually take days to come back. That's about to change -- thanks to Abbott Laboratories (NYSE: ABT).
Abbott won FDA Emergency Use Authorization (EUA) last Friday for a new point-of-care test for novel coronavirus disease COVID-19 that can deliver positive results in as quickly as five minutes and negative results within 13 minutes. The test runs on the company's ID NOW platform that's about the size of a toaster.
It's no exaggeration to say that Abbott's new test could be a game-changer in the fight against COVID-19. But is Abbott Labs stock now a screaming buy as a result of its promising new product?
Image source: Abbott Labs.
Going viral
Expect Abbott's new COVID-19 test to fly off the shelves. The company's ID NOW platform on which the test runs is already the most widely available molecular point-of-care testing platform in the country. This platform is popular with physicians and scientists because of its high degree of accuracy and its portability.
Now, the ID NOW platform will support the fastest molecular point-of-care test available for diagnosing infection by the novel coronavirus. Abbott is working with the federal government to ship the tests beginning next week with priority to areas where the new tests could have the biggest impact.
But you can bet that healthcare providers all over the country that already have the ID NOW platform in place will be anxious to get Abbott's new COVID-19 test. Providers that don't have ID NOW already, especially those in urgent care settings, will likely be eager to buy Abbott's platform as well.
This isn't Abbott's first effort in diagnosing COVID-19. Just a little over a week ago, the company launched a COVID-19 test that runs on its m2000 RealTime System that's used by hospitals and reference labs. Abbott thinks that it will be able to produce around 5 million tests each month between its two molecular diagnostics platforms.
And there's more
While Abbott's tremendous progress in COVID-19 testing is gaining a lot of attention right now, there's actually a lot more to like about the healthcare stock. Abbott is a leader in multiple areas beyond its coronavirus efforts.
You can put the company's Freestyle Libre continuous glucose monitoring (CGM) system near the top of the list. Abbott hopes to soon win FDA clearance for a new version of the product that's already used by many individuals with diabetes to monitor their blood sugar levels. This new version is likely to open the door to an even bigger market opportunity for Freestyle Libre, which chalked up sales of close to $2 billion last year.
Abbott's Alinity family of lab diagnostics systems is another major growth driver for the company. Alinity boasts strong sales momentum in Europe. Abbott expects a tremendous launch in the U.S. market as well. It won FDA approval for the Alinity blood and plasma screening system last year and is working toward gaining approvals for its immunoassay and clinical chemistry diagnostics.
There are also other products that should fuel Abbott's growth. MitraClip already ranks as the market leader in minimally invasive treatment of a leaky heart valve condition known as mitral regurgitation. The product is gaining even greater market share thanks to a new FDA approval last year. Abbott's HeartMate 3 left ventricular assist device (LVAD) is another big winner in helping heart failure patients recover.
Scream away
So is Abbott Labs stock a screaming buy right now because of its new COVID-19 test? No -- at least, not only because of this test. But I think the stock is a good pick based on all that Abbott has to offer. The company's coronavirus products are just part of a compelling growth story.
Don't overlook Abbott's dividend program, either. The healthcare giant now claims a track record of 48 consecutive years of dividend increases. Abbott's dividend currently yields a little under 2%.
Abbott Labs' growth prospects already looked great coming into 2020 but now look even better with its launch of a super-fast coronavirus test. With a strong dividend to boot, my view is that Abbott is a stock that just might be worth screaming about.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | That's about to change -- thanks to Abbott Laboratories (NYSE: ABT). This new version is likely to open the door to an even bigger market opportunity for Freestyle Libre, which chalked up sales of close to $2 billion last year. MitraClip already ranks as the market leader in minimally invasive treatment of a leaky heart valve condition known as mitral regurgitation. | That's about to change -- thanks to Abbott Laboratories (NYSE: ABT). But is Abbott Labs stock now a screaming buy as a result of its promising new product? It won FDA approval for the Alinity blood and plasma screening system last year and is working toward gaining approvals for its immunoassay and clinical chemistry diagnostics. | That's about to change -- thanks to Abbott Laboratories (NYSE: ABT). The company's ID NOW platform on which the test runs is already the most widely available molecular point-of-care testing platform in the country. And there's more While Abbott's tremendous progress in COVID-19 testing is gaining a lot of attention right now, there's actually a lot more to like about the healthcare stock. | That's about to change -- thanks to Abbott Laboratories (NYSE: ABT). But is Abbott Labs stock now a screaming buy as a result of its promising new product? Abbott's Alinity family of lab diagnostics systems is another major growth driver for the company. |
32743.0 | 2020-03-30 00:00:00 UTC | 5 Top Stock Trades for Tuesday: ZM, WORK, TWTR, ABT, DDD | ABT | https://www.nasdaq.com/articles/5-top-stock-trades-for-tuesday%3A-zm-work-twtr-abt-ddd-2020-03-30 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Stocks cautiously climbed higher on Monday, as investors continue to test the validity of the current rebound. That said, let’s look at a few top stock trades.
Top Stock Trades for Tomorrow No. 1: Zoom Video (ZM)
Click to Enlarge
Source: Chart courtesy of StockCharts.com
Zoom Video (NYSE:ZM) tried pushing to new 52-week highs on Monday, but was unable to do so. It leaves shares being rejected from the $160 mark — again — as bulls wonder if ZM is losing momentum.
If ZM does lose momentum, we could see a pullback to the $125 to $130 area, which was previously resistance. It could also catch a bounce from its rising 20-day moving average. Below this area puts the $105 mark and the 50-day moving average in play.
7 Strong Stocks to Buy to Survive the Coronavirus Crisis
Above $165 could fuel even more upside in Zoom Video.
Top Stock Trades for Tomorrow No. 2: Slack (WORK)
Click to Enlarge
Source: Chart courtesy of StockCharts.com
When Slack (NYSE:WORK) reported earnings a few weeks ago, shares plunged to a low below $16. After several tests of this level, though, shares found this mark as support, surging through $20 and climbing up toward $30.
However, this $28 to $30 has been a difficult area of resistance for Slack stock. If it breaks, WORK could rip higher, with a move into the mid-$30s in the realm of possibilities.
However, if this area continues to act as resistance, look for a pullback down to the 50-day and 100-day moving averages, between $23 and $24. Below that and $20 is back in play.
Given how hot this name has been, I wouldn’t expect it to break below $20, which was pre-earnings support. If by chance it does, though, it puts $16 in play.
Top Stock Trades for Tomorrow No. 3: Twitter (TWTR)
Click to Enlarge
Source: Chart courtesy of StockCharts.com
Twitter (NYSE:TWTR) shares remain under pressure, although at least there is a low to measure against.
The $26 to $28 zone has been support for several years, as has the 200-week moving average. It’s clear that for now, the latter is acting as resistance, while Twitter is having trouble reclaiming the former as well.
It will need reclaim both marks in order for bulls to regain control. Below $26 and sellers can continue to drive the narrative here. Below $24 and momentum may drive shares back down toward $20.
5 Stocks to Buy That Are Holding Strong While Everything Else Crumbles
On a move over $28, $30 is on the table. Above that and $34 to $35 is possible.
Top Trades for Tomorrow No. 4: Abbott Labs (ABT)
Click to Enlarge
Source: Chart courtesy of StockCharts.com
Despite good news about its new coronavirus testing kit, Abbott Labs (NYSE:ABT) was unable to push through resistance on Monday. Shares still put together a solid rally, though, up 7% at the time of this writing.
Since losing the $82 mark in late-February, this level has been acting as resistance. If ABT stock could have held this mark on Monday, I would have felt better about it on the long side. That’s even as the 50-day, 100-day and 200-day moving averages between $83 and $84 are acting as resistance.
Over $82 puts this trifecta back in play. Over its major moving averages and a gap fill up toward $88 is possible. Below $82 keeps $76 on the table. Below that and $70 or lower is possible.
Top Trades for Tomorrow No. 5: 3D Systems (DDD)
Click to Enlarge
Source: Chart courtesy of StockCharts.com
Go ahead and count 3D Systems (NASDAQ:DDD) among those that are posting solid rebounds from this month’s low.
Over $7.50 and DDD can continue higher, potentially up to its 200-day moving average at $8.81. Above that and the 100-day and 50-day moving averages are possible.
Below $7.50 and $6.50 is in play. Below that and — yep, you guessed it — $5.50 is possible. Keep it simple whenever possible.
Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, he did not hold a position in any of the aforementioned securities.
The post 5 Top Stock Trades for Tuesday: ZM, WORK, TWTR, ABT, DDD appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to Enlarge Source: Chart courtesy of StockCharts.com Despite good news about its new coronavirus testing kit, Abbott Labs (NYSE:ABT) was unable to push through resistance on Monday. 4: Abbott Labs (ABT) If ABT stock could have held this mark on Monday, I would have felt better about it on the long side. | Click to Enlarge Source: Chart courtesy of StockCharts.com Despite good news about its new coronavirus testing kit, Abbott Labs (NYSE:ABT) was unable to push through resistance on Monday. 4: Abbott Labs (ABT) If ABT stock could have held this mark on Monday, I would have felt better about it on the long side. | The post 5 Top Stock Trades for Tuesday: ZM, WORK, TWTR, ABT, DDD appeared first on InvestorPlace. 4: Abbott Labs (ABT) Click to Enlarge Source: Chart courtesy of StockCharts.com Despite good news about its new coronavirus testing kit, Abbott Labs (NYSE:ABT) was unable to push through resistance on Monday. | The post 5 Top Stock Trades for Tuesday: ZM, WORK, TWTR, ABT, DDD appeared first on InvestorPlace. 4: Abbott Labs (ABT) Click to Enlarge Source: Chart courtesy of StockCharts.com Despite good news about its new coronavirus testing kit, Abbott Labs (NYSE:ABT) was unable to push through resistance on Monday. |
32744.0 | 2020-03-30 00:00:00 UTC | FDA Approves Abbott's 5-minute Coronavirus Test | ABT | https://www.nasdaq.com/articles/fda-approves-abbotts-5-minute-coronavirus-test-2020-03-30 | nan | nan | (RTTNews) - The U.S. Food and Drug Administration has approved Abbott's diagnostic test for coronavirus.
Abbott received emergency use authorization from the FDA for its test for the detection of COVID-19, which delivers fast positive results in as little as five minutes and negative results in 13 minutes.
The new Abbott ID NOW COVID-19 test runs on Abbott's ID NOWTM platform—a lightweight box.
"The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus," said CEO Robert Ford. "With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots."
Abbott will be making ID NOW COVID-19 tests available next week to healthcare providers in urgent care settings in the U.S.
The U.S. has now crossed China to become the country with most number of COVID-19 patients.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - The U.S. Food and Drug Administration has approved Abbott's diagnostic test for coronavirus. "The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus," said CEO Robert Ford. Abbott will be making ID NOW COVID-19 tests available next week to healthcare providers in urgent care settings in the U.S. | (RTTNews) - The U.S. Food and Drug Administration has approved Abbott's diagnostic test for coronavirus. The new Abbott ID NOW COVID-19 test runs on Abbott's ID NOWTM platform—a lightweight box. "With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots." | Abbott received emergency use authorization from the FDA for its test for the detection of COVID-19, which delivers fast positive results in as little as five minutes and negative results in 13 minutes. The new Abbott ID NOW COVID-19 test runs on Abbott's ID NOWTM platform—a lightweight box. "With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots." | (RTTNews) - The U.S. Food and Drug Administration has approved Abbott's diagnostic test for coronavirus. Abbott received emergency use authorization from the FDA for its test for the detection of COVID-19, which delivers fast positive results in as little as five minutes and negative results in 13 minutes. Abbott will be making ID NOW COVID-19 tests available next week to healthcare providers in urgent care settings in the U.S. |
32745.0 | 2020-03-30 00:00:00 UTC | Stock Market News: These 2 Coronavirus-Fighting Stocks Are Taking Off | ABT | https://www.nasdaq.com/articles/stock-market-news%3A-these-2-coronavirus-fighting-stocks-are-taking-off-2020-03-30 | nan | nan | The stock market gained ground on Monday, bouncing back from its Friday losses as market participants continued to watch the status of the global COVID-19 pandemic closely. The spread of the coronavirus has been worrying lately, but investors hope that the federal government's efforts to shore up the economy will help to mitigate some of the negative impacts of the outbreak. As of 11 a.m. EDT, the Dow Jones Industrial Average (DJINDICES: ^DJI) was up 331 points to 21,967. The S&P 500 (SNPINDEX: ^GSPC) rose 49 points to 2,590, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) gained 180 points to 7,683.
Companies in a wide variety of industries are working hard to fight the coronavirus outbreak, but investors are seeing the most notable progress in the healthcare industry. Both Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) had good news on the coronavirus front, and while it could take a while for the global community to see the positive impacts, their actions are adding to the overall success of efforts around the world.
Image source: Getty Images.
Abbott passes the test
Shares of Abbott Labs were higher by 8% as investors got their first chance to react to news from last Friday. Abbott worked hard to get a COVID-19 point-of-care test out to healthcare professionals, and it got the go-ahead to make those tests available to those who need them within the next week.
Abbott received an emergency use authorization from the U.S. Food and Drug Administration for its coronavirus detection test. The test delivers results quickly, with positive results coming in as little as five minutes and negative results within 13 minutes. Running on Abbott's ID NOW platform, the tests will allow healthcare workers to administer the tests and get results in hospitals, urgent care clinics, and doctors' offices.
Abbott's test uses molecular technology, which has a track record of high levels of accuracy. It's also portable, making it available for use in the field in areas with high exposure to the pandemic. Abbott expects to boost its manufacturing capacity to 50,000 tests per day, with deliveries of the test starting in the coming week. All told, Abbott believes it can produce 5 million tests per month when you add in a second testing platform the company launched just a week ago.
Abbott isn't the only healthcare company offering coronavirus testing. However, with tests still in short supply in many areas, every advance should help in the fight to diagnose and treat coronavirus patients.
J&J hopes for a vaccine win
Elsewhere, shares of Johnson & Johnson were up 6%. The healthcare giant said that it's chosen a lead candidate toward developing a coronavirus vaccine, and it'll spend more than $1 billion on research and development to get the treatment moving forward quickly.
Johnson & Johnson has worked on multiple vaccine candidates since the outbreak began, and now that it's chosen its best prospect, the company wants to get ready to manufacture more than 1 billion doses if it's successful. J&J anticipates that it will start human clinical studies by September, with the hope of gaining emergency use authorization from the FDA by early 2021.
J&J will work together with the Biomedical Advanced Research and Development Authority, which is a sub-department of the U.S. Department of Health and Human Services. The two entities will find various funding sources and commit personnel toward finding a viable vaccine even as J&J ramps up its production capacity.
As J&J CEO Alex Gorsky explained, "The world is facing an urgent public health crisis, and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible." Shareholders are enthusiastic about that prospect, and even if a successful coronavirus vaccine doesn't produce huge profits for J&J, they're confident the reputational gain will pay off in the long run.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Both Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) had good news on the coronavirus front, and while it could take a while for the global community to see the positive impacts, their actions are adding to the overall success of efforts around the world. The spread of the coronavirus has been worrying lately, but investors hope that the federal government's efforts to shore up the economy will help to mitigate some of the negative impacts of the outbreak. As J&J CEO Alex Gorsky explained, "The world is facing an urgent public health crisis, and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible." | Both Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) had good news on the coronavirus front, and while it could take a while for the global community to see the positive impacts, their actions are adding to the overall success of efforts around the world. Companies in a wide variety of industries are working hard to fight the coronavirus outbreak, but investors are seeing the most notable progress in the healthcare industry. The test delivers results quickly, with positive results coming in as little as five minutes and negative results within 13 minutes. | Both Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) had good news on the coronavirus front, and while it could take a while for the global community to see the positive impacts, their actions are adding to the overall success of efforts around the world. Abbott worked hard to get a COVID-19 point-of-care test out to healthcare professionals, and it got the go-ahead to make those tests available to those who need them within the next week. Running on Abbott's ID NOW platform, the tests will allow healthcare workers to administer the tests and get results in hospitals, urgent care clinics, and doctors' offices. | Both Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) had good news on the coronavirus front, and while it could take a while for the global community to see the positive impacts, their actions are adding to the overall success of efforts around the world. Abbott isn't the only healthcare company offering coronavirus testing. Johnson & Johnson has worked on multiple vaccine candidates since the outbreak began, and now that it's chosen its best prospect, the company wants to get ready to manufacture more than 1 billion doses if it's successful. |
32746.0 | 2020-03-30 00:00:00 UTC | New Shutdown Repeal Dates and a Testing Breakthrough Could Be Game-Changers for the Market | ABT | https://www.nasdaq.com/articles/new-shutdown-repeal-dates-and-a-testing-breakthrough-could-be-game-changers-for-the-market | nan | nan | Many have wondered how much longer the Western developed world will remain on lockdown. This is an especially important question not only for public health, but also for the economy at large. The longer a wide range of businesses operate at near-zero revenue, the more dire the financial straits will be. That could either turn this downturn into a prolonged recession or necessitate even more help from the federal government, beyond the $2.2 trillion it has already passed.
More recently, Germany marked its own date for reexamining its social distance guidelines, one that is later -- though not by much -- than the date President Donald Trump recently gave.
Trump had said that he hopes to have the economy opened back up by Easter, which is April 12, yet basically all experts think that would be a premature and dangerous date to relax the social distancing rules. Fortunately, on Sunday, March 29, President Trump revised that projection, pushing back a potential reopening even later than the Germans have outlined.
A new test could help isolate COVID-19 and get the economy up and running. Image source: Getty Images.
Germany: 4/20
Last week, Helge Braun, the head of Angela Merkel's Chancellery, said that Germany would not consider relaxing current restrictions on public gatherings in the country until at least April 20. Germany shut down all restaurants, bars, entertainment venues, schools, and other non-essential shops as part of its social distancing guidelines as of March 16.
Braun said, "We will not discuss any relaxing [of restrictions] until April 20, and until then, all measures will remain in place." The justification is that by that time, about three weeks from now, it should be clear that cases are either topping out and beginning to decline or not. Germany's new cases are currently doubling every three to five days, and the government will not even consider opening the country at all until a doubling of cases slows to a rate of 10-14 days, Braun said.
While the April 20 date is one at which German authorities will reassess their policies, it could be a while longer before they actually decide to fully relax restrictions.
The U.S.: 4/30
Meanwhile, on Sunday, March 29, President Trump went back on his earlier hope to have the economy open by Easter, instead pushing back the easing of restrictions to at least April 30, adding, "We think we'll be well on our way to recovering by June 1."
That new timeline lines up with the one Bill Gates gave about two weeks ago. The new reassessment date would be roughly six weeks since social distancing guidelines were put in place in most U.S. states. Meanwhile, June 1 would mark roughly 10 weeks.
Two weeks ago, Gates had said that it would take roughly six to 10 weeks of social distancing in order to break the chain of transmission and get cases down to a level where we could once again begin relaxing social distance restrictions. My own feeling is that since some states have been late to shut down all public gatherings, it may take the U.S. a bit more time than smaller countries such as Germany or South Korea.
Abbott's new test
That being said, in order to really get things back to quasi-normal, Gates says we also need a national database as well as widespread testing, as happened in South Korea.
Fortunately, there has been great recent news on the testing front. The Food and Drug Administration just gave an emergency use authorization for a new test from Abbott Laboratories (NYSE: ABT) that can test a person for COVID-19 in just five minutes. That's even better than the test recently released by Danaher (NYSE: DHR) that can give a test reading in 45 minutes.
A five-minute test could be a game-changer for getting the economy back to work quicker than envisioned. Think about it -- a five-minute test could potentially be administered to employees as they are allowed back into their office buildings, enabling large businesses to get back up and running.
Tests could also be done on the spot at large gatherings such as sporting events, potentially getting Major League Baseball, the NBA, and other major sports leagues up and going. You could even administer tests for anyone entering a large theme park, helping Disney (NYSE: DIS) or Six Flags (NYSE: SIX) begin to get back to normal. You could also potentially administer tests to anyone getting on a commercial airline or a cruise ship to make sure no one is positive, maybe getting those industries up at least to partial revenue in the medium term.
Of course, that would take millions of tests, and it will likely be a big manufacturing challenge to get that many tests into the system. Nevertheless, the combination of a more realistic quarantine period with widespread testing enabled by the Abbott test could get COVID-19 under control sooner than some think. That would be a game-changer for not only public health, but also the stock market, as it could prevent the lockdown from turning into a severe recession.
Getting more optimistic on the markets and health
Despite the morbid and tragic headlines regarding rising coronavirus cases and deaths -- and there are likely more to come in the weeks ahead -- these positives on the quarantine and testing fronts have brightened the intermediate-term outlook. With the potential for positive therapeutics data coming out in the coming weeks on top of fast testing, recent events have made me much more optimistic that the economy can potentially normalize by this summer once we get past this difficult near-term period. That being said, we all have to be just a little more patient for a little while longer to reap the benefits.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Billy Duberstein owns shares of Walt Disney. His clients may own shares of the companies mentioned. The Motley Fool owns shares of and recommends Walt Disney and recommends the following options: long January 2021 $60 calls on Walt Disney and short April 2020 $135 calls on Walt Disney. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Food and Drug Administration just gave an emergency use authorization for a new test from Abbott Laboratories (NYSE: ABT) that can test a person for COVID-19 in just five minutes. Trump had said that he hopes to have the economy opened back up by Easter, which is April 12, yet basically all experts think that would be a premature and dangerous date to relax the social distancing rules. My own feeling is that since some states have been late to shut down all public gatherings, it may take the U.S. a bit more time than smaller countries such as Germany or South Korea. | The Food and Drug Administration just gave an emergency use authorization for a new test from Abbott Laboratories (NYSE: ABT) that can test a person for COVID-19 in just five minutes. More recently, Germany marked its own date for reexamining its social distance guidelines, one that is later -- though not by much -- than the date President Donald Trump recently gave. The U.S.: 4/30 Meanwhile, on Sunday, March 29, President Trump went back on his earlier hope to have the economy open by Easter, instead pushing back the easing of restrictions to at least April 30, adding, "We think we'll be well on our way to recovering by June 1." | The Food and Drug Administration just gave an emergency use authorization for a new test from Abbott Laboratories (NYSE: ABT) that can test a person for COVID-19 in just five minutes. Two weeks ago, Gates had said that it would take roughly six to 10 weeks of social distancing in order to break the chain of transmission and get cases down to a level where we could once again begin relaxing social distance restrictions. Abbott's new test That being said, in order to really get things back to quasi-normal, Gates says we also need a national database as well as widespread testing, as happened in South Korea. | The Food and Drug Administration just gave an emergency use authorization for a new test from Abbott Laboratories (NYSE: ABT) that can test a person for COVID-19 in just five minutes. Two weeks ago, Gates had said that it would take roughly six to 10 weeks of social distancing in order to break the chain of transmission and get cases down to a level where we could once again begin relaxing social distance restrictions. Think about it -- a five-minute test could potentially be administered to employees as they are allowed back into their office buildings, enabling large businesses to get back up and running. |
32747.0 | 2020-03-30 00:00:00 UTC | Why Abbott Laboratories Stock Is on Fire Today | ABT | https://www.nasdaq.com/articles/why-abbott-laboratories-stock-is-on-fire-today-2020-03-30 | nan | nan | What happened
Shares of Abbott Laboratories (NYSE: ABT), a large-cap medical device and molecular diagnostic company, are gearing up for a potentially historic day Monday. The company's stock is already up by a jaw-dropping 14.2% in early pre-market action this morning. If this move holds, Abbott will add approximately $18 billion to its market cap today.
The spark? Last Friday, Abbott announced that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for its rapid point-of-care COVID-19 test known as ID NOW COVID-19. This is the second Abbott-manufactured COVID-19 test the FDA has approved under the EUA provision this month.
Image source: Getty Images.
So what
This latest COVID-19 molecular diagnostic is unique in that it can provide positive test results in as little as five minutes, and negative results within 13 minutes. It is also compact enough to be used in almost any healthcare setting, such as a doctor's office, an urgent care clinic, or hospital emergency departments. The company's other COVID-19 test, Abbott m2000 RealTime SARS-CoV-2 EUA test, can process a far higher volume of samples per day, but it requires a centralized location to do so.
The big picture is that the U.S. desperately needs to ramp up testing for COVID-19 throughout the country. Abbott's portable point-of-care molecular diagnostic should thus help with this effort in a big way. Keeping with this theme, the company expects to start delivering units as soon as this week, with production slated to hit 50,000 units per day by April 1. Between the two platforms, Abbott expects to produce approximately 5 million COVID-19 molecular diagnostic tests per month for the foreseeable future.
Now what
Is Abbott's stock worth buying on this double-digit jump? While an $18 billion jump in market cap in a single trading session may seem a bit overdone, Abbott has been a consistent winner for shareholders for a very long time. The company is an industry leader in terms of innovation and it has one of the best management teams in the entire healthcare sector. That's a powerful combination, to be sure. Therefore, Abbott's stock is arguably still a worthwhile buy and hold for long-term investors, even after this monstrous jump.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Abbott Laboratories (NYSE: ABT), a large-cap medical device and molecular diagnostic company, are gearing up for a potentially historic day Monday. Last Friday, Abbott announced that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for its rapid point-of-care COVID-19 test known as ID NOW COVID-19. While an $18 billion jump in market cap in a single trading session may seem a bit overdone, Abbott has been a consistent winner for shareholders for a very long time. | What happened Shares of Abbott Laboratories (NYSE: ABT), a large-cap medical device and molecular diagnostic company, are gearing up for a potentially historic day Monday. If this move holds, Abbott will add approximately $18 billion to its market cap today. The company's other COVID-19 test, Abbott m2000 RealTime SARS-CoV-2 EUA test, can process a far higher volume of samples per day, but it requires a centralized location to do so. | What happened Shares of Abbott Laboratories (NYSE: ABT), a large-cap medical device and molecular diagnostic company, are gearing up for a potentially historic day Monday. The company's other COVID-19 test, Abbott m2000 RealTime SARS-CoV-2 EUA test, can process a far higher volume of samples per day, but it requires a centralized location to do so. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | What happened Shares of Abbott Laboratories (NYSE: ABT), a large-cap medical device and molecular diagnostic company, are gearing up for a potentially historic day Monday. Abbott's portable point-of-care molecular diagnostic should thus help with this effort in a big way. Between the two platforms, Abbott expects to produce approximately 5 million COVID-19 molecular diagnostic tests per month for the foreseeable future. |
32748.0 | 2020-03-28 00:00:00 UTC | FDA Approves New 5 Minute Test to Accelerate U.S. Coronavirus Response | ABT | https://www.nasdaq.com/articles/fda-approves-new-5-minute-test-to-accelerate-u.s.-coronavirus-response-2020-03-28 | nan | nan | Rapid testing for the novel coronavirus that's responsible for at least 100,000 cases of COVID-19 in the U.S. is getting an important upgrade. Abbott (NYSE: ABT) recently received an emergency use authorization (EUA) for a test that can provide results in just five minutes.
The fastest test yet
Abbott isn't the first company in the U.S. to launch a point-of-care coronavirus test, but the Abbott ID NOW COVID-19 test is much quicker than the competition. On March 22, Danaher (NYSE: DHR) received a EUA for a test that can provide a result in about 45 minutes.
Image source: Getty Images.
This is Abbott's second EUA for a COVID-19 test this month. About a week ago, the FDA green-lighted a test that runs on systems generally limited to laboratories and hospitals.
Ramping up
According to Abbott, more ID NOW machines are available to run its new COVID-19 test than any other point-of-care molecular diagnostic platform. Since its launch in 2014, the toaster-size nucleic acid amplification machine has become popular in doctor's offices and urgent care centers across the U.S.
The ID NOW platform is already the most common method that American healthcare providers use to check patients for influenza and respiratory syncytial virus, which means Abbott should be able to dramatically ramp up test availability. For both platforms combined, the company expects to produce around 5 million tests per month.
Next week, Abbott will begin making ID NOW COVID-19 tests available to urgent care centers in an attempt to create the greatest immediate impact, with wider distribution to follow.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (NYSE: ABT) recently received an emergency use authorization (EUA) for a test that can provide results in just five minutes. The ID NOW platform is already the most common method that American healthcare providers use to check patients for influenza and respiratory syncytial virus, which means Abbott should be able to dramatically ramp up test availability. Next week, Abbott will begin making ID NOW COVID-19 tests available to urgent care centers in an attempt to create the greatest immediate impact, with wider distribution to follow. | Abbott (NYSE: ABT) recently received an emergency use authorization (EUA) for a test that can provide results in just five minutes. The fastest test yet Abbott isn't the first company in the U.S. to launch a point-of-care coronavirus test, but the Abbott ID NOW COVID-19 test is much quicker than the competition. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | Abbott (NYSE: ABT) recently received an emergency use authorization (EUA) for a test that can provide results in just five minutes. The fastest test yet Abbott isn't the first company in the U.S. to launch a point-of-care coronavirus test, but the Abbott ID NOW COVID-19 test is much quicker than the competition. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Abbott (NYSE: ABT) recently received an emergency use authorization (EUA) for a test that can provide results in just five minutes. The fastest test yet Abbott isn't the first company in the U.S. to launch a point-of-care coronavirus test, but the Abbott ID NOW COVID-19 test is much quicker than the competition. This is Abbott's second EUA for a COVID-19 test this month. |
32749.0 | 2020-03-26 00:00:00 UTC | Health Care Sector Update for 03/26/2020: JNJ, PFE, ABT, MRK, AMGN, HTGM, RKDA, BIOC | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-03-26-2020%3A-jnj-pfe-abt-mrk-amgn-htgm-rkda-bioc-2020-03-26 | nan | nan | Top Health Care Stocks:
JNJ: +0.51%
PFE: +0.67%
ABT: +0.27%
MRK: -0.25%
AMGN: +0.29%
Most top health care stocks were rising during pre-market hours on Thursday.
Among health care stocks moving on news:
(+) HTG Molecular Diagnostics (HTGM), which rose more than 11% after the company reported a net loss of $0.51 per share for the year ended Dec. 31, 2019, compared with a loss of $0.60 per share a year earlier. This figure beat the consensus estimate of a loss of $0.53 per share as compiled by Capital IQ.
(-) Arcadia Biosciences (RKDA), which was down more than 15% after posting Q4 net loss of $0.72 per share, or $6.2 million, compared with a loss of $646,000 in the year-ago quarter. Two analysts were expecting a loss of $0.58 per share.
(=) Biocept (BIOC), which was flat after the company Wednesday said Q4 sales gained 108% to $1.8 million year over year. This topped the consensus estimate of $1.7 million from analysts polled by Capital IQ.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Most top health care stocks were rising during pre-market hours on Thursday. Among health care stocks moving on news: (+) HTG Molecular Diagnostics (HTGM), which rose more than 11% after the company reported a net loss of $0.51 per share for the year ended Dec. 31, 2019, compared with a loss of $0.60 per share a year earlier. This figure beat the consensus estimate of a loss of $0.53 per share as compiled by Capital IQ. | Top Health Care Stocks: Most top health care stocks were rising during pre-market hours on Thursday. This topped the consensus estimate of $1.7 million from analysts polled by Capital IQ. | Among health care stocks moving on news: (+) HTG Molecular Diagnostics (HTGM), which rose more than 11% after the company reported a net loss of $0.51 per share for the year ended Dec. 31, 2019, compared with a loss of $0.60 per share a year earlier. (-) Arcadia Biosciences (RKDA), which was down more than 15% after posting Q4 net loss of $0.72 per share, or $6.2 million, compared with a loss of $646,000 in the year-ago quarter. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top Health Care Stocks: Among health care stocks moving on news: (+) HTG Molecular Diagnostics (HTGM), which rose more than 11% after the company reported a net loss of $0.51 per share for the year ended Dec. 31, 2019, compared with a loss of $0.60 per share a year earlier. This topped the consensus estimate of $1.7 million from analysts polled by Capital IQ. |
32750.0 | 2020-03-25 00:00:00 UTC | ABT a Top 25 Dividend Giant With $10.86B Held By ETFs | ABT | https://www.nasdaq.com/articles/abt-a-top-25-dividend-giant-with-%2410.86b-held-by-etfs-2020-03-25 | nan | nan | Abbott Laboratories (Symbol: ABT) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $10.86B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.07% yield, according to the most recent Dividend Channel ''DividendRank'' report. The report noted a strong quarterly dividend history at Abbott Laboratories, and favorable long-term multi-year growth rates in key fundamental data points.
The annualized dividend paid by Abbott Laboratories is $1.44/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 04/14/2020. Below is a long-term dividend history chart for ABT, which the report stressed as being of key importance. Indeed, studying a company's past dividend history can be of good help in judging whether the most recent dividend is likely to continue.
25 Dividend Giants Widely Held By ETFs »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (Symbol: ABT) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $10.86B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.07% yield, according to the most recent Dividend Channel ''DividendRank'' report. Below is a long-term dividend history chart for ABT, which the report stressed as being of key importance. The report noted a strong quarterly dividend history at Abbott Laboratories, and favorable long-term multi-year growth rates in key fundamental data points. | Abbott Laboratories (Symbol: ABT) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $10.86B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.07% yield, according to the most recent Dividend Channel ''DividendRank'' report. Below is a long-term dividend history chart for ABT, which the report stressed as being of key importance. The report noted a strong quarterly dividend history at Abbott Laboratories, and favorable long-term multi-year growth rates in key fundamental data points. | Abbott Laboratories (Symbol: ABT) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $10.86B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.07% yield, according to the most recent Dividend Channel ''DividendRank'' report. Below is a long-term dividend history chart for ABT, which the report stressed as being of key importance. The report noted a strong quarterly dividend history at Abbott Laboratories, and favorable long-term multi-year growth rates in key fundamental data points. | Abbott Laboratories (Symbol: ABT) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $10.86B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 2.07% yield, according to the most recent Dividend Channel ''DividendRank'' report. Below is a long-term dividend history chart for ABT, which the report stressed as being of key importance. The report noted a strong quarterly dividend history at Abbott Laboratories, and favorable long-term multi-year growth rates in key fundamental data points. |
32751.0 | 2020-03-24 00:00:00 UTC | Better Buy: AbbVie vs. Biogen | ABT | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-biogen-2020-03-24 | nan | nan | For investors seeking stocks to put into their portfolios for the long term, healthcare's a great place to look. It's an industry where there's always going to be significant demand, especially as the population ages. Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the industry, and their stocks offer investors two enticing approaches: one that's focused on growth, and another that's centered around stability and recurring income. Let's take a look at which is the better option today.
Is Biogen too volatile?
To say that Biogen's stock price has been unstable over the past year would be an understatement. Over the past 52 weeks, the drug manufacturer's stock has traded within a wide range of $215 to $375. Although it's technically down 18% since March 1, 2019, that number doesn't tell investors the full story. About a year ago, the company's stock went over a cliff, falling from $320 down to a low of about $215 after Biogen said it was going to scrap drug trials related to aducanumab, which treats Alzheimer's.
Then, in October, the company revived the drug, saying it was going to seek approval from U.S. regulators after collecting more data which showed the drug was making progress in fighting the disease after all. Shares popped, rising from about $220 to over $300 in the days following the news.
Image source: Getty Images.
Last month, Biogen's stock price got another boost when investors learned that Mylan (NASDAQ: MYL) had been unsuccessful in its patent challenge against Biogen's multiple sclerosis drug, Tecfidera. Biogen's stock is down 19% over the past month; the company has been unable to avoid the market's recent instability around rising concerns surrounding the spread of COVID-19. That said, it's ahead of the S&P 500, which is down 31% over the same time.
Biogen's stock isn't for the faint of heart. But the good news is that the company's consistently stayed in the black, with its profit margin remaining above 20% in each of the past 10 years.
It's an impressive feat, especially amid strong growth. From $4.7 billion in revenue in 2010, Biogen's sales reached $14.4 billion this past year. In 2019, its annual growth rate was a solid 6.9% from 2018's tally of $13.5 billion. Despite the strong numbers, Biogen still trades for less than 10 times its earnings.
Does the acquisition of Allergan make AbbVie a stronger buy?
On its own, AbbVie is a solid healthcare stock; its strong, consistent revenue has topped $30 billion for the past two years. It also pays a dividend that has increased for more than 40 consecutive years (counting the time it spent as part of Abbott Laboratories (NYSE: ABT)), making it a Dividend Aristocrat. Currently, it pays a quarterly dividend of $1.18 per share, which yields an impressive 6.8% today. Biogen doesn't pay its shareholders a dividend.
The problem for AbbVie is that in its most recent fiscal year, it generated sales growth of just 1.6%. That's where it needs something to jump-start its growth -- and its $63 billion acquisition of Allergan (NYSE: AGN) could play a big part in that. The deal, which the companies expect will close in May of this year, will give AbbVie access to Botox, which was Allergan's top-selling drug in 2019, generating $3.8 billion in revenue.
While it's a good addition, Allergan hasn't been blowing the doors off its revenue numbers, either. In 2019, revenue totaled $16.1 billion, which was just a 1.9% improvement from the previous year. Even with the acquisition, there may not be sufficient growth in AbbVie to make the investment attractive for investors who are looking for more than just value.
AbbVie is the safer buy, but growth investors may opt for Biogen
A quick look at how these two stocks have performed over the past year shows little difference, despite their very different paths along the way:
ABBV data by YCharts.
Deciding between these two stocks ultimately comes down to your investing approach. If you're a value-oriented investor who is risk-averse, then AbbVie, with its impressive dividend, is a solid pick. The stock trades at a very reasonable 12 times earnings, which is only slightly higher than Biogen's price. In addition, AbbVie can be a solid long-term pick for investors looking to benefit from a growing dividend. But investors who aren't so risk-averse may be willing to take a chance on Biogen, especially in light of the positive developments that have taken place over the past six months.
10 stocks we like better than Biogen
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Biogen wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It also pays a dividend that has increased for more than 40 consecutive years (counting the time it spent as part of Abbott Laboratories (NYSE: ABT)), making it a Dividend Aristocrat. Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the industry, and their stocks offer investors two enticing approaches: one that's focused on growth, and another that's centered around stability and recurring income. About a year ago, the company's stock went over a cliff, falling from $320 down to a low of about $215 after Biogen said it was going to scrap drug trials related to aducanumab, which treats Alzheimer's. | It also pays a dividend that has increased for more than 40 consecutive years (counting the time it spent as part of Abbott Laboratories (NYSE: ABT)), making it a Dividend Aristocrat. Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the industry, and their stocks offer investors two enticing approaches: one that's focused on growth, and another that's centered around stability and recurring income. From $4.7 billion in revenue in 2010, Biogen's sales reached $14.4 billion this past year. | It also pays a dividend that has increased for more than 40 consecutive years (counting the time it spent as part of Abbott Laboratories (NYSE: ABT)), making it a Dividend Aristocrat. Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the industry, and their stocks offer investors two enticing approaches: one that's focused on growth, and another that's centered around stability and recurring income. Last month, Biogen's stock price got another boost when investors learned that Mylan (NASDAQ: MYL) had been unsuccessful in its patent challenge against Biogen's multiple sclerosis drug, Tecfidera. | It also pays a dividend that has increased for more than 40 consecutive years (counting the time it spent as part of Abbott Laboratories (NYSE: ABT)), making it a Dividend Aristocrat. On its own, AbbVie is a solid healthcare stock; its strong, consistent revenue has topped $30 billion for the past two years. Currently, it pays a quarterly dividend of $1.18 per share, which yields an impressive 6.8% today. |
32752.0 | 2020-03-23 00:00:00 UTC | S&P 500 Analyst Moves: ABT | ABT | https://www.nasdaq.com/articles/sp-500-analyst-moves%3A-abt-2020-03-23 | nan | nan | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #60 analyst pick, moving up by 1 spot.
This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values.
Looking at the stock price movement year to date, Abbott Laboratories is lower by about 25.6%.
VIDEO: S&P 500 Analyst Moves: ABT
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #60 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. | VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #60 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. | VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #60 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. | VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #60 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. |
32753.0 | 2020-03-23 00:00:00 UTC | These 3 Dividend Stocks Are Now Yielding Up to 20% | ABT | https://www.nasdaq.com/articles/these-3-dividend-stocks-are-now-yielding-up-to-20-2020-03-23 | nan | nan | The coronavirus pandemic is having a significant impact on the markets. This month, the Dow Jones dropped below 20,000 -- the lowest it's been in three years. And when share prices fall, dividend yields rise.
For dividend investors, it could be an opportune time to buy. But investors still need to be careful as a high dividend may not be sustainable. Let's take a look at three high-yielding stocks to see whether they're good buys today, or if investors should steer clear of them:
1. AbbVie
AbbVie (NYSE: ABBV) is down about 20% since the start of 2020. That's stronger than the S&P 500, which entering trading on Friday was down 26%. The healthcare stock's quarterly dividend of $1.18 is now yielding 6.6% annually. The company has raised its payouts by 195% since the stock began trading in 2013. It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories (NYSE: ABT).
It's a high yield for the drug manufacturer, and investors may be wondering if it's sustainable.
One way that investors gauge the health of a dividend is by looking at its payout ratio, which involves looking at its earnings and annual dividend. In the company's year-end results, which AbbVie released on Feb. 7, it reported diluted earnings per share (EPS) of $5.28. That's up 44% from the prior year. With an EPS $5.28, the company has enough room to accommodate its dividend, which on an annual basis pays $4.72 per share. Although the payout ratio is a bit high at 89%, it looks to be sustainable.
Image source: Getty Images.
The statement of cash flow also corroborates the company's ability to continue paying its dividend. Operating cash flow was $13.3 billion in 2019, and after deducting acquisitions of $1.7 billion, there's still plenty left over to cover the company's dividend payments, which during the year totaled $6.4 billion.
AbbVie's future looks strong, and with healthcare in the spotlight as a result of the coronavirus and a possible shortage of drugs, the company's business shouldn't be a concern for long-term investors.
2. Carnival Corporation
Carnival Corporation (NYSE: CCL) stock has collapsed by 76% year to date as the coronavirus pandemic hit travel stocks particularly hard. With governments encouraging people to stay home, cruise ships are in low demand. And it certainly doesn't help that COVID-19's been spreading on cruise ships and stranding customers in the process.
The cruise ship operator pays a quarterly dividend of $0.50 per share, which at a price of around $12 yields more than 20% per year. The stock pays well above the S&P 500's average yield of 2%. It's a staggering yield, but whether it's sustainable is a separate issue.
The company released its fiscal 2019 results on Dec. 20. For the year, Carnival reported diluted EPS of $4.32, which makes the company's payout ratio a very manageable 46% of earnings. From a cash flow perspective, things were tighter as Carnival's operating activities generated $5.5 billion -- just enough to cover property and equipment purchases during the year totaling $5.4 billion. That wouldn't leave nearly enough to cover the $1.4 billion that Carnival paid out in dividends during the year.
However, even if cash flow wasn't a concern, the company's future is. The longer COVID-19 keeps customers from traveling, the longer the stock will stay down and the larger the impact will be on Carnival's future financials. The company has cut dividends in the past, and it wouldn't be surprising to see that happen again.
3. Enbridge
Enbridge (NYSE: ENB) is normally a safe long-term buy, but the recent uncertainty relating to not just COVID-19, but also a low price of oil, has sent the pipeline company into a tailspin.
The energy stock is down 30% this year as concerns in the Canadian oil and gas industry continue to rise, and both the coronavirus and low oil prices threaten the survival of many Alberta-based companies like Enbridge. The company transports oil through its pipelines, and it needs a strong oil and gas industry for there to be demand for its infrastructure.
Like AbbVie, Enbridge is a Dividend Aristocrat. When the company announced in December that it would raise its payouts by 9.8%, it was the 25th consecutive year Enbridge had done so. Shareholders now receive a quarterly dividend of 0.81 Canadian dollars per share, which yields 9% annually.
In its annual report released on Feb. 14, Enbridge had a strong showing, posting a diluted EPS of CA$2.63 for the full year of 2019. That was up 80% from the prior year.
However, its EPS is less than the annual dividend payment it pays of CA$3.24, and the payout appears to be unsustainable from a cash flow perspective as well. Cash from the company's operating activities of CA$9.4 billion during the year was insufficient to cover dividend payments of CA$6 billion after factoring in CA$5.5 billion in capital spending.
Despite its streak, Enbridge's dividend may be in danger if oil prices don't improve along with conditions in the Canadian oil and gas industry.
Which stock is the safest to buy today?
The safest of the three dividend stocks listed above is AbbVie. It offers the lowest payout, but at 6.6% it's still a very strong dividend yield, especially given that it'll likely grow over the years as well.
Image Source: YCharts
Enbridge offers a growing dividend as well, but the oil price war involving Saudi Arabia and Russia makes any oil and gas stock a risky buy today, even one like Enbridge that's normally pretty safe.
Carnival is the riskiest stock on the list. Not only has it cut its payouts in the past, but it has plenty of incentive to do so now. Investors would be taking a significant risk by assuming this dividend will remain intact.
AbbVie is the best buy of the three, and it's the most likely to continue paying its dividend in 2020 and beyond.
10 stocks we like better than Carnival
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Carnival wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Enbridge. The Motley Fool recommends Carnival. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories (NYSE: ABT). AbbVie's future looks strong, and with healthcare in the spotlight as a result of the coronavirus and a possible shortage of drugs, the company's business shouldn't be a concern for long-term investors. In its annual report released on Feb. 14, Enbridge had a strong showing, posting a diluted EPS of CA$2.63 for the full year of 2019. | It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories (NYSE: ABT). For the year, Carnival reported diluted EPS of $4.32, which makes the company's payout ratio a very manageable 46% of earnings. The energy stock is down 30% this year as concerns in the Canadian oil and gas industry continue to rise, and both the coronavirus and low oil prices threaten the survival of many Alberta-based companies like Enbridge. | It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories (NYSE: ABT). The energy stock is down 30% this year as concerns in the Canadian oil and gas industry continue to rise, and both the coronavirus and low oil prices threaten the survival of many Alberta-based companies like Enbridge. Cash from the company's operating activities of CA$9.4 billion during the year was insufficient to cover dividend payments of CA$6 billion after factoring in CA$5.5 billion in capital spending. | It's a Dividend Aristocrat, as its payouts have increased for more than 25 years including AbbVie's time as part of Abbott Laboratories (NYSE: ABT). Image Source: YCharts Enbridge offers a growing dividend as well, but the oil price war involving Saudi Arabia and Russia makes any oil and gas stock a risky buy today, even one like Enbridge that's normally pretty safe. AbbVie is the best buy of the three, and it's the most likely to continue paying its dividend in 2020 and beyond. |
32754.0 | 2020-03-22 00:00:00 UTC | You Won't Regret Buying These 3 Bargain Stocks | ABT | https://www.nasdaq.com/articles/you-wont-regret-buying-these-3-bargain-stocks-2020-03-22 | nan | nan | Two music legends, Frank Sinatra and Elvis Presley, each had a big hit with the song "My Way." The lyrics of the song include a line that says, "Regrets, I've had a few. But then again, too few to mention."
I don't know about you, but I've had more regrets with investing than I'd care to mention. And most of them aren't related to stocks that I bought. Instead, my biggest investing regrets are about the stocks that I didn't buy.
The coronavirus-caused bear market is presenting more great opportunities to buy high-quality stocks at attractive prices than we've seen in a very long time. Here are three bargain stocks that you won't regret buying.
Image source: Getty Images.
1. AbbVie
AbbVie (NYSE: ABBV) has been a bargain for a while in my view. But the stock is now even more attractively valued. The drugmaker's shares trade at a little over nine times expected earnings.
There have been some concerns about how AbbVie will fare after its top-selling drug Humira faces biosimilar competition in the U.S. starting in 2023. I think the company should be in good shape. For one thing, sales for Humira won't evaporate overnight. The immunology drug already faces biosimilar rivals in Europe and still raked in $4.3 billion in international sales last year.
More importantly, momentum for AbbVie's other drugs is reducing its dependence on Humira. Sales for cancer drugs Imbruvica and Venclexta continue to climb. New immunology drugs Rinvoq and Skyrizi should both become megablockbusters. AbbVie should soon close its acquisition of Allergan, which will bring even more successful drugs into its product lineup and candidates into its pipeline.
We can't leave out AbbVie's dividend yield, which stands at 6.6% right now. The company has increased its dividend for 47 consecutive years, including the time it was part of Abbott Labs. Since being spun off from Abbott in 2013, AbbVie has nearly tripled its dividend payout. I think AbbVie will deliver solid share price appreciation over the long run, but it won't have to do too much to provide a market-beating total return with its awesome dividend program.
2. Bristol Myers Squibb
Bristol Myers Squibb (NYSE: BMY) is another stock that looked relatively inexpensive to me even before the coronavirus pandemic hit. With its shares trading below 10 times expected earnings, BMS is even cheaper now.
The drugmaker's acquisition of Celgene last year puts it in the same boat as AbbVie to some extent. Celgene's blockbuster blood disease drug Remicade will face generic competition beginning in 2022. The good news, though, that generic rivals will only be able to sell limited volumes of their products for a few years under their agreements with Celgene.
In the meantime, BMS' current lineup, including enormously successful drugs Eliquis, Empliciti, Opdivo, Orencia, and Pomalyst, should gain even more traction. Thanks to the Celgene deal, BMS' pipeline is as strong as it's ever been. The company expects to launch multiple drugs with blockbuster potential over the next couple of years, including ozanimod in treating multiple sclerosis and cancer cell therapies ide-cel and liso-cel.
BMS' dividend yield currently stands at 3.7%. That's the icing on the cake for a company that Wall Street expects will grow earnings by an average of more than 18% annually over the next five years.
3. Pfizer
Pfizer (NYSE: PFE) is more expensive than AbbVie or Bristol Myers Squibb. But I would still categorize shares of a profitable company that are trading at only 13 times expected earnings as a bargain.
Loss of exclusivity for Lyrica weighed on Pfizer's top and bottom lines in 2019. However, the drug shouldn't be an anchor for Pfizer very much longer. That's because Pfizer plans to merge its Upjohn unit, which is home to Lyrica and other older drugs, with Mylan.
I like this deal because it will make Pfizer a smaller yet faster-growing company. The "new" Pfizer will keep blockbuster drugs including Ibrance and Eliquis (which it co-markets with BMS). Pfizer will also still have newer rising stars such as rare-disease drug Vyndaquel and a pipeline with potential winners including its 20-valent pneumococcal vaccine.
Granted, the Upjohn-Mylan combination will cause Pfizer's dividend to be lower. However, Pfizer shareholders will own part of the new company, to be named Viatris, which will pay a dividend of its own. The combination of Pfizer's and Viatris' dividends should be roughly at the same level as Pfizer's current dividend, which yields 5% right now.
Notice something in common?
You might have noticed that all three of the bargain buys that I like are major pharmaceutical stocks. That's no accident. My view is that these big drugmakers have a greater ability than most companies to keep trucking through the coronavirus crisis and its aftermath.
AbbVie, Bristol Myers Squibb, and Pfizer each have strong cash flows. They've weathered previous economic storms in the past. They all sell products that people will need regardless of pandemics and quarantines. And they're priced attractively, of course. Those are the kinds of bargains I don't think anyone will regret buying.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Keith Speights owns shares of AbbVie, Bristol-Myers Squibb, and Pfizer. The Motley Fool owns shares of and recommends Bristol-Myers Squibb. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The coronavirus-caused bear market is presenting more great opportunities to buy high-quality stocks at attractive prices than we've seen in a very long time. I think AbbVie will deliver solid share price appreciation over the long run, but it won't have to do too much to provide a market-beating total return with its awesome dividend program. In the meantime, BMS' current lineup, including enormously successful drugs Eliquis, Empliciti, Opdivo, Orencia, and Pomalyst, should gain even more traction. | Bristol Myers Squibb Bristol Myers Squibb (NYSE: BMY) is another stock that looked relatively inexpensive to me even before the coronavirus pandemic hit. In the meantime, BMS' current lineup, including enormously successful drugs Eliquis, Empliciti, Opdivo, Orencia, and Pomalyst, should gain even more traction. The Motley Fool owns shares of and recommends Bristol-Myers Squibb. | Pfizer Pfizer (NYSE: PFE) is more expensive than AbbVie or Bristol Myers Squibb. The combination of Pfizer's and Viatris' dividends should be roughly at the same level as Pfizer's current dividend, which yields 5% right now. See the 10 stocks *Stock Advisor returns as of March 18, 2020 Keith Speights owns shares of AbbVie, Bristol-Myers Squibb, and Pfizer. | Here are three bargain stocks that you won't regret buying. AbbVie AbbVie (NYSE: ABBV) has been a bargain for a while in my view. Thanks to the Celgene deal, BMS' pipeline is as strong as it's ever been. |
32755.0 | 2020-03-20 00:00:00 UTC | FDA Warns About Unauthorized Fraudulent COVID-19 Tests | ABT | https://www.nasdaq.com/articles/fda-warns-about-unauthorized-fraudulent-covid-19-tests-2020-03-21 | nan | nan | The Food and Drug Administration (FDA) is warning consumers about the marketing of unauthorized fraudulent in-home test kits designed for COVID-19, the disease caused by the new coronavirus. The FDA is worried about potential false-negative results from the kits. "They may keep some patients from seeking care or delay necessary medical treatment," the agency warned in a statement.
The FDA plans to scan ports of entry, including international mail facilities, for fake tests. It's also calling on the public to report fraudulent test kits for COVID-19 if they see them.
"We will continue to aggressively pursue those who place the public health at risk and hold bad actors accountable," the agency said.
Image source: Getty Images.
The FDA hasn't approved any test kits for use in homes, although it's working with test-makers on taking in-home samples that can be shipped to labs to be tested. Privately held Everlywell, Nurx, and Carbon Health have all started shipping in-home sample collection kits.
The FDA has authorized tests from Abbott Labs (NYSE: ABT), Thermo Fisher Scientific (NYSE: TMO), and Roche (OTC: RHHBY) under its Emergency Use Authorization program. The agency also gives leeway to diagnostic laboratories to develop their own tests for use in their facilities.
Despite the ramp up in authorization and production of tests, there still aren't enough tests for mass screening in the U.S., Roche's CEO Severin Schwan warned earlier this week. The lack of available tests is likely making some people desperate to get tested any way they can -- thus the FDA's warning on Friday to be on the lookout for unauthorized fraudulent test kits.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 18, 2020
Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The FDA has authorized tests from Abbott Labs (NYSE: ABT), Thermo Fisher Scientific (NYSE: TMO), and Roche (OTC: RHHBY) under its Emergency Use Authorization program. The Food and Drug Administration (FDA) is warning consumers about the marketing of unauthorized fraudulent in-home test kits designed for COVID-19, the disease caused by the new coronavirus. "We will continue to aggressively pursue those who place the public health at risk and hold bad actors accountable," the agency said. | The FDA has authorized tests from Abbott Labs (NYSE: ABT), Thermo Fisher Scientific (NYSE: TMO), and Roche (OTC: RHHBY) under its Emergency Use Authorization program. The Food and Drug Administration (FDA) is warning consumers about the marketing of unauthorized fraudulent in-home test kits designed for COVID-19, the disease caused by the new coronavirus. The lack of available tests is likely making some people desperate to get tested any way they can -- thus the FDA's warning on Friday to be on the lookout for unauthorized fraudulent test kits. | The FDA has authorized tests from Abbott Labs (NYSE: ABT), Thermo Fisher Scientific (NYSE: TMO), and Roche (OTC: RHHBY) under its Emergency Use Authorization program. The FDA hasn't approved any test kits for use in homes, although it's working with test-makers on taking in-home samples that can be shipped to labs to be tested. The lack of available tests is likely making some people desperate to get tested any way they can -- thus the FDA's warning on Friday to be on the lookout for unauthorized fraudulent test kits. | The FDA has authorized tests from Abbott Labs (NYSE: ABT), Thermo Fisher Scientific (NYSE: TMO), and Roche (OTC: RHHBY) under its Emergency Use Authorization program. The lack of available tests is likely making some people desperate to get tested any way they can -- thus the FDA's warning on Friday to be on the lookout for unauthorized fraudulent test kits. That's right -- they think these 10 stocks are even better buys. |
32756.0 | 2020-03-20 00:00:00 UTC | Notable ETF Inflow Detected - OEF, ABT, CVX, MCD | ABT | https://www.nasdaq.com/articles/notable-etf-inflow-detected-oef-abt-cvx-mcd-2020-03-20 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $134.3 million dollar inflow -- that's a 3.1% increase week over week in outstanding units (from 38,300,000 to 39,500,000). Among the largest underlying components of OEF, in trading today Abbott Laboratories (Symbol: ABT) is down about 2.2%, Chevron Corporation (Symbol: CVX) is up about 3.7%, and McDonald's Corp (Symbol: MCD) is up by about 6.2%. For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average:
Looking at the chart above, OEF's low point in its 52 week range is $106.01 per share, with $152.576 as the 52 week high point — that compares with a last trade of $112.72. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of OEF, in trading today Abbott Laboratories (Symbol: ABT) is down about 2.2%, Chevron Corporation (Symbol: CVX) is up about 3.7%, and McDonald's Corp (Symbol: MCD) is up by about 6.2%. For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $106.01 per share, with $152.576 as the 52 week high point — that compares with a last trade of $112.72. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of OEF, in trading today Abbott Laboratories (Symbol: ABT) is down about 2.2%, Chevron Corporation (Symbol: CVX) is up about 3.7%, and McDonald's Corp (Symbol: MCD) is up by about 6.2%. For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $106.01 per share, with $152.576 as the 52 week high point — that compares with a last trade of $112.72. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of OEF, in trading today Abbott Laboratories (Symbol: ABT) is down about 2.2%, Chevron Corporation (Symbol: CVX) is up about 3.7%, and McDonald's Corp (Symbol: MCD) is up by about 6.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $134.3 million dollar inflow -- that's a 3.1% increase week over week in outstanding units (from 38,300,000 to 39,500,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $106.01 per share, with $152.576 as the 52 week high point — that compares with a last trade of $112.72. | Among the largest underlying components of OEF, in trading today Abbott Laboratories (Symbol: ABT) is down about 2.2%, Chevron Corporation (Symbol: CVX) is up about 3.7%, and McDonald's Corp (Symbol: MCD) is up by about 6.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $134.3 million dollar inflow -- that's a 3.1% increase week over week in outstanding units (from 38,300,000 to 39,500,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $106.01 per share, with $152.576 as the 52 week high point — that compares with a last trade of $112.72. |
32757.0 | 2020-03-20 00:00:00 UTC | 3 Dividend Stocks Ideal for Retirees With Money To Invest In The Bear Market | ABT | https://www.nasdaq.com/articles/3-dividend-stocks-ideal-for-retirees-with-money-to-invest-in-the-bear-market-2020-03-20 | nan | nan | Dividend stocks provide many people with a viable option for retirement income. The S&P 500 average dividend stands at approximately 2.4%, exceeding what most bank-related instruments yield in a savings account. Moreover, the return on many dividend stocks dramatically exceeds the S&P 500's average price appreciation. Several dividend-paying companies have increased their payout annually for years, or in some cases, decades.
Furthermore, the sell-off driven by the COVID-19 pandemic has significantly raised dividend yields. The S&P 500 has fallen by nearly 30% from its recent high. Consequently, the average return on dividends, which stood at an estimated 1.78% in February, has risen by almost 35% in less than one month. Those with the courage to buy into a volatile market could earn significant, long-term returns on the payout alone.
Some of these stocks are in a position to benefit from the growing number of baby boomers entering retirement. This is a large population that could drive revenue growth for certain dividend stocks. To earn some of this dividend income, retirees should consider buying these three stocks.
1. AbbVie
AbbVie (NYSE: ABBV) finds itself in a transition phase. Since it split from Abbott Laboratories in 2013, Its injectable biologic drug Humira has driven much of its revenue. Investors sold off the stock as Humira patents began to expire across the world. AbbVie traded as high as $125.86 per share in 2018. Thanks in large part to Humira-related selling, it has fallen below the $75 per share range.
However, AbbVie did not rest on its laurels with Humira. Even though Humira's sales have begun to fall, the company has seen a massive surge in growth from its hematologic oncology, or blood cancer, drugs. For 2019, sales of Imbruvica rose by 30.2%. Venclexta saw an increase in revenue for the same period exceeding 100%.
Image Source: Getty Images
The sales increases should not end there. Evaluate Pharma ranked Upadacitinib, a rheumatoid arthritis treatment, the second most valuable research and development project. Upadacitinib already received Food and Drug Administration approval for rheumatoid arthritis in the U.S. Evaluate Pharma estimates that drug can generate more than $2.5 billion in annual sales by 2024. The rising number of enrollees in the Medicare Part D Drug coverage should help to boost these sales.
Thanks to the recent market decline, AbbVie's stock trades for just over 8.6 times forward earnings. However, analysts forecast earnings to increase by 8.2% this year and 8.7% in fiscal 2021.
The new bear market has left the company with a dividend yield of more than 6.6%. Moreover, thanks to its previous history as part of Abbott, its $4.72 annual payout has been raised for 47 consecutive years. Profit increases appear set to continue, and the payout ratio indicates that AbbVie pays out around 48.8% of profits in the form of dividends meaning the annual payout hikes should continue for the foreseeable future.
The dividend income could also help to fund the retirement of baby boomers. Since it offers a higher-than-average return that rises annually, it could serve as a viable income stream in retirement.
2. Innovative Industrial Properties
The massive decline in marijuana stocks may make Innovative Industrial Properties (NYSE: IIPR) seem like a strange choice. The fact that the Horizons Life Sciences Index has fallen by about 80% from its 52-week high describes the extent to which marijuana stocks have dropped. As a real estate investment trust (REIT) known as a "marijuana REIT," it may look like a stock to avoid considering the performance of cannabis stocks recently.
However, Grandview Research forecasted a compound annual growth rate (CAGR) for the cannabis industry of 18.7% until 2027. Moreover, with hemp, a form of marijuana, becoming legal in the U.S. in 2018, farmers in all 50 states can grow at least some type of cannabis legally. Further, since the company merely owns and leases property, it does not face the federal schedule 1 drug restrictions hampering most marijuana stocks.
The freedom from schedule 1 restrictions provides a competitive advantage for Innovative Industrial, which owns 35 properties in 15 U.S. states. Its recent growth has been fueled by buying the property of financially troubled marijuana companies and leasing it back to them. This provides the company with assets while giving Innovative Industrial Properties a source of cash flow. Early this year, the company bought and leased back a property in Yellow Springs, Ohio, to Cresco Labs.
This strategy has helped to boost the top and bottom lines as analysts predict profits for Innovative Industrial Properties will increase by 108.4% this year and 24.1% the next. The recent stock sell-off means investors can buy the stock for less than half of what it sold for in July, a move that brought its forward P/E ratio to about 11. This has taken its $4 per share payout to a yield of around 8.6%.
Moreover, considering the 90% minimum payout required of REITs, the payout ratio of about 93.6% is nothing unusual. Much like AbbVie's payout, this dividend offers a possible income stream for retirees. Innovative Industrial may benefit indirectly if more seniors choose to use medical cannabis products. As the marijuana industry continues its expansion, Innovative Industrial Properties and its dividend should grow along with it.
3. Omega Healthcare Investors
With an estimated 10,000 Americans turning 65 every day, this means a similar number of people are aging into the Medicare system daily. Such a statistic plays into the hands of another REIT stock: Omega Healthcare Investors (NYSE: OHI). An aging population increases the demand for healthcare services, and, by extension, demand for healthcare-related properties. Omega owns 964 skilled nursing and assisted living facilities across 40 U.S. states and the U.K.
Thanks to the current market sell-off, the company has lost more than two-thirds of its value since February. This swoon took its current P/E ratio to about 9.4. Though analysts only forecast 5.8% profit growth for this fiscal year, they expect earnings increases to average 15.8% per year for the next five years.
Not only does Omega Healthcare offer a dividend yield of about 18%, but it has also increased the payout for 10 consecutive years. Understandably, the payout ratio of over 159% might concern some investors. However, this does not mean that 159% of the company's net income is going to dividends. REITs derive the cash to pay their dividends through funds from operations (FFO). Investors have to remember that net income includes deductions. Hence, these companies may bring in significantly more cash than their net income might indicate.
In the case of Omega Healthcare, it earned $0.78 per share of FFO income in the previous quarter. This left the company easily able to cover the $0.67 per share it paid in quarterly dividends. Hence, even with only $0.268 per share of quarterly net income, the REIT can pay a dividend far exceeding that amount. Admittedly, a dividend yield at current levels makes it unclear whether the company will maintain the annual streak of payout hikes. Still, with an increasing customer base and the cash to maintain the payout, Omega Healthcare will likely remain a lucrative dividend investment.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Will Healy owns shares of AbbVie. The Motley Fool owns shares of and recommends Cresco Labs Inc. and Innovative Industrial Properties. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This strategy has helped to boost the top and bottom lines as analysts predict profits for Innovative Industrial Properties will increase by 108.4% this year and 24.1% the next. Omega Healthcare Investors With an estimated 10,000 Americans turning 65 every day, this means a similar number of people are aging into the Medicare system daily. Admittedly, a dividend yield at current levels makes it unclear whether the company will maintain the annual streak of payout hikes. | Profit increases appear set to continue, and the payout ratio indicates that AbbVie pays out around 48.8% of profits in the form of dividends meaning the annual payout hikes should continue for the foreseeable future. Innovative Industrial Properties The massive decline in marijuana stocks may make Innovative Industrial Properties (NYSE: IIPR) seem like a strange choice. The Motley Fool owns shares of and recommends Cresco Labs Inc. and Innovative Industrial Properties. | Profit increases appear set to continue, and the payout ratio indicates that AbbVie pays out around 48.8% of profits in the form of dividends meaning the annual payout hikes should continue for the foreseeable future. Innovative Industrial Properties The massive decline in marijuana stocks may make Innovative Industrial Properties (NYSE: IIPR) seem like a strange choice. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Will Healy owns shares of AbbVie. | This has taken its $4 per share payout to a yield of around 8.6%. As the marijuana industry continues its expansion, Innovative Industrial Properties and its dividend should grow along with it. Not only does Omega Healthcare offer a dividend yield of about 18%, but it has also increased the payout for 10 consecutive years. |
32758.0 | 2020-03-18 00:00:00 UTC | Coronavirus Test-makers Ramp Up Production | ABT | https://www.nasdaq.com/articles/coronavirus-test-makers-ramp-up-production-2020-03-19 | nan | nan | The difficulty of testing people who may have COVID-19 has become a bottleneck to stopping the coronavirus pandemic in the U.S. But soon, this obstacle should be cleared with multiple drug and diagnostic companies seeing their SARS-CoV-2 tests pass the health regulator's muster.
On Wednesday, Abbott Labs (NYSE: ABT) was granted an Emergency Use Authorization (EUA) from the Food and Drug Administration for its RealTime SARS-CoV-2, which tests for the coronavirus that causes COVID-19. The tests run on Abbott's m2000 RealTime Systems that are used in hospital and diagnostic laboratories.
Abbott's machines can run up to 470 tests in 24 hours. The company has 150,000 tests ready to distribute and is ramping up production with a goal of up to 1 million tests per week.
Image source: Getty Images.
Last week, the FDA granted an EUA to Roche's (OTC: RHHBY) cobas SARS-CoV-2 test, which runs on two different machines sold by Roche and has a higher throughput of 1,440 or 4,128 tests per hour depending on the machine. Roche committed to producing "millions" of tests per month.
On Wednesday, Qiagen (NYSE: QGEN) launched its QIAstat-Dx Respiratory SARS-CoV-2 Panel test for the coronavirus that goes by the name SARS-CoV-2. The test, which can produce a result in about one hour, obtained CE marking, allowing it to be sold in countries that accept the CE designation, such as countries in the EU.
Qiagen's tests run on its QIAstat-Dx Analyzer, which are in more than 1,000 hospitals, clinics, and labs worldwide. The test is a so-called syndromic test that can test for multiple respiratory infections at the same time -- thus the "panel" in the name. In addition to SARS-CoV-2, the test also looks for other coronaviruses, flu viruses, and some other viruses and bacteria that cause repository issues, making it a one-stop-shop for doctors.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Qiagen. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Wednesday, Abbott Labs (NYSE: ABT) was granted an Emergency Use Authorization (EUA) from the Food and Drug Administration for its RealTime SARS-CoV-2, which tests for the coronavirus that causes COVID-19. But soon, this obstacle should be cleared with multiple drug and diagnostic companies seeing their SARS-CoV-2 tests pass the health regulator's muster. On Wednesday, Qiagen (NYSE: QGEN) launched its QIAstat-Dx Respiratory SARS-CoV-2 Panel test for the coronavirus that goes by the name SARS-CoV-2. | On Wednesday, Abbott Labs (NYSE: ABT) was granted an Emergency Use Authorization (EUA) from the Food and Drug Administration for its RealTime SARS-CoV-2, which tests for the coronavirus that causes COVID-19. On Wednesday, Qiagen (NYSE: QGEN) launched its QIAstat-Dx Respiratory SARS-CoV-2 Panel test for the coronavirus that goes by the name SARS-CoV-2. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | On Wednesday, Abbott Labs (NYSE: ABT) was granted an Emergency Use Authorization (EUA) from the Food and Drug Administration for its RealTime SARS-CoV-2, which tests for the coronavirus that causes COVID-19. The company has 150,000 tests ready to distribute and is ramping up production with a goal of up to 1 million tests per week. Last week, the FDA granted an EUA to Roche's (OTC: RHHBY) cobas SARS-CoV-2 test, which runs on two different machines sold by Roche and has a higher throughput of 1,440 or 4,128 tests per hour depending on the machine. | On Wednesday, Abbott Labs (NYSE: ABT) was granted an Emergency Use Authorization (EUA) from the Food and Drug Administration for its RealTime SARS-CoV-2, which tests for the coronavirus that causes COVID-19. The tests run on Abbott's m2000 RealTime Systems that are used in hospital and diagnostic laboratories. On Wednesday, Qiagen (NYSE: QGEN) launched its QIAstat-Dx Respiratory SARS-CoV-2 Panel test for the coronavirus that goes by the name SARS-CoV-2. |
32759.0 | 2020-03-17 00:00:00 UTC | Health Care Sector Update for 03/17/2020: JNJ, PFE, ABT, MRK, AMGN, DBVT, AVRO, MRNA | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-03-17-2020%3A-jnj-pfe-abt-mrk-amgn-dbvt-avro-mrna-2020-03-17 | nan | nan | Top Health Care Stocks:
JNJ: +0.69%
PFE: +2.72%
ABT: +1.95%
MRK: +1.97%
AMGN: +0.73%
Top health care stocks rose during pre-market trading hours on Tuesday.
Health care stocks moving on news include:
(-) DBV Technologies (DBVT), which fell more than 50%. The company said the US Food and Drug Administration has identified questions on the efficacy of its drug candidate Viaskin during the FDA's Biologics License Application review.
(+) Biotechnology company Moderna (MRNA), which rose more than 9% after the company said the first participant in its phase 1 study for mRNA-1273 was dosed, a total of 63 days from sequence selection to first human dosing. mRNA-1273 is the company's intended treatment for COVID-19.
(+) Gene therapy company AVROBIO (AVRO), which was up more than 4% after reporting Q4 loss of $0.72 per share, compared with a loss of $0.67 a year ago and missing the consensus estimate of $0.61 loss compiled by Capital IQ.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top health care stocks rose during pre-market trading hours on Tuesday. Health care stocks moving on news include: (-) DBV Technologies (DBVT), which fell more than 50%. (+) Biotechnology company Moderna (MRNA), which rose more than 9% after the company said the first participant in its phase 1 study for mRNA-1273 was dosed, a total of 63 days from sequence selection to first human dosing. | Top Health Care Stocks: Top health care stocks rose during pre-market trading hours on Tuesday. Health care stocks moving on news include: (-) DBV Technologies (DBVT), which fell more than 50%. | Top health care stocks rose during pre-market trading hours on Tuesday. (+) Biotechnology company Moderna (MRNA), which rose more than 9% after the company said the first participant in its phase 1 study for mRNA-1273 was dosed, a total of 63 days from sequence selection to first human dosing. (+) Gene therapy company AVROBIO (AVRO), which was up more than 4% after reporting Q4 loss of $0.72 per share, compared with a loss of $0.67 a year ago and missing the consensus estimate of $0.61 loss compiled by Capital IQ. | Top Health Care Stocks: Top health care stocks rose during pre-market trading hours on Tuesday. Health care stocks moving on news include: (-) DBV Technologies (DBVT), which fell more than 50%. |
32760.0 | 2020-03-12 00:00:00 UTC | Validea Peter Lynch Strategy Daily Upgrade Report - 3/12/2020 | ABT | https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-3-12-2020-2020-03-12 | nan | nan | The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch changed from 69% to 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
CEDAR FAIR, L.P. (FUN) is a small-cap value stock in the Recreational Activities industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Cedar Fair, L.P. is an operator of regional amusement parks. The Company operates within a segment of amusement/water parks with accompanying resort facilities. As of December 31, 2016, the Company owned approximately 11 amusement parks, two separately gated outdoor water parks, one indoor water park and five hotels. The amusement parks include Cedar Point, located on Lake Erie between Cleveland and Toledo in Sandusky, Ohio; Knott's Berry Farm, near Los Angeles, California; Canada's Wonderland, near Toronto, Canada; Kings Island, near Cincinnati, Ohio; Carowinds, in Charlotte, North Carolina; Dorney Park & Wildwater Kingdom (Dorney Park), in Allentown, Pennsylvania; Kings Dominion, near Richmond, Virginia; California's Great America, in Santa Clara, California; Valleyfair, near Minneapolis/St. Paul, Minnesota; Worlds of Fun, in Kansas City, Missouri, and Michigan's Adventure, in Muskegon, Michigan. It manages and operates Gilroy Gardens Family Theme Park in Gilroy, California.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
MASTERCRAFT BOAT HOLDINGS INC (MCFT) is a small-cap value stock in the Recreational Products industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: MasterCraft Boat Holdings, Inc., formerly MCBC Holdings, Inc., is a holding company. The Company through its subsidiaries, is a designer, manufacturer and marketer of recreational powerboats. It operates through two segments: MasterCraft and NauticStar. Its subsidiaries include MasterCraft Boat Company, LLC; Nautic Star, LLC; NS Transport, LLC; MasterCraft Services, Inc.; MasterCraft Parts, Ltd.; and MasterCraft International Sales Administration, Inc. Its MasterCraft product brand consists of recreational performance boats primarily used for water skiing, wakeboarding, wake surfing, and general recreational boating. The NauticStar product brand consists of outboard boats primarily used for salt water fishing, and general recreational boating. It distributes the MasterCraft product brand and the NauticStar product brand through its dealer network.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
TELEPHONE & DATA SYSTEMS, INC. (TDS) is a small-cap growth stock in the Communications Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Telephone and Data Systems, Inc. is a diversified telecommunications company. The Company is engaged in conducting its Wireless operations through its subsidiary, United States Cellular Corporation (U.S. Cellular), as well as providing its wireline services, cable services, and hosted and managed services (HMS), through its subsidiary, TDS Telecommunications Corporation (TDS Telecom). It operates through four business segments: U.S. Cellular, Wireline, Cable, and Hosted and Managed Services. U.S. Cellular provides service to postpaid and prepaid customers. Wireline operations provide retail telecommunications services to both residential and commercial customers. Wireline offers services, including broadband, video, voice and network access services. Cable offers broadband, video and voice services under TDS and BendBroadband brand names. It provides a range of information technology (IT) services, including colocation, and cloud and hosting solutions through its HMS business.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
FIRST BANCSHARES INC (MISSISSIPPI) (FBMS) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: First Bancshares, Inc. is a bank holding company for The First, A National Banking Association (the Bank). The Company and the Bank engage in a general commercial and retail banking business for small to medium-sized businesses, professional concerns and individuals. The Bank provides a range of banking services across Mississippi, Louisiana, Alabama, Florida and Georgia. The Bank offers a range of commercial and personal loans. Commercial loans include both secured and unsecured loans for working capital (including loans secured by inventory and accounts receivable), business expansion (including acquisition of real estate and improvements), and purchase of equipment and machinery. The Bank offers a range of deposit services, including noninterest-bearing accounts, negotiable order of withdrawal (NOW) accounts, money market accounts, savings accounts and time deposits.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ZAGG INC (ZAGG) is a small-cap value stock in the Fabricated Plastic & Rubber industry. The rating according to our strategy based on Peter Lynch changed from 87% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: ZAGG Inc (ZAGG) designs, produces and distributes professional product solutions for mobile devices, including screen protection (glass and film), keyboards for tablet computers and mobile devices, keyboard cases, earbuds, mobile power solutions, cables, and cases under the ZAGG and InvisibleShield brands. In addition, the Company designs, produces and distributes earbuds, headphones, mobile power solutions, Bluetooth speakers, cases and cables for mobile devices under the iFrogz brand in the fashion and youth oriented lifestyle sector. The Company designs product solutions for users of mobile devices, and sells these products to consumers through global distribution partners and online. The Company offers products for various market segments of handheld electronic devices, including smartphones, tablets, notebook computers, laptops, gaming devices, global positioning system (GPS) devices, watch faces, and similar devices and surfaces. Its other brands include mophie and BRAVEN.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
CRACKER BARREL OLD COUNTRY STORE, INC. (CBRL) is a mid-cap value stock in the Restaurants industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Cracker Barrel Old Country Store, Inc. is engaged in the operation and development of the Cracker Barrel Old Country Store concept (Cracker Barrel). The Company's segments include Restaurant and Retail. The Company operates approximately 660 Cracker Barrel stores in 45 states. The format of its stores consists of a rustic old country-store design offering a restaurant menu that features home-style country food and a range of decorative and functional items, such as rocking chairs, holiday and seasonal gifts and toys, apparel, cookware and foods. Its restaurants offer home-style country cooking featuring of its own recipes. Its restaurants serve breakfast, lunch and dinner. Its breakfast items include juices, eggs, pancakes, grits, and a range of biscuit specialties. Its lunch and dinner items include country ham, chicken and dumplings, chicken fried chicken, meatloaf, fresh side items and specialty items, such as pinto beans and turnip greens.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
STARWOOD PROPERTY TRUST, INC. (STWD) is a mid-cap value stock in the Consumer Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Starwood Property Trust, Inc. is a real estate investment trust. The Company operates through three business segments: Real estate lending (the Lending Segment), which engages primarily in originating, acquiring, financing and managing commercial first mortgages, subordinated mortgages, mezzanine loans, preferred equity, commercial mortgage-backed securities (CMBS), residential mortgage-backed securities, and other real estate and real estate-related debt investments; Real estate investing and servicing (the Investing and Servicing Segment), which includes a servicing business in the United States that manages and works out problem assets; an investment business that selectively acquires and manages unrated, investment grade and non-investment grade rated CMBS, and a mortgage loan business, and Real estate property (the Property Segment), which engages primarily in acquiring and managing equity interests in stabilized commercial real estate properties.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
MARATHON PETROLEUM CORP (MPC) is a large-cap value stock in the Oil & Gas Operations industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Marathon Petroleum Corporation is engaged in refining, marketing, retail and transportation businesses in the United States and the largest east of the Mississippi. The Company operates through three segments: Refining & Marketing; Speedway; and Midstream. The Refining & Marketing segment refines crude oil and other feedstocks at the Company's seven refineries in the Gulf Coast and Midwest regions of the United States. Its Speedway segment sells transportation fuels and convenience products in the retail market in the Midwest, East Coast and Southeast regions of the United States. The Company's Midstream is engaged in the operations of MPLX LP and certain other related operations. It gathers, processes and transports natural gas, natural gas liquids (NGLs), crude oil and refined products. MPLX is a limited partnership which owns, operates, develops and acquires midstream energy infrastructure assets.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
INVENTORY TO SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
OCEANFIRST FINANCIAL CORP. (OCFC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: OceanFirst Financial Corp. is a holding company for OceanFirst Bank (the Bank). The Company is a savings and loan holding company. The Bank's principal business is attracting retail and business deposits in the communities surrounding its branch offices and investing those deposits primarily in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate and other commercial loans. The Bank also invests in other types of loans, including residential construction and consumer loans. In addition, the Bank invests in mortgage-backed securities (MBS), securities issued by the United States Government and agencies thereof, corporate securities and other investments. The Bank originates home equity loans typically as fixed-rate loans with terms ranging from 5 to 20 years. The Bank also offers variable-rate home equity lines of credit.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
DICKS SPORTING GOODS INC (DKS) is a mid-cap value stock in the Retail (Specialty) industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Dick's Sporting Goods, Inc. is an omni-channel sporting goods retailer offering an assortment of sports equipment, apparel, footwear and accessories in its specialty retail stores primarily in the eastern United States. The Company also owns and operates Golf Galaxy, Field & Stream and other specialty concept stores, and Dick's Team Sports HQ, an all-in-one youth sports digital platform offering free league management services, mobile applications for scheduling, communications and live scorekeeping, custom uniforms and FanWear and access to donations and sponsorships. The Company offers its products through a content-rich e-commerce platform that is integrated with its store network and provides customers with the convenience and expertise of a 24-hour storefront. It offers products to its customers through its retail stores and online. The Company offers hardlines, which include items, such as sporting goods equipment, fitness equipment, golf equipment, and hunting and fishing gear.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
PIPER SANDLER COMPANIES (PIPR) is a small-cap value stock in the Investment Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Piper Sandler Companies, formerly Piper Jaffray Companies, is an investment bank and institutional securities company. The Company offers advice to clients across various sectors, such as healthcare, energy, consumer and retail, financial services, agriculture, clean tech and renewables, technology, diversified industrials and business services. Its advisory services include sell-side and buy-side mergers and acquisitions (M&A), equity and debt capital markets, private placements and restructuring and special situations. Its public finance products include financial advisory services, municipal bond underwriting, municipal derivatives and reinvestment products and loan placements. Its institutional equities services include equity sales, equity trading, equity research and corporate and venture services. It provides fixed income investment solutions to corporations, public and private, public entities, money managers, financial institutions, foundations and endowments.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BANK OF COMMERCE HOLDINGS (BOCH) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Bank of Commerce Holdings (Holding Company) is a bank holding company. The Company's principal business is to serve as a holding company for Redding Bank of Commerce (Bank), which operates under two separate names (Redding Bank of Commerce and Sacramento Bank of Commerce). The Bank operates over four full service facilities in two diverse markets in Northern California. The Bank provides a range of financial services and products for business and retail customers. Its principal products include various types of accounts, such as checking, interest-bearing checking, savings, certificate of deposit and money market deposit. It also offers sweep arrangements, commercial loans, construction loans, term loans, safe deposit boxes and electronic banking services. The primary focus of the Bank is to provide banking and related services to small and mid-sized businesses and not-for-profit organizations, as well as banking services for consumers, primarily business owners and their employees.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
DIAMONDROCK HOSPITALITY COMPANY (DRH) is a small-cap value stock in the Real Estate Operations industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: DiamondRock Hospitality Company is a real estate investment trust (REIT). As of December 31, 2016, the Company owned a portfolio of 26 hotels and resorts that contains 9,472 guest rooms located in 17 different markets in North America and the United States Virgin Islands. Its business is to acquire, own, asset manage and renovate hotel properties in the United States. Its portfolio is concentrated in gateway cities and destination resort locations. It conducts its business through an umbrella partnership REIT (UPREIT) in, which its hotels are owned by subsidiaries of its operating partnership, DiamondRock Hospitality Limited Partnership. The Company is the general partner of its operating partnership and owns, either directly or indirectly, all of the limited partnership units of its operating partnership. The Company leases all of its domestic hotels to taxable REIT subsidiary, Bloodstone TRS, Inc. (TRS) lessees.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: FAIL
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ONEOK, INC. (OKE) is a large-cap value stock in the Oil & Gas - Integrated industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: ONEOK, Inc. is an energy midstream service provider in the United States. The Company owns and operates natural gas liquids (NGL) systems, and is engaged in the gathering, processing, storage and transportation of natural gas. THe Company's operations include a 38,000-mile integrated network of NGL and natural gas pipelines, processing plants, fractionators and storage facilities in the Mid-Continent, Williston, Permian and Rocky Mountain regions. The Company operates through three business segments. The Natural Gas Gathering and Processing segment provides midstream services to contracted producers in North Dakota, Montana, Wyoming, Kansas and Oklahoma. The Natural Gas Liquids segment owns and operates facilities that gather, fractionate, treat and distribute NGLs and store NGL products primarily in the Mid-Continental, Permian Basin and the Rocky Mountain regions. The Natural Gas Pipelines segment provides transportation and storage services to end users.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
CHEESECAKE FACTORY INC (CAKE) is a small-cap value stock in the Restaurants industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: The Cheesecake Factory Incorporated is engaged in the restaurant and bakery business. As of March 2, 2017, the Company operated 208 Company-owned restaurants: 194 under The Cheesecake Factory mark, 13 under the Grand Lux Cafe mark and one under the Rock Sugar Pan Asian Kitchen mark. The Company's segments include The Cheesecake Factory restaurants, and other. It also operates bakery production facilities, which produce desserts for its restaurants, international licensees and third-party bakery customers. Its restaurants offer lunch and dinner, as well as Sunday brunch. Its restaurants also offer a bar. As of January 3, 2017, its menu consisted of over 200 items in addition to items presented on supplemental menus, such as its SkinnyLicious menu, which offers approximately 50 items. Its Grand Lux Cafe is a casual dining concept that offers artisan cuisine. It offers appetizers, seafood and steaks.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
UNIVERSAL HEALTH SERVICES, INC. (UHS) is a mid-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Universal Health Services, Inc. is a holding company. The Company's principal business is owning and operating, through its subsidiaries, acute care hospitals and outpatient facilities, and behavioral healthcare facilities. The Company's segments include Acute Care Hospital Services, Behavioral Health Services and Other. As of August 1, 2018, the Company owned and/or operated more than 326 inpatient facilities, and 32 outpatient and other facilities, located in 37 states, Washington, District of Columbia, the United Kingdom, Puerto Rico and the United States Virgin Islands. The Company's hospitals provide a range of services, such as oncology, diagnostic care, coronary care, pediatric services, pharmacy services and/or behavioral health services. As of February 28, 2017, its acute care facilities located in the United States included 26 inpatient acute care hospitals; four free-standing emergency departments, and four outpatient surgery/cancer care centers and one surgical hospital.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
VALERO ENERGY CORPORATION (VLO) is a large-cap value stock in the Oil & Gas Operations industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Valero Energy Corporation (Valero) is an independent petroleum refiner and ethanol producer. The Company's segments include refining, ethanol and Valero Energy Partners LP (VLP). The refining segment includes its refining operations and the associated marketing activities. The ethanol segment includes its ethanol operations and the associated marketing activities, and logistics assets that support its ethanol operations. The Company owns logistics assets (crude oil pipelines, refined petroleum product pipelines, terminals, tanks, marine docks, truck rack bays and other assets) that support its refining operations. Some of these assets are owned by VLP, which is a midstream master limited partnership owned by the Company. VLP's assets include crude oil and refined petroleum products pipeline and terminal systems in the United States Gulf Coast and the United States Mid-Continent regions. Its refineries produce conventional gasolines, premium gasolines and lubricants, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
INVENTORY TO SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
VULCAN MATERIALS COMPANY (VMC) is a large-cap growth stock in the Construction - Raw Materials industry. The rating according to our strategy based on Peter Lynch changed from 87% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Vulcan Materials Company is a supplier of construction aggregates (primarily crushed stone, sand and gravel) and a producer of asphalt mix and ready-mixed concrete. The Company operates through four segments: Aggregates, Asphalt Mix, Concrete and Calcium. The Aggregates segment produces and sells aggregates (crushed stone, sand and gravel, sand, and other aggregates) and related products and services (transportation and other). The Company produces and sells asphalt mix in Arizona, California, New Mexico and Texas. The Company produces and sells ready-mixed concrete in Georgia, Maryland, New Mexico, Texas, Virginia, Washington District of Columbia and the Bahamas. The Calcium segment consists of a Florida facility that mines, produces and sells calcium products. As of December 31, 2016, it had 337 active aggregates facilities. The Company sells aggregates that are used as ballast for construction and maintenance of railroad tracks.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
WILLIAMS-SONOMA, INC. (WSM) is a mid-cap value stock in the Furniture & Fixtures industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Williams-Sonoma, Inc. is a multi-channel specialty retailer of products for the home. The Company operates retail stores in the United States, Canada, Puerto Rico, Australia and the United Kingdom. It operates through two segments: e-commerce and retail. The e-commerce segment has various merchandising strategies, such as Williams-Sonoma, Pottery Barn, Pottery Barn Kids, West Elm, PBteen, Williams-Sonoma Home, Rejuvenation and Mark and Graham, which sell its products through the Company's e-commerce Websites and direct-mail catalogs. The retail segment has various merchandising strategies, such as Williams-Sonoma, Pottery Barn, Pottery Barn Kids, West Elm and Rejuvenation, which sell its products through the Company's retail stores. The Company franchises its brands to third parties in a number of countries in the Middle East, the Philippines and Mexico. The Company's products are also available to customers through its catalogs and online across the world.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
INVENTORY TO SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
CONAGRA BRANDS INC (CAG) is a large-cap growth stock in the Food Processing industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Conagra Brands, Inc., formerly ConAgra Foods, Inc., operates as a packaged food company. The Company operates through two segments: Consumer Foods and Commercial Foods. The Company sells branded and customized food products, as well as commercially branded foods. It also supplies vegetable, spice and grain products to a range of restaurants, foodservice operators and commercial customers. Conagra Foodservice offers products to restaurants, retailers, commercial customers and other foodservice suppliers. The Company also operates in the countries outside the United States, such as Canada and Mexico. The Company's brands include Marie Callender's, Healthy Choice, Slim Jim, Hebrew National, Orville Redenbacher's, Peter Pan, Reddi-wip, PAM, Snack Pack, Banquet, Chef Boyardee, Egg Beaters, Rosarita, Fleischmann's and Hunt's. The Company sells its products in grocery, convenience, mass merchandise and club stores.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
LITHIA MOTORS INC (LAD) is a mid-cap value stock in the Retail (Specialty) industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Lithia Motors, Inc. is an operator of automotive franchises and a retailer of new and used vehicles and related services. As of February 28, 2017, it offered 30 brands of new vehicles and all brands of used vehicles in 154 stores in the United States and online at Lithia.com, DCHauto.com and CarboneCars.com. It operates through three segments: Domestic, Import and Luxury. Its Domestic segment consists of retail automotive franchises that sell new vehicles manufactured by Chrysler, General Motors and Ford. Its Import segment consists of retail automotive franchises that sell new vehicles manufactured primarily by Honda, Toyota, Subaru, Nissan and Volkswagen. Its Luxury segment consists of retail automotive franchises that sell new vehicles manufactured primarily by BMW, Mercedes-Benz and Lexus. The franchises in each segment also sell used vehicles, parts and automotive services, and automotive finance and insurance products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
Since its inception, Validea's strategy based on Peter Lynch has returned 302.02% vs. 175.77% for the S&P 500. For more details on this strategy, click here
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The Natural Gas Liquids segment owns and operates facilities that gather, fractionate, treat and distribute NGLs and store NGL products primarily in the Mid-Continental, Permian Basin and the Rocky Mountain regions. The Company's brands include Marie Callender's, Healthy Choice, Slim Jim, Hebrew National, Orville Redenbacher's, Peter Pan, Reddi-wip, PAM, Snack Pack, Banquet, Chef Boyardee, Egg Beaters, Rosarita, Fleischmann's and Hunt's. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Its subsidiaries include MasterCraft Boat Company, LLC; Nautic Star, LLC; NS Transport, LLC; MasterCraft Services, Inc.; MasterCraft Parts, Ltd.; and MasterCraft International Sales Administration, Inc. Its MasterCraft product brand consists of recreational performance boats primarily used for water skiing, wakeboarding, wake surfing, and general recreational boating. The Company is engaged in conducting its Wireless operations through its subsidiary, United States Cellular Corporation (U.S. Cellular), as well as providing its wireline services, cable services, and hosted and managed services (HMS), through its subsidiary, TDS Telecommunications Corporation (TDS Telecom). | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products. The Company operates through three business segments: Real estate lending (the Lending Segment), which engages primarily in originating, acquiring, financing and managing commercial first mortgages, subordinated mortgages, mezzanine loans, preferred equity, commercial mortgage-backed securities (CMBS), residential mortgage-backed securities, and other real estate and real estate-related debt investments; Real estate investing and servicing (the Investing and Servicing Segment), which includes a servicing business in the United States that manages and works out problem assets; an investment business that selectively acquires and manages unrated, investment grade and non-investment grade rated CMBS, and a mortgage loan business, and Real estate property (the Property Segment), which engages primarily in acquiring and managing equity interests in stabilized commercial real estate properties. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The Bank provides a range of financial services and products for business and retail customers. The Company operates through three business segments. |
32761.0 | 2020-03-12 00:00:00 UTC | iShares MSCI World ETF Experiences Big Inflow | ABT | https://www.nasdaq.com/articles/ishares-msci-world-etf-experiences-big-inflow-2020-03-12 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI World ETF (Symbol: URTH) where we have detected an approximate $106.9 million dollar inflow -- that's a 12.1% increase week over week in outstanding units (from 10,700,000 to 12,000,000). Among the largest underlying components of URTH, in trading today Visa Inc (Symbol: V) is down about 7.4%, Mastercard Inc (Symbol: MA) is down about 9.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 3.1%. For a complete list of holdings, visit the URTH Holdings page » The chart below shows the one year price performance of URTH, versus its 200 day moving average:
Looking at the chart above, URTH's low point in its 52 week range is $74.10 per share, with $102.2778 as the 52 week high point — that compares with a last trade of $76.11. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of URTH, in trading today Visa Inc (Symbol: V) is down about 7.4%, Mastercard Inc (Symbol: MA) is down about 9.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 3.1%. For a complete list of holdings, visit the URTH Holdings page » The chart below shows the one year price performance of URTH, versus its 200 day moving average: Looking at the chart above, URTH's low point in its 52 week range is $74.10 per share, with $102.2778 as the 52 week high point — that compares with a last trade of $76.11. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of URTH, in trading today Visa Inc (Symbol: V) is down about 7.4%, Mastercard Inc (Symbol: MA) is down about 9.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 3.1%. For a complete list of holdings, visit the URTH Holdings page » The chart below shows the one year price performance of URTH, versus its 200 day moving average: Looking at the chart above, URTH's low point in its 52 week range is $74.10 per share, with $102.2778 as the 52 week high point — that compares with a last trade of $76.11. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of URTH, in trading today Visa Inc (Symbol: V) is down about 7.4%, Mastercard Inc (Symbol: MA) is down about 9.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 3.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI World ETF (Symbol: URTH) where we have detected an approximate $106.9 million dollar inflow -- that's a 12.1% increase week over week in outstanding units (from 10,700,000 to 12,000,000). For a complete list of holdings, visit the URTH Holdings page » The chart below shows the one year price performance of URTH, versus its 200 day moving average: Looking at the chart above, URTH's low point in its 52 week range is $74.10 per share, with $102.2778 as the 52 week high point — that compares with a last trade of $76.11. | Among the largest underlying components of URTH, in trading today Visa Inc (Symbol: V) is down about 7.4%, Mastercard Inc (Symbol: MA) is down about 9.2%, and Abbott Laboratories (Symbol: ABT) is lower by about 3.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI World ETF (Symbol: URTH) where we have detected an approximate $106.9 million dollar inflow -- that's a 12.1% increase week over week in outstanding units (from 10,700,000 to 12,000,000). For a complete list of holdings, visit the URTH Holdings page » The chart below shows the one year price performance of URTH, versus its 200 day moving average: Looking at the chart above, URTH's low point in its 52 week range is $74.10 per share, with $102.2778 as the 52 week high point — that compares with a last trade of $76.11. |
32762.0 | 2020-03-12 00:00:00 UTC | ABT May 1st Options Begin Trading | ABT | https://www.nasdaq.com/articles/abt-may-1st-options-begin-trading-2020-03-12 | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the May 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 1st contracts and identified one put and one call contract of particular interest.
The put contract at the $73.50 strike price has a current bid of $3.25. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $73.50, but will also collect the premium, putting the cost basis of the shares at $70.25 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $75.61/share today.
Because the $73.50 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 64%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 4.42% return on the cash commitment, or 32.28% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $73.50 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $79.50 strike price has a current bid of $1.01. If an investor was to purchase shares of ABT stock at the current price level of $75.61/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $79.50. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 6.48% if the stock gets called away at the May 1st expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $79.50 strike highlighted in red:
Considering the fact that the $79.50 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 72%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 1.34% boost of extra return to the investor, or 9.75% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 72%, while the implied volatility in the call contract example is 60%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $75.61) to be 23%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks Analysts Like »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $79.50 strike highlighted in red: Considering the fact that the $79.50 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the May 1st expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $79.50 strike highlighted in red: Considering the fact that the $79.50 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the May 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 1st contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $79.50 strike highlighted in red: Considering the fact that the $79.50 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the May 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 1st contracts and identified one put and one call contract of particular interest. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 1st contracts and identified one put and one call contract of particular interest. Below is a chart showing ABT's trailing twelve month trading history, with the $79.50 strike highlighted in red: Considering the fact that the $79.50 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the May 1st expiration. |
32763.0 | 2020-03-11 00:00:00 UTC | Health Care Sector Update for 03/11/2020: JNJ, PFE, ABT, MRK, AMGN, SPHS, CDMO, KALA | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-03-11-2020%3A-jnj-pfe-abt-mrk-amgn-sphs-cdmo-kala-2020-03-11 | nan | nan | Top Health Care Stocks:
JNJ: -2.86%
PFE: -2.02%
ABT: -2.32%
MRK: -3.05%
AMGN: -4.06%
The leading health care stocks slipped during the pre-market trading session on Wednesday.
Health care stocks moving on news include:
(-) Sophiris Bio (SPHS), which dropped more than 38% after the biopharmaceutical company announced that its shares will be delisted from Nasdaq on March 12.
(-) Avid Bioservices (CDMO), which was also down more than 21% after reporting fiscal Q3 net loss of $0.06 per share, compared with a loss of $0.05 per share from a year earlier and missing the consensus estimate of a loss of $0.05 per share from analysts polled by Capital IQ.
(+) Meanwhile, Kala Pharmaceuticals (KALA) rose more than 7% after pricing its offering of 16 million common shares at $7.89 per share for gross proceeds of about $126.2 million.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The leading health care stocks slipped during the pre-market trading session on Wednesday. Health care stocks moving on news include: (-) Sophiris Bio (SPHS), which dropped more than 38% after the biopharmaceutical company announced that its shares will be delisted from Nasdaq on March 12. (-) Avid Bioservices (CDMO), which was also down more than 21% after reporting fiscal Q3 net loss of $0.06 per share, compared with a loss of $0.05 per share from a year earlier and missing the consensus estimate of a loss of $0.05 per share from analysts polled by Capital IQ. | Top Health Care Stocks: The leading health care stocks slipped during the pre-market trading session on Wednesday. Health care stocks moving on news include: (-) Sophiris Bio (SPHS), which dropped more than 38% after the biopharmaceutical company announced that its shares will be delisted from Nasdaq on March 12. | Health care stocks moving on news include: (-) Sophiris Bio (SPHS), which dropped more than 38% after the biopharmaceutical company announced that its shares will be delisted from Nasdaq on March 12. (-) Avid Bioservices (CDMO), which was also down more than 21% after reporting fiscal Q3 net loss of $0.06 per share, compared with a loss of $0.05 per share from a year earlier and missing the consensus estimate of a loss of $0.05 per share from analysts polled by Capital IQ. (+) Meanwhile, Kala Pharmaceuticals (KALA) rose more than 7% after pricing its offering of 16 million common shares at $7.89 per share for gross proceeds of about $126.2 million. | Top Health Care Stocks: The leading health care stocks slipped during the pre-market trading session on Wednesday. Health care stocks moving on news include: (-) Sophiris Bio (SPHS), which dropped more than 38% after the biopharmaceutical company announced that its shares will be delisted from Nasdaq on March 12. |
32764.0 | 2020-03-08 00:00:00 UTC | 5 High-Yield Dividend Stocks to Watch in the Coronavirus Sell-Off | ABT | https://www.nasdaq.com/articles/5-high-yield-dividend-stocks-to-watch-in-the-coronavirus-sell-off-2020-03-08 | nan | nan | In a world where investors struggle to earn decent returns from fixed-income instruments, dividend stocks have emerged as a strategy for earning higher returns. The average dividend yield for the S&P 500 is just over 1.9%, dramatically higher than the 0.09% in interest people earn in a savings account on average.
Moreover, the stock market offers investments that not only produce dividend yields that significantly exceed that average, but they also provide the income or cash flow that will allow them to maintain or increase dividends over time. Here are five stocks in five different industries that fit that description. Investors with cash on the sidelines to deploy at current discounted prices should consider these high-paying stocks.
1. AbbVie
AbbVie (NYSE: ABBV) stock sold off in recent years due to the impending patent expiration of its primary revenue driver, Humira. As it began to recover amid new drug developments, the announcement of its purchase of Allergan initially weighed further on the stock.
However, AbbVie looks positioned to move on from Humira. Two hematologic oncology drugs, Imbruvica and Venclexta, together registered 37% in reported revenue growth year over year. Humira saw no net increase over the same period.
Image source: Getty Images.
Moreover, AbbVie has shown signs of recovery in recent months. Despite this increase, AbbVie stock trades at a forward P/E ratio of around 8.7. This occurred despite the fact that analysts forecast earnings increases of 8.3% this year and 8.7% in fiscal 2021.
Furthermore, due to its history as a subsidiary of Abbott Laboratories, it has now benefited from 47 consecutive years of payout hikes. This year's annual payout of $4.72 per share yields around 5.3%.
The company should be able to easily maintain this dividend. The dividend payout ratio stands at about 48.8%, and cash flow has consistently come in well above the cost of paying the dividend. Moreover, Dividend Aristocrats such as AbbVie tend to continue dividend hikes unless the company's financial condition makes payout raises untenable. As sales of its hematologic oncology drugs continue to grow, investors could find it hard to pass up on this growth and income play.
2. AT&T
AT&T (NYSE: T) struggled for much of the decade as wireless competition and cord-cutting ate into the telecom giant's profits. On top of that, the cost of building out a 5G network weighed on the company. Then, acquisitions of DirecTV and the division now known as WarnerMedia placed further pressure on AT&T's balance sheet.
The company's dividend is another significant cost. In 2019, dividend payments set the company back $14.89 billion. The yearly payout has since risen from $2.04 to $2.08 per share.
However, AT&T is also a Dividend Aristocrat, and the company probably wants to avoid the pain of ending the 35-year streak of payout hikes. Hence, even at a yield of around 5.8%, the dividend will likely keep rising. Furthermore, at a payout ratio of about 57.6%, AT&T can probably continue to fund the dividend.
To be sure, the profit growth rate of 1.1% forecasted for the year will likely not inspire investors. However, profit growth should improve, and once 5G takes off, AT&T will be one of only three companies providing this next-generation service in the U.S. Furthermore, with a forward P/E ratio of around 9.9, investors can pick this stock up at a relative bargain.
3. Altria
Altria (NYSE: MO) continues to defy odds. The Surgeon General's report that warned of the dangers of smoking came out more than 56 years ago. At that time, around 42% of Americans smoked cigarettes.
That number fell to 15.5% by 2016. Nonetheless, both Altria stock and its dividend continued to rise amid the smoking decline. In January 1964, Altria traded at a split-adjusted level of about $0.13 per share. The stock has since seen seven stock splits and numerous dividend increases. The current $3.36 per share annual dividend yields around 8.3% and has risen for 11 consecutive years.
Further, even with the massive increases, Altria sells for only about 9.2 times forward earnings. While the payout ratio of around 75.8% may appear elevated, earnings growth of 5% for the current year should be enough to keep the high payout and the subsequent increases coming.
Altria continues to face challenges. Declines in smoking could still hurt the company's growth. Also, the SEC probe of the JUUL Labs investment could weigh on Altria stock for now. However, Altria also invested $1.8 billion in Canadian marijuana giant Cronos Group. As more jurisdictions legalize cannabis for both medical and recreational purposes, this investment could eventually drive earnings growth for Altria stock.
4. ExxonMobil
ExxonMobil's (NYSE: XOM) yearly dividend of $3.48 per share, or a yield of 6.75%, seems impressive. However, a slowdown in China related to the coronavirus has reduced overall energy consumption. This caused ExxonMobil stock to drop by nearly 27% in the first two months of 2020.
Still, some seem to forget that ExxonMobil is a diversified energy play. Yes, its upstream segment deals with volatility as fluctuating oil prices often make or break the profitability of drilling projects. However, the company also refines and sells petroleum products and chemicals, a relatively steady business regardless of oil prices.
Moreover, for all of the focus on renewables, electric vehicles only made up 1.8% of all vehicle sales in March 2019. Hence, investors can safely assume that fossil fuels are not going anywhere.
Nonetheless, ExxonMobil now trades at a forward P/E ratio of around 14. With five-year profit growth projections averaging 5.65% per year, the dividend is arguably the primary motivation to buy Exxon stock now.
More importantly, ExxonMobil has maintained a 37-year streak of consecutive annual payout hikes. This means the dividend rose in both high and low-oil-price environments. It also means that dividends increased when the payout ratio reached 108.9%, as it has now. Free cash flow fell well below the dividend expense in 2019. Still, even if prices remain depressed, both divestitures and new ventures could fund annual payout hikes for the foreseeable future.
5. PennyMac Mortgage Investment Trust
PennyMac Mortgage Investment Trust (NYSE: PMT) specializes in mortgage-related assets, particularly on the residential side. As a real estate investment trust, it must pay out at least 90% of its net income in the form of dividends to avoid most income taxes.
PennyMac is not a household name among stocks. However, the payout could compensate for a lack of name recognition. Current shareholders receive an annual payout of $1.88 per share, a yield of around 8.75%.
Moreover, given the previously mentioned 90% payout requirement, the dividend payout ratio of about 84.5% appears slightly low. Also, in 2019, it generated almost $201.42 million in net income attributable to common shareholders, more than enough to cover the required dividend payments.
Furthermore, in addition to the dividend, PennyMac stock trades at a reasonable valuation. It sells for just over 10.1 times forward earnings. The average annual earnings growth rate of 4.15% may not excite investors. Still, given its dividend, investors will more than likely buy PennyMac primarily for its payout, which has remained steady since 2015. Moreover, as income rises, payouts will have to rise for the company to maintain its REIT status.
10 stocks we like better than AT&T
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AT&T wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Will Healy owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As sales of its hematologic oncology drugs continue to grow, investors could find it hard to pass up on this growth and income play. As more jurisdictions legalize cannabis for both medical and recreational purposes, this investment could eventually drive earnings growth for Altria stock. With five-year profit growth projections averaging 5.65% per year, the dividend is arguably the primary motivation to buy Exxon stock now. | Nonetheless, both Altria stock and its dividend continued to rise amid the smoking decline. PennyMac Mortgage Investment Trust PennyMac Mortgage Investment Trust (NYSE: PMT) specializes in mortgage-related assets, particularly on the residential side. Moreover, given the previously mentioned 90% payout requirement, the dividend payout ratio of about 84.5% appears slightly low. | Moreover, the stock market offers investments that not only produce dividend yields that significantly exceed that average, but they also provide the income or cash flow that will allow them to maintain or increase dividends over time. Moreover, Dividend Aristocrats such as AbbVie tend to continue dividend hikes unless the company's financial condition makes payout raises untenable. The stock has since seen seven stock splits and numerous dividend increases. | Moreover, the stock market offers investments that not only produce dividend yields that significantly exceed that average, but they also provide the income or cash flow that will allow them to maintain or increase dividends over time. Furthermore, at a payout ratio of about 57.6%, AT&T can probably continue to fund the dividend. Further, even with the massive increases, Altria sells for only about 9.2 times forward earnings. |
32765.0 | 2020-03-05 00:00:00 UTC | Why Abbott Labs Shares Fell 11.6% in February | ABT | https://www.nasdaq.com/articles/why-abbott-labs-shares-fell-11.6-in-february-2020-03-05 | nan | nan | What happened
Shares of Abbott Laboratories (NYSE: ABT) slipped 11.6% in February, according to data provided by S&P Global Market Intelligence, amid concern that a deepening of the coronavirus outbreak may hurt sales of companies with business in the country.
China is Abbott's second-biggest single market after the U.S. The country accounts for 7.6% of Abbott's $31 billion in net sales to external customers, according to the company's 2018 annual report. Abbott's pediatric-nutrition business is a good example of the company's exposure to China, as its Eleva is the country's leading organic infant formula.
Image source: Getty Images.
So what
So far, more than 80,000 coronavirus cases have been confirmed in China. As a result, quarantines have been put into place, and people in areas such as Wuhan -- where the virus began -- have been prohibited from leaving their neighborhoods, even for necessities.
While Abbott and other companies that sell products in China likely will record a dip in sales there in February, it's unlikely the impact will be significant for Abbot. The company makes 35% of its sales in the U.S., and more than half of its business is spread across many countries worldwide. The diversity of businesses also should insulate Abbott from the crisis, as the company is presently in areas including diabetes care, heart failure management, and diagnostics.
Now what
Speaking of diagnostics, Abbott might eventually see a lift in that area from the coronavirus outbreak. Reuters reported that the company is developing a test and said Abbott was one of several diagnostics companies to meet with President Trump this week to discuss making tests more accessible. Though it will be interesting to keep an eye on those developments, Abbott's earnings and share movement most likely won't be led higher or lower by the coronavirus in the long term. And that, as mentioned above, is due to the company's many sources of income.
Abbott shares clearly tracked the losses of the S&P 500 Index in February after rising 20% last year. Wall Street expects 26% upside from Abbott's current price. Once the coronavirus outbreak eases, the shares should have a better chance of making those gains.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Abbott Laboratories (NYSE: ABT) slipped 11.6% in February, according to data provided by S&P Global Market Intelligence, amid concern that a deepening of the coronavirus outbreak may hurt sales of companies with business in the country. The diversity of businesses also should insulate Abbott from the crisis, as the company is presently in areas including diabetes care, heart failure management, and diagnostics. Though it will be interesting to keep an eye on those developments, Abbott's earnings and share movement most likely won't be led higher or lower by the coronavirus in the long term. | What happened Shares of Abbott Laboratories (NYSE: ABT) slipped 11.6% in February, according to data provided by S&P Global Market Intelligence, amid concern that a deepening of the coronavirus outbreak may hurt sales of companies with business in the country. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Adria Cimino has no position in any of the stocks mentioned. | What happened Shares of Abbott Laboratories (NYSE: ABT) slipped 11.6% in February, according to data provided by S&P Global Market Intelligence, amid concern that a deepening of the coronavirus outbreak may hurt sales of companies with business in the country. Reuters reported that the company is developing a test and said Abbott was one of several diagnostics companies to meet with President Trump this week to discuss making tests more accessible. 10 stocks we like better than Abbott Laboratories When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | What happened Shares of Abbott Laboratories (NYSE: ABT) slipped 11.6% in February, according to data provided by S&P Global Market Intelligence, amid concern that a deepening of the coronavirus outbreak may hurt sales of companies with business in the country. The company makes 35% of its sales in the U.S., and more than half of its business is spread across many countries worldwide. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. |
32766.0 | 2020-03-05 00:00:00 UTC | Abbott Receives EU Approval For FlexNav Delivery System | ABT | https://www.nasdaq.com/articles/abbott-receives-eu-approval-for-flexnav-delivery-system-2020-03-05 | nan | nan | (RTTNews) - Abbott (ABT) said Thursday that it has received CE Mark for the new FlexNav delivery system for the company's Portico transcatheter aortic valve implantation system, enabling marketing authorization in Europe.
Transcatheter aortic valve replacement is a minimally invasive alternative to surgical aortic valve replacement for patients at high or extreme risk for open heart surgery who are diagnosed with severe aortic stenosis, a condition which restricts blood flow through the valve.
While valve technology improvements have helped reduce adverse events and improve patient outcomes, improvements to delivery systems are critical to improving the placement and positioning of the valve.
The Portico Transcatheter Aortic Valve and FlexNav Delivery System are approved for investigational use only in the U.S.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) said Thursday that it has received CE Mark for the new FlexNav delivery system for the company's Portico transcatheter aortic valve implantation system, enabling marketing authorization in Europe. Transcatheter aortic valve replacement is a minimally invasive alternative to surgical aortic valve replacement for patients at high or extreme risk for open heart surgery who are diagnosed with severe aortic stenosis, a condition which restricts blood flow through the valve. The Portico Transcatheter Aortic Valve and FlexNav Delivery System are approved for investigational use only in the U.S. | (RTTNews) - Abbott (ABT) said Thursday that it has received CE Mark for the new FlexNav delivery system for the company's Portico transcatheter aortic valve implantation system, enabling marketing authorization in Europe. Transcatheter aortic valve replacement is a minimally invasive alternative to surgical aortic valve replacement for patients at high or extreme risk for open heart surgery who are diagnosed with severe aortic stenosis, a condition which restricts blood flow through the valve. The Portico Transcatheter Aortic Valve and FlexNav Delivery System are approved for investigational use only in the U.S. | (RTTNews) - Abbott (ABT) said Thursday that it has received CE Mark for the new FlexNav delivery system for the company's Portico transcatheter aortic valve implantation system, enabling marketing authorization in Europe. Transcatheter aortic valve replacement is a minimally invasive alternative to surgical aortic valve replacement for patients at high or extreme risk for open heart surgery who are diagnosed with severe aortic stenosis, a condition which restricts blood flow through the valve. While valve technology improvements have helped reduce adverse events and improve patient outcomes, improvements to delivery systems are critical to improving the placement and positioning of the valve. | (RTTNews) - Abbott (ABT) said Thursday that it has received CE Mark for the new FlexNav delivery system for the company's Portico transcatheter aortic valve implantation system, enabling marketing authorization in Europe. Transcatheter aortic valve replacement is a minimally invasive alternative to surgical aortic valve replacement for patients at high or extreme risk for open heart surgery who are diagnosed with severe aortic stenosis, a condition which restricts blood flow through the valve. While valve technology improvements have helped reduce adverse events and improve patient outcomes, improvements to delivery systems are critical to improving the placement and positioning of the valve. |
32767.0 | 2020-03-04 00:00:00 UTC | Health Care Sector Update for 03/04/2020: JNJ, PFE, ABT, MRK, AMGN, MRNA, REPH, CNC, DRRX | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-03-04-2020%3A-jnj-pfe-abt-mrk-amgn-mrna-reph-cnc-drrx-2020-03 | nan | nan | Top Health Care Stocks:
JNJ: +3.98%
PFE: +4.42%
ABT: +3.26%
MRK: +3.80%
AMGN: +2.51%
Health care stocks were stronger, including a 4% gain for the NYSE Health Care Index in recent trade. Also, shares of health care companies in the S&P 500 were also up more than 4% as a group while the Nasdaq Biotechnology index was 3% ahead.
Health care stocks moving on news include:
(+) Moderna (MRNA) gained almost 1% after the US Food and Drug Administration allowed its SARS-CoV-2 vaccine candidate, mRNA-1273, to advance into the clinic following a review of its new drug application.
(-) Recro Pharma (REPH) slumped 30% after the company reported 2019 revenue that trailed the Street estimate, and issued 2020 revenue guidance below estimates.
(+) Centene (CNC) rose more than 13% after its subsidiary Centurion secured two contracts from the Delaware Department of Correction for its medical and behavioral health services.
(+) Durect (DRRX) gained more than 10% after its Q4 loss came in as expected in a poll by Capital IQ.
(+) VIVUS (VVUS) was up more than 4% after reporting Q4 net loss of $0.61 per share, compared with a loss of $1.04 per share sequentially and beating the consensus estimate of a loss of $0.68 per share in a Capital IQ poll.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also, shares of health care companies in the S&P 500 were also up more than 4% as a group while the Nasdaq Biotechnology index was 3% ahead. Health care stocks moving on news include: (+) Moderna (MRNA) gained almost 1% after the US Food and Drug Administration allowed its SARS-CoV-2 vaccine candidate, mRNA-1273, to advance into the clinic following a review of its new drug application. (+) Centene (CNC) rose more than 13% after its subsidiary Centurion secured two contracts from the Delaware Department of Correction for its medical and behavioral health services. | Top Health Care Stocks: Health care stocks were stronger, including a 4% gain for the NYSE Health Care Index in recent trade. Also, shares of health care companies in the S&P 500 were also up more than 4% as a group while the Nasdaq Biotechnology index was 3% ahead. | Health care stocks were stronger, including a 4% gain for the NYSE Health Care Index in recent trade. Health care stocks moving on news include: (+) Moderna (MRNA) gained almost 1% after the US Food and Drug Administration allowed its SARS-CoV-2 vaccine candidate, mRNA-1273, to advance into the clinic following a review of its new drug application. (+) VIVUS (VVUS) was up more than 4% after reporting Q4 net loss of $0.61 per share, compared with a loss of $1.04 per share sequentially and beating the consensus estimate of a loss of $0.68 per share in a Capital IQ poll. | Health care stocks were stronger, including a 4% gain for the NYSE Health Care Index in recent trade. (-) Recro Pharma (REPH) slumped 30% after the company reported 2019 revenue that trailed the Street estimate, and issued 2020 revenue guidance below estimates. (+) VIVUS (VVUS) was up more than 4% after reporting Q4 net loss of $0.61 per share, compared with a loss of $1.04 per share sequentially and beating the consensus estimate of a loss of $0.68 per share in a Capital IQ poll. |
32768.0 | 2020-03-04 00:00:00 UTC | Health Care Sector Update for 03/04/2020: JNJ, PFE, ABT, MRK, AMGN, DRRX, VVUS, VYGR | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-03-04-2020%3A-jnj-pfe-abt-mrk-amgn-drrx-vvus-vygr-2020-03-04 | nan | nan | Top Health Care Stocks:
JNJ: +1.78%
PFE: +2.77%
ABT: +3.00%
MRK: +2.73%
AMGN: +2.24%
Top health care stocks were up before markets open on Wednesday.
Health care stocks moving on news include:
(+) Durect (DRRX), which gained more than 13%. The biopharmaceutical company reported a Q4 loss of $0.02 per share, narrowing from $0.05 a year ago and in line with the consensus estimate compiled by Capital IQ.
(+) VIVUS (VVUS), which was up more than 6% after reporting Q4 net loss of $0.61 per share, compared with a loss of $1.04 per share sequentially and beating the consensus estimate of a loss of $0.68 per share from analysts polled by Capital IQ.
(+) Voyager Therapeutics (VYGR), which added more than 2% after reporting Q4 net loss of $0.34 per share, narrower than the year-ago loss of $0.77 per share and beating the consensus estimate of a loss of $0.81 per share compiled by Capital IQ.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Top health care stocks were up before markets open on Wednesday. Health care stocks moving on news include: (+) Durect (DRRX), which gained more than 13%. The biopharmaceutical company reported a Q4 loss of $0.02 per share, narrowing from $0.05 a year ago and in line with the consensus estimate compiled by Capital IQ. | The biopharmaceutical company reported a Q4 loss of $0.02 per share, narrowing from $0.05 a year ago and in line with the consensus estimate compiled by Capital IQ. (+) VIVUS (VVUS), which was up more than 6% after reporting Q4 net loss of $0.61 per share, compared with a loss of $1.04 per share sequentially and beating the consensus estimate of a loss of $0.68 per share from analysts polled by Capital IQ. (+) Voyager Therapeutics (VYGR), which added more than 2% after reporting Q4 net loss of $0.34 per share, narrower than the year-ago loss of $0.77 per share and beating the consensus estimate of a loss of $0.81 per share compiled by Capital IQ. | Top health care stocks were up before markets open on Wednesday. (+) VIVUS (VVUS), which was up more than 6% after reporting Q4 net loss of $0.61 per share, compared with a loss of $1.04 per share sequentially and beating the consensus estimate of a loss of $0.68 per share from analysts polled by Capital IQ. (+) Voyager Therapeutics (VYGR), which added more than 2% after reporting Q4 net loss of $0.34 per share, narrower than the year-ago loss of $0.77 per share and beating the consensus estimate of a loss of $0.81 per share compiled by Capital IQ. | Top Health Care Stocks: Top health care stocks were up before markets open on Wednesday. Health care stocks moving on news include: (+) Durect (DRRX), which gained more than 13%. |
32769.0 | 2020-03-03 00:00:00 UTC | Health Care Sector Update for 03/03/2020: JNJ, PFE, ABT, MRK, AMGN, KMPH, OMER, GNMK | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-03-03-2020%3A-jnj-pfe-abt-mrk-amgn-kmph-omer-gnmk-2020-03-03 | nan | nan | Top Health Care Stocks:
JNJ: +0.71%
PFE: +1.26%
ABT: -0.66%
MRK: -0.34%
AMGN: -1.09%
The largest health care stocks were mostly down before markets open on Tuesday.
Stocks moving on news include:
(+) KemPharm (KMPH), which jumped more than 41% after submitting to the US Food and Drug Administration a new drug application for KP415, which is intended for the treatment of attention deficit hyperactivity disorder.
(+) GenMark Diagnostics (GNMK), which gained more than 26% after the company narrowed its net loss to $0.17 per share in Q4 from $0.21 per share a year ago, but missed the analysts' estimates of $0.16 loss per share in a Capital IQ poll. Revenue rose 40% to $27.2 million from last year, beating the $26.76 million Street estimate.
(+) Omer (OMER), which rose almost 13% after reporting Q4 GAAP net loss of $0.58 per share, wider than both the $0.48 loss per share reported a year ago and the $0.35 loss per share average estimate of analysts surveyed by Capital IQ. Revenue totaled $33.4 million for the quarter, up from $22 million a year ago, and beating the $31.8 million Street forecast.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The largest health care stocks were mostly down before markets open on Tuesday. Stocks moving on news include: (+) KemPharm (KMPH), which jumped more than 41% after submitting to the US Food and Drug Administration a new drug application for KP415, which is intended for the treatment of attention deficit hyperactivity disorder. (+) Omer (OMER), which rose almost 13% after reporting Q4 GAAP net loss of $0.58 per share, wider than both the $0.48 loss per share reported a year ago and the $0.35 loss per share average estimate of analysts surveyed by Capital IQ. | (+) GenMark Diagnostics (GNMK), which gained more than 26% after the company narrowed its net loss to $0.17 per share in Q4 from $0.21 per share a year ago, but missed the analysts' estimates of $0.16 loss per share in a Capital IQ poll. Revenue rose 40% to $27.2 million from last year, beating the $26.76 million Street estimate. (+) Omer (OMER), which rose almost 13% after reporting Q4 GAAP net loss of $0.58 per share, wider than both the $0.48 loss per share reported a year ago and the $0.35 loss per share average estimate of analysts surveyed by Capital IQ. | Stocks moving on news include: (+) KemPharm (KMPH), which jumped more than 41% after submitting to the US Food and Drug Administration a new drug application for KP415, which is intended for the treatment of attention deficit hyperactivity disorder. (+) GenMark Diagnostics (GNMK), which gained more than 26% after the company narrowed its net loss to $0.17 per share in Q4 from $0.21 per share a year ago, but missed the analysts' estimates of $0.16 loss per share in a Capital IQ poll. (+) Omer (OMER), which rose almost 13% after reporting Q4 GAAP net loss of $0.58 per share, wider than both the $0.48 loss per share reported a year ago and the $0.35 loss per share average estimate of analysts surveyed by Capital IQ. | Top Health Care Stocks: The largest health care stocks were mostly down before markets open on Tuesday. Stocks moving on news include: (+) KemPharm (KMPH), which jumped more than 41% after submitting to the US Food and Drug Administration a new drug application for KP415, which is intended for the treatment of attention deficit hyperactivity disorder. |
32770.0 | 2020-03-02 00:00:00 UTC | Notable ETF Outflow Detected - IWB, CVX, MCD, ABT | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-iwb-cvx-mcd-abt-2020-03-02 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $115.0 million dollar outflow -- that's a 0.6% decrease week over week (from 124,700,000 to 124,000,000). Among the largest underlying components of IWB, in trading today Chevron Corporation (Symbol: CVX) is up about 0.1%, McDonald's Corp (Symbol: MCD) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.4%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average:
Looking at the chart above, IWB's low point in its 52 week range is $151.66 per share, with $188.47 as the 52 week high point — that compares with a last trade of $164.44. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWB, in trading today Chevron Corporation (Symbol: CVX) is up about 0.1%, McDonald's Corp (Symbol: MCD) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.4%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $151.66 per share, with $188.47 as the 52 week high point — that compares with a last trade of $164.44. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWB, in trading today Chevron Corporation (Symbol: CVX) is up about 0.1%, McDonald's Corp (Symbol: MCD) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.4%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $151.66 per share, with $188.47 as the 52 week high point — that compares with a last trade of $164.44. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IWB, in trading today Chevron Corporation (Symbol: CVX) is up about 0.1%, McDonald's Corp (Symbol: MCD) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $115.0 million dollar outflow -- that's a 0.6% decrease week over week (from 124,700,000 to 124,000,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $151.66 per share, with $188.47 as the 52 week high point — that compares with a last trade of $164.44. | Among the largest underlying components of IWB, in trading today Chevron Corporation (Symbol: CVX) is up about 0.1%, McDonald's Corp (Symbol: MCD) is up about 0.2%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $115.0 million dollar outflow -- that's a 0.6% decrease week over week (from 124,700,000 to 124,000,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $151.66 per share, with $188.47 as the 52 week high point — that compares with a last trade of $164.44. |
32771.0 | 2020-03-01 00:00:00 UTC | The Best Dividend Aristocrat You Can Buy Right Now | ABT | https://www.nasdaq.com/articles/the-best-dividend-aristocrat-you-can-buy-right-now-2020-03-01 | nan | nan | Dividends are really good. Dividends that keep coming every year are great. But dividends that keep growing year after year are absolutely fantastic.
There's a category of stocks that delivers such fantastic dividends. Dividend Aristocrats are companies in the S&P 500 that have increased their dividends annually for at least 25 consecutive years. Only 57 companies are currently on the list.
Some of these dividend-hiking stocks are better than others. But I think that the best Dividend Aristocrat you can buy right now is Abbot Laboratories (NYSE: ABT).
Image source: Getty Images.
A rock-solid business
What I like the most about Abbott Labs is that it's simply a great company with a rock-solid business. Abbott ranks as one of the biggest healthcare stocks on the market. It generated $31.9 billion in revenue last year, with a profit of nearly $3.7 billion.
Abbott's medical devices segment rakes in the most money, with sales of more than $12.2 billion in 2019. This unit develops and markets a wide range of products, including cardiac monitors, diabetes-care devices, heart ablation catheters, heart valve clips, neuromodulation devices, and stents.
The company's diagnostics products segment made $7.7 billion in revenue last year. This segment's products include core laboratory testing, molecular diagnostics, point of care diagnostics systems, and rapid diagnostics products for infectious-disease and cardio-metabolic testing.
Trailing close behind is Abbott's nutritional products segment, which generated $7.4 billion in 2019. This business sells nutritional products for children and adults such as Similac and PediaSure.
Although Abbott spun off big drugmaker AbbVie as a stand-alone business in 2013, it still has an established pharmaceuticals segment that pulled in $4.5 billion in sales last year. This unit focuses on marketing drugs to emerging countries including India, Russia, China, and Brazil.
I'm not the only one who thinks Abbott is a great company. Fortune magazine has ranked Abbott among its most admired companies in the world every year since 1984. Abbott has taken the No. 1 spot among medical products companies in Fortune's list in each of the last seven years. Working Mother magazine has listed Abbott in its 100 best companies ranking for 19 consecutive years. And Science magazine has picked Abbott as one of the top employers for 16 years.
Exceptional growth prospects
To be fair, most of the other Dividend Aristocrats also have solid business models. But what I think especially sets Abbott Labs apart from the pack is its exceptionally strong growth prospects. Wall Street analysts project that Abbott will increase its earnings by more than 11% annually over the next five years.
Granted, analysts have higher earnings growth projections for four other Dividend Aristocrats -- Lowe's (NYSE: LOW), ADP (NASDAQ: ADP), Air Products & Chemicals (NYSE: APD), and Linde (NYSE: LIN). However, I think Abbott's growth is more assured than any of these companies.
All of these other companies depend on a strong economy to achieve their growth. A housing downturn would probably hurt sales for both ADP and Lowe's. A global recession would weaken the financial performance for both of these companies as well as Air Products & Chemicals and Linde. Abbott, on the other hand, should be able to deliver strong earnings growth regardless of what happens at the macroeconomic level.
Just look at some of the key products that should drive Abbott's growth. Freestyle Libre is a continuous glucose monitoring (CGM) system for individuals with diabetes. The Alimta line of diagnostics systems is used for blood and plasma screening and more. MitraClip is a device used to treat mitral regurgitation caused by a leaky heart valve. These devices are going to enjoy strong demand whether the economy is surging or sagging.
A pretty good dividend, too
What about Abbott's dividend? Admittedly, its dividend yield of close to 1.8% isn't as high as the yield of many other Dividend Aristocrats. However, Abbott ranks in the top tier in terms of dividend growth over the last three years and recently boosted its dividend by 12.5%. Abbott also claims one of the more impressive streaks of dividend increases, with 48 consecutive years of dividend hikes.
Most of the Dividend Aristocrats are relatively good options for income-seeking investors. Abbott is a good pick for growth investors as well. Putting these two positives together along with Abbott's strong position in multiple relatively safe healthcare markets makes this stock the best Dividend Aristocrat around, in my view.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Keith Speights owns shares of AbbVie and Air Products & Chemicals. The Motley Fool recommends Lowe's. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But I think that the best Dividend Aristocrat you can buy right now is Abbot Laboratories (NYSE: ABT). Although Abbott spun off big drugmaker AbbVie as a stand-alone business in 2013, it still has an established pharmaceuticals segment that pulled in $4.5 billion in sales last year. This unit focuses on marketing drugs to emerging countries including India, Russia, China, and Brazil. | But I think that the best Dividend Aristocrat you can buy right now is Abbot Laboratories (NYSE: ABT). The company's diagnostics products segment made $7.7 billion in revenue last year. This segment's products include core laboratory testing, molecular diagnostics, point of care diagnostics systems, and rapid diagnostics products for infectious-disease and cardio-metabolic testing. | But I think that the best Dividend Aristocrat you can buy right now is Abbot Laboratories (NYSE: ABT). Granted, analysts have higher earnings growth projections for four other Dividend Aristocrats -- Lowe's (NYSE: LOW), ADP (NASDAQ: ADP), Air Products & Chemicals (NYSE: APD), and Linde (NYSE: LIN). However, Abbott ranks in the top tier in terms of dividend growth over the last three years and recently boosted its dividend by 12.5%. | But I think that the best Dividend Aristocrat you can buy right now is Abbot Laboratories (NYSE: ABT). Dividend Aristocrats are companies in the S&P 500 that have increased their dividends annually for at least 25 consecutive years. The company's diagnostics products segment made $7.7 billion in revenue last year. |
32772.0 | 2020-02-28 00:00:00 UTC | Validea Peter Lynch Strategy Daily Upgrade Report - 2/28/2020 | ABT | https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-2-28-2020-2020-02-28 | nan | nan | The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
KENNEDY-WILSON HOLDINGS INC (KW) is a mid-cap value stock in the Real Estate Operations industry. The rating according to our strategy based on Peter Lynch changed from 69% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Kennedy-Wilson Holdings, Inc. is a real estate investment company. The Company owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on commercial properties located in the Western United States, the United Kingdom, Ireland, Spain, Italy and Japan. The Company also provides real estate services primarily to financial services clients. The Company's segments include KW Investments, and KW Investment Management and Real Estate Services (IMRES). KW Investments invests in residential and commercial properties, as well as loans secured by real estate. IMRES provides real estate-related services to investors and lenders, with a focus on financial institution-based clients. As of December 31, 2017, the Company had an ownership interest in approximately 53.1 million square feet of property globally.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
TERRENO REALTY CORPORATION (TRNO) is a mid-cap growth stock in the Real Estate Operations industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Terreno Realty Corporation acquires, owns and operates industrial real estate in coastal markets in the United States, such as Los Angeles, Northern New Jersey/New York City, Hayward, San Francisco Bay Area, Seattle, Miami and Washington, District of Columbia (D.C.). The Company invests in a range of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development) and trans-shipment. As of March 9, 2018, the Company owned 198 buildings aggregating approximately 13.3 million square feet and five land parcels consisting of 22.8 acres and the Company had leased its properties to 426 customers. The Company focuses on functional buildings in infill locations that may be shared by multiple tenants and that cater to customer demand within the various submarkets in which it operates.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: FAIL
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ENTERPRISE BANCORP, INC (EBTC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Enterprise Bancorp, Inc. operates as the holding company of Enterprise Bank and Trust Company (the Bank). The Company is engaged in the business of gathering deposits from the general public and investing primarily in loans and investment securities and utilizing the resulting cash flows to conduct operations, expand the branch network, and pay dividends to stockholders. Through the Bank and its subsidiaries, the Company offers a range of commercial and consumer loan products, deposit products and cash management services. The Company also offers investment advisory and wealth management, trust and insurance services. The Company offers lending services to business entities, non-profit organizations, professionals and individuals. Loans made to businesses include commercial mortgage loans; construction and land development loans; secured and unsecured commercial loans; lines of credit, and standby letters of credit.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
MONOLITHIC POWER SYSTEMS, INC. (MPWR) is a mid-cap growth stock in the Semiconductors industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Monolithic Power Systems, Inc. designs, develops and markets integrated power semiconductor solutions and power delivery architectures. The Company operates in the design, development, marketing and sale of power solutions for the communications, storage and computing, consumer and industrial markets segment. The Company's product families include Direct Current (DC) to DC Products, and Lighting Control Products. The Company's DC to DC integrated circuits (ICs) are used to convert and control voltages within a range of electronic systems, such as portable electronic devices, wireless local area network (LAN) access points, computers, monitors, automobiles and medical equipment. Lighting control ICs are used in backlighting and general illumination products. In addition to Alternating Current (AC)/DC offline solutions for lighting illumination applications, the Company also offers AC/DC power conversion solutions for end products that plug into a wall outlet.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: FAIL
SALES AND P/E RATIO: NEUTRAL
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
WALKER & DUNLOP, INC. (WD) is a mid-cap value stock in the Consumer Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Walker & Dunlop, Inc. is a holding company, which conducts its operations through Walker & Dunlop, LLC. The Company provides commercial real estate financial products and services primarily to developers and owners of multifamily properties. The Company originates, sells and services a range of multifamily and other commercial real estate financing products, including Multifamily Finance, Federal Housing Administration (FHA) Finance, Capital Markets, and Proprietary Capital. It originates and sells loans through the programs of the Federal National Mortgage Association (Fannie Mae), the Federal Home Loan Mortgage Corporation (Freddie Mac, and together with Fannie Mae, the government-sponsored enterprises (GSEs)), the Government National Mortgage Association (Ginnie Mae) and the Federal Housing Administration, a division of the United States Department of Housing and Urban Development (together with Ginnie Mae, HUD).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BANKUNITED (BKU) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 63% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: BankUnited, Inc. is the bank holding company of BankUnited (the Bank). The bank is a national banking association. As of December 31, 2016, the Bank provided a range of banking services to individual and corporate customers through 94 banking centers located in 15 Florida counties and six banking centers in the New York metropolitan area. The Bank also provides a range of traditional banking products and services to both its commercial and retail customers. The Company offers a range of lending products, including small business loans, commercial real estate loans, equipment loans and leases, term loans, formula-based loans, municipal and non-profit loans and leases, commercial and mortgage warehouse lines of credit, letters of credit and consumer loans. It offers traditional deposit products, including checking accounts, money market deposit accounts, savings accounts and certificates of deposit with a range of terms and rates.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: FAIL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
NATIONAL BANK HOLDINGS CORP (NBHC) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 0% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: National Bank Holdings Corporation is a bank holding company. The Company's primary operations are conducted through its subsidiary, NBH Bank (the Bank), through which it provides a range of banking products to both commercial and consumer clients. Through NBH Bank, it operates under the brand names: Bank Midwest in Kansas and Missouri; Community Banks of Colorado in Colorado, and Hillcrest Bank in Texas. In addition to traditional banking activities, it provides an array of treasury management solutions to its clients, including online and mobile banking, wire transfers, automated clearing house services, electronic bill payment, lock box services, remote deposit capture services, merchant processing services, cash vault, controlled disbursements, positive pay and other auxiliary services (including account reconciliation, collections, repurchase accounts, zero balance accounts and sweep accounts).
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: FAIL
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ORCHID ISLAND CAPITAL INC (ORC) is a small-cap value stock in the Misc. Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Orchid Island Capital, Inc. is a specialty finance company that invests in residential mortgage-backed securities (RMBS). The Company's business objective is to provide attractive risk-adjusted total returns to its investors over the long term through a combination of capital appreciation and the payment of regular monthly distributions. Its portfolio consists of two categories of Agency RMBS: pass-through Agency RMBS and structured Agency RMBS. It invests in pass-through securities, which are securities secured by residential real property in which payments of both interest and principal on the securities are generally made monthly. The mortgage loans underlying pass-through certificates are classified into three categories, including fixed-rate mortgages, adjustable-rate mortgages (ARMs) and Hybrid ARMs. It invests in structured Agency RMBS, which include collateralized mortgage obligations, interest only securities, inverse interest only securities and principal only securities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: FAIL
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: BONUS PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
PHILLIPS 66 PARTNERS LP (PSXP) is a large-cap value stock in the Oil Well Services & Equipment industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Phillips 66 Partners LP (Phillips 66) owns, operates, develops and acquires fee-based crude oil, refined petroleum product and natural gas liquids (NGL) pipelines, terminals and other transportation and midstream assets. The Company's assets consist of systems, such as Clifton Ridge Crude System, Eagle Ford Gathering System, Ponca Crude System, Billings Crude System, Borger Crude System, Sweeny to Pasadena Products System, Hartford Connector Products System, Gold Line Products System, Cross-Channel Connector Products System, Ponca Products System, Billings Products System, Bayway Products System, Standish Pipeline, Borger Products System, River Parish NGL System, Medford Spheres, Bayway Rail Rack, Ferndale Rail Rack, Sand Hills/Southern Hills Joint Ventures, Explorer Pipeline Joint Venture, Bakken Joint Ventures, Bayou Bridge Pipeline Joint Venture, STACK Pipeline Joint Venture, and Sweeny Fractionator and Clemens Caverns.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
NAVIENT CORP (NAVI) is a mid-cap value stock in the Consumer Financial Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Navient Corporation provides asset management and business processing services to education, healthcare and government clients at the federal, state and local levels. The Company holds the portfolio of education loans insured or federally guaranteed under the Federal Family Education Loan Program (FFELP). It operates through four segments: FFELP Loans, Private Education Loans, Business Services and Other. It also holds the portfolio of Private Education Loans. It services its own portfolio of education loans, as well as education loans owned by the United States Department of Education (ED), financial institutions and nonprofit education lenders. It also provides business processing services to education-related clients, such as guaranty agencies and colleges and universities. It provides additional business processing services to a range of other clients, including federal agencies, state and local governments, healthcare systems and other healthcare providers and municipalities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: FAIL
RETURN ON ASSETS: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
RCI HOSPITALITY HOLDINGS INC (RICK) is a small-cap value stock in the Restaurants industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: RCI Hospitality Holdings, Inc. is a holding company. The Company, through its subsidiaries, owns and operates gentlemen's clubs and sports bars/restaurants. Its segments are Nightclubs; Bombshells Restaurants and Bars, Other and General corporate. Its other activities include media and Internet divisions. Its General corporate expenses include health insurance and social security taxes for officers, legal, accounting and information technology employees, corporate taxes and insurance, and certain legal and accounting fees. As of May 9, 2017, the Company, through its subsidiaries, operated a total of 44 establishments that offer live adult entertainment, and/or restaurant and bar operations. Its clubs in New York City, Miami, Philadelphia, Charlotte, Dallas/ Fort Worth, Houston, Minneapolis, and other cities operate under brand names, such as Rick's Cabaret, Club Onyx, Vivid Cabaret, Jaguars and Tootsie's Cabaret. Its sports bars/restaurants operate under the brand name, Bombshells.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
AVANGRID INC (AGR) is a large-cap growth stock in the Electric Utilities industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Avangrid, Inc. is a renewable energy and utility company. The Company operates through two segments: Networks and Renewables. The Networks segment includes all the energy transmission and distribution activities, and any other regulated activity originating in New York and Maine, and regulated electric distribution, electric transmission and gas distribution activities originating in Connecticut and Massachusetts. The Renewables segment owns, develops, constructs and operates electricity generation, including renewable and thermal generators, and associated transmission facilities. The Renewables segment includes activities relating to renewable energy, mainly wind energy generation and trading related with such activities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BANK OF N.T. BUTTERFIELD & SON LTD (NTB) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 0% to 89% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: The Bank of N.T. Butterfield & Son Limited (the Bank) provides banking services and wealth management services. The Bank's geographic segments include Bermuda, the Cayman Islands and Guernsey, where its banking operations are located, and The Bahamas, Switzerland, and the United Kingdom, where it offers specialized financial services. It offers banking services, including retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. In Bermuda and Cayman Islands segments, it offers both banking and wealth management. In Guernsey, Bahamas, and Switzerland segments, it offers wealth management. In the United Kingdom segment, it offers residential property lending. The Bank provides foreign exchange services in the normal course of business in all jurisdictions. Its wealth management platform has three lines of business: trust, private banking, and asset management.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: BONUS PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
CTS CORPORATION (CTS) is a small-cap growth stock in the Scientific & Technical Instr. industry. The rating according to our strategy based on Peter Lynch changed from 87% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: CTS Corporation is a manufacturer of sensors, electronic components and actuators. The Company designs, manufactures and sells a line of sensors, electronic components and actuators primarily to original equipment manufacturers (OEMs) for the transportation, industrial, medical, information technology, defense and aerospace, and communications markets. It operates manufacturing facilities in North America, Asia and Europe. Its products perform specific electronic functions for a given product family and are intended for use in customer assemblies. The Company's products consist principally of sensors and actuators used in passenger or commercial vehicles; electronic components used in communications infrastructure, information technology and other high-speed applications; switches and potentiometers supplied to multiple markets, and fabricated piezoelectric materials and substrates used primarily in medical, industrial, defense and aerospace, and information technology markets.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
U.S. BANCORP (USB) is a large-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: U.S. Bancorp is a multi-state financial services holding company. The Company provides a full range of financial services, including lending and depository services, cash management, capital markets, and trust and investment management services. It also engages in credit card services, merchant and automated teller machine (ATM) processing, mortgage banking, insurance, brokerage and leasing. The Company's banking subsidiary, U.S. Bank National Association, is engaged in the general banking business, principally in domestic markets. U.S. Bank National Association provides a range of products and services to individuals, businesses, institutional organizations, governmental entities and other financial institutions. As of December 31, 2016, the Company's loan portfolio was $273.2 billion. As of December 31, 2016, its investment securities amounted to $109.3 billion. As of December 31, 2016, the Company's deposits amounted to $334,590 billion.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch changed from 69% to 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
BARRETT BUSINESS SERVICES, INC. (BBSI) is a small-cap value stock in the Business Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Barrett Business Services, Inc. (BBSI) is a provider of business management solutions for small and mid-sized companies. The Company has developed a management platform that integrates a knowledge-based approach from the management consulting industry with tools from the human resource outsourcing industry. BBSI's purpose is to advocate for business owners, particularly in the small and mid-sized business segment. The Company offers two categories of services: Professional Employer Services (PEO) and Staffing. Its staffing services include on-demand or short-term staffing assignments, contract staffing, direct placement, and long-term or indefinite-term on-site management. As of December 31, 2016, the Company operated in 20 states and the District of Columbia through a network of 57 branch locations in California, Oregon, Utah, Washington, Idaho, Arizona, Colorado, Maryland, North Carolina, Delaware, Nevada, Pennsylvania and Virginia.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
CATHAY GENERAL BANCORP (CATY) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Cathay General Bancorp is a bank holding company. The Company holds Cathay Bank, a California state-chartered commercial bank (the Bank); seven limited partnerships investing in affordable housing investments; GBC Venture Capital, Inc., and Asia Realty Corp. The Company also owns the common stock of five statutory business trusts created for issuing capital securities. The Bank primarily services individuals, professionals and small to medium-sized businesses in the local markets and provides commercial mortgage loans, commercial loans, small business administration (SBA) loans, residential mortgage loans, real estate construction loans, home equity lines of credit and installment loans to individuals for automobile, household and other consumer expenditures. The Bank offers passbook accounts, checking accounts, money market deposit accounts, certificates of deposit, individual retirement accounts, college certificates of deposit and public funds deposits.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
IBERIABANK CORP (IBKC) is a mid-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: IBERIABANK Corporation is a financial holding company. The Company is a holding company for IBERIABANK, a Louisiana state chartered banking corporation; Lenders Title Company, an Arkansas-chartered title insurance and closing services agency (Lenders Title); IBERIA Capital Partners LLC (ICP), a corporate finance services firm; 1887 Leasing, LLC, a holding company for its aircraft; IBERIA Asset Management, Inc. (IAM), which provides wealth management and trust advisory services to high net worth individuals, pension funds, corporations and trusts; 840 Denning, LLC, which invests in a commercial rental property, and IBERIA CDE, LLC (CDE), which invests in purchased tax credits. IBERIABANK offers commercial and retail banking products and services. These products and services include an array of commercial, consumer, mortgage, and private banking products and services, trust advisory services, cash management, deposit and annuity products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
SANDY SPRING BANCORP INC. (SASR) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Sandy Spring Bancorp, Inc. is the bank holding company for Sandy Spring Bank (the Bank). The Company operates through three segments: Community Banking, Insurance and Investment Management. The Company's Community Banking segment operates through Sandy Spring Bank and involves delivering a range of financial products and services, including various loan and deposit products to both individuals and businesses. The Insurance segment operates through Sandy Spring Insurance Corporation, a subsidiary of the Bank, and offers annuities as an alternative to traditional deposit accounts. The Investment Management segment operates through West Financial Services, Inc., a subsidiary of the Bank, which provides investment management and financial planning services. As of December 31, 2016, the Bank conducted commercial banking business through 44 community offices and six financial centers located in Central Maryland, Northern Virginia and Washington D.C.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
TETRA TECH, INC. (TTEK) is a mid-cap growth stock in the Waste Management Services industry. The rating according to our strategy based on Peter Lynch changed from 87% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Tetra Tech, Inc. is a provider of consulting, engineering, program management, construction management, and technical services. The Company's segments include Water, Environment and Infrastructure (WEI), Resource Management and Energy (RME), and Remediation and Construction Management (RCM). The WEI segment provides consulting and engineering services. The RME segment provides consulting and engineering services across the world for a range of resource management and energy needs. The Company includes wind-down of its non-core construction activities in the RCM segment. Its solutions span the entire life cycle of consulting and engineering projects and include applied science, research and technology, engineering, design, construction management, operations and maintenance, and information technology. It provides its services to a diverse base of international, the United States commercial, the United Sates federal clients.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
UBS GROUP AG (USA) (UBS) is a large-cap value stock in the Investment Services industry. The rating according to our strategy based on Peter Lynch changed from 0% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: UBS Group AG is a holding company and conducts its operations through UBS AG and its subsidiaries. The Company comprises Corporate Center and five business divisions: Wealth Management, Wealth Management Americas, Personal & Corporate Banking, Asset Management and the Investment Bank. Wealth Management division provides advice and tailored financial services to wealthy private clients around the world, except those served by Wealth Management Americas. Wealth Management Americas division is a wealth manager in the Americas in terms of financial advisor productivity and invested assets by financial advisor. Personal & Corporate Banking division provides financial products and services to private, corporate and institutional clients in Switzerland. Asset Management division provides investment management products and services, platform solutions and advisory support. Investment Bank division providesinvestment advice financial solutions and capital markets access.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: FAIL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
COMPX INTERNATIONAL INC. (CIX) is a small-cap value stock in the Misc. Fabricated Products industry. The rating according to our strategy based on Peter Lynch changed from 72% to 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: CompX International Inc. is a manufacturer of security products used in the recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare and other industries, and stainless steel exhaust systems, gauges and throttle controls for the recreational marine industry. The Company operates through two business segments: Security Products and Marine Components. Its security products include disc tumbler locks; pin tumbler locking mechanisms, and CompX eLock and StealthLock electronic locks. Its marine components include original equipment and aftermarket stainless steel exhaust headers, exhaust pipes, mufflers and other exhaust components; gauges; mechanical and electronic controls and throttles; steering wheels and other billet aluminum accessories, and dash panels. The Company's brands include National Cabinet Lock, Fort Lock, Timberline Lock, Chicago Lock, Mega Rim, Race Rim, Vantage View and GEN-X.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: BONUS PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
ILLUMINA, INC. (ILMN) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating according to our strategy based on Peter Lynch changed from 56% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: FAIL
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
SUMMIT FINANCIAL GROUP, INC. (SMMF) is a small-cap value stock in the Regional Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Summit Financial Group, Inc. (Summit) is a financial holding company. The Company provides community banking services primarily in the Eastern Panhandle and South Central regions of West Virginia and the Shenandoah Valley, and Northern region of Virginia. The Company provides these services through its community bank subsidiary, Summit Community Bank (Summit Community or the Bank). The Company operates through two segments: community banking, and insurance & financial services. The community banking segment consists of its full service banks, which offer customers traditional banking products and services through various delivery channels. The insurance & financial services segment includes three insurance agency offices that sell insurance products. The Company also operates Summit Insurance Services, LLC in Moorefield, West Virginia and Leesburg, Virginia, which provides insurance brokerage services to individuals and businesses.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
PERION NETWORK LTD (PERI) is a small-cap value stock in the Computer Services industry. The rating according to our strategy based on Peter Lynch changed from 72% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Perion Network Ltd is an Israel-based global technology company. It delivers online advertising solutions and search monetization to brands and publishers. It provides data-driven execution, from high-impact ad formats to branded search and a unified social and mobile programmatic platform. Its business solutions include Undertone, Codefuel, MakeMeReach and Smilebox. Undertone's synchronized digital branding solution delivers creative experiences through cohesive stories to the portfolio of Websites, mobile applications, touchpoints, screens, and platforms. CodeFuel is search solution platform, which allows publishers to create new revenue streams and search experience by bringing monetization to content and application developers. MakeMeReach platform helps advertisers and agencies create, manage and optimize their marketing campaigns on multiple social channels. Smilebox enables people to tell the stories of their lives with customizable eCards, slideshows and invitations.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
INVENTORY TO SALES: FAIL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
For a full detailed analysis using NASDAQ's Guru Analysis tool, click here
Since its inception, Validea's strategy based on Peter Lynch has returned 370.61% vs. 199.65% for the S&P 500. For more details on this strategy, click here
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Company Description: Terreno Realty Corporation acquires, owns and operates industrial real estate in coastal markets in the United States, such as Los Angeles, Northern New Jersey/New York City, Hayward, San Francisco Bay Area, Seattle, Miami and Washington, District of Columbia (D.C.). As of December 31, 2016, the Company operated in 20 states and the District of Columbia through a network of 57 branch locations in California, Oregon, Utah, Washington, Idaho, Arizona, Colorado, Maryland, North Carolina, Delaware, Nevada, Pennsylvania and Virginia. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The Company offers a range of lending products, including small business loans, commercial real estate loans, equipment loans and leases, term loans, formula-based loans, municipal and non-profit loans and leases, commercial and mortgage warehouse lines of credit, letters of credit and consumer loans. The Company's assets consist of systems, such as Clifton Ridge Crude System, Eagle Ford Gathering System, Ponca Crude System, Billings Crude System, Borger Crude System, Sweeny to Pasadena Products System, Hartford Connector Products System, Gold Line Products System, Cross-Channel Connector Products System, Ponca Products System, Billings Products System, Bayway Products System, Standish Pipeline, Borger Products System, River Parish NGL System, Medford Spheres, Bayway Rail Rack, Ferndale Rail Rack, Sand Hills/Southern Hills Joint Ventures, Explorer Pipeline Joint Venture, Bakken Joint Ventures, Bayou Bridge Pipeline Joint Venture, STACK Pipeline Joint Venture, and Sweeny Fractionator and Clemens Caverns. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The Company's assets consist of systems, such as Clifton Ridge Crude System, Eagle Ford Gathering System, Ponca Crude System, Billings Crude System, Borger Crude System, Sweeny to Pasadena Products System, Hartford Connector Products System, Gold Line Products System, Cross-Channel Connector Products System, Ponca Products System, Billings Products System, Bayway Products System, Standish Pipeline, Borger Products System, River Parish NGL System, Medford Spheres, Bayway Rail Rack, Ferndale Rail Rack, Sand Hills/Southern Hills Joint Ventures, Explorer Pipeline Joint Venture, Bakken Joint Ventures, Bayou Bridge Pipeline Joint Venture, STACK Pipeline Joint Venture, and Sweeny Fractionator and Clemens Caverns. The Company is a holding company for IBERIABANK, a Louisiana state chartered banking corporation; Lenders Title Company, an Arkansas-chartered title insurance and closing services agency (Lenders Title); IBERIA Capital Partners LLC (ICP), a corporate finance services firm; 1887 Leasing, LLC, a holding company for its aircraft; IBERIA Asset Management, Inc. (IAM), which provides wealth management and trust advisory services to high net worth individuals, pension funds, corporations and trusts; 840 Denning, LLC, which invests in a commercial rental property, and IBERIA CDE, LLC (CDE), which invests in purchased tax credits. | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Through the Bank and its subsidiaries, the Company offers a range of commercial and consumer loan products, deposit products and cash management services. The Company's Community Banking segment operates through Sandy Spring Bank and involves delivering a range of financial products and services, including various loan and deposit products to both individuals and businesses. |
32773.0 | 2020-02-27 00:00:00 UTC | Mylan Q4 Beats on Sales, Misses on EPS | ABT | https://www.nasdaq.com/articles/mylan-q4-beats-on-sales-misses-on-eps-2020-02-28 | nan | nan | Mylan (NASDAQ: MYL) was down by almost 4% in after-market trading on Thursday, following the release of its Q4 of fiscal 2019 results in late afternoon.
The pharmaceutical giant managed to raise its total revenue by 4% on a year-over-year basis during the quarter, to $3.19 billion. On the bottom line, non-GAAP (adjusted) net profit was nearly 8% higher at $721 million ($1.40 per share).
Image source: Getty Images.
On average, prognosticators tracking the stock expected $3.23 billion in revenue and an adjusted per-share net profit of $1.30.
Mylan benefited from relatively robust sales in its "rest of world" regional classification, which covers all markets that are not North America and Europe. Rest of world saw an 8% uptick in sales; the company said new products in markets such as Australia and India helped in this regard.
In terms of products, Mylan singled out drugs such as pancreatic enzyme replacement treatment Creon and flu vaccine Influvac as being brisk sellers worldwide. Both of those medications landed in the company's portfolio from its 2014 deal with Abbott Laboratories.
Zooming out to the full year, overall revenue was $11.5 billion, representing a marginal improvement over the 2018 figure. Adjusted net profit slipped to $2.28 billion from the previous year's $2.36 billion.
Mylan provided guidance for fiscal 2020. The company believes it will book total revenue of $11.5 billion to $12.5 billion. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) should come in at $3.2 billion to $3.9 billion against the latest result of $3.54 billion. The company didn't supply any projections for net profit.
10 stocks we like better than Mylan
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Mylan wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Mylan (NASDAQ: MYL) was down by almost 4% in after-market trading on Thursday, following the release of its Q4 of fiscal 2019 results in late afternoon. Mylan benefited from relatively robust sales in its "rest of world" regional classification, which covers all markets that are not North America and Europe. In terms of products, Mylan singled out drugs such as pancreatic enzyme replacement treatment Creon and flu vaccine Influvac as being brisk sellers worldwide. | On average, prognosticators tracking the stock expected $3.23 billion in revenue and an adjusted per-share net profit of $1.30. Adjusted net profit slipped to $2.28 billion from the previous year's $2.36 billion. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | On average, prognosticators tracking the stock expected $3.23 billion in revenue and an adjusted per-share net profit of $1.30. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) should come in at $3.2 billion to $3.9 billion against the latest result of $3.54 billion. 10 stocks we like better than Mylan When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | On average, prognosticators tracking the stock expected $3.23 billion in revenue and an adjusted per-share net profit of $1.30. Adjusted net profit slipped to $2.28 billion from the previous year's $2.36 billion. The company believes it will book total revenue of $11.5 billion to $12.5 billion. |
32774.0 | 2020-02-26 00:00:00 UTC | Abbott's EPS Growth Is 2x Compared To Medtronic's | ABT | https://www.nasdaq.com/articles/abbotts-eps-growth-is-2x-compared-to-medtronics-2020-02-27 | nan | nan | Abbott’s (NYSE:ABT) adjusted earnings per share (EPS) grew at a CAGR of 11% from $2.16 in 2015 to $3.26 in 2019. This was almost 2x the CAGR of 5.1% for Medtronic’s (NYSE:MDT) adjusted EPS, which grew from $4.28 in fiscal 2015 to $5.22 in fiscal 2019. This clubbed with Abbott’s lower debt levels explains its higher price to earnings multiple of 25x in comparison to Medtronic’s 20x based on the current market price and average consensus earnings estimate for 2020. In this dashboard, Medtronic vs Abbott: How Have Revenues & Other Key Metrics Changed Over Recent Years?, we have analyzed the revenues and other key metrics of both the companies over recent years.
#1 Market Cap: Both Medtronic And Abbott’s Market Cap Is Similar
Medtronic’s market capitalization grew from $109 billion in 2015 to $152 billion in 2019.
Abbott’s market capitalization grew from $68 billion to $154 billion over the same period.
#2 Revenues: Medtronic’s Revenues of $31 Billion Are Slightly Lower Than $32 Billion For Abbott.
Medtronic’s revenue grew from $20.3 billion in fiscal 2015 to $30.6 billion in fiscal 2019. Look at our interactive dashboard analysis for more details on Medtronic’s revenues.
Abbott’s revenues grew from $20.4 billion in 2015 to $30.6 billion in 2018. Look at our analysis on Abbott’s revenues for more details.
#2.1 Revenue Growth: Both Medtronic And Abbott’s Revenues Grew At A CAGR of Around 12% Between 2015 And 2019
Both Abbott and Boston Scientific saw similar growth in revenues in the recent years. And for both there was some impact of acquisitions in the sales growth.
While Abbott’s growth in 2017 was aided by the St Jude acquisition and 2018 growth aided by the Alere acquisition, Medtronic’s growth in 2016 was bolstered by the Covidien acquisition.
#3 US Sales: US Accounts For A Significant Portion of Total Sales For Both The Companies
US sales accounted for 53% of Medtronic’s total sales in 2019.
For Abbott, the figure stood at 36% in 2019.
#4 Gross Margins: Gross Profit Margin For Medtronic Is Better Than That For Abbott
Abbott’s Gross Profit Margin grew from 57.1% in 2015 to 58.5% in 2019.
Gross Profit Margin for Medtronic grew from 68.9% in fiscal 2015 to 70.0% in fiscal 2019.
#5 Net Income Margin: Medtronic’s Adjusted Net Income Margin Is Better Than That of Abbott
Medtronic’s adjusted net income margin declined from 23.4% in fiscal 2015 to 21.6% in 2016, post the Covidien acquisition. However, it grew thereafter to 23.2% in fiscal 2019.
Abbott’s adjusted net income margin grew from 16.0% to 18.2% between 2015 and 2019.
#6 EPS Growth: Abbott’s EPS Grew 2x Faster Than Medtronic’s
Medtronic’s adjusted EPS grew at a CAGR of 5.1% from $4.28 in fiscal 2015 to $5.22 in fiscal 2019.
Abbott’s adjusted EPS grew at a CAGR of 10.9% from 2.16 in 2015 to $3.26 in 2019.
#7 Total Debt: Medtronic’s Total Debt Stood Stood At $24.5 Billion In 2019, Compared To $19.4 Billion For Abbott, As Shown In Medtronic vs Abbott Dashboard.
#8 Valuation: Medtronic Trades At 20x 2020 EPS, while Abbott trades at 25x 2020 EPS
Medtronic’s current market price of about $113 per share implies that it trades at 20x its projected 2020 average consensus earnings.
In comparison, Abbott’s current market price of about $89 implies a P/E multiple of about 25x based on projected 2020 average consensus earnings.
Abbott’s higher multiple is due to its strong revenue growth and lower debt load, which likely reduces its risks.
#8.1 Medtronic Valuation
Our price estimate of $115 for Medtronic is based on our Detailed Valuation Model, and implies a 20.5x P/E Multiple on expected fiscal 2020 Adjusted EPS of $5.60.
#8.2 Abbott Valuation
Our price estimate of $96 for Abbott is based on our Detailed Valuation Model, and implies a 26.8x P/E Multiple on expected 2020 Adjusted EPS of $3.60.
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott’s (NYSE:ABT) adjusted earnings per share (EPS) grew at a CAGR of 11% from $2.16 in 2015 to $3.26 in 2019. In comparison, Abbott’s current market price of about $89 implies a P/E multiple of about 25x based on projected 2020 average consensus earnings. Abbott’s higher multiple is due to its strong revenue growth and lower debt load, which likely reduces its risks. | Abbott’s (NYSE:ABT) adjusted earnings per share (EPS) grew at a CAGR of 11% from $2.16 in 2015 to $3.26 in 2019. This clubbed with Abbott’s lower debt levels explains its higher price to earnings multiple of 25x in comparison to Medtronic’s 20x based on the current market price and average consensus earnings estimate for 2020. #8 Valuation: Medtronic Trades At 20x 2020 EPS, while Abbott trades at 25x 2020 EPS Medtronic’s current market price of about $113 per share implies that it trades at 20x its projected 2020 average consensus earnings. | Abbott’s (NYSE:ABT) adjusted earnings per share (EPS) grew at a CAGR of 11% from $2.16 in 2015 to $3.26 in 2019. #2.1 Revenue Growth: Both Medtronic And Abbott’s Revenues Grew At A CAGR of Around 12% Between 2015 And 2019 Both Abbott and Boston Scientific saw similar growth in revenues in the recent years. #6 EPS Growth: Abbott’s EPS Grew 2x Faster Than Medtronic’s Medtronic’s adjusted EPS grew at a CAGR of 5.1% from $4.28 in fiscal 2015 to $5.22 in fiscal 2019. | Abbott’s (NYSE:ABT) adjusted earnings per share (EPS) grew at a CAGR of 11% from $2.16 in 2015 to $3.26 in 2019. #2 Revenues: Medtronic’s Revenues of $31 Billion Are Slightly Lower Than $32 Billion For Abbott. #2.1 Revenue Growth: Both Medtronic And Abbott’s Revenues Grew At A CAGR of Around 12% Between 2015 And 2019 Both Abbott and Boston Scientific saw similar growth in revenues in the recent years. |
32775.0 | 2020-02-26 00:00:00 UTC | Diabetes Stock Insulet Drops 8.5% on Earnings Miss and Softer-Than-Expected Outlook | ABT | https://www.nasdaq.com/articles/diabetes-stock-insulet-drops-8.5-on-earnings-miss-and-softer-than-expected-outlook-2020-02 | nan | nan | Insulet (NASDAQ: PODD) reported fourth quarter and full year 2019 results after the market closed on Tuesday, Feb. 25. The tubeless insulin pump specialist's revenue grew 27%, and its earnings per share declined 50% year over year.
Shares of the Massachusetts-based healthcare company fell 8.5% on Wednesday. We can attribute the market's reaction to earnings missing Wall Street's consensus estimate, along with guidance for both the first quarter and full year 2020 coming in lower than analysts had been projecting. Over the last year, Insulet stock has doubled, while the S&P 500 has returned 13.7%.
Image source: Insulet.
Insulet's key numbers
METRIC
Q4 2019
Q4 2018
CHANGE
Revenue
$209.4 million $164.9 million 27%
Operating income
$18.2 million $16.2 million 12%
Net income
$5.0 million $9.9 million (49%)
Earnings per share (EPS)
$0.08 $0.16 (50%)
Data source: Insulet.
Revenue easily beat Insulet's guidance range of $193 million to $201 million. For context, in the first, second, and third quarters, year over year revenue growth was 43%, 29%, and 27%, respectively.
Wall Street was looking for EPS of $0.11 on revenue of $195.5 million. So the company fell short on the bottom line, but surpassed the top line expectation.
What happened with Insulet?
In the fourth quarter, global Omnipod revenue surged 30% year over year to $192.5 million.
U.S. Omnipod revenue jumped 36% to $126.7 million.
International Omnipod revenue rose 20% to $65.8 million.
Drug delivery revenue edged up 1% to $16.9 million.
Fourth quarter gross margin was 64%, down from 66.9% in the year-ago period, and slightly lower than last quarter's 64.1%. As with last quarter, the year over year decline was due to the ramp-up of the company's manufacturing capabilities at its new U.S. facility, located in Massachusetts.
The company installed a second U.S. manufacturing line, with commercial production on this line expected by mid-year 2020.
It "entered pivotal trial for the Omnipod Horizon automated insulin delivery system, including 240 participants ages 6 to 70 years old," according to the earnings release. This system, expected to launch late this year, uses a DexCom continuous glucose monitor (CGM) to dose insulin.
The company "broadened collaboration with DexCom to integrate its G6 and future G7 continuous glucose monitoring systems into the Omnipod Horizon system."
It "expanded partnership with Abbott [Laboratories] to integrate its next-generation Libre glucose sensing technology into the next-generation Omnipod Horizon system."
What management had to say
Here's what CEO Shacey Petrovic had to say in the press release:
2019 was a remarkable year for Insulet, marked by disciplined execution of our strategy that allowed us to deliver consistent financial outperformance and strong operational results. With a solid foundation, pipeline of innovative technologies and proven strategy firmly in place, we made progress investing across our global organization to drive sustainable, long-term growth.
As we look ahead to 2020, Insulet has a clear trajectory to strengthen our leadership position and make even greater treatment options a reality for the large and underserved global diabetes market. We are well on track to meet our 2021 financial targets of $1 billion in revenue, 70% gross margin and mid-teens operating margin, and remain focused on advancing our mission to ease the burden of people living with diabetes.
Looking ahead
Insulet ended a great year with a solid quarter. Management issued first quarter and full year revenue guidance:
Q1: Revenue growth 17% to 20% year over year.
2020: Revenue growth of 14% to 18% over 2019.
Going into earnings, Wall Street had been modeling for year over year revenue growth of 27.4% in the first quarter and 20.8% for 2020. So, Insulet's outlook for both periods came in lighter than analysts expected. This was surely a big factor in the stock's decline on Wednesday.
Insulet has a great track record of beating its quarterly revenue guidance and increasing its annual guidance several times each year. So, the revenue growth outlooks for the first quarter and 2021 are probably quite conservative.
10 stocks we like better than Insulet
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Insulet wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Beth McKenna has no position in any of the stocks mentioned. The Motley Fool recommends DexCom and Insulet. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We can attribute the market's reaction to earnings missing Wall Street's consensus estimate, along with guidance for both the first quarter and full year 2020 coming in lower than analysts had been projecting. What management had to say Here's what CEO Shacey Petrovic had to say in the press release: 2019 was a remarkable year for Insulet, marked by disciplined execution of our strategy that allowed us to deliver consistent financial outperformance and strong operational results. With a solid foundation, pipeline of innovative technologies and proven strategy firmly in place, we made progress investing across our global organization to drive sustainable, long-term growth. | Revenue $209.4 million $164.9 million 27% Operating income $18.2 million $16.2 million 12% Net income $5.0 million $9.9 million (49%) Earnings per share (EPS) $0.08 $0.16 (50%) Data source: Insulet. In the fourth quarter, global Omnipod revenue surged 30% year over year to $192.5 million. Management issued first quarter and full year revenue guidance: Q1: Revenue growth 17% to 20% year over year. | Revenue $209.4 million $164.9 million 27% Operating income $18.2 million $16.2 million 12% Net income $5.0 million $9.9 million (49%) Earnings per share (EPS) $0.08 $0.16 (50%) Data source: Insulet. In the fourth quarter, global Omnipod revenue surged 30% year over year to $192.5 million. Management issued first quarter and full year revenue guidance: Q1: Revenue growth 17% to 20% year over year. | For context, in the first, second, and third quarters, year over year revenue growth was 43%, 29%, and 27%, respectively. In the fourth quarter, global Omnipod revenue surged 30% year over year to $192.5 million. Management issued first quarter and full year revenue guidance: Q1: Revenue growth 17% to 20% year over year. |
32776.0 | 2020-02-26 00:00:00 UTC | Better Buy: Exact Sciences vs. Bio-Rad Laboratories | ABT | https://www.nasdaq.com/articles/better-buy%3A-exact-sciences-vs.-bio-rad-laboratories-2020-02-26 | nan | nan | There are plenty of interesting healthcare stocks to choose from on the market right now. Whether they be small-cap biotechs, large-cap pharmaceutical giants, or anything in between, investors have no shortage of interesting investment possibilities to consider.
Two stocks that you might have heard of are Exact Sciences (NASDAQ: EXAS) and Bio-Rad Laboratories (NYSE: BIO). They are similarly sized with market caps above $10 billion. Exact is focused on developing early detection diagnostics to identify signs of colon and rectal cancer in patients. Bio-Rad also develops diagnostic equipment but has a much broader scope and isn't focused on one particular condition like Exact Sciences.
While both companies have their pros and cons, is there a clear winner between these two healthcare companies?
Image source: Getty Images.
What's behind Bio-Rad's growth?
Over the past 12 months, shares of Bio-Rad have risen 34%, handily outperforming the S&P 500's 12% gain during the same period. The company offers more than 10,000 products across a variety of different areas.
For simplicity's sake, the company's business can be broken down into two main segments: life science and clinical diagnostics. Life science includes developing reagents, laboratory apparatuses and instruments, and similar equipment used by medical labs and research organizations around the world. Its customers include universities, medical schools, research groups (private and public), and pharmaceutical drug makers.
Clinical diagnostics also involves selling to clinical labs, but with an emphasis on specific diagnostic tests including in vitro diagnostics, a type of test done on blood or tissue samples to detect diseases. Bio-Rad offers over 3,000 different diagnostic test products to laboratories.
Both of Bio-Rad's main business segments are reporting decent growth figures, although the numbers themselves might not be all that exciting. Revenue from the company's life science segment is up 1.8% on a currency-neutral basis, while clinical diagnostics is up 2.8% as well from last year. Growth, while a bit slow, is steady for Bio-Rad, and that's despite operating in a highly competitive market with rivals like Abbott Laboratories and Roche.
The case for Exact Sciences
In contrast to Bio-Rad, Exact Sciences has performed relatively poorly over the past 12 months, having lost 6% of its value over that period compared to the S&P 500's 12% gain. Exact focuses on providing cancer diagnostic tests and products in the colorectal market, with its most iconic product being Cologuard, a noninvasive colon cancer diagnostic test. Sales for Cologuard have been surging, with 447,000 individual tests ordered in the fourth quarter of 2019, up 63% from Q4 2018.
Cologuard. Image Source: Exact Sciences
Exact completed its $2.8 billion acquisition of a molecular diagnostics company called Genomic Health in November. The deal is seen as an excellent way to expand given the similarities between the two companies. Genomic Health has its own successful product, the Oncotype DX diagnostic test, which determines the likelihood of breast cancer reoccurring in previously diagnosed women and predicts how that cancer is likely to respond to different treatments. Although the Oncotype DX isn't a noninvasive test -- it requires a tissue sample -- it's still a highly sought-after product by medical professionals and labs around the world.
Breast cancer and colorectal cancer are two of the most common cancer types around the world, accounting for approximately 2.1 million and 1.8 million new cases in 2018 respectively. Adding the Oncotype DX to Exact's Cologuard gives the company two major selling products with significant growth potential.
This growth potential is seen in the company's revenue figures, which have more than doubled over a one-year period. While the company is essentially operating at a loss (without income tax benefits pushing the company into the positive for this quarter), Exact has plenty of growth potential going forward.
Looking at the financials
Despite being similarly sized, Bio-Rad and Exact have radically different financials. At first glance, Bio-Rad's top-line revenue growth looks like it would belong to a blue-chip healthcare stock. However, a deeper look reveals that the company has seen a significant shift in profitability over the past year.
Bio-Rad's fourth-quarter revenue came in at $624.4 million, up 2.3% on a currency-neutral basis. Bio-Rad has a reasonable operating margin of 9.5% and a net income of $553.5 million. This is a massive turnaround from the $828.5 million net loss reporting in Q4 2018, so while top-line growth seems relatively stable, the bottom line has seen a massive shift over just 12 months.
METRIC MARKET CAP QUARTERLY REVENUE REVENUE GROWTH (%) NET INCOME (LOSS) PRICE-TO-SALES RATIO (P/S)
Bio-Rad $12.3 billion $624.4 million 2.3% $553.5 million 5.3x
Exact Sciences $15.1 billion $295.6 million 106.7% $77.9 million 15.5x
Data Source: YCharts, Bio-Rad, Exact Sciences.
Exact Sciences is the opposite in this regard. Fourth-quarter revenue reached $295.6 million, more than double the $143.0 million reported in Q4 2018. While the company did technically report a profit of $77.9 million, this appears to be a one-time occurrence due to a hefty income tax benefit. Without this $184.6 million tax benefit, the company reported a fourth-quarter net loss of $106.7 million, which is significantly worse than the $53.9 million net loss seen a year ago.
The difference between the two stocks becomes even more apparent when looking at their price-to-sales (P/S) ratios. Exact trades at a 15.5 P/S ratio, while Bio-Rad trades at only 5.3. Investors can look at this and conclude that Bio-Rad is comparatively cheaper, but it also means that Exact trades at a premium, and for good reason. The company has seen major revenue growth, which Bio-Rad hasn't.
Which is the better buy?
Whether Bio-Rad or Exact Sciences is right for you depends largely on what you're looking for. If you are interested in a stable, slower-growing, more established healthcare stock, Bio-Rad fits the bill. The only thing that could be uncomfortable for a risk-averse investor is the company's dramatic shift in the bottom line. However, the stock trades at a pretty cheap valuation, which is quite appealing.
On the other hand, if you're more of a growth investor, Exact Sciences would be the better pick. Exact has seen a significant increase in revenue, and with the addition of Genomic Health's Oncotype DX product, revenue growth is expected to surge even more. The company isn't profitable yet (at least when you factor out one-time tax benefits), but that's par for the course when looking for a growth-oriented company.
Since I tend to prefer a higher-risk approach to investing, I'm going to go with Exact Sciences as the better buy today. Besides all the aforementioned reasons, it's nice to know that the company's products have relatively little competition in the market. That can't be said for Bio-Rad, which competes with behemoths like Abbott Laboratories.
10 stocks we like better than Bio-Rad Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Bio-Rad Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool recommends Exact Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Life science includes developing reagents, laboratory apparatuses and instruments, and similar equipment used by medical labs and research organizations around the world. Growth, while a bit slow, is steady for Bio-Rad, and that's despite operating in a highly competitive market with rivals like Abbott Laboratories and Roche. Although the Oncotype DX isn't a noninvasive test -- it requires a tissue sample -- it's still a highly sought-after product by medical professionals and labs around the world. | Adding the Oncotype DX to Exact's Cologuard gives the company two major selling products with significant growth potential. Bio-Rad $12.3 billion $624.4 million 2.3% $553.5 million 5.3x Exact Sciences $15.1 billion $295.6 million 106.7% $77.9 million 15.5x Data Source: YCharts, Bio-Rad, Exact Sciences. Without this $184.6 million tax benefit, the company reported a fourth-quarter net loss of $106.7 million, which is significantly worse than the $53.9 million net loss seen a year ago. | The case for Exact Sciences In contrast to Bio-Rad, Exact Sciences has performed relatively poorly over the past 12 months, having lost 6% of its value over that period compared to the S&P 500's 12% gain. Exact focuses on providing cancer diagnostic tests and products in the colorectal market, with its most iconic product being Cologuard, a noninvasive colon cancer diagnostic test. Bio-Rad $12.3 billion $624.4 million 2.3% $553.5 million 5.3x Exact Sciences $15.1 billion $295.6 million 106.7% $77.9 million 15.5x Data Source: YCharts, Bio-Rad, Exact Sciences. | There are plenty of interesting healthcare stocks to choose from on the market right now. Bio-Rad offers over 3,000 different diagnostic test products to laboratories. That's right -- they think these 10 stocks are even better buys. |
32777.0 | 2020-02-26 00:00:00 UTC | If You Invested $5,000 in AbbVie IPO, This Is How Much Money You'd Have Now | ABT | https://www.nasdaq.com/articles/if-you-invested-%245000-in-abbvie-ipo-this-is-how-much-money-youd-have-now-2020-02-26 | nan | nan | AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013 as a spinoff from Abbott Laboratories (NYSE: ABT). That was the first day the company traded on the New York Stock Exchange. The move was made so that Abbott could focus on its business of manufacturing medical devices and equipment, while AbbVie would prioritize pharmaceuticals.
AbbVie took with it the rheumatoid arthritis drug Humira, which has been the worldʻs top-selling pharmaceutical since 2012. In 2018, it did about $20 billion in global sales, and it was on pace for a similar number in 2019. Sales of Humira were basically flat in the fourth quarter of 2019 compared to the previous yearʻs quarter at $4.92 billion. However, the drug is expected to remain in the top two in worldwide sales until 2024.
Given the sustained success of Humira, how much money would you have made if you had invested $5,000 in AbbVie when the firm spun off on Jan. 2, 2013? Before we do the math, letʻs look at the company in a little more depth.
AbbVie produces Humira, the worldʻs top-selling drug. Image source: Getty Images.
Beyond Humira
But AbbVie has more than just Humira going for it. Cancer drug Imbruvica, which was the 14th best-seller in 2018, saw sales increase 28.9% in the fourth quarter, year over year, to $1.3 billion. Venclexta, another cancer drug, did $251 million in sales in the quarter (up 100%), while new immunology drug Skyrizi did $216 million in the quarter. A drug to treat Hepatitis C, Mavyret, the firmʻs third-largest seller, saw revenue decline 23% to $628 million in the quarter.
AbbVie is also closing on a deal to acquire Allergan (NYSE: AGN), the pharmaceutical company that produces cosmetic Botox, which generated $991 million in sales in 2019 -- an increase of about 9% over 2018. Bipolar depression drug Vraylar also generated net revenue of $857 million last year, up 76% from the previous year. The deal should close in the first quarter of this year.
An annual return that beats the S&P 500
AbbVieʻs performance has fluctuated over the years. This year, through Feb. 24, the stock is up about 5%. However, the share price has declined each of the past two years, down 3.9% in 2019 and 4.7% in 2018. But the company outperformed in 2017 as the stock rose 54.4%.
When it debuted on the NYSE on Jan. 2, 2013, AbbVie was trading at $26.33 per share. At the end of trading on Feb. 24, 2020, it closed at $93.29.
If you had invested $5,000 when it launched, your investment would have purchased about 142 shares. Over the ensuing seven-plus years, the stock has returned about 20.1% per year with a total return of about 168%. That beats the S&P 500, which returned about 14% over that same period. It also beats Abbott Labs, which posted an average annual return of about 17% over that same time frame.
Letʻs not forget dividends. AbbVie has a great track record of paying dividends, having increased them every year since inception. The company started with a $0.40 annual dividend in 2013 and has increased it almost every year since -- without reducing it once. In February, the company bumped up the dividend from $1.07 to $1.18.
So, including reinvesting quarterly dividends, that $5,000 invested on Jan. 2, 2013 would now be worth $18,377. Not a bad chunk of change.
While it's got a good track record and delivers an excellent dividend, AbbVie is in a period of transition now with Humira sales slowing down and the Allergan sale pending, so investors may want to watch and wait before picking up new shares.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Dave Kovaleski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013 as a spinoff from Abbott Laboratories (NYSE: ABT). The move was made so that Abbott could focus on its business of manufacturing medical devices and equipment, while AbbVie would prioritize pharmaceuticals. A drug to treat Hepatitis C, Mavyret, the firmʻs third-largest seller, saw revenue decline 23% to $628 million in the quarter. | AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013 as a spinoff from Abbott Laboratories (NYSE: ABT). AbbVie produces Humira, the worldʻs top-selling drug. Cancer drug Imbruvica, which was the 14th best-seller in 2018, saw sales increase 28.9% in the fourth quarter, year over year, to $1.3 billion. | AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013 as a spinoff from Abbott Laboratories (NYSE: ABT). Cancer drug Imbruvica, which was the 14th best-seller in 2018, saw sales increase 28.9% in the fourth quarter, year over year, to $1.3 billion. Over the ensuing seven-plus years, the stock has returned about 20.1% per year with a total return of about 168%. | AbbVie (NYSE: ABBV) was officially launched on Jan. 2, 2013 as a spinoff from Abbott Laboratories (NYSE: ABT). Cancer drug Imbruvica, which was the 14th best-seller in 2018, saw sales increase 28.9% in the fourth quarter, year over year, to $1.3 billion. AbbVie is also closing on a deal to acquire Allergan (NYSE: AGN), the pharmaceutical company that produces cosmetic Botox, which generated $991 million in sales in 2019 -- an increase of about 9% over 2018. |
32778.0 | 2020-02-26 00:00:00 UTC | What's The Upside For Intuitive Surgical's Stock? | ABT | https://www.nasdaq.com/articles/whats-the-upside-for-intuitive-surgicals-stock-2020-02-26 | nan | nan | There is an upside of over 6% for Intuitive Surgical’s (NASDAQ:ISRG) stock, in our view. We estimate Intuitive Surgical’s fair price estimate to be around $652, based on expected EPS of $14.59 on an adjusted basis for full year 2020 and price to earnings multiple of 44.7x. This compares with the current market price of $611, implying a 45.4x P/E Multiple based on average consensus EPS estimate of $13.46 for 2020. Intuitive Surgical’s stock price has seen steady growth over the last few years, led by steady EPS growth. In this dashboard on Intuitive Surgical’s valuation, we focus on four factors: revenue, net income margin, number of shares, and price to earnings multiple to arrive at our price estimate.
Intuitive Surgical primarily serves the robotic surgical systems market. Its primary device is the da Vinci Surgical System, which helps surgeons perform minimally invasive surgeries through directions from a console. Its customers include Hospitals, surgeons, and healthcare institutions. It competes with other robotical surgical devices companies, including SOFAR S.p.A., Eterne, Titan Medical, Hitachi, Olympus, and Mazor Robotics.
#1. Estimating Intuitive Surgical’s Total Revenues:
Total revenue grew at a CAGR of 18% from $2.7 billion in 2016 to $4.5 billion in 2019, and it could grow 16% to $5.2 billion in 2020.
The revenue growth was driven by the overall increase in the company’s installed base of its robotic devices.
More people opting for procedures through robotic platforms is driving the demand for the company’s products. In fact, total number of procedures performed by Intuitive Surgical’s systems grew 18% y-o-y to 1.23 million in 2019.
Our interactive dashboard analysis, ISRG Revenues: How Does Intuitive Surgical Make Money?, provides an in depth view of the company’s revenues.
#2. Deriving Intuitive Surgical’s Adjusted Net Income:
Adjusted Net Income grew from $0.9 billion in 2016 to $1.5 Billion in 2019, and we expect it to be around $1.7 billion in 2020.
This growth will likely be led by higher revenues, partly offset by a modest decline in net income margin, as the company sees higher sales of newer products and makes infrastructure investments.
The jump In Adjusted Net Income Margin in 2018 can be attributed to the impact of the U.S. Tax Act.
Our interactive dashboard analysis, ISRG Expenses: How Does Intuitive Surgical Spend Money?, provides an in depth view of the company’s expenses.
#3. Determining Intuitive Surgical’s Adjusted EPS:
Adjusted EPS declined from $22.42 in 2016 to $9.09 in 2017, due to change in shares outstanding. The company split its share in the ratio of 3:1.
EPS grew thereafter to $12.76 in 2019, and it is estimated to be $14.59 in 2020.
EPS growth can be attributed to higher adjusted net income, partly offset by an increase in number of shares.
#4. Estimating Intuitive Surgical’s Stock Price:
Our price estimate of $652 for Intuitive Surgical’s stock is based on our Detailed Valuation Model, and implies 44.7x P/E Multiple on expected 2020 Adjusted EPS of $14.59.
This compares with the current market price of $611, implying a 45.5x P/E Multiple based on average consensus EPS estimate of $13.46 for 2020.
Comparing Intuitive Surgical’s Historical P/E Multiple With That of Its Peers
P/E Multiples are based on Share Price at the end of year, and reported adjusted EPS for the full year (fiscal).
Intuitive Surgical’s P/E Multiple has been higher than that of Abbott, Boston Scientific, and Medtronic, primarily due to strong revenue growth.
See all Trefis Price Estimates and Download Trefis Data here
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Its primary device is the da Vinci Surgical System, which helps surgeons perform minimally invasive surgeries through directions from a console. EPS growth can be attributed to higher adjusted net income, partly offset by an increase in number of shares. Intuitive Surgical’s P/E Multiple has been higher than that of Abbott, Boston Scientific, and Medtronic, primarily due to strong revenue growth. | Our interactive dashboard analysis, ISRG Revenues: How Does Intuitive Surgical Make Money?, provides an in depth view of the company’s revenues. Deriving Intuitive Surgical’s Adjusted Net Income: Adjusted Net Income grew from $0.9 billion in 2016 to $1.5 Billion in 2019, and we expect it to be around $1.7 billion in 2020. Estimating Intuitive Surgical’s Stock Price: Our price estimate of $652 for Intuitive Surgical’s stock is based on our Detailed Valuation Model, and implies 44.7x P/E Multiple on expected 2020 Adjusted EPS of $14.59. | We estimate Intuitive Surgical’s fair price estimate to be around $652, based on expected EPS of $14.59 on an adjusted basis for full year 2020 and price to earnings multiple of 44.7x. In this dashboard on Intuitive Surgical’s valuation, we focus on four factors: revenue, net income margin, number of shares, and price to earnings multiple to arrive at our price estimate. Estimating Intuitive Surgical’s Stock Price: Our price estimate of $652 for Intuitive Surgical’s stock is based on our Detailed Valuation Model, and implies 44.7x P/E Multiple on expected 2020 Adjusted EPS of $14.59. | There is an upside of over 6% for Intuitive Surgical’s (NASDAQ:ISRG) stock, in our view. Intuitive Surgical primarily serves the robotic surgical systems market. The revenue growth was driven by the overall increase in the company’s installed base of its robotic devices. |
32779.0 | 2020-02-26 00:00:00 UTC | What Happens With AbbVie If Its Allergan Buyout Is Blocked? | ABT | https://www.nasdaq.com/articles/what-happens-with-abbvie-if-its-allergan-buyout-is-blocked-2020-02-26 | nan | nan | A deal isn't done until the ink dries on the paper. And for AbbVie's (NYSE: ABBV) pending acquisition of Allergan (NYSE: AGN), the ink hasn't dried yet.
AbbVie first announced plans to buy Allergan in June 2019. CEO Rick Gonzalez stated in the company's Q4 conference call earlier this month that the deal was on track to close in the first quarter of 2020.
But now there's a threat that could prevent the transaction from receiving regulatory clearance from the U.S. Federal Trade Commission (FTC). What happens for AbbVie if its Allergan buyout is blocked?
Image source: Getty Images.
Mounting opposition
A coalition of consumer groups and trade unions representing over 10 millions subscribers and members oppose AbbVie's takeover of Allergan. These organizations sent a letter to the director of the FTC's Bureau of Competition on Feb. 18, stating that Allergan's sale of brazikumab to AstraZeneca isn't enough to address the anti-competitive impact of the acquisition.
AstraZeneca initially developed brazikumab. The drug is currently in mid-stage clinical studies for treating Crohn's disease and ulcerative colitis. Allergan's divestiture of the immunology drug enabled AstraZeneca to recover its full commercialization rights.
But the allied consumer groups and trade unions are concerned that AstraZeneca won't be able to compete against AbbVie's immunology juggernaut. These groups pointed out in the letter to the FTC that AstraZeneca wasn't able to bring brazikumab to the market in the past and doesn't have the immunology infrastructure in place to be successful against AbbVie.
The consumer groups and unions are also worried that AbbVie will gain increased bargaining leverage with payers by picking up Allergan's lineup of drugs. Allergan claims current blockbuster products including Botox and a fast-rising star in antipsychotic drug Vraylar.
AbbVie's plan B
What would AbbVie's backup plan be if the FTC blocks its acquisition of Allergan? For one thing, the company wouldn't probably walk away from the deal without putting up a fight. It's spent too much time and money trying to make the acquisition happen to immediately throw in the towel.
If, however, the transaction does fall apart, it seems likely that AbbVie would go back to the drawing board to identify other potential transformative acquisitions. The problem is that if the FTC scuttles the Allergan buyout, it would probably be opposed to nearly any major deal that AbbVie might want to make.
One possible candidate that would be an intriguing pick for AbbVie is Vertex Pharmaceuticals (NASDAQ: VRTX). The only significant overlap between the two companies' pipelines and product lineups is in cystic fibrosis (CF). But AbbVie's CF drugs are only in early-stage development, while Vertex claims four FDA-approved CF drugs.
Vertex and Allergan have similar market caps. However, the price tag for AbbVie to acquire Vertex would probably have to be well above what it plans to pay for Allergan because of Vertex's strong growth prospects. It's also doubtful that Vertex would be interested in an acquisition at this point.
Another potential plan B strategy for AbbVie would be to go with the "string-of-pearls" approach and scoop up multiple smaller biotech stocks. The problem with this, though, is that AbbVie is looking for reliable revenue to reduce its dependence on Humira. A string-of-pearls shopping spree wouldn't likely achieve the big drugmaker's objective.
AbbVie could also go back to its roots and acquire a medical device maker instead of a biopharmaceutical company. Before it was a stand-alone company, AbbVie was part of Abbott Labs, which ranks as one of the biggest medical device makers in the world. The chances that AbbVie would take this course of action, though, are probably really low.
Most likely scenario
The most likely scenario of all for AbbVie is that it doesn't have to find a plan B at all. AbbVie has already obtained a green light from the European Union for its buyout of Allergan. Allergan sold Zenpep in addition to brazikumab to grease the wheels for the EU's blessing. It also sold pancreatic enzyme Viokace as a sweetener to gain FTC approval.
It's still possible that the FTC could block AbbVie's acquisition of Allergan. However, any arguments that the deal will significantly boost the company's competitive position in immunology or oncology don't appear to be compelling ones. Look for the ink to dry on the $63 billion transaction sooner rather than later.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Keith Speights owns shares of AbbVie and Vertex Pharmaceuticals. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Mounting opposition A coalition of consumer groups and trade unions representing over 10 millions subscribers and members oppose AbbVie's takeover of Allergan. These organizations sent a letter to the director of the FTC's Bureau of Competition on Feb. 18, stating that Allergan's sale of brazikumab to AstraZeneca isn't enough to address the anti-competitive impact of the acquisition. The consumer groups and unions are also worried that AbbVie will gain increased bargaining leverage with payers by picking up Allergan's lineup of drugs. | And for AbbVie's (NYSE: ABBV) pending acquisition of Allergan (NYSE: AGN), the ink hasn't dried yet. AbbVie's plan B What would AbbVie's backup plan be if the FTC blocks its acquisition of Allergan? One possible candidate that would be an intriguing pick for AbbVie is Vertex Pharmaceuticals (NASDAQ: VRTX). | And for AbbVie's (NYSE: ABBV) pending acquisition of Allergan (NYSE: AGN), the ink hasn't dried yet. These groups pointed out in the letter to the FTC that AstraZeneca wasn't able to bring brazikumab to the market in the past and doesn't have the immunology infrastructure in place to be successful against AbbVie. AbbVie's plan B What would AbbVie's backup plan be if the FTC blocks its acquisition of Allergan? | The problem is that if the FTC scuttles the Allergan buyout, it would probably be opposed to nearly any major deal that AbbVie might want to make. But AbbVie's CF drugs are only in early-stage development, while Vertex claims four FDA-approved CF drugs. It's still possible that the FTC could block AbbVie's acquisition of Allergan. |
32780.0 | 2020-02-25 00:00:00 UTC | 3 Value Stocks to Buy if the Stock Market Implodes | ABT | https://www.nasdaq.com/articles/3-value-stocks-to-buy-if-the-stock-market-implodes-2020-02-25 | nan | nan | The U.S. stock markets took a sizable step backwards yesterday, presumably on the emerging COVID-19 threat. A more careful look, however, suggests that the market was basically due for a correction. After all, most major indices were bumping up against their all-time highs, and valuations across the large-cap space were close to twice the historical average prior to this viral outbreak. So while the COVID-19 illness may have sparked this sell-off, it was arguably long overdue from a fundamental standpoint. In fact, Warren Buffett warned the retail crowd about this very issue via Berkshire Hathaway's 2019 annual letter to shareholders.
Despite these unfavorable market dynamics, there are a few rare gems still worth buying. Who are these unicorns? The pharmaceutical companies AbbVie (NYSE: ABBV), Bausch Health Companies Inc. (NYSE: BHC), and Bristol-Myers Squibb (NYSE: BMY) are all trading at less than 10 times next year's projected earnings right now. Here's why risk-averse investors might want to pounce on these three value stocks in the days and weeks ahead.
Image source: Getty Images.
An incredibly cheap dividend growth play
AbbVie, an Illinois-based drugmaker, is currently trading at 8.85 times next year's projected earnings. That's one of the lowest valuations within its peer group, as well as one of the lowest for a Dividend Aristocrat, a status it gained through its former parent company Abbott Laboratories. AbbVie, though, arguably doesn't deserve such a ridiculously low valuation.
The bugaboo with this large-cap biopharma stock is the upcoming patent cliff for its flagship arthritis medication Humira. However, this overhang has now been dealt with through the commercial launch of the immunology meds Rinvoq and Skyrizi, as well as the forthcoming merger with Allergan (NYSE: AGN) that's expected to close before the end of the first quarter.
What makes AbbVie an outstanding defensive stock? Apart from its rock-bottom valuation, AbbVie should ultimately post near industry-leading levels of top-line growth with Allergan in the fold. What's more, the drugmaker offers a dividend yield of almost 5% at current levels. That's essentially a junk-bond-type yield attached to a Dividend Aristocrat. In all, AbbVie's shares may pull back with the broader market, but it should hold its own better than most because of its attractive valuation and sky-high dividend yield.
A well-diversified Canadian pharma on the mend
After Bausch Health's blistering rebound in 2019, its comeback has largely stalled in 2020. The company's less-than-stellar fourth-quarter 2019 results, combined with its ongoing debt overhang, has apparently been reason enough for some investors to take profits this year. The direct consequence of Bausch's latest downturn is that its stock is now trading at a paltry 5.76 times next year's estimated earnings. That's ridiculously cheap any way you slice it.
Why should bargain hunters consider this name during this turbulent period in the market? The simple answer is management. Bausch's new management team has guided the company from the brink of bankruptcy just a few years ago to where it is today -- a solid mid-cap biopharma set to post low-single-digit sales growth for the next few years.
Of course, the debt issue will continue to loom large for perhaps the next five years. But Bausch's creative management team should be able to navigate these troubled waters. As proof, they successfully reinvigorated the flagging commercialization of the constipation med Trulance since taking it over from Synergy Pharmaceuticals. That's an impressive feat, to be sure.
Now, Bausch will arguably need to unearth a few more hidden gems like Trulance to complete its comeback. But the company's brain trust has given investors a surfeit of reasons to be optimistic about the future. In turn, this Canadian pharma stock probably shouldn't be trading like a distressed asset gearing up for a bankruptcy filing.
A rock-solid competitive moat
Bristol's shares have failed to capture Wall Street's imagination of late, thanks to the dwindling market share for its immuno-oncology med Opdivo. Underscoring this point, this big pharma stock is being presently valued at less than 9 times 2021 estimated earnings, which is among the cheapest valuations within its entire peer group. Wall Street, however, is arguably dead wrong about this name.
Following the company's tie-up with cancer behemoth Celgene, Bristol now sports eight blockbuster-level products and one of the most robust oncology pipelines in the pharmaceutical industry. The company's highly diverse product portfolio and top-shelf pipeline should thus translate into a a rock-solid competitive moat in the years ahead. Put simply, Wall Street is making far too much of a fuss over Opdivo's competitive positioning. Bristol is no longer a one-trick pony, after all.
What's more, Bristol also offers investors a respectable annualized yield of 2.74% at current levels. The drugmaker's fairly average yield for a big pharma stock may not be overly exciting, but it does give investors another avenue for capital appreciation. Dividends of any kind, after all, have proven to be a powerful way to generate substantial returns on capital over the long term.
All told, defensive-minded investors may want to consider this big pharma stock for its attractive near-term growth prospects, robust clinical pipeline, dirt-cheap valuation, and prospects as a steady income play in an increasingly uncertain environment.
10 stocks we like better than Bristol-Myers Squibb
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Bristol-Myers Squibb wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bausch Health Companies, Berkshire Hathaway (B shares), and Bristol-Myers Squibb and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and short March 2020 $225 calls on Berkshire Hathaway (B shares). The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, this overhang has now been dealt with through the commercial launch of the immunology meds Rinvoq and Skyrizi, as well as the forthcoming merger with Allergan (NYSE: AGN) that's expected to close before the end of the first quarter. Underscoring this point, this big pharma stock is being presently valued at less than 9 times 2021 estimated earnings, which is among the cheapest valuations within its entire peer group. The drugmaker's fairly average yield for a big pharma stock may not be overly exciting, but it does give investors another avenue for capital appreciation. | The pharmaceutical companies AbbVie (NYSE: ABBV), Bausch Health Companies Inc. (NYSE: BHC), and Bristol-Myers Squibb (NYSE: BMY) are all trading at less than 10 times next year's projected earnings right now. An incredibly cheap dividend growth play AbbVie, an Illinois-based drugmaker, is currently trading at 8.85 times next year's projected earnings. The Motley Fool owns shares of and recommends Bausch Health Companies, Berkshire Hathaway (B shares), and Bristol-Myers Squibb and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and short March 2020 $225 calls on Berkshire Hathaway (B shares). | The pharmaceutical companies AbbVie (NYSE: ABBV), Bausch Health Companies Inc. (NYSE: BHC), and Bristol-Myers Squibb (NYSE: BMY) are all trading at less than 10 times next year's projected earnings right now. See the 10 stocks *Stock Advisor returns as of December 1, 2019 George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bausch Health Companies, Berkshire Hathaway (B shares), and Bristol-Myers Squibb and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and short March 2020 $225 calls on Berkshire Hathaway (B shares). | An incredibly cheap dividend growth play AbbVie, an Illinois-based drugmaker, is currently trading at 8.85 times next year's projected earnings. Wall Street, however, is arguably dead wrong about this name. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Bristol-Myers Squibb wasn't one of them! |
32781.0 | 2020-02-24 00:00:00 UTC | Interesting ABT Put And Call Options For April 17th | ABT | https://www.nasdaq.com/articles/interesting-abt-put-and-call-options-for-april-17th-2020-02-24 | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new April 17th contracts and identified one put and one call contract of particular interest.
The put contract at the $75.00 strike price has a current bid of 61 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $75.00, but will also collect the premium, putting the cost basis of the shares at $74.39 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $85.20/share today.
Because the $75.00 strike represents an approximate 12% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 97%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.81% return on the cash commitment, or 5.61% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $75.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $87.50 strike price has a current bid of $1.51. If an investor was to purchase shares of ABT stock at the current price level of $85.20/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $87.50. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 4.47% if the stock gets called away at the April 17th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $87.50 strike highlighted in red:
Considering the fact that the $87.50 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 64%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 1.77% boost of extra return to the investor, or 12.22% annualized, which we refer to as the YieldBoost.
The implied volatility in the put contract example is 33%, while the implied volatility in the call contract example is 23%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $85.20) to be 18%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks Analysts Like »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $87.50 strike highlighted in red: Considering the fact that the $87.50 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the April 17th expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $87.50 strike highlighted in red: Considering the fact that the $87.50 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new April 17th contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $87.50 strike highlighted in red: Considering the fact that the $87.50 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new April 17th contracts and identified one put and one call contract of particular interest. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new April 17th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABT's trailing twelve month trading history, with the $87.50 strike highlighted in red: Considering the fact that the $87.50 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the April 17th expiration. |
32782.0 | 2020-02-21 00:00:00 UTC | IWB, ABT, AMGN, LIN: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/iwb-abt-amgn-lin%3A-large-outflows-detected-at-etf-2020-02-21 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $75.0 million dollar outflow -- that's a 0.3% decrease week over week (from 125,100,000 to 124,700,000). Among the largest underlying components of IWB, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.7%, Amgen Inc (Symbol: AMGN) is up about 0.2%, and Linde plc (Symbol: LIN) is lower by about 1%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average:
Looking at the chart above, IWB's low point in its 52 week range is $151.66 per share, with $188.47 as the 52 week high point — that compares with a last trade of $185.83. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWB, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.7%, Amgen Inc (Symbol: AMGN) is up about 0.2%, and Linde plc (Symbol: LIN) is lower by about 1%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $151.66 per share, with $188.47 as the 52 week high point — that compares with a last trade of $185.83. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWB, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.7%, Amgen Inc (Symbol: AMGN) is up about 0.2%, and Linde plc (Symbol: LIN) is lower by about 1%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $151.66 per share, with $188.47 as the 52 week high point — that compares with a last trade of $185.83. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IWB, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.7%, Amgen Inc (Symbol: AMGN) is up about 0.2%, and Linde plc (Symbol: LIN) is lower by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $75.0 million dollar outflow -- that's a 0.3% decrease week over week (from 125,100,000 to 124,700,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $151.66 per share, with $188.47 as the 52 week high point — that compares with a last trade of $185.83. | Among the largest underlying components of IWB, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.7%, Amgen Inc (Symbol: AMGN) is up about 0.2%, and Linde plc (Symbol: LIN) is lower by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $75.0 million dollar outflow -- that's a 0.3% decrease week over week (from 125,100,000 to 124,700,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $151.66 per share, with $188.47 as the 52 week high point — that compares with a last trade of $185.83. |
32783.0 | 2020-02-20 00:00:00 UTC | Abbott Presents Data Showing its Glucose Monitor Helps People With Diabetes | ABT | https://www.nasdaq.com/articles/abbott-presents-data-showing-its-glucose-monitor-helps-people-with-diabetes-2020-02-20 | nan | nan | At the 13th Advanced Technologies & Treatments for Diabetes meeting, Abbott Laboratories (NYSE: ABT) is presenting a series of studies showing that its glucose monitor FreeStyle Libre system helped people with diabetes across the globe improved their glucose levels. The system uses a sensor that's worn on the back of the patient's upper arm, eliminating the need for routine finger pricks.
In a study of patients with Type 1 or Type 2 diabetes in Germany, after using the FreeStyle Libre system for 12 months, patients were able to reduce their HbA1c level, a measure of long-term glucose levels. Type 1 patients with starting values greater than 7.5% lowered their HbA1c by 1.4%, while Type 2 patients reduced the measurement by 1.2%.
An analysis by Abbott of patients in Sweden's National Diabetes Register showed patients using the system for three months to nine months had a 0.44% reduction in HbA1c for people with Type 1 diabetes and 0.67% for people with Type 2 diabetes.
Image source: Abbott Labs
In a study of patients in Canada, the healthcare company found more frequent scanning increased the ability of patients to stay within their target glucose range. Patients with the lowest frequency of scans (3.3 scans per day) spent 54.6% of the time in range, compared to 66.7% of the time in range for patients with the highest scanning frequency (29.3 scans per day).
Finally, a study from the U.S. of more than 12,000 people with diabetes who switched from using test strips to using a continuous glucose monitor, including the FreeStyle Libre, showed that switching reduced acute diabetes complications by 44% in patients with Type 1 diabetes and by 51% in patients with Type 2 diabetes.
10 stocks we like better than Abbott
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At the 13th Advanced Technologies & Treatments for Diabetes meeting, Abbott Laboratories (NYSE: ABT) is presenting a series of studies showing that its glucose monitor FreeStyle Libre system helped people with diabetes across the globe improved their glucose levels. The system uses a sensor that's worn on the back of the patient's upper arm, eliminating the need for routine finger pricks. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | At the 13th Advanced Technologies & Treatments for Diabetes meeting, Abbott Laboratories (NYSE: ABT) is presenting a series of studies showing that its glucose monitor FreeStyle Libre system helped people with diabetes across the globe improved their glucose levels. In a study of patients with Type 1 or Type 2 diabetes in Germany, after using the FreeStyle Libre system for 12 months, patients were able to reduce their HbA1c level, a measure of long-term glucose levels. Finally, a study from the U.S. of more than 12,000 people with diabetes who switched from using test strips to using a continuous glucose monitor, including the FreeStyle Libre, showed that switching reduced acute diabetes complications by 44% in patients with Type 1 diabetes and by 51% in patients with Type 2 diabetes. | At the 13th Advanced Technologies & Treatments for Diabetes meeting, Abbott Laboratories (NYSE: ABT) is presenting a series of studies showing that its glucose monitor FreeStyle Libre system helped people with diabetes across the globe improved their glucose levels. An analysis by Abbott of patients in Sweden's National Diabetes Register showed patients using the system for three months to nine months had a 0.44% reduction in HbA1c for people with Type 1 diabetes and 0.67% for people with Type 2 diabetes. Finally, a study from the U.S. of more than 12,000 people with diabetes who switched from using test strips to using a continuous glucose monitor, including the FreeStyle Libre, showed that switching reduced acute diabetes complications by 44% in patients with Type 1 diabetes and by 51% in patients with Type 2 diabetes. | At the 13th Advanced Technologies & Treatments for Diabetes meeting, Abbott Laboratories (NYSE: ABT) is presenting a series of studies showing that its glucose monitor FreeStyle Libre system helped people with diabetes across the globe improved their glucose levels. In a study of patients with Type 1 or Type 2 diabetes in Germany, after using the FreeStyle Libre system for 12 months, patients were able to reduce their HbA1c level, a measure of long-term glucose levels. An analysis by Abbott of patients in Sweden's National Diabetes Register showed patients using the system for three months to nine months had a 0.44% reduction in HbA1c for people with Type 1 diabetes and 0.67% for people with Type 2 diabetes. |
32784.0 | 2020-02-20 00:00:00 UTC | Abbott Labs Recalls Some Catheters Due to Possible Defects | ABT | https://www.nasdaq.com/articles/abbott-labs-recalls-some-catheters-due-to-possible-defects-2020-02-20 | nan | nan | The U.S. Food and Drug Administration stated on Wednesday that some lots of two catheters models sold by Abbott Laboratories (NYSE: ABT) needed to be recalled due to potentially severe safety issues. The agency defined them as Class I recalls, the most serious type, and it warned that using these devices could cause serious injury or even death.
The models in question are the NC Trek RX and the NC Traveler RX coronary dilation catheters with balloon diameters of 4.0mm, 4.5mm, and 5.0mm. The issue is that the balloons may not deflate the way they are supposed to. The problem seems to have been caused by overexposure to heat during the manufacturing process, which weakens the material near the balloon.
Image source: Getty Images.
"Use of these devices may cause serious adverse health consequences, such as prolonged cardiac ischemia (reduced blow flow to the heart), air embolism, thrombosis (clot in the artery), myocardial infarction (heart attack), and additional surgery that could lead to post-operative complications, including death," warned the agency in an official statement.
Additional details
The recall applies to 13,891 devices that were distributed between August 2019 and January 2020. So far, there have been 13 complaints recorded relating to the problem, with one confirmed death.
This isn't the first time there's been an issue with Abbott's catheters. Back in 2017, the healthcare giant warned hospitals and healthcare professionals to stop using a number of its catheters due to problems with the balloon sheath. As many as 449,661 catheters were identified as potentially being defective at the time.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The U.S. Food and Drug Administration stated on Wednesday that some lots of two catheters models sold by Abbott Laboratories (NYSE: ABT) needed to be recalled due to potentially severe safety issues. "Use of these devices may cause serious adverse health consequences, such as prolonged cardiac ischemia (reduced blow flow to the heart), air embolism, thrombosis (clot in the artery), myocardial infarction (heart attack), and additional surgery that could lead to post-operative complications, including death," warned the agency in an official statement. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! | The U.S. Food and Drug Administration stated on Wednesday that some lots of two catheters models sold by Abbott Laboratories (NYSE: ABT) needed to be recalled due to potentially severe safety issues. The models in question are the NC Trek RX and the NC Traveler RX coronary dilation catheters with balloon diameters of 4.0mm, 4.5mm, and 5.0mm. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | The U.S. Food and Drug Administration stated on Wednesday that some lots of two catheters models sold by Abbott Laboratories (NYSE: ABT) needed to be recalled due to potentially severe safety issues. "Use of these devices may cause serious adverse health consequences, such as prolonged cardiac ischemia (reduced blow flow to the heart), air embolism, thrombosis (clot in the artery), myocardial infarction (heart attack), and additional surgery that could lead to post-operative complications, including death," warned the agency in an official statement. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Mark Prvulovic has no position in any of the stocks mentioned. | The U.S. Food and Drug Administration stated on Wednesday that some lots of two catheters models sold by Abbott Laboratories (NYSE: ABT) needed to be recalled due to potentially severe safety issues. The agency defined them as Class I recalls, the most serious type, and it warned that using these devices could cause serious injury or even death. This isn't the first time there's been an issue with Abbott's catheters. |
32785.0 | 2020-02-20 00:00:00 UTC | Health Care Sector Update for 02/20/2020: TOCA, FMS, TEVA, JNJ, ABT, MRK, PFE, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-02-20-2020%3A-toca-fms-teva-jnj-abt-mrk-pfe-amgn-2020-02-20 | nan | nan | Top Health Care Stocks:
JNJ: +0.10%
PFE: -0.52%
ABT: Flat
MRK: Flat
AMGN: +0.02%
Health care giants were mixed pre-market Thursday.
Moving stocks include:
(+) Tocagen (TOCA), which was surging 70% after saying it entered into an agreement to merge with privately held Forte Biosciences in an all-stock transaction.
(+) Fresenius Medical Care (FMS) was up more than 1% after it reported Q4 2019 adjusted earnings per share of EUR1.36 ($1.47), up from EUR1.29 in Q4 2018.
(-) Teva Pharmaceutical (TEVA) was declining more than 2% after saying its two clinical trials evaluating deutetrabenazine as treatment for pediatric patients with moderate to severe Tourette syndrome failed to meet the primary endpoint.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: Flat MRK: Flat Moving stocks include: (+) Tocagen (TOCA), which was surging 70% after saying it entered into an agreement to merge with privately held Forte Biosciences in an all-stock transaction. (+) Fresenius Medical Care (FMS) was up more than 1% after it reported Q4 2019 adjusted earnings per share of EUR1.36 ($1.47), up from EUR1.29 in Q4 2018. | ABT: Flat MRK: Flat Top Health Care Stocks: Health care giants were mixed pre-market Thursday. | ABT: Flat MRK: Flat Moving stocks include: (+) Tocagen (TOCA), which was surging 70% after saying it entered into an agreement to merge with privately held Forte Biosciences in an all-stock transaction. (-) Teva Pharmaceutical (TEVA) was declining more than 2% after saying its two clinical trials evaluating deutetrabenazine as treatment for pediatric patients with moderate to severe Tourette syndrome failed to meet the primary endpoint. | ABT: Flat MRK: Flat Top Health Care Stocks: Health care giants were mixed pre-market Thursday. |
32786.0 | 2020-02-20 00:00:00 UTC | The Growth Opportunity That Will Move Medtronic Ahead of Its Rivals | ABT | https://www.nasdaq.com/articles/the-growth-opportunity-that-will-move-medtronic-ahead-of-its-rivals-2020-02-20 | nan | nan | One of the world's largest medical device companies, Medtronic (NYSE: MDT), has seen a more than 55% rise in its stock price over the past five years.
The 71-year-old company serves more than 150 countries worldwide, with success in diagnostic tools for heart disease, surgery, restorative therapies, and diabetes. Over the past 12 months alone, the stock is up nearly 24%. Can this momentum continue?
There is one key division that may offer clues to Medtronic's long-term growth.
Image Source: Getty Images.
A major growth opportunity
Medtronic is broken down into four key divisions, as seen in the table below.
DIVISION PRODUCT FOCUS PERCENTAGE OF REVENUE, YEAR TO DATE (Q1-Q3 2020) PERCENTAGE OF REVENUE, FY 2019 PERCENTAGE OF REVENUE, FY 2018 PERCENTAGE OF REVENUE, FY 2017 CHANGE (FY2017- FY2019)
Cardiac and Vascular Group
Heart failure, coronary heart disease, surgical tools
36.9% 37.7% 37.9% 35.3% 9.6%
Minimally Invasive Therapies Group
Surgical tools; therapies for lungs, stomach, kidneys
28% 27.7% 29.1% 33.4% (14.5%)
Restorative Therapies Group
Therapies for spine, neurological disorders, and pain
27.2% 26.8% 25.9% 24.8% 11.1%
Diabetes Group
Insulin pumps, blood sugar monitors (continuous glucose monitoring), therapy management software
7.9% 7.8% 7.1% 6.5% 24.1%
Source: Medtronic.
Of the four, the diabetes division shows the most promise for Medtronic investors. Diabetes affects roughly 30.3 million people, or 9.4% of the population, in the United States; worldwide, about 425 million adults live with the condition. Diabetes impairs the body's ability to process sugar, and patients must continually monitor their blood sugar levels and manage them with a hormone called insulin.
At Medtronic, the diabetes division includes key products such as MiniMed insulin pumps and accessories, Guardian continuous glucose monitoring (CGM), and therapy management software. Worldwide, sales of insulin pumps and CGM across all manufacturers are expected to grow at a compound annual growth rate (CAGR) of more than 12%, and as the table shows, divisional revenue at Medtronic is up 24.1% since 2017 -- the highest increase of the four divisions.
The company's most recent earnings report, for the third quarter of fiscal 2020, showed that Medtronic's strength is in theglobal market-- worldwide sales accounted for approximately half of the total, resulting in 16% growth year over year and offsetting some U.S. revenue challenges from increased competition.
Global strength in CGM
The CGM market showed strong results in both integrated and stand-alone products. CGM products that are integrated with Medtronic's MiniMed insulin pump led sales, with a particular boost from new patient acquisitions in international markets. The stand-alone CGM market continues to show progress as well, with 50% growth in the third quarter; here, Medtronic competes with market leader DexCom (NASDAQ: DXCM) as well as emerging rival Abbott Laboratories (NYSE: ABT).
DexCom has an advantage over its competitors in the U.S. market, with growth coming from CGM orders by Medicare plans, durable medical equipment (DME) suppliers, and pharmacy orders. DexCom continues to expand in these areas, but there's still room to grow for rivals like Medtronic, too. New products with additional capabilities and accuracy may help Medtronic regain market share, and its position as UnitedHealthcare's preferred insulin pump provider should help it expand in the integrated CGM market both domestically and internationally.
Dominance in the insulin pump space
Medtronic's MiniMed pumps have been a major sales driver in the past, and the international markets provide growth opportunities that should offset a U.S. revenue decline brought on by increased competition. Medtronic already sells its insulin pumps in Western Europe and many emerging markets, and a key catalyst will come this week, when the company is set to present data on its new insulin pump at the International Conference on Advanced Technologies and Treatments for Diabetes. This data should advance the creation of a timeline for milestones and eventual approval of the new 780G insulin pump by the U.S. Food and Drug Administration (FDA).
The 780G already has a European Commission mark of approval (CE mark) and has achieved conformity for products sold in the European Economic Area (EEA), and investors should gear up for more data in June, which will discuss results from a feasibility study for in-home use of the 780G to automate insulin delivery in patients with diabetes. Positive results from this study would allow the device to progress toward FDA approval, which would create an additional growth driver for Medtronic and improve its competitiveness in the market for insulin pumps.
Medtronic also has a plan in place to retain many of its current users -- the Next Tech Pathway program allows purchasers of the former 670G product to upgrade their device for free when the 780G arrives. This will be a key factor in improving U.S. sales and should allow Medtronic to stay at the forefront of the competition.
Medtronic boasts roughly 60% ofglobal marketshare in the insulin pump market, where it squares off against competitors such as Tandem Diabetes Care (NASDAQ: TNDM) and Insulet Corporation (NASDAQ: PODD). Its partnership with UnitedHealthcare (NYSE: UNH) is key here, and Medtronic can also expect growth from its continuing outcomes-based agreements with select healthcare providers such as Aetna; these value-based plans pay providers based on patient outcomes and quality of services performed, and Medtronic's participation could improve brand awareness and recognition among consumers and strengthen U.S. market share.
A recent recall of two MiniMed products because of safety concerns may have short-term effects, but it's unlikely to change the long-term growth trajectory. The diabetes division makes up just 8% of Medtronic's revenue, and the potential financial consequences of litigation and replacement will be offset in the short term by revenue from the company's diversified portfolio of other products. When considering longer-term prospects, the growth of the insulin pump market in international markets along with integrated and stand-alone CGM sales will contribute to further revenue streams, offsetting declines in other divisions (including the minimally invasive therapies division). In addition, the release of new products such as the 780G pump will improve Medtronic's strength in the U.S. market, where it's currently struggling because of competitive challenges.
Long-term opportunities
Medtronic's diabetes division offers a window into the company's long-term prospects. Currently, the division makes up less than 10% of the company's revenue, meaning there's significant opportunity for growth here -- especially with a CAGR of 12% for both insulin pumps and CGM. Given its solid partnerships and agreements with healthcare providers and the opportunities presented in international markets, Medtronic has an opportunity to remain the market leader in insulin pumps over the long term. As the company dominates in the diabetes segment, shareholders and healthcare investors should see results on both the company's top and bottom lines.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Amar Khatri has no position in any of the stocks mentioned. The Motley Fool recommends Insulet and UnitedHealth Group. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The stand-alone CGM market continues to show progress as well, with 50% growth in the third quarter; here, Medtronic competes with market leader DexCom (NASDAQ: DXCM) as well as emerging rival Abbott Laboratories (NYSE: ABT). At Medtronic, the diabetes division includes key products such as MiniMed insulin pumps and accessories, Guardian continuous glucose monitoring (CGM), and therapy management software. Worldwide, sales of insulin pumps and CGM across all manufacturers are expected to grow at a compound annual growth rate (CAGR) of more than 12%, and as the table shows, divisional revenue at Medtronic is up 24.1% since 2017 -- the highest increase of the four divisions. | The stand-alone CGM market continues to show progress as well, with 50% growth in the third quarter; here, Medtronic competes with market leader DexCom (NASDAQ: DXCM) as well as emerging rival Abbott Laboratories (NYSE: ABT). Cardiac and Vascular Group Heart failure, coronary heart disease, surgical tools 36.9% 37.7% 37.9% 35.3% 9.6% Minimally Invasive Therapies Group Surgical tools; therapies for lungs, stomach, kidneys 28% 27.7% 29.1% 33.4% (14.5%) Restorative Therapies Group Therapies for spine, neurological disorders, and pain 27.2% 26.8% 25.9% 24.8% 11.1% Diabetes Group Insulin pumps, blood sugar monitors (continuous glucose monitoring), therapy management software 7.9% 7.8% 7.1% 6.5% 24.1% Source: Medtronic. At Medtronic, the diabetes division includes key products such as MiniMed insulin pumps and accessories, Guardian continuous glucose monitoring (CGM), and therapy management software. | The stand-alone CGM market continues to show progress as well, with 50% growth in the third quarter; here, Medtronic competes with market leader DexCom (NASDAQ: DXCM) as well as emerging rival Abbott Laboratories (NYSE: ABT). Cardiac and Vascular Group Heart failure, coronary heart disease, surgical tools 36.9% 37.7% 37.9% 35.3% 9.6% Minimally Invasive Therapies Group Surgical tools; therapies for lungs, stomach, kidneys 28% 27.7% 29.1% 33.4% (14.5%) Restorative Therapies Group Therapies for spine, neurological disorders, and pain 27.2% 26.8% 25.9% 24.8% 11.1% Diabetes Group Insulin pumps, blood sugar monitors (continuous glucose monitoring), therapy management software 7.9% 7.8% 7.1% 6.5% 24.1% Source: Medtronic. Dominance in the insulin pump space Medtronic's MiniMed pumps have been a major sales driver in the past, and the international markets provide growth opportunities that should offset a U.S. revenue decline brought on by increased competition. | The stand-alone CGM market continues to show progress as well, with 50% growth in the third quarter; here, Medtronic competes with market leader DexCom (NASDAQ: DXCM) as well as emerging rival Abbott Laboratories (NYSE: ABT). Dominance in the insulin pump space Medtronic's MiniMed pumps have been a major sales driver in the past, and the international markets provide growth opportunities that should offset a U.S. revenue decline brought on by increased competition. When considering longer-term prospects, the growth of the insulin pump market in international markets along with integrated and stand-alone CGM sales will contribute to further revenue streams, offsetting declines in other divisions (including the minimally invasive therapies division). |
32787.0 | 2020-02-20 00:00:00 UTC | Abbott's FreeStyle Libre Shows Positive Outcomes For Type 1, Type 2 Diabetes | ABT | https://www.nasdaq.com/articles/abbotts-freestyle-libre-shows-positive-outcomes-for-type-1-type-2-diabetes-2020-02-20 | nan | nan | (RTTNews) - Abbott (ABT) said four real-world data showed that users of the FreeStyle Libre system have improved glucose control, increased time in target glucose range, and decreased time in hyperglycemiaiv or high glucose levels and hypoglycemia or low glucose levels, as well as reduced HbA1Ci (average glucose levels over a three month period).
Abbott's FreeStyle Libre system is now being used by more than 2 million people living with diabetes across 46 countries.Abbott has secured partial or full reimbursement for the FreeStyle Libre system in 36 countries, including France, Ireland, Japan, the United Kingdom, and the U.S.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) said four real-world data showed that users of the FreeStyle Libre system have improved glucose control, increased time in target glucose range, and decreased time in hyperglycemiaiv or high glucose levels and hypoglycemia or low glucose levels, as well as reduced HbA1Ci (average glucose levels over a three month period). Abbott's FreeStyle Libre system is now being used by more than 2 million people living with diabetes across 46 countries.Abbott has secured partial or full reimbursement for the FreeStyle Libre system in 36 countries, including France, Ireland, Japan, the United Kingdom, and the U.S. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) said four real-world data showed that users of the FreeStyle Libre system have improved glucose control, increased time in target glucose range, and decreased time in hyperglycemiaiv or high glucose levels and hypoglycemia or low glucose levels, as well as reduced HbA1Ci (average glucose levels over a three month period). Abbott's FreeStyle Libre system is now being used by more than 2 million people living with diabetes across 46 countries.Abbott has secured partial or full reimbursement for the FreeStyle Libre system in 36 countries, including France, Ireland, Japan, the United Kingdom, and the U.S. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) said four real-world data showed that users of the FreeStyle Libre system have improved glucose control, increased time in target glucose range, and decreased time in hyperglycemiaiv or high glucose levels and hypoglycemia or low glucose levels, as well as reduced HbA1Ci (average glucose levels over a three month period). Abbott's FreeStyle Libre system is now being used by more than 2 million people living with diabetes across 46 countries.Abbott has secured partial or full reimbursement for the FreeStyle Libre system in 36 countries, including France, Ireland, Japan, the United Kingdom, and the U.S. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) said four real-world data showed that users of the FreeStyle Libre system have improved glucose control, increased time in target glucose range, and decreased time in hyperglycemiaiv or high glucose levels and hypoglycemia or low glucose levels, as well as reduced HbA1Ci (average glucose levels over a three month period). Abbott's FreeStyle Libre system is now being used by more than 2 million people living with diabetes across 46 countries.Abbott has secured partial or full reimbursement for the FreeStyle Libre system in 36 countries, including France, Ireland, Japan, the United Kingdom, and the U.S. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
32788.0 | 2020-02-19 00:00:00 UTC | Insulet Announces Agreements With Abbott and DexCom | ABT | https://www.nasdaq.com/articles/insulet-announces-agreements-with-abbott-and-dexcom-2020-02-19 | nan | nan | On Wednesday, insulin pump maker Insulet (NASDAQ: PODD) announced agreements with Abbott (NYSE: ABT) and DexCom (NASDAQ: DXCM), two leading sellers of continuous glucose monitors (CGMs), to sell automated insulin delivery systems. Shares of Insulet were up by more than 2% on the news as of 2 p.m. EST.
The integrated systems will allow patients to have their insulin delivery controlled automatically according to their blood glucose levels using disposable CGMs and Insulet's wearable, tubeless insulin delivery pods. The systems will use Insulet's Omnipod Horizon system, which it expects to launch in the second half of 2020.
Image source: Getty Images.
The increasing cooperation between Insulet and DexCom on an integrated system should come as little surprise, as the companies had already announced their partnership as part of Insulet's development program for Horizon, which is in a pivotal trial with up to 240 participants. Wednesday's press release announced a commercialization agreement between the companies, but the terms were not disclosed.
The bigger news regarded the agreement with Abbott. The Horizon system was designed to work with multiple sensors, and although Abbott was the logical choice as a second partner, Insulet hadn't previously confirmed the companies were working on an integrated product.
Abbott's FreeStyle Libre CGM is the market leader, and could be more important to Insulet's business than DexCom's devices. Core to the growth strategy of the rapidly expanding diabetes company is international expansion, and the massive Abbott already has 2 million FreeStyle Libre users in 46 countries.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Jim Crumly has no position in any of the stocks mentioned. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Wednesday, insulin pump maker Insulet (NASDAQ: PODD) announced agreements with Abbott (NYSE: ABT) and DexCom (NASDAQ: DXCM), two leading sellers of continuous glucose monitors (CGMs), to sell automated insulin delivery systems. Abbott's FreeStyle Libre CGM is the market leader, and could be more important to Insulet's business than DexCom's devices. Core to the growth strategy of the rapidly expanding diabetes company is international expansion, and the massive Abbott already has 2 million FreeStyle Libre users in 46 countries. | On Wednesday, insulin pump maker Insulet (NASDAQ: PODD) announced agreements with Abbott (NYSE: ABT) and DexCom (NASDAQ: DXCM), two leading sellers of continuous glucose monitors (CGMs), to sell automated insulin delivery systems. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Jim Crumly has no position in any of the stocks mentioned. | On Wednesday, insulin pump maker Insulet (NASDAQ: PODD) announced agreements with Abbott (NYSE: ABT) and DexCom (NASDAQ: DXCM), two leading sellers of continuous glucose monitors (CGMs), to sell automated insulin delivery systems. The increasing cooperation between Insulet and DexCom on an integrated system should come as little surprise, as the companies had already announced their partnership as part of Insulet's development program for Horizon, which is in a pivotal trial with up to 240 participants. The Horizon system was designed to work with multiple sensors, and although Abbott was the logical choice as a second partner, Insulet hadn't previously confirmed the companies were working on an integrated product. | On Wednesday, insulin pump maker Insulet (NASDAQ: PODD) announced agreements with Abbott (NYSE: ABT) and DexCom (NASDAQ: DXCM), two leading sellers of continuous glucose monitors (CGMs), to sell automated insulin delivery systems. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. That's right -- they think these 10 stocks are even better buys. |
32789.0 | 2020-02-19 00:00:00 UTC | Health Care Sector Update for 02/19/2020: JNJ, PFE, ABT, MRK, AMGN, MREO, AMED, CTSO | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-02-19-2020%3A-jnj-pfe-abt-mrk-amgn-mreo-amed-ctso-2020-02-19 | nan | nan | Top Health Care Stocks
JNJ: +0.14%
PFE: +0.10%
ABT: +0.14%
MRK: +0.45%
AMGN: flat
Most leading stocks in the health care sector were trading higher during the pre-market hours on Wednesday.
Among stocks moving on news:
(+) Cytosorbents (CTSO), which gained nearly 14% after announcing that it has signed a deal with pharmaceutical company China Medical System to bring CytoSorb to mainland China to treat critically ill patients infected by the novel coronavirus.
(-) Amedisys (AMED), which slipped almost 9% after reporting Q4 adjusted EPS of $0.94 from $0.91 a year earlier, just ahead of analysts' estimates of $0.93 in a Capital IQ poll. Revenue grew to $500.68 million from $434.38 million a year ago, lagging the $511.58 million estimate.
(+) Mereo BioPharma (MREO), which gained almost 5% after announcing that a US-based institutional health care investor agreed to invest $3 million to purchase 12.3 million of the company's common shares.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AMGN: flat Most leading stocks in the health care sector were trading higher during the pre-market hours on Wednesday. Among stocks moving on news: (+) Cytosorbents (CTSO), which gained nearly 14% after announcing that it has signed a deal with pharmaceutical company China Medical System to bring CytoSorb to mainland China to treat critically ill patients infected by the novel coronavirus. (-) Amedisys (AMED), which slipped almost 9% after reporting Q4 adjusted EPS of $0.94 from $0.91 a year earlier, just ahead of analysts' estimates of $0.93 in a Capital IQ poll. | Top Health Care Stocks Among stocks moving on news: (+) Cytosorbents (CTSO), which gained nearly 14% after announcing that it has signed a deal with pharmaceutical company China Medical System to bring CytoSorb to mainland China to treat critically ill patients infected by the novel coronavirus. Revenue grew to $500.68 million from $434.38 million a year ago, lagging the $511.58 million estimate. | Among stocks moving on news: (+) Cytosorbents (CTSO), which gained nearly 14% after announcing that it has signed a deal with pharmaceutical company China Medical System to bring CytoSorb to mainland China to treat critically ill patients infected by the novel coronavirus. Revenue grew to $500.68 million from $434.38 million a year ago, lagging the $511.58 million estimate. (+) Mereo BioPharma (MREO), which gained almost 5% after announcing that a US-based institutional health care investor agreed to invest $3 million to purchase 12.3 million of the company's common shares. | Top Health Care Stocks AMGN: flat Most leading stocks in the health care sector were trading higher during the pre-market hours on Wednesday. Among stocks moving on news: (+) Cytosorbents (CTSO), which gained nearly 14% after announcing that it has signed a deal with pharmaceutical company China Medical System to bring CytoSorb to mainland China to treat critically ill patients infected by the novel coronavirus. |
32790.0 | 2020-02-19 00:00:00 UTC | Is DexCom's Stock a Buy? | ABT | https://www.nasdaq.com/articles/is-dexcoms-stock-a-buy-2020-02-19 | nan | nan | Diabetes is a growing problem in the U.S. and around the world. In the U.S., researchers estimate that nearly 55 million Americans will have either type 1 or type 2 diabetes by 2030. In the U.S., costs related to diabetes, both healthcare and societal, will reach $622 billion, which is a 53% increase from 2015.
That's why buying shares of a company that helps patients with diabetes can make for a sound, long-term investment. One company that has stood out in this area is DexCom (NASDAQ: DXCM). But with the stock having achieved significant gains and up more than 400% in just the past two years, investors may be wondering whether it's still a good buy or whether it has peaked. Let's take a look.
The company is coming off a strong earnings beat
DexCom released its fourth-quarter and full-year results for 2019 on Feb. 13, and it beat analyst expectations for both revenue and earnings. Sales in Q4 were up 37% year over year. And for the full year, its top line increased by 43% from 2018, reaching $1.5 billion in revenue. It was the second straight year where sales grew by at least 40%. But the company expects revenue for 2020 to grow at a slower rate, between 17% and 20%. It also expects its gross margin to remain at around 64%, which is in line with 2019.
Image Source: DexCom
This year was also the first full year that the company recorded a positive net income, with profits totaling $101 million. In 2018, DexCom incurred a loss of $127 million, and it had a $50 million loss the year before that.
Why there's still lots of growth left
One of the reasons the company is likely to keep growing is that it continues to enhance and improve its products. The company's continuous glucose monitoring (CGM) system is driving its growth as DexCom credits the growing awareness of its real-time CGM as one of the reasons for its strong performance in Q4. Its latest product, the DexCom G6 CGM, provides patients with real-time glucose readings and does not use finger sticks, which the previous G5 product required for calibration.
Medicare does cover the G6, but DexCom notes in its earnings release that it only began shipping the product to Medicare patients in Q4. It is available at Walgreens locations, and continuing to raise awareness and rolling out the product to more patients is a key initiative for DexCom in 2020.
Another initiative the company is focusing on is a new G7 product, with DexCom looking to offer patients a slimmer, less expensive product. The company does not expect a full commercial launch of the G7 until 2021.
With better, more discreet ways to monitor glucose levels that are less invasive than before, DexCom's products become attractive options for people with diabetes who are looking for more innovative solutions. And with the number of people with diabetes growing, the market for the company's products will only get larger.
Abbott Labs' competing product, the FreeStyle Libre, generated worldwide sales of $534 million in the company's recent fourth-quarter results, which was a 58.5% improvement from the prior-year quarter. Medtronic, another competitor, offers both integrated and stand-alone CGM products. In its third-quarter earnings released on Feb. 18, the company noted that sales for its CGM products grew in the "mid-teens." However, the company's total diabetes sales of $610 million were flat from the prior-year quarter. Tandem Diabetes is another diabetes company that had revenue of $94.7 million in its third-quarter, which is more than double the sales the company recorded in the prior-year quarter. Tandem's flagship product is the t:slim X2 insulin pump and one of its features is the ability to integrate with the DexCom G6.
While there are many CGM products available on the market, and many are cheaper than DexCom's, the company's impressive sales numbers suggest that's not a concern, at least not yet.
Should you buy DexCom today?
In 2019, shares of DexCom soared 82%, eclipsing the S&P 500's returns of 30%. The stock's been a high performer, and it's trading at its 52-week high. But that's what can happen when a company is doing very well, and it shouldn't be a deterrent from buying shares.
But a concern for value-oriented investors is that the stock trades at some hefty multiples. With a forward price-to-earnings ratio of over 94, investors are paying a steep price for future earnings. And with sales of $1.5 billion in its most recent fiscal year, investors are also paying about 16 times sales as well.
DexCom isn't a cheap stock, and given how bullish the markets are today, a slowdown could hurt its price. With the company expecting its growth to slow in 2020, paying more than 90 times earnings or 16 times sales is a bit excessive. While the company's growth opportunities are encouraging, the shares' valuation would have to come down to more reasonable levels (around 25 to 30 times forward earnings) for the healthcare stock to be a good buy.
10 stocks we like better than DexCom
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With better, more discreet ways to monitor glucose levels that are less invasive than before, DexCom's products become attractive options for people with diabetes who are looking for more innovative solutions. Abbott Labs' competing product, the FreeStyle Libre, generated worldwide sales of $534 million in the company's recent fourth-quarter results, which was a 58.5% improvement from the prior-year quarter. While the company's growth opportunities are encouraging, the shares' valuation would have to come down to more reasonable levels (around 25 to 30 times forward earnings) for the healthcare stock to be a good buy. | The company's continuous glucose monitoring (CGM) system is driving its growth as DexCom credits the growing awareness of its real-time CGM as one of the reasons for its strong performance in Q4. In its third-quarter earnings released on Feb. 18, the company noted that sales for its CGM products grew in the "mid-teens." While the company's growth opportunities are encouraging, the shares' valuation would have to come down to more reasonable levels (around 25 to 30 times forward earnings) for the healthcare stock to be a good buy. | Another initiative the company is focusing on is a new G7 product, with DexCom looking to offer patients a slimmer, less expensive product. Tandem Diabetes is another diabetes company that had revenue of $94.7 million in its third-quarter, which is more than double the sales the company recorded in the prior-year quarter. While there are many CGM products available on the market, and many are cheaper than DexCom's, the company's impressive sales numbers suggest that's not a concern, at least not yet. | Tandem Diabetes is another diabetes company that had revenue of $94.7 million in its third-quarter, which is more than double the sales the company recorded in the prior-year quarter. And with sales of $1.5 billion in its most recent fiscal year, investors are also paying about 16 times sales as well. That's right -- they think these 10 stocks are even better buys. |
32791.0 | 2020-02-18 00:00:00 UTC | Want to Know What Your Heart Defibrillator Is Doing? Abbott Has an App for That | ABT | https://www.nasdaq.com/articles/want-to-know-what-your-heart-defibrillator-is-doing-abbott-has-an-app-for-that-2020-02-18 | nan | nan | Abbott (NYSE: ABT) has received European approval for its new Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices for patients with abnormal heart rhythms and heart failure. In addition to all the normal functions of a defibrillator, which shocks a patient's heart back into normal rhythms if it starts beating erratically, the new devices can connect to Abbott's myMerlinPulse mobile app via Bluetooth to give doctors and patients more information on what's happening with the device.
Data from the device is sent straight to the patient's doctor, but the patient can see the transmission history and device performance as well. Patients can also trigger transmissions to their doctors if they feel something is awry. The app can even prompt patients to schedule their next appointments. On the physician side, the automatic transmissions can help doctors identify asymptomatic episodes, which can lead to earlier intervention and potentially better patient outcomes.
"The positive impact of remote monitoring has been proven repeatedly and leads to better patient outcomes and reduced burden on the healthcare system," Avi Fischer, chief medical officer for Abbott's cardiac rhythm management business said in a statement.
Image source: Getty Images.
With connectivity comes risk from hackers and malware, but Abbott has built-in cybersecurity controls. The devices also have the capacity to be upgraded to meet evolving digital threats.
In addition their remote-monitoring capabilities, the Gallant devices have all the bells and whistles of its earlier model defibrillators, including the ability to program the ICD to a patient's specific needs and Abbott's MultiPoint Pacing and SyncAV features in the CRT-D, which increase the likelihood that patients will respond to CRT therapy.
10 stocks we like better than Abbott
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (NYSE: ABT) has received European approval for its new Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices for patients with abnormal heart rhythms and heart failure. On the physician side, the automatic transmissions can help doctors identify asymptomatic episodes, which can lead to earlier intervention and potentially better patient outcomes. "The positive impact of remote monitoring has been proven repeatedly and leads to better patient outcomes and reduced burden on the healthcare system," Avi Fischer, chief medical officer for Abbott's cardiac rhythm management business said in a statement. | Abbott (NYSE: ABT) has received European approval for its new Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices for patients with abnormal heart rhythms and heart failure. "The positive impact of remote monitoring has been proven repeatedly and leads to better patient outcomes and reduced burden on the healthcare system," Avi Fischer, chief medical officer for Abbott's cardiac rhythm management business said in a statement. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | Abbott (NYSE: ABT) has received European approval for its new Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices for patients with abnormal heart rhythms and heart failure. In addition to all the normal functions of a defibrillator, which shocks a patient's heart back into normal rhythms if it starts beating erratically, the new devices can connect to Abbott's myMerlinPulse mobile app via Bluetooth to give doctors and patients more information on what's happening with the device. In addition their remote-monitoring capabilities, the Gallant devices have all the bells and whistles of its earlier model defibrillators, including the ability to program the ICD to a patient's specific needs and Abbott's MultiPoint Pacing and SyncAV features in the CRT-D, which increase the likelihood that patients will respond to CRT therapy. | Abbott (NYSE: ABT) has received European approval for its new Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices for patients with abnormal heart rhythms and heart failure. Data from the device is sent straight to the patient's doctor, but the patient can see the transmission history and device performance as well. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. |
32792.0 | 2020-02-16 00:00:00 UTC | Better Buy: AbbVie vs. Gilead Sciences | ABT | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-gilead-sciences-2020-02-16 | nan | nan | AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) must have missed the invitation to the party the stock market threw last year. Both stocks trailed the S&P 500 index's performance in 2019 by a wide margin.
However, both AbbVie and Gilead have been big winners in the past. And they both could deliver strong returns in the future. Which of these two stocks is the better pick right now? Here's how AbbVie and Gilead compare.
Image source: Getty Images.
Growth
Some investors have focused primarily on AbbVie's challenges with its top-selling drug Humira facing biosimilar competition in Europe already and on the way in the U.S. in 2023. To be sure, those challenges are real and daunting. But AbbVie's strong fourth-quarter results showed that there's more to its story than just Humira.
The reality is that AbbVie has multiple growth drivers. Put Imbruvica at the top of the list. Market researcher EvaluatePharma projects that the blood cancer drug will rank among the world's top five best-selling blockbusters by 2024. Another blood cancer drug, Venclexta, is also a fast-rising star.
Probably the best thing going for AbbVie, though, is its two drugs that could take the immunology baton from Humira -- Rinvoq and Skyrizi. Both drugs should become megablockbusters within the next few years.
In addition, AbbVie is betting that its pending acquisition of Allergan will help offset the inevitable sales declines on the way for Humira. Allergan's Botox franchise and up-and-coming new drugs such as antipsychotic Vraylar should give AbbVie a boost once the deal is done.
Gilead Sciences' biggest trouble spot in recent years has been its hepatitis C virus (HCV) franchise. Part of the problem has been competition from AbbVie, but the main issue is that there are simply fewer patients now that so many patients have been cured of hep-C. The good news for Gilead, though, is that its HCV sales are stabilizing somewhat.
This stabilization should allow Gilead to generate growth with its other drugs. The company has long dominated the HIV market. It should continue to do so with powerhouse drug Biktarvy and a promising long-acting HIV capsid in the pipeline.
Gilead also expects to soon expand into the immunology market with filgotinib, a drug licensed from Galapagos. The big biotech hopes to win FDA approval for filgotinib in treating rheumatoid arthritis later this year and is evaluating the drug in late-stage clinical studies targeting several other immunology indications.
Although Yescarta hasn't delivered the sales growth so far that some predicted, the cell therapy should continue to pick up momentum. Gilead also has several other cell therapies in development that could be winners in the future.
Valuation
Both AbbVie and Gilead appear to be cheap based on their forward earnings multiples. AbbVie's shares trade at only nine times expected earnings, while Gilead's shares trade at 10.5 times expected earnings.
However, Gilead appears to be more attractively valued using another metric. Its enterprise value-to-sales multiple currently stands at 3.9 compared to AbbVie's EV-to-sales ratio of 5.2.
Dividends
You won't find many if any biotech stocks with more attractive dividends than AbbVie and Gilead Sciences. AbbVie's dividend yield currently stands north of 4.8%. Gilead's dividend yields a little over 4%.
Gilead has boosted its dividend by an impressive 58% since initiating its dividend program in 2015. However, AbbVie's dividend track record is hard to top. The company has increased its dividend for 47 consecutive years, including the time it was part of Abbott Labs. And since being spun off from Abbott in 2013, AbbVie has raised its dividend by a total of 195%.
Better buy
I like both AbbVie and Gilead Sciences. I've owned both stocks for years. But if I had to pick just one of these two stocks, it would be AbbVie.
My view is that AbbVie's strategy to reduce its dependence on Humira is working. I think that the combination of solid growth despite the headwinds for Humira with an exceptionally strong dividend should enable AbbVie to deliver market-beating total returns over the long run.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Keith Speights owns shares of AbbVie and Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) must have missed the invitation to the party the stock market threw last year. The big biotech hopes to win FDA approval for filgotinib in treating rheumatoid arthritis later this year and is evaluating the drug in late-stage clinical studies targeting several other immunology indications. I think that the combination of solid growth despite the headwinds for Humira with an exceptionally strong dividend should enable AbbVie to deliver market-beating total returns over the long run. | AbbVie's shares trade at only nine times expected earnings, while Gilead's shares trade at 10.5 times expected earnings. Dividends You won't find many if any biotech stocks with more attractive dividends than AbbVie and Gilead Sciences. I think that the combination of solid growth despite the headwinds for Humira with an exceptionally strong dividend should enable AbbVie to deliver market-beating total returns over the long run. | AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) must have missed the invitation to the party the stock market threw last year. Dividends You won't find many if any biotech stocks with more attractive dividends than AbbVie and Gilead Sciences. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Gilead Sciences. | Dividends You won't find many if any biotech stocks with more attractive dividends than AbbVie and Gilead Sciences. I've owned both stocks for years. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Keith Speights owns shares of AbbVie and Gilead Sciences. |
32793.0 | 2020-02-14 00:00:00 UTC | 3 Reasons AbbVie Is a Better Bargain Than You Might Think | ABT | https://www.nasdaq.com/articles/3-reasons-abbvie-is-a-better-bargain-than-you-might-think-2020-02-14 | nan | nan | At first glance, the picture for AbbVie (NYSE: ABBV) looks bad. The company's top-selling drug that generated over half of the company's total revenue in the past has lost patent exclusivity in Europe and will do so in the U.S. within the next three years. Last year, while the overall market skyrocketed AbbVie's shares fell 4%.
But I think that AbbVie is a much better bargain right now than you might think. Here are three reasons why that's the case.
Image source: Getty Images.
1. Humira protection plan is working
AbbVie has known for years that the day would come when Humira would face biosimilar competition. The company has been planning for that day, which has now arrived (at least in part).
To be sure, AbbVie didn't foresee everything that has happened with Humira. The company didn't expect its competitors to price their biosimilars so aggressively. As a result, the initial hit to Humira's international sales was bigger than AbbVie initially anticipated.
However, AbbVie CEO Rick Gonzalez noted in the drugmaker's Q4 conference call last week that the company has held on to around two-thirds of the volume for Humira. In Europe, where the biosimilars are challenging the immunology drug, Humira's sales have eroded by around 45%. This means that AbbVie has been able to retain roughly 55% of the previous sales level for Humira. That's actually pretty good.
The company has also learned some lessons from its experience in Europe that could help it better handle the entrance of biosimilars in the U.S. market in 2023. For investors who have fretted about the impact that loss of exclusivity for Humira would have on AbbVie, the fact that the company's protection plan for the drug appears to be working well overall is very good news.
2. Post-Humira strategy is paying off
AbbVie didn't just bank on playing defense with Humira, though. The company has invested heavily in its pipeline and made strategic acquisitions along the way with the goal of reducing its dependence on Humira. Several signs seem to point to this strategy paying off.
The company's blood cancer drugs continue to perform really well. In the fourth quarter, sales for Imbruvica jumped nearly 29% year over year to $1.3 billion. It's on track to become one of the top five best-selling drugs in the world by 2024. Venclexta appears destined to become another blockbuster for AbbVie, with the drug racking up sales of $251 million in Q4.
Two successors to Humira are also delivering tremendous sales growth. Skyrizi, which won FDA approval in April 2019 for treating plaque psoriasis, more than doubled its sales in Q4 compared to Q3, pulling in $216 million. Sales for Rinvoq, which received FDA approval for treating rheumatoid arthritis in August 2019, totaled $33 million in Q4. That might seem a little low, but the drug didn't gain fuller market access until January. Even better, Rinvoq doesn't appear to be cannibalizing sales of Humira too much so far.
AbbVie awaits the closing of its acquisition of Allergan (NYSE: AGN), which should be on track to wrap up later in the first quarter of 2020. Even though some were initially skeptical of the deal, Allergan brings several drugs to AbbVie's lineup that will lower its reliance on Humira. Botox stands at the top of the list, but several other Allergan products -- notably including antipsychotic drug Vraylar and gastrointestinal drug Linzess/Constella -- should also boost AbbVie's growth prospects.
3. AbbVie has an ace in the hole
While AbbVie's shares trade at only nine times expected earnings, some investors won't consider the stock a bargain because of its longer-term prospects are clouded by the future for Humira. However, we've already seen evidence that AbbVie's strategy for defending Humira as much as possible while reducing its dependence on the drug appears to be working.
Perhaps just as important, though, AbbVie's earnings growth doesn't have to be all that high to make the stock an attractive investment because of the company's ace in the hole: its strong dividend. AbbVie ranks as one of the most appealing dividend stocks on the market with a juicy yield of nearly 5%.
The company's track record of dividend hikes is nothing short of spectacular. AbbVie has increased its dividend for 47 consecutive years including the time that it was a part of Abbott Labs. Since being spun off from Abbott in 2013, AbbVie has boosted its dividend by a whopping 195%.
Can AbbVie keep the dividends flowing and growing in the future? I think so, especially with the solid cash flow that the acquisition of Allergan will bring to the table.
A pretty good picture after all
I'm not dismissing the challenges that AbbVie faces with the inevitable decline of sales for Humira that's on the way. However, my view is that the company is effectively tackling those challenges head on. The combination of a strong lineup of other drugs with fast-growing sales, the likely addition of more drugs on the way with the close of the Allergan deal, and its mouth-watering dividend should provide solid total returns for AbbVie over the long run.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, AbbVie CEO Rick Gonzalez noted in the drugmaker's Q4 conference call last week that the company has held on to around two-thirds of the volume for Humira. For investors who have fretted about the impact that loss of exclusivity for Humira would have on AbbVie, the fact that the company's protection plan for the drug appears to be working well overall is very good news. Perhaps just as important, though, AbbVie's earnings growth doesn't have to be all that high to make the stock an attractive investment because of the company's ace in the hole: its strong dividend. | Humira protection plan is working AbbVie has known for years that the day would come when Humira would face biosimilar competition. Even though some were initially skeptical of the deal, Allergan brings several drugs to AbbVie's lineup that will lower its reliance on Humira. AbbVie has an ace in the hole While AbbVie's shares trade at only nine times expected earnings, some investors won't consider the stock a bargain because of its longer-term prospects are clouded by the future for Humira. | For investors who have fretted about the impact that loss of exclusivity for Humira would have on AbbVie, the fact that the company's protection plan for the drug appears to be working well overall is very good news. AbbVie has an ace in the hole While AbbVie's shares trade at only nine times expected earnings, some investors won't consider the stock a bargain because of its longer-term prospects are clouded by the future for Humira. The combination of a strong lineup of other drugs with fast-growing sales, the likely addition of more drugs on the way with the close of the Allergan deal, and its mouth-watering dividend should provide solid total returns for AbbVie over the long run. | AbbVie awaits the closing of its acquisition of Allergan (NYSE: AGN), which should be on track to wrap up later in the first quarter of 2020. AbbVie has an ace in the hole While AbbVie's shares trade at only nine times expected earnings, some investors won't consider the stock a bargain because of its longer-term prospects are clouded by the future for Humira. However, we've already seen evidence that AbbVie's strategy for defending Humira as much as possible while reducing its dependence on the drug appears to be working. |
32794.0 | 2020-02-13 00:00:00 UTC | Notable ETF Inflow Detected - IHI, ABT, DHR, SYK | ABT | https://www.nasdaq.com/articles/notable-etf-inflow-detected-ihi-abt-dhr-syk-2020-02-13 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $68.0 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 18,300,000 to 18,550,000). Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.9%, Danaher Corp (Symbol: DHR) is off about 0.8%, and Stryker Corp (Symbol: SYK) is up by about 0.2%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $211.47 per share, with $278.19 as the 52 week high point — that compares with a last trade of $270.69. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.9%, Danaher Corp (Symbol: DHR) is off about 0.8%, and Stryker Corp (Symbol: SYK) is up by about 0.2%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $211.47 per share, with $278.19 as the 52 week high point — that compares with a last trade of $270.69. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.9%, Danaher Corp (Symbol: DHR) is off about 0.8%, and Stryker Corp (Symbol: SYK) is up by about 0.2%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $211.47 per share, with $278.19 as the 52 week high point — that compares with a last trade of $270.69. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.9%, Danaher Corp (Symbol: DHR) is off about 0.8%, and Stryker Corp (Symbol: SYK) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $68.0 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 18,300,000 to 18,550,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $211.47 per share, with $278.19 as the 52 week high point — that compares with a last trade of $270.69. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.9%, Danaher Corp (Symbol: DHR) is off about 0.8%, and Stryker Corp (Symbol: SYK) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $68.0 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (from 18,300,000 to 18,550,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $211.47 per share, with $278.19 as the 52 week high point — that compares with a last trade of $270.69. |
32795.0 | 2020-02-13 00:00:00 UTC | Better Buy: Abbott Laboratories vs. Novo Nordisk | ABT | https://www.nasdaq.com/articles/better-buy%3A-abbott-laboratories-vs.-novo-nordisk-2020-02-13 | nan | nan | As enticing as new up-and-coming biotech stocks may be, the safer and potentially better long-term play for investors is to buy shares of more established brands. Both Novo Nordisk (NYSE: NVO) and Abbott Laboratories (NYSE: ABT) are great examples, with market caps of around $150 billion each.
These healthcare giants are mature companies that have no problem recording profits and even paying dividends -- and won't take investors on wild rides. Choosing between the two stocks can be difficult, however, as they focus on different areas and also possess different risks. Let's take a closer look at the two to see which stock is the better buy today.
Abbott's strength is its diversification
For investors who are in search of consistency, Abbott Laboratories offers a strong mix of dividends and growth that other stocks simply can't beat. The medical device company has a variety of products that allows it to continue growing -- cardiovascular and neuromodulation, diagnostic, and nutritional. From glucose monitors to infant formula and to its popular Ensure brand of nutritional products, Abbott is a well-diversified stock that isn't dependent on one area or segment to continue growing.
The company is coming off a strong fourth quarter where it beat analyst expectations for revenue with growth of 7.1%, as the company's medical device segment and its pharmaceuticals segment were both up 10% year over year. What's encouraging is that not only is the company still growing, it's also not standing pat as it continues to develop new devices. Abbott announced in February that the Food and Drug Administration approved a trial for the company's Amplatzer Amulet device, which looks to help people with atrial fibrillation and reduce their risk of stroke and bleeding.
Image source: Getty Images
Abbott looks like a good buy even before discussing what may be most attractive about the stock: its dividend. With a solid track record of paying dividends that includes increasing payouts for 40-plus years, Abbott becomes an even better buy when factoring in the recurring income you can expect to hold from owning shares of the company. Admittedly, its quarterly dividend of $0.36 will only produce a modest dividend yield of 1.65%, which is below the S&P 500 average of 1.85%. The real value is from holding over the long term and seeing the dividend payments rise over time. Investors who have held shares of the stock since 2013 have seen their dividend payments more than double from the $0.14 that Abbott was paying back then.
Novo is comparable, but with a focus on diabetes
Novo Nordisk has a lot in common with Abbott, as it also offers a strong dividend and is still showing good growth. The company released its fourth-quarter results on Feb. 5, and while it generated 9% sales growth during the quarter, the company expects its growth rate, without the impact of foreign exchange, to grow between 3% and 6% in 2020. One difference from Abbott is Novo's revenue mix is not as diverse, with 84% of the company's revenue in Q4, as well as for the entire year, coming from diabetes and obesity care products. Novo's biopharma segment contributed the remaining 16% of its sales.
In addition to having less diversification, the Danish company also has more exposure to foreign exchange. Although its Q4 numbers saw 9% sales growth from the prior year, at constant exchange rates, that growth was more modest, at just 6%. Without foreign exchange, its diabetes and obesity segment rose by 7% in Q4 while biopharma sales were up 2%.
Novo pays a dividend of around 2% per year, and it too has increased its dividend payments annually -- although, with just more than 10 years of consecutive increases to its payouts, it's nowhere near Abbott's impressive track record.
Which stock is the better buy today?
Both of these stocks look to be attractive long-term buys, and in three years both have outperformed the Health Care Select Sector SPDR ETF:
ABT data by YCharts.
There isn't a lot separating them and that's where valuation can help break the tie. Abbott is trading at a forward price-to-earnings ratio of 22, which is slightly less than the 24 times investors are valuing Novo at today. With a slightly better valuation, more diversification in its revenue, and less foreign-exchange risk, Abbott is the better buy of these two healthcare stocks, but not by much.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Both Novo Nordisk (NYSE: NVO) and Abbott Laboratories (NYSE: ABT) are great examples, with market caps of around $150 billion each. Both of these stocks look to be attractive long-term buys, and in three years both have outperformed the Health Care Select Sector SPDR ETF: ABT data by YCharts. From glucose monitors to infant formula and to its popular Ensure brand of nutritional products, Abbott is a well-diversified stock that isn't dependent on one area or segment to continue growing. | Both Novo Nordisk (NYSE: NVO) and Abbott Laboratories (NYSE: ABT) are great examples, with market caps of around $150 billion each. Both of these stocks look to be attractive long-term buys, and in three years both have outperformed the Health Care Select Sector SPDR ETF: ABT data by YCharts. Abbott's strength is its diversification For investors who are in search of consistency, Abbott Laboratories offers a strong mix of dividends and growth that other stocks simply can't beat. | Both Novo Nordisk (NYSE: NVO) and Abbott Laboratories (NYSE: ABT) are great examples, with market caps of around $150 billion each. Both of these stocks look to be attractive long-term buys, and in three years both have outperformed the Health Care Select Sector SPDR ETF: ABT data by YCharts. Abbott's strength is its diversification For investors who are in search of consistency, Abbott Laboratories offers a strong mix of dividends and growth that other stocks simply can't beat. | Both Novo Nordisk (NYSE: NVO) and Abbott Laboratories (NYSE: ABT) are great examples, with market caps of around $150 billion each. Both of these stocks look to be attractive long-term buys, and in three years both have outperformed the Health Care Select Sector SPDR ETF: ABT data by YCharts. The company is coming off a strong fourth quarter where it beat analyst expectations for revenue with growth of 7.1%, as the company's medical device segment and its pharmaceuticals segment were both up 10% year over year. |
32796.0 | 2020-02-12 00:00:00 UTC | AbbVie Is a Dividend Growth Stock at a Bargain Price | ABT | https://www.nasdaq.com/articles/abbvie-is-a-dividend-growth-stock-at-a-bargain-price-2020-02-12 | nan | nan | AbbVie (NYSE: ABBV) reported fourth-quarter earnings on Friday that were above consensus and the company raised its guidance for 2020. The results suggested that there was life after Humira, its mainstay immunology product, which is the world's best-selling drug.
On a day when the market was down 1%, AbbVie's shares rose 5%. With the stock still trading at a discount to the market multiple and a dividend yield of 4.6%, AbbVie still has plenty of appeal for the long-term investor.
Image source: Getty Images.
AbbVie beat expectations and raised its guidance
AbbVie's results were resoundingly positive. Worldwide revenues rose 5.3% operationally to $8.7 billion despite international Humira sales declining 25% -- excluding this, revenues were up 11%. Adjusted earnings per share (EPS) grew 16% year over year and came in a penny ahead of consensus. And next year's guidance was raised to a range of $9.61 to $9.71 per share, with the midpoint representing an increase of 8.1%.
It's no small wonder, then, that the stock rose as much as it did. For much of last year, AbbVie's shares lagged the overall market. Much of this had to do with concern about Humira, which accounted for up to 60% of AbbVie's sales and a higher percentage of its profits, and which was scheduled to go off-patent in 2023 in the U.S. The company's fourth-quarter results went a long way in mitigating these fears.
Concerns about Humira are exaggerated
Although Humira still accounted for a hefty 56% of sales in the fourth quarter, stronger growth was seen in the company's other drugs. Sales of AbbVie's hematological oncology drugs grew 39% to over $1.5 billion, driven by Imbruvica and Venclexta which combined for $5.5 billion in sales in 2019. In the immunology area, Skyrizi and Rinvoq exceeded expectations and sales are expected to more than triple next year to $1.7 billion. This highlights the company's R&D efforts which, as CEO Richard A. Gonzalez points out, over the last seven years has led to the development of drugs generating $9 billion in sales in 2019.
To further wean its dependency off Humira, AbbVie will soon complete its acquisition of Allergan. Allergan brings with it $16 billion in annual revenue in mostly unrelated therapeutic markets, and is expected to be immediately accretive, contributing 10% to adjusted EPS in the first year. The combined AbbVie/Allergan entity will rank fourth in overall revenues and third in operating cash flow, creating significant scale in an industry where the costs of delivering a new drug to the market is in excess of $2 billion and rising.
This cash flow should suffice in funding further dividend increases. Having grown its dividend 195% since separating from Abbott Laboratories in 2013, AbbVie still has plenty of room to grow it further. And at current yield of 4.6%, the company's dividend is among the highest in the healthcare sector. With the stock trading at half the market price-to-earnings ratio, AbbVie represents a rare bargain in the healthcare sector that is too good to miss.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of December 1, 2019
Greg Jones owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Allergan brings with it $16 billion in annual revenue in mostly unrelated therapeutic markets, and is expected to be immediately accretive, contributing 10% to adjusted EPS in the first year. The combined AbbVie/Allergan entity will rank fourth in overall revenues and third in operating cash flow, creating significant scale in an industry where the costs of delivering a new drug to the market is in excess of $2 billion and rising. With the stock trading at half the market price-to-earnings ratio, AbbVie represents a rare bargain in the healthcare sector that is too good to miss. | AbbVie beat expectations and raised its guidance AbbVie's results were resoundingly positive. Adjusted earnings per share (EPS) grew 16% year over year and came in a penny ahead of consensus. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. | With the stock still trading at a discount to the market multiple and a dividend yield of 4.6%, AbbVie still has plenty of appeal for the long-term investor. Sales of AbbVie's hematological oncology drugs grew 39% to over $1.5 billion, driven by Imbruvica and Venclexta which combined for $5.5 billion in sales in 2019. See the 10 stocks *Stock Advisor returns as of December 1, 2019 Greg Jones owns shares of AbbVie. | With the stock still trading at a discount to the market multiple and a dividend yield of 4.6%, AbbVie still has plenty of appeal for the long-term investor. And next year's guidance was raised to a range of $9.61 to $9.71 per share, with the midpoint representing an increase of 8.1%. Concerns about Humira are exaggerated Although Humira still accounted for a hefty 56% of sales in the fourth quarter, stronger growth was seen in the company's other drugs. |
32797.0 | 2020-02-07 00:00:00 UTC | Health Care Sector Update for 02/07/2020: JNJ, PFE, ABT, MRK, AMGN, ASRT, ZGNX, MYGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-02-07-2020%3A-jnj-pfe-abt-mrk-amgn-asrt-zgnx-mygn-2020-02-07 | nan | nan | Top Health Care Stocks:
JNJ: -0.24%
PFE: -0.05%
ABT: flat
MRK: +0.14%
AMGN: flat
Top health care stocks were mixed during pre-market trading hours on Friday.
Health care stocks moving on news include:
(+) Assertio Therapeutics (ASRT), which jumped more than 65% after the pharmaceutical company agreed to sell the Nucynta franchise products to Collegium Pharmaceutical for $375 million in cash. The deal is expected to close by Feb. 14.
(-) Zogenix (ZGNX), which fell more than 28% after posting positive results from its phase 3 clinical study of Fintepla in Lennox-Gastaut Syndrome, a severe and treatment-resistant childhood-onset epilepsy. The study achieved its primary endpoint as it showed a highly statistically significant reduction in monthly drop seizure frequency compared with placebo.
(+) Myriad Genetics (MYGN), which dropped more than 30% after reporting fiscal Q2 net income of $0.23 per share, compared with $0.38 in the year-ago quarter and missing the Capital IQ estimate of $0.29. Revenue for the quarter ended Dec. 31 was $195.1 million, compared with $216.8 million a year ago and below the Street forecast of $209.61 million.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: flat (-) Zogenix (ZGNX), which fell more than 28% after posting positive results from its phase 3 clinical study of Fintepla in Lennox-Gastaut Syndrome, a severe and treatment-resistant childhood-onset epilepsy. The study achieved its primary endpoint as it showed a highly statistically significant reduction in monthly drop seizure frequency compared with placebo. | ABT: flat Top Health Care Stocks: AMGN: flat Top health care stocks were mixed during pre-market trading hours on Friday. | ABT: flat AMGN: flat Top health care stocks were mixed during pre-market trading hours on Friday. Health care stocks moving on news include: (+) Assertio Therapeutics (ASRT), which jumped more than 65% after the pharmaceutical company agreed to sell the Nucynta franchise products to Collegium Pharmaceutical for $375 million in cash. | ABT: flat Top Health Care Stocks: AMGN: flat Top health care stocks were mixed during pre-market trading hours on Friday. |
32798.0 | 2020-02-06 00:00:00 UTC | Health Care Sector Update for 02/06/2020: BDX, CAH, CI, JNJ, ABT, MRK, PFE, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-02-06-2020%3A-bdx-cah-ci-jnj-abt-mrk-pfe-amgn-2020-02-06 | nan | nan | Top Health Care Stocks:
JNJ: +0.16%
PFE: +0.63%
ABT: +0.20%
MRK: +0.16%
AMGN: +1.32%
Heath care giants were climbing pre-bell Thursday.
Stocks moving on news include:
(-) Becton Dickinson (BDX), which was slipping more than 9% as it booked fiscal Q1 adjusted earnings of $2.65 per share, down from $2.70 a year ago and beating the $2.64 average estimate from analysts polled by Capital IQ.
(+) Cardinal Health (CAH) was rallying more than 6% after it posted fiscal Q2 non-GAAP EPS of $1.52, up from $1.29 in the year-ago quarter and above the Capital IQ estimate of $1.22 a share.
(+) Cigna (CI) was up more than 2% after it reported a Q4 net income of $4.31 per share in adjusted terms, up from $2.46 per share in the year-ago period and well above the consensus of $4.20 per share from analysts polled by Capital IQ.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Heath care giants were climbing pre-bell Thursday. Stocks moving on news include: (-) Becton Dickinson (BDX), which was slipping more than 9% as it booked fiscal Q1 adjusted earnings of $2.65 per share, down from $2.70 a year ago and beating the $2.64 average estimate from analysts polled by Capital IQ. (+) Cardinal Health (CAH) was rallying more than 6% after it posted fiscal Q2 non-GAAP EPS of $1.52, up from $1.29 in the year-ago quarter and above the Capital IQ estimate of $1.22 a share. | Top Health Care Stocks: Stocks moving on news include: (-) Becton Dickinson (BDX), which was slipping more than 9% as it booked fiscal Q1 adjusted earnings of $2.65 per share, down from $2.70 a year ago and beating the $2.64 average estimate from analysts polled by Capital IQ. (+) Cigna (CI) was up more than 2% after it reported a Q4 net income of $4.31 per share in adjusted terms, up from $2.46 per share in the year-ago period and well above the consensus of $4.20 per share from analysts polled by Capital IQ. | Stocks moving on news include: (-) Becton Dickinson (BDX), which was slipping more than 9% as it booked fiscal Q1 adjusted earnings of $2.65 per share, down from $2.70 a year ago and beating the $2.64 average estimate from analysts polled by Capital IQ. (+) Cardinal Health (CAH) was rallying more than 6% after it posted fiscal Q2 non-GAAP EPS of $1.52, up from $1.29 in the year-ago quarter and above the Capital IQ estimate of $1.22 a share. (+) Cigna (CI) was up more than 2% after it reported a Q4 net income of $4.31 per share in adjusted terms, up from $2.46 per share in the year-ago period and well above the consensus of $4.20 per share from analysts polled by Capital IQ. | Top Health Care Stocks: Heath care giants were climbing pre-bell Thursday. Stocks moving on news include: (-) Becton Dickinson (BDX), which was slipping more than 9% as it booked fiscal Q1 adjusted earnings of $2.65 per share, down from $2.70 a year ago and beating the $2.64 average estimate from analysts polled by Capital IQ. |
32799.0 | 2020-02-05 00:00:00 UTC | Noteworthy ETF Outflows: IWB, WMT, ABT, BMY | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-iwb-wmt-abt-bmy-2020-02-05 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $91.5 million dollar outflow -- that's a 0.4% decrease week over week (from 125,200,000 to 124,700,000). Among the largest underlying components of IWB, in trading today Walmart Inc (Symbol: WMT) is up about 0.2%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Bristol-Myers Squibb Co. (Symbol: BMY) is higher by about 1.4%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average:
Looking at the chart above, IWB's low point in its 52 week range is $149.19 per share, with $184.79 as the 52 week high point — that compares with a last trade of $183.87. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWB, in trading today Walmart Inc (Symbol: WMT) is up about 0.2%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Bristol-Myers Squibb Co. (Symbol: BMY) is higher by about 1.4%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $149.19 per share, with $184.79 as the 52 week high point — that compares with a last trade of $183.87. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWB, in trading today Walmart Inc (Symbol: WMT) is up about 0.2%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Bristol-Myers Squibb Co. (Symbol: BMY) is higher by about 1.4%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $149.19 per share, with $184.79 as the 52 week high point — that compares with a last trade of $183.87. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IWB, in trading today Walmart Inc (Symbol: WMT) is up about 0.2%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Bristol-Myers Squibb Co. (Symbol: BMY) is higher by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $91.5 million dollar outflow -- that's a 0.4% decrease week over week (from 125,200,000 to 124,700,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $149.19 per share, with $184.79 as the 52 week high point — that compares with a last trade of $183.87. | Among the largest underlying components of IWB, in trading today Walmart Inc (Symbol: WMT) is up about 0.2%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Bristol-Myers Squibb Co. (Symbol: BMY) is higher by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $91.5 million dollar outflow -- that's a 0.4% decrease week over week (from 125,200,000 to 124,700,000). For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $149.19 per share, with $184.79 as the 52 week high point — that compares with a last trade of $183.87. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.